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Abstract 
To date no definite treatment exists for acute lung injury (ALI), only supportive 
therapy, among which mechanical ventilation is an important tool; however 
ventilation itself may exacerbate the underlying injury, termed ventilator-induced lung 
injury (VILI). The pro-inflammatory cytokine tumour necrosis factor alpha (TNF) has 
been consistently implicated in the pathogenesis of ALI/VILI, however clinical trials 
with anti-TNF therapy failed to improve the outcome.  
TNF acts on two cel-surface receptors (TNFRs), p55 and p75, and knock-out 
studies in ALI/VILI indicate they have directly opposing roles, i.e. promoting or 
protecting against pulmonary oedema, respectively, but it remains unclear where 
these signaling mechanisms take place, being the endothelial or epithelial side of 
the alveolar-capilary membrane. This project had two main aims: to characterise the 
expression profile and roles of TNF receptor subtypes on each side of the alveolar-
capilary membrane and to modulate ALI progression in mouse models by targeting 
individual TNFRs accordingly. 
Characterisation studies on freshly harvested mouse pulmonary endothelial 
cels (PECs) using flow cytometry indicated expression of both receptors with 
dominance of p55. Knock-out and pharmacological inhibition studies in vivo and in 
vitro, respectively, found p55 to be the major mediator of TNF-induced adhesion 
molecule expression on PECs, with a similar but less potent role for p75 that varied 
across adhesion molecules. Endotoxaemia resulted in rapid shedding of p55 on 
PECs while expression of p75 was preserved, indicating that the relative role of the 
receptors may change during inflammatory conditions. 
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Specific inhibition of intraalveolar p55 signalling by domain antibodies 
significantly atenuated both pulmonary oedema and inflammation in mouse models 
of VILI and acid-aspiration. 
These data ofer new, potentialy clinicaly applicable insights into the 
involvement of TNFR biology in ALI and the novel domain antibody technology may 
open a new therapeutic approach for patients who sufer from, or at risk of ALI. 
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1.1 Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) 
1.1. Definition 
ALI and its more severe form ARDS are characterised by acute onset of hypoxaemia 
secondary to inflammatory pulmonary oedema, and bilateral changes on chest 
radiograph. The entities were first described by Ashbaugh et al in 1967, who 
reported very similar pathologies, i.e. acute onset of tachypnoea, hypoxaemia, 
difuse pulmonary infiltrates and loss of compliance, in 12 adult patients despite 
having varying underlying conditions ranging from pneumonia to traumatic injury 
which did not respond to ordinary respiratory therapy [3]. However, a uniform 
definition of ARDS was lacking for almost another 30 years causing uncertainties 
around its true incidence and clinical outcome, which prompted the American-
European Consensus Conference (AECC) on ARDS in 1994 to standardise the 
diagnostic criteria for ALI and ARDS in order to alow comparison of epidemiological 
and treatment studies across the world (or at least in North America and Europe) 
(Table 1.1) [4]. 
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Table 1.1 - Diagnostic  criteria for  acute lung injury (ALI)  and  acute respiratory  distress 
syndrome (ARDS) set by the American-European Consensus Conference on ARDS in 1994 [4]. 
ALI and ARDS only difer in the extent of hypoxaemia, which is more severe in the later. 
 
Using these criteria the incidence of ALI/ARDS in the US was estimated at 17-78.9 
cases per 100,000 person-years [5-7] in diferent cohorts, whereas the figures are 
generaly lower in Europe and Australia ranging from 7.2 to 34 cases per 100,000 
person-years [8-10]. Mortality rates can vary in the range of 24 to 60%, depending 
on the severity and nature of the underlying disease and the patients’ age and 
comorbidities [7]. Based on the ARDS Network trial 60-day mortality has declined 
from 36% in 1996–1997 to 26% in 2004–2005 [11], probably secondary to more 
wide-spread use of lung-protective ventilation strategies, conservative use of blood 
products and beter control of nosocomial infections [12, 13], whereas the most 
recent ARDS Network clinical trials reported a 60-day mortality of 22% in adult 
patients [14, 15], which is stil unacceptably high. 
 Although the AECC definition significantly helped to orchestrate international 
research eforts in the field of ALI/ARDS, its validity has been criticised. For example 
the interpretation of the term ‘acute’ may difer amongst clinicians and similar 
problems may arise around the determination of ‘bilateral infiltrates on chest 
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radiograph’ due to interobserver variability [16, 17]. It also ignores that the PaO2/FiO2 
ratio is not constant over a range of FiO2 and may vary in response to ventilator 
setings particularly PEEP [18-20]. 
In order to overcome these and other limitations, the European Society of 
Intensive Care Medicine, the American Thoracic Society and the Society of Critical 
Care Medicine drafted a revision of the AECC definitions, termed the ‘Berlin 
definition’ [21]. The main changes made to the AECC are summarised in Table 1.2, 
and include 1) the elimination of the term ‘acute lung injury’ and replacing it with 
three levels of ARDS severity based on PaO2/FiO2 ratio measured at a minimum 
PEEP of 5cmH2O, 2) defining ‘acute’ as ≤7 days from the predisposing insult and 3) 
eliminating pulmonary artery wedge pressure cut-of values as discriminating factor 
from cardiogenic pulmonary oedema [21]. 
The Berlin Definition was empiricaly evaluated using patient level meta-
analysis of patients with ARDS from 4 multi-centre (N=4188) and 3 single-centre (N= 
269) clinical data sets containing physiologic information [21]. The Berlin Definition 
provided significantly beter predictive ability for mortality compared to the AECC 
definition. Therefore, it may help to beter identify patients that benefit the most from 
treatment that have been tested in clinical trials. It also gives recommendations for 
clinical research to focus its atention on other treatment options that might be also 
beneficial in the relevant subgroups of ARDS, such as testing the feasibility and 
benefits of non-invasive ventilation in mild ARDS, partial extracorporeal support in 
moderate to severe forms, and high-frequency ventilation, inhaled nitric oxide, 
neuromuscular blockade and extracorporeal membrane oxygenation in the severe 
forms. These and other therapeutic approaches to ARDS wil be discussed in more 
detail later in this chapter. 
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Table 1.2 - Comparison of the American-European Consensus Conference (AECC) definition of 
acute lung injury (ALI)  and the  Berlin  definition  on  acute respiratory  distress  syndrome 
(ARDS). Main changes to the AECC definition include a clear definition of the term ‘acute’; elimination 
of the term ‘acute lung injury’ and seting three severity levels of ARDS based on oxygenation at 
standardised positive end-expiratory pressure (PEEP) levels; elimination of the use of pulmonary 
capilary wedge pressure cut-of values to define non-cardiogenic pulmonary oedema, mainly 
because this is rarely measured routinely and because cardiogenic oedema and ARDS may co-
exist/overlap clinicaly. 
1.1. Aetiology 
ARDS can result from a variety of insults, both from direct (pulmonary) injury, where 
the initial insult afects the lung parenchyma, and from an indirect (extra-pulmonary) 
cause, where lung injury is part of a systemic process. While pneumonia is the most 
18 
common pulmonary cause, sepsis accounts for most of the extra-pulmonary cases 
(Table 1.3) and overal is associated with highest risk of progression to ARDS, 
approximately 40 per cent [22]. 
 
Table 1.3 – Clinical disorders associated with the development of ARDS [22]. Pneumonia and 
sepsis are the most common direct and indirect causes of ARDS, respectively. 
The awareness of conditions that are commonly associated with ARDS helps 
identifying patients who are at risk of or in the early stage of lung injury development, 
thus aid choosing the appropriate prophylactic and or therapeutic approach. Also, 
several environmental and genetic factors have been identified that contribute to the 
susceptibility and severity of ARDS. For example, chronic alcohol abuse has been 
shown to increase the risk of developing ARDS and multiple organ failure in septic 
shock [23, 24], whereas cigarete smoke exposure, both active and passive, has 
been associated with development of ARDS after blunt chest trauma [25]. Common 
variants of genes that regulate processes, such as inflammation, coagulation, 
endothelial cel function, apoptosis and generation of reactive oxygen species, which 
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are al involved in the pathogenesis of acute lung injury (see below), have been also 
linked with susceptibility to ARDS and the clinical outcome [26-31]. 
1.1. Pathophysiology 
Although some of the clinical features might difer depending on whether ARDS 
originates from a pulmonary or extra-pulmonary insult [32], the main 
pathophysiological processes are very similar, and involve a complex interplay of 
celular and molecular mechanisms leading to an imbalance of pulmonary 
homeostasis that can develop within hours to days from the initial insult and progress 
over days to weeks, and often takes months to resolve, if at al [22, 33-35]. The 
pathogenesis of ARDS can be separated into three main stages, and although these 
have some overlap, each of them has its own characteristics. 
Acute phase – increased permeability oedema and inflammation 
Clinicaly, the initial acute or exudative phase of ARDS is characterised by rapid 
onset of dyspnoea, hypoxaemia, respiratory failure and bilateral opacities on chest 
radiograph, features that are consistent with increased permeability oedema [22] and 
often indicate mechanical ventilation. From a respiratory physiology perspective it is 
associated with decreased lung compliance and increased tendency to alveolar 
colapse secondary to the oedema and surfactant dysfunction [36, 37], and 
increased dead space due to a pro-thrombotic state in the pulmonary 
microvasculature [38], the later of which has been identified as a risk of death in 
ARDS [39]. Histology features microthrombi in the microvasculature, disrupted 
alveolar-capilary barier with denuded basement membrane often lined with protein-
rich eosinophilic hyaline membrane, and alveoli that are colapsed or filed with 
oedema fluid, inflammatory cels, and red blood cels [40, 41]. 
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Pulmonary microvascular endothelial injury 
Under normal conditions, a synchronised colaboration between the pulmonary 
endothelium and alveolar epithelium strictly controls fluid and molecular movement 
across the alveolar-capilary membrane in each direction, thus ensuring an 
appropriate fluid balance. Any disturbance to this finely-controled system can result 
in disequilibrium and consequently lead to pulmonary oedema. Indeed, injury to and 
activation of the pulmonary microvascular endothelium is a key step towards the 
development of increased permeability oedema in the acute phase of ARDS [22]. It 
is important to note that oedema formation is a consequence of increased 
permeability rather than hydrostatic forces, thus the content of oedema fluid difers 
from that seen in cardiogenic oedema, which has less protein content as indicated 
by a lower oedema fluid protein to plasma protein ratio, a tool validated for bedside 
use to diferentiate between the two aetiologies [42, 43]. 
Vascular endothelial (VE-) cadherin, an adherens junction protein, has been 
identified as one of the critical regulators of endothelial barier integrity in the lung 
microvasculature [44, 45]. VE-cadherin is a calcium-dependent cel–cel adhesion 
glycoprotein functioning as a classic cadherin controling the cohesion and 
organization of the intercelular junctions. Disruption of these VE-cadherin bonds 
destabilises vascular barier function [44, 46]. It is regulated by cytoplasmic 
associations with catenins and other cytoskeletal structures, and by 
phosphorylation/dephosphorylation on tyrosine residues of the cadherin-catenin 
complex. Phosphorylation of the complex leads to internalisation of VE-cadherin 
compromising barier function. In contrast, vascular endothelial receptor-type protein 
tyrosine phosphatase (VE-PTP) associated with VE-cadherin supports its adhesive 
function by maintaining a dephosphorylated state [47, 48]. It has been shown in in 
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vitro and in vivo studies that humoral factors, such as tumour necrosis factor alpha 
(TNF),  vascular  endothelial  growth factor (VEGF),  histamine, thrombin  and 
interaction with leukocytes can al interupt VE-cadherin bonds by inducing 
phosphorylation of the cadherin-catenin complex, which ultimately leads to 
pulmonary and extra-pulmonary oedema formation [49-51]. In contrast, prevention of 
dissociation of VE-PTP from VE-cadherin reduced lavage fluid protein and leukocyte 
content in LPS-treated mice [52]. 
Beside increased vascular permeability, inflammation is the other main 
halmark of ARDS, in which the pulmonary microvasculature is both a target and a 
mediator [22]. Once activated by inflammatory stimuli such as cytokines (TNF alpha, 
IL-1 beta) or bacterial products (lipopolysaccharide - LPS, lipoteichoic acid - LTA), 
pulmonary endothelial cels express chemotactic chemokines (e.g. interleukin (IL)-8) 
and adhesion molecules (e.g. E- and P-selectin, vascular cel and intercelular 
adhesion molecule (VCAM and ICAM)-1) to facilitate pulmonary entrapment and 
extravasation of circulating inflammatory leukocytes and propagate a systemic 
inflammatory response [35, 53, 54]. 
Several biological markers of endothelial cel injury and activation have been 
studied in patients with ARDS [55]. For instance, endothelin-1 is a molecule secreted 
by endothelial cels upon injury [56-58] that has both vasoconstrictor and pro-
inflammatory activities and is increased in the plasma of ARDS patients [59-61]. Von 
Wilebrand factor (vWF), secreted by the Weibel-Palade granules of endothelial cels 
[62], is also increased in the circulation during ARDS and is an independent predictor 
of mortality [63, 64]. 
 
Alveolar epithelial injury 
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Although injury to the pulmonary endothelium is a critical step in the pathogenesis 
this alone appears to be insuficient to develop the characteristic changes of the 
acute phase [65], and injury to the alveolar epithelium is also required [22, 40, 41, 
55]. Under normal conditions, the alveolar epithelium is predominantly composed of 
squamous, elongated type I cels that cover approximately 95% of the alveolar 
surface area and are prone to injury [66]. The thinness of the cels ensures rapid 
difusion of oxygen and carbon-dioxide across the alveolar epithelium. Type I cels 
may also play a role in vectorial fluid transport across the alveolar-capilary 
membrane, thus contributing to the maintenance of alveolar fluid balance, although 
this is less wel established compared to that in type I cels, which cover the rest of 
the alveolar surface [66]. Type I cels have a cuboidal shape and are more resistant 
to injury. Beside their role in alveolar fluid transport, type I cels are also the source 
of surfactant proteins, and are progenitors of type I cels [66]. 
  Under normal conditions, the epithelial barier is much tighter than the 
endothelial barier, thus loss of epithelial integrity significantly contributes to alveolar 
oedema [35]. A study in sheep indicated that over 92% of the resistance to albumin 
flux across the alveolar-capilary barrier lies in the epithelial barier [67]. This is 
maintained by cadherin-mediated adherens junctions (E-cadherin substitutes for VE-
cadherin) and tight junctions [66]. Inflammatory cytokines, bacterial products, 
proteases and oxidants can al lead to disruption of this system [22]. 
 Although leukocytes (and molecules as wel) can migrate passively through a 
quasi-physicaly damaged epithelial barier, there is evidence that alveolar epithelial 
cels (AECs) can actively control and assist this process, which may be relevant in 
the early stages of the syndrome when the alveolar epithelium may stil be physicaly 
intact. This is mediated, in part, by induced expression of chemotactic cytokines by 
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AECs, such as IL-8 (or its rodent functional homologues, macrophage inflammatory 
protein (MIP)-2 and keratinocyte-derived chemokine (KC)  and monocyte 
chemotactic protein (MCP)-1 [68-71], that wil lead to a build-up of chemokine 
gradient across the epithelial membrane and prompt neutrophils and monocytes to 
marginate to the lung microvasculature, extravasate and migrate to the alveolar 
space [68].  This later step is facilitated and mediated by induced epithelial 
expression of adhesion molecules, such as ICAM-1 [72, 73] and VCAM-1 [74] and 
the interaction with their counterpart ligands on leukocytes. Beside the role in 
neutrophil adherence, surface expressed ICAM-1 on epithelial cels also facilitates 
alveolar macrophage and neutrophil phagocytic activity [75, 76]. On the other hand, 
soluble form of ICAM-1 (sICAM-1) released by alveolar epithelial cels can activate 
alveolar macrophages and enhance their TNF and MIP-2 production, thus further 
increasing leukocyte accumulation in the lung and intensifying injury [77]. Moreover, 
sICAM-1 (which may have both endothelial and epithelial origin) is elevated in 
pulmonary oedema fluid and plasma of ARDS patients, the later of which is 
associated with poor outcome [78]. 
Neutrophils 
Histology on ARDS lungs indicate a marked accumulation of neutrophils [40, 41], 
and these cels also dominate in the pulmonary oedema and bronchoalveolar lavage 
fluid (BALF) obtained from these patients [55]. Also, several animal models of ARDS 
are neutrophil dependent [79-83].  
Leukocyte migration into the alveolar compartments involves several steps, 
which are regulated in part, by specific endothelial-leukocyte adhesion molecules 
[84]. This is diferent from that happening in the systemic circulation where the initial 
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interaction between circulating neutrophils and endothelium appears to be transient, 
resulting in the roling of leukocytes along the vessel wal in which selectins such as 
P- and E-selectin expressed on endothelial cels play a role [85]. The roling 
neutrophils then become activated by local factors generated by the endothelium, 
resulting in their arest and firm adhesion to the vessel wal. This step is mainly 
regulated by VCAM-1 and ICAM-1 and their counterpart ligands on neutrophils. 
Finaly, the neutrophils transmigrate through the endothelium [85]. 
In the lung, however, much of the leukocyte margination and transmigration 
takes place through pulmonary capilaries which are too narow to alow roling, and 
adhesion molecules appear not to mediate the initial events, but are important to 
keep leukocytes in the lungs [86]. Under normal conditions, neutrophils have to 
deform to pass through the pulmonary microvasculature [87]. The deformability of 
neutrophils however is adversely afected by the pro-inflammatory mediators 
released by the lung of ARDS patients, such as leukotriene B4, IL-8, C5a and 
endotoxin, which wil result in stifer neutrophils and entrapment in the pulmonary 
microvasculature [87-90]. IL-8 wil also prompt the entrapped neutrophils to leave the 
vasculature and enter the alveoli [91]. Neutrophils can migrate through the 
endothelium at the site of inter-endothelial junctions or alternatively using a trans-
celular route [92]. Cel-to-cel interactions between neutrophils and pulmonary 
endothelial cels as wel as the release of pro-inflammatory mediators by neutrophils 
induce cytoskeletal changes in the endothelial cels, resulting in a transient 
remodeling of intercelular junctions, alowing easier penetration through the 
endothelium [93-95].         
 Once retained and activated in the lung parenchyma, leukocytes can release 
products that wil ultimately lead to further damage to the alveolar-capilary barier 
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and propagate lung injury. These include proteolytic enzymes, oxidative radicals, 
cytokines and diferent growth factors [96]. Elastase, the predominant protease 
released by neutrophils in ARDS, wil cause damage to the alveolar-capilary 
membrane by destruction of the extracelular matrix and induce apoptosis in alveolar 
epithelial cels, thus facilitating further migration of neutrophils from the 
microvasculature to the alveolar space [55, 97]. Elastase was found to be elevated 
both in plasma and bronchoalveolar lavage fluid from patients who are at risk for or 
already have established ARDS [98, 99]. Other neutrophil derived proteases, such 
as gelatinases and colagenase are also elevated in the bronchoalveolar lavage fluid 
of ARDS patients [100-104]. 
Monocytes 
Although recruitment of neutrophils to the lung is a key event in the development of 
ALI/ARDS [22], and studies investigating the role of leukocytes in ARDS 
pathogenesis predominantly focused on these cels [105-110], ARDS can also 
develop in neutropenic patients [111, 112], suggesting that other leukocyte subsets 
might be also important in the pathogenesis. Indeed, there is accumulating evidence 
from our group and others, that monocytes may also play an important role [113-
119]. While it can be argued that neutropenic patients are often monocytopenic as 
wel, at least in the aforementioned study by Sivan et al. 10 out of 26 neutropenic 
patients had moderate infiltration of monocytes on post-mortem lung histology [111]. 
Moreover, these observations only underline the importance of neutrophil 
independent mechanisms (both celular and humoral) in ARDS pathogenesis. 
Monocytes are a pluripotent, heterogeneous population of cels of the 
mononuclear phagocytic system. Upon activation, they can release a variety of 
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inflammatory mediators, including TNF. These cels exist in two phenotypicaly 
distinct subsets based on their expression of Gr-1 (specificaly the Ly6C epitope) in 
mice and CD14 and CD16 in humans [120, 121]. Immature monocytes - defined in 
mice as Gr-1high and CD14high/CD16- in humans - enter the circulation from the bone 
marow and migrate to the site of inflammation and injury [120, 122, 123], and hence 
are caled the inflammatory subset. During maturation of monocytes there is a 
change to less inflammatory phenotype – Gr-1low and CD14low/CD16high in mice and 
humans, respectively - [124] and these cels diferentiate into tissue resident 
macrophages and dendritic cels [120, 125]. 
O’Dea et al. have  shown in  mice that inflammatory  Gr-1high monocytes 
marginate to the lung during early endotoxaemia and by promoting pulmonary 
endothelium activation contribute to the progression of ALI [115]. This was found to 
be mediated by TNF, expressed on these lung-marginated inflammatory monocytes. 
Furthermore, Wilson and co-workers have also demonstrated in a mouse two-hit 
LPS/VILI model that recruitment of inflammatory monocytes exacerbated lung injury 
[116]. In a more recent study in mice, Dhaliwal and co-workers demonstrated that 
monocytes play an important role in the second-phase neutrophil emigration in 
established acute lung injury, thus contribute to injury development [118].  On the 
contrary, D’Alessio et al showed in a model of LPS-induced lung injury, that 
monocytes are important regulators of injury resolution but did not investigate the 
individual role of monocyte subsets [117]. 
These findings indicate that monocytes are also important in the pathogenesis 
of ARDS, and more investigation should be dedicated to them in the future in order 
to beter understand the inflammatory mechanisms underlying ALI. 
Platelets 
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There is piling evidence suggesting that platelets also play a significant role in the 
pathogenesis of acute respiratory distress syndrome [110, 126, 127]. In sepsis, 
platelets rol along and firmly adhere to capilary endothelial cels in the pulmonary 
circulation that is mainly mediated by platelet P-selectin and an unknown counter-
receptor on the endothelium [126]. This adherence mediated activation of platelets 
results in subsequent release of chemokines and lipid mediators, which then either 
activate atached leukocytes or induce further activation of endothelial cels by 
releasing pro-inflammatory mediators [110]. Platelet activation is associated with 
increased expression of P-selectin [128], which mediates further capturing of freely 
roling neutrophils in the pulmonary capilaries. The physical interaction between 
these two cel types leads to a reciprocal activation and results in the release of 
thromboxane A2 [110], which then further activates endothelial cels and induces the 
expression of adhesion molecules, polymerisation of actin, and contraction, which 
ultimately results in vascular leak and pulmonary oedema formation [110]. When this 
interaction is prevented by elimination or blockade of platelet P-selectin, pulmonary 
margination of neutrophils is significantly reduced and mice are protected from acid-
induced lung injury [110]. 
 On the other hand, platelets are an important source of sphingosine-1 
phosphate (S1P), a lipid mediator that has been shown to play an important role in 
regulating  inter-endothelial  cel  junctions  and  consequently  in  the  
maintenance/restoration of vascular integrity [129, 130]. 
Alveolar macrophages 
Alveolar macrophages (AMs) are members of the mononuclear phagocyte system 
(MPS), along with monocytes. AMs are present in the alveoli and alveolar ducts and 
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serve as the first line of defence in the lungs [131]. They actively phagocytise and kil 
invading airborne and blood-borne pathogens and regulate the inflammatory 
reactions in the lungs [132-135]. In order to induce and potentiate the inflammatory 
and immune processes, AMs release cytokines (TNF, IL-1 and -6, IFN-gamma), 
chemokines (CXC chemokines such as IL-8 or its rodent homologue MIP-2 and KC, 
CC chemokines such as MCP-1, MIP-1alpha and beta) and prostaglandin-E2 during 
the initial phase of lung inflammation [135-137]. The cytokines TNF and IL-1 wil 
induce expression of adhesion molecules (such as E-selectin, VCAM-1 and ICAM-1) 
on both endothelial and epithelial cels to facilitate migration of leukocytes across the 
alveolar-capilary membrane [135]. Up-regulated ICAM-1 on alveolar epithelial cels 
wil enhance the adhesiveness of alveolar macrophages that subsequently results in 
intensified production of cytokines and chemokines and enhanced phagocytic 
function [75, 76, 135]. Release of IL-6 by AMs also facilitates the secretion of 
inflammatory mediators by alveolar epithelial and pulmonary endothelial cels [135]. 
Production of IL-8 (or MIP-2 and KC in rodents) atracts neutrophils to the lung 
parenchyma and alveolar space, MCP-1 enhances lung margination of monocytes 
and neutrophils, whereas MIP-1 alpha and beta wil further intensify the production of 
CXC chemokines by macrophages in an autocrine manner [135]. 
There is large amount of evidence to suggest that AMs play a pivotal role in 
regulating the pro- and anti-inflammatory events during sepsis-related ARDS [138, 
139]. It has been suggested that, neutrophils recruited to the alveolar space by AM-
induced or derived chemokines stimulate the release of IL-10 from the AMs [140-
143], a powerful suppressor of the NF-kappaB (NFkB) inflammatory pathway. Thus, 
whilst AMs play an important role in initiating the inflammatory response in the early 
stage of ARDS, they also counteract at later stages during the pathogenesis by 
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triggering an anti-inflammatory response. This temporal dichotomy is perhaps 
demonstrated by depletion studies. For example, in more acute animal models of 
ARDS, such as ventilator-induced lung injury [144, 145] and lung ischaemia-
reperfusion injury [146] depletion of AMs by clodronate-liposomes ameliorates injury, 
while in more chronic models, such as polymicrobial sepsis [147] and intra-alveolar 
activation of the Fas/FasL pathway by agonist antibodies [148] lung injury is 
intensified. On the other hand, it is also possible that this diferential efect of AM 
depletion is more related to other model diferences.  
Surfactant dysfunction  
Pulmonary surfactant is important in maintaining lung homeostasis because of its 
role in reducing work of breathing by decreasing surface tension in the alveoli, and in 
host defence [149, 150]. It is composed of phospholipids (80%), cholesterol (10%) 
and four surfactant-associated proteins, namely SP-A, B, C and D.   The 
components of surfactant mainly responsible for its biophysical properties are 
dipalmitoyl-phosphatidyl-choline (DPPC) and SP-B and –C [151], whereas  SP-A 
and –D play a major role in host defence [152-154], although SP-A can also reverse 
the inhibitory efect of blood-borne proteins (fibrinogen and albumin) on the surface 
activity of surfactant in vitro [155]. 
 Surfactant is synthesised by type I AECs and exocytosed in lamelar bodies 
into the alveoli, which then solve to form tubular myelin-like structures [156-158] that 
adsorb to the air-liquid interface [159, 160]. These lamelar bodies and myelin-like 
structures give the denser subfraction of surfactant obtained by lung lavage, and are 
so caled large aggregates (LAs) [161, 162]. They reduce surface tension to levels 
that wil prevent alveolar colapse during exhalation, and thus decrease breathing 
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efort during inhalation [163, 164], and wil also prevent alveolar flooding due to 
hydrostatic forces. Secondary to the repeated expansion and surface contraction 
that comes with respiration, this fine surfactant film continuously breaks up into smal 
vesicles which are then endocytosed by type I alveolar epithelial cels, where they 
are recycled for the synthesis of new surfactant, or by alveolar macrophages in 
which case they are permanently removed from the air spaces [165-167]. These 
vesicular structures form the less dense fraction of the lavaged surfactant caled 
smal aggregates (SAs). As opposed to the LAs, these do not contain al the proteins 
and lipids required to reduce surface tension [163, 164]. Within the normal lung, the 
ratio of LA:SA is consistent and maintained by a dynamic process of on-going 
secretion of LAs, conversion of LAs into SAs during respiration, and the clearance 
and/or recycling of SAs by AMs and type I AECs, respectively [165, 168]. 
 The physiological features observed in ARDS, such as hypoxaemia and 
decreased compliance are both consequences of a dysfunctional surfactant system 
[150]. Changes in the surfactant obtained from ARDS patients include an imbalance 
of the diferent phospholipids and decreased levels of surfactant-associated proteins 
[36, 169]. These changes are, in part, a result of the damage to the type I AECs and 
their metabolic dysfunction, as wel as of the increased alveolar permeability leading 
to accumulation of proteins [170, 171], enzymes (e.g. proteases, phospholipases) 
[172-178] and oxidants (ROS, RNS) [179-182] that either biophysicaly or chemicaly 
inhibit surfactant function. Decreased synthesis of LAs by dysfunctional type I AECs 
and increased conversion of LAs into SAs triggered by mechanical ventilation [183-
187] wil result in a proportionaly lower amount of functional LAs relative to non-
functional SAs [188, 189], which ultimately leads to alveolar instability. While the role 
of surfactant in host defence is wel established in vitro and in animal models, it 
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remains unknown how these alterations afect the immune response and 
susceptibility to further insult in ARDS patients. 
Inflammatory cytokines/chemokines 
A dysregulated inflammatory response is central to the pathogenesis of acute lung 
injury. Activation of the inflammatory cascade starts with recognition of microbial 
products (so caled pathogen-associated molecular paterns [PAMPs], e.g. 
lipoteichoic acid [LTA], LPS, flagelin, double-stranded RNA [dsRNA]) and/or cel 
injury-associated molecules (so caled danger-associated molecular paterns 
[DAMPs], e.g. heat-shock proteins, high-mobility group box 1 [HMGB1], hyaluronan, 
oxidised phospholipids, DNA) by patern recognition receptors (PRR) expressed on 
pulmonary cels (such as AECs, AMs, pulmonary endothelial cels [PECs], dendritic 
cels) [190]. Tol-like receptors (TLRs) are the most wel-known members of PRR, 
whereas others include the cytosolic NOD-like receptors (NLRs),  RIG-I–like 
receptors (RLRs), and DNA sensors [190]. These receptors have a close 
downstream link with the inflammatory transcription factor NFkB and interferon 
regulatory factor (IRF). Upon ligand binding, these transcription factors become 
activated leading to the production of inflammatory cytokines TNF, IL-1 beta, IL-6, 
IFN-beta and chemokine IL-8, predominantly by AMs [190]. IFN-beta enhances the 
production of antimicrobial peptides by AMs and AECs in an autocrine and paracrine 
fashion, respectively, whereas TNF and IL-1 beta wil trigger the release of other CC 
(e.g. MCP-1, MIP-1 alpha and beta) and CXC chemokines (e.g. KC, MIP-2) by AECs 
and PECs. These chemokines are then retained localy by matrix heparan sulphate 
proteoglycans establishing a chemokine gradient which wil result in the recruitment 
of neutrophils and monocytes to the lung microvasculature and alveolar space [190]. 
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These recruited cels then cause further activation of the local pulmonary cels 
amplifying the inflammatory response.  
However, as the inflammatory response progresses, several endogenous 
anti-inflammatory mediators are also released. For example, IL-10 (also known as 
human cytokine synthesis inhibitory factor [CSIF]), IL-11 and IL-13, predominantly 
expressed by monocytes/macrophages and T-cels, can suppress NFkB by inhibiting 
the hydrolysis of IkB-alpha, thus preventing NFkB to translocate to the nucleus and 
initiate transcription of pro-inflammatory mediators [191-193]. Exogenous 
administration of these substances in animal models of acute lung injury atenuated 
injury and improved survival [194-197]. Expression of autoantibodies against IL-8 
neutralises the chemotactic efect of IL-8 [198] and levels of IL-8:anti-IL-8 
autoantibody complexes in the BALF beter predict clinical outcome of ARDS than 
IL-8 levels alone [199]. Level of IL-1 receptor antagonist (IL-1Ra), the natural 
antagonist to IL-1 beta, is also elevated in the BALF of patients with ARDS, and may 
play an important role in the resolution of the fibroproliferative process of ARDS (see 
below) [200]. Soluble receptors of TNF are also present in the alveolar space of 
ARDS and may dampen the inflammatory response by preventing TNF binding to its 
membrane receptors [22]. Therefore in summary one can say that the balance 
between these pro- and anti-inflammatory mediators may be more important in 
determining the overal inflammatory response and the clinical outcome of ALI/ARDS 
than the absolute levels of one or several specific pro-inflammatory cytokines [201]. 
The detailed involvement of al cytokines/chemokines is beyond the scope of this 
study, but the actions of TNF wil be explored in more detail in a separate section. 
Oxidative injury and redox imbalance  
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There is mounting evidence in the literature that reactive oxygen and nitrogen 
species (ROS and RNS, respectively) are key modulators in the pathogenesis of 
ARDS, particularly in mediating pulmonary endothelial cel dysfunction [202-205]. For 
example, patients with ARDS have increased levels of hydrogen peroxide (H2O2) in 
their exhaled breath condensate (EBC) [202], myeloperoxidase (MPO) and oxidised 
alpha1-antitrypsin in their BALF [204], and show increased plasma lipid peroxidation 
[203, 205]. 
 The majority of ROS during the development of ARDS is generated by the 
inflammatory response, primarily by neutrophils and monocytes/macrophages [35]. 
In response to the appropriate stimuli (e.g. LPS, TNF, IL-1, platelet activating factor 
[PAF]), these cels release large amounts of  superoxide  anion (•O2-) produced by 
xanthine oxidase (XO) and nicotinamide adenine dinucleotide phosphate (NADPH)-
oxidase. In  addition to •O2-, XO can also produce H2O2 [206]. Superoxide is 
dismutated by superoxide dismutase (SOD) forming H2O2 which plays a central role 
in bacterial kiling [207]. 
 Nitric oxide (NO) is a free radical and signaling molecule with multiple 
physiological efects. It is synthesised from L-arginine by the enzyme nitric oxide 
synthase (NOS). There are three NOS isozymes: neuronal NOS (nNOS or NOS-1), 
cytokine-inducible NOS (iNOS or NOS-2) and endothelial NOS (eNOS or NOS-3). 
The main sources of NO in the lung are iNOS and eNOS. While eNOS is 
constitutively active in pulmonary endothelial cels and produces a moderate amount 
of NO that is mainly involved in regulating vascular functions, iNOS which is mainly 
expressed by AMs, PMNs and type I AECs, is only activated by diferent 
inflammatory cytokines (e.g. TNF) and has a high output providing an opportunity for 
NO to react  with •O2- leading to the production of peroxynitrite (ONOO-). ONOO- is 
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also a highly active radical that can cause DNA and protein damage leading to 
apoptosis and cel necrosis. Patients who died from ARDS show markers of 
peroxynitrite formation in their lungs [208]. 
 In addition to the inflammatory response, the therapeutic administration of 
oxygen to patients with ARDS may also increase the production of ROS and 
exacerbate the injury [209-212]. However, it is not only the excess production of free 
radicals but the deprivation of the endogenous antioxidant systems and the resultant 
imbalance of the pulmonary redox state that leads to lung injury [206]. 
Thiols are an important group of antioxidants, among which glutathione (GSH) 
is  one  of the  most important.  GSH  exerts its  antioxidant  efect  by  1)  directly 
scavenging free radicals, 2) regenerating the active (reduced) forms of Vitamins C 
and E, 3) maintaining critical protein thiols, and 4) acting as a co-factor for the 
detoxifying enzymes glutathione-peroxidase (GPX)  and  glutathione-S-transferase 
(GST) [213].  To  undertake these functions,  GSH  needs to  be in its reduced form, 
which depends on the activity of glutathione reductase. However, the activity of this 
enzyme can reduce in oxidative stress such as that occurs in ARDS patients, who 
therefore have 500,000-fold less plasma thiols than controls [214], and their  GSH 
level both in plasma and BALF is also depleted [215, 216]. 
ROS/RNS can activate transcription factor NFkB  via p38 and ERK MAPKs 
[217], but also the activator protein (AP)-1 family, which leads to production of 
inflammatory proteins, AEC apoptosis and increased vascular and epithelial 
permeability in the lung [218, 219]. It has been also demonstrated, that IL-1-beta and 
TNF-induced activation of hypoxia-inducible factor (HIF)-1-alpha, the transcription 
factor that regulates the production of VEGF and iNOS, is mediated by induction of 
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intracelular ROS. This is quite important as both VEGF and increased iNOS activity 
is associated with endothelial barier dysfunction in the lung [220, 221]. 
In summary, excess production of free radicals in conjunction with a depleted 
antioxidant system favours a pro-oxidant state in the lung which ultimately leads to 
injury by diferent mechanisms, including direct cel injury and activation of signaling 
pathways involved in inflammation and apoptosis.  
Coagulation pathway 
Intra-alveolar fibrin deposition is a histological halmark of ARDS resulting in 
abnormalities in gas exchange [41]. Besides its efects on gas exchange, activation 
of the coagulation pathway is also closely linked with the inflammatory response 
seen in sepsis and ARDS [38]. Firstly, activation of the coagulation pathway through 
tissue factor (TF) leads to thrombin formation on the endothelial surface, which then 
activates inflammatory leukocytes by binding to their protease-activated receptors 
(PARs) with a subsequent up-regulation of inflammatory mediator production and 
release [222]. Secondly, inflammatory mediators produced during the pathogenesis 
of sepsis/ALI/ARDS can induce TF expression and down-regulate its natural 
inhibitors protein C and S, which eventualy results in thrombin formation and 
deposition of fibrin [223]. 
TF is the most potent initiator of the coagulation pathway.  Tissue factor 
pathway inhibitor (TFPI) expressed by endothelial cels is the endogenous inhibitor of 
TF, and can be found in the plasma and on the surface of platelets [224]. The 
balance between TF and TFPI wil determine the degree of TF-initiated coagulation. 
Several cel types in the lung can produce TF, including AMs [225], AECs [226, 227] 
and PECs, and its production is up-regulated in response to pro-inflammatory 
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cytokines (IL-1beta, TNF and IFN-gamma) in vitro [228], and in animal models of 
direct [229, 230] and indirect [231] lung injury that is in part mediated by the NFkB 
pathway [232]. In the clinical seting, patients who are at risk for ARDS and those 
with established syndrome have increased TF-dependent pro-coagulant activity in 
the alveolar compartment compared to healthy controls regardless of the aetiology 
[229, 233, 234], indicating the importance of TF in the pathogenesis of ALI/ARDS. 
Protein C (PC) is one of the most important regulators of the coagulation 
pathway. When PC encounters the thrombomodulin (TM)-thrombin complex on the 
cel surface, it is transformed into its activated form (APC) [235]. Once activated, 
APC suppresses further generation of thrombin by proteolytic inactivation of 
coagulation factors Va and VIIa [236, 237]. Activation of PC is further amplified 
when it binds to the endothelial cel PC receptor (EPCR) [238]. APC also plays an 
important role in regulating the inflammatory response during sepsis/ALI. In vitro, 
APC supresses TNF production by monocytes through inhibition of the NFkB-
pathway [239, 240], and inhibits neutrophil activation and leukocyte chemotaxis in 
vivo [241, 242]. Patients with sepsis or ALI/ARDS have reduced PC levels and ability 
to produce APC that is associated with ventilator dependency, higher prevalence of 
ARDS and increased mortality [243-245]. 
In ALI/ARDS there is a shift toward a pro-coagulant state, where up-regulation 
of TF and down-regulation of APC is accompanied by inhibition of fibrinolysis by an 
increased activity of the plasminogen activator inhibitor (PAI-1) system. Plasminogen 
activator (PA) and PAI-1 are the most important regulators of fibrinolysis. During 
sepsis there is an initial up-regulation of fibrinolytic activity, shortly after folowed by a 
prolonged increase in circulating PAI-1 [246] favouring the persistence of fibrin and 
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microvascular thrombosis, leading to organ ischaemia and dysfunction that is 
associated with higher mortality [247]. 
Similarly to the TF and PC pathways, PAI-1 has been also linked with 
inflammation. For example, TNF has been shown to induce PAI-1 expression by 
endothelial cels in vitro, through activation of the NFkB pathway [248]. On the 
contrary, blockade of TNF by monoclonal antibodies did not atenuate the increase in 
PAI-1 levels in a rabbit model of endotoxaemia, suggesting that other mechanisms 
are also likely to be involved [249]. Also, human AMs exposed to endotoxin convert 
to an anti-fibrinolytic phenotype and increase PAI-1 activity, and AMs in lung biopsy 
from ARDS patients also exhibit increased expression of PAI-1 [250]. There is also a 
change in the haemostatic phenotype of pulmonary microvascular endothelial cels 
(PECs) [251]. PECs isolated from ARDS patients express constitutively more PAI-1 
than controls and have lower fibrinolytic activity as expressed by tPA:PAI-1 ratio 
[251]. Patients with ARDS have increased levels of PAI-1 in their pulmonary oedema 
fluid as wel as in their circulation and demonstrate reduced fibrinolytic activity [234, 
252-254] associated with higher mortality [244]. Nevertheless, it is important to 
realise that this anti-fibrinolytic profile in sepsis and ARDS may play an important 
role in detaining infection. 
Fibrosing alveolitis 
After the initial exudative phase of ALI/ARDS, some patients display an 
uncomplicated course with rapid resolution [22]. Others, however, develop 
pulmonary fibrosis observed as soon as 5 to 7 days after the onset of ALI/ARDS [22, 
40, 41]. This process is considered to be a result of a maladaptive reparative 
response to injury, characterised by proliferation of myofibroblasts and fibroblasts, 
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prolonged  presence  of  interstitial  inflammatory  leukocytes,  pronounced  
vascularisation and deposition of connective tissue in the alveolar space [35]. 
Fibrosing alveolitis is associated with increased risk of death [255], and those dying 
from ARDS have increased lung content of colagen type I and II as wel as 
fibronectin [256]. It is thought that the molecular mechanisms that wil determine 
whether a patient develops fibrosing alveolitis or not may be set early in the course 
of ARDS, and likely reflects the severity of the initial lung injury. For example, 
alveolar levels of pro-colagen II can be elevated even at the time of diagnosis and 
are associated with increased mortality [257-259]. Pro-inflammatory cytokines, such 
as IL-1 may be important in promoting the initiation of fibrogenesis [260]. For 
instance, lavage fluid from patients with early ARDS is mitogenic for human 
fibroblasts in vitro, which is dependent on active IL-1 [261, 262]. 
Resolution of lung injury 
Resolution of lung injury happens in phases which may overlap in time and depends 
on several humoral and celular factors. To start with, intrapulmonary inflammation 
must cease for a successful resolution process. This involves scavenging of the 
chemotactic cytokines/chemokines [263, 264], so that recruitment of neutrophils to 
the lung parenchyma can be halted. Then the neutrophils already present in the lung 
have to go through apoptosis [265] and be cleared via phagocytosis by resident and 
recruited macrophages [119, 266]. It has been recently demonstrated that a specific 
subtype of regulatory T-cels (Treg lymphocytes) also appears in the alveolar space 
in gradualy increasing numbers peaking around 10 days from the onset of lung 
injury [267, 268],  and  play  an important role in the resolution  phase through  TGF-
beta mediated mechanisms [267]. 
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At the same time, to restore the adequate gas exchange, pulmonary oedema 
must resolve. This is driven by vectorial transport of sodium and chloride from the 
alveoli to the lung interstitium, creating an osmotic gradient, which prompts water to 
folow passively through transcelular water channels, the aquaporins (AQ), 
predominantly AQ5 expressed on type I cels [66]. From the interstitium, oedema 
fluid is then removed by the lymphatic circulation. Sodium is transported 
basolateraly by sodium-potassium ATPase (NaKATPase), which exchanges 3 
intracelular Na+ for 2 extracelular K+ in an energy consuming process that generates 
a gradient alowing sodium transport across the apical sodium channels, such as the 
amiloride-sensitive epithelial sodium channel (ENaC) and other amiloride-insensitive 
sodium channels (e.g. cyclic nucleotide-gated cation channels (CNG) [66]. Chloride 
is transported by trans- and paracelular pathways. The rate of alveolar fluid 
clearance increases substantialy in the presence of cAMP, which enhances the 
expression and activity of ENaC and NaKATPase and the opening of the cystic 
fibrosis conductance regulator (CFTR) on the apical surface to facilitate chloride 
uptake [66]. In addition to water, soluble and insoluble protein must also be removed 
from the alveolar space. Insoluble proteins are predominantly removed by 
endocytosis and transcytosis by AECs and phagocytosis by AMs, whereas soluble 
proteins are removed primarily by difusion between AECs [269]. Patients with intact 
alveolar fluid clearance require shorter period of mechanical ventilation, have 
improved oxygenation and a beter survival rate [270]. 
In order to achieve a net fluid clearance, the alveolar epithelial barier also 
needs to be restored. Re-epithelialisation of the epithelial surface is accomplished by 
diferentiation of type I epithelial cels into type I cels, which is facilitated by growth 
factors, such as keratinocyte growth factor (KGF) and hepatocyte growth factor [271, 
40 
272]. Recent evidence indicates that bronchoalveolar and bone marow-derived 
stem cels also contribute to epithelial repair [273-276]. Bone marow-derived stem 
cels are likely recruited by stromal-derived factor-1 and other chemokines and 
cytokines (e.g. IL-8, TNF, macrophage inhibitory factor (MIF), TGF-beta) released by 
the injured lung, as they express the relevant receptors for these factors [277-281]. 
The migration of bone marow-derived endothelial progenitor cels to the injured lung 
is mediated by CXCL1 and 2 chemokines [282], and increased number of these cels 
in the circulation of patients with ALI/ARDS is apparently associated with improved 
survival [273]. 
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1.2 Mechanical ventilation and Ventilator-Induced Lung Injury 
Patients who develop ALI/ARDS - of any aetiology – require positive pressure 
ventilation in order to maintain appropriate gas exchange. However there is 
accumulating evidence that mechanical ventilation has its own deleterious efects, 
and can cause high-stretch related injury also known as ventilator induced lung injury 
(VILI)[283]. 
Although it has been recognised clinicaly for many decades that ventilation 
with high airway pressures can cause alveolar rupture and air leak into the 
surounding  tissues,  leading  to  pneumothorax,  pneumomediastinum,  
pneumopericardium, subcutaneous emphysema and air emboli [284, 285], the 
concept of VILI mainly originates from animal models, where more subtle lung injury 
(i.e. without alveolar air leak) can be induced by overdistention of healthy lung units 
using high inspiratory pressures. The first example of this is the seminal study by 
Webb and Tierney which showed that rats ventilated with a PIP of 45cmH2O (without 
PEEP) developed more severe and more rapid pulmonary oedema than those 
ventilated with a PIP of 30cmH2O, whereas ventilation with a PIP of 14cmH2O for 1 
hour caused no histological changes in the lungs [286]. Similar findings were later 
observed in rabbits [287], sheep [288] and dogs [289]. 
VILI models show the same pathophysiological features as clinical ARDS, 
such as pulmonary oedema, epithelial damage and hyaline membrane formation 
[290], making VILI indistinguishable from ARDS in the clinical seting. Mechanical 
ventilation, through VILI can exacerbate the existing injury, and generate a vicious 
cycle of inflammatory mechanisms that eventualy leads to systemic inflammatory 
response syndrome (SIRS) and multi-organ failure (MOF)[291]. 
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 VILI and the associated injuries are not solely due to excessive lung inflation, 
but a combination of insults with various mechanisms, namely: volutrauma, 
atelectrauma and biotrauma. These mechanisms now wil be discussed. 
Volutrauma 
In early animal studies of VILI, it was suggested that injury occurs in response to 
high airway pressures, it was relatively soon realised that it is the associated 
overdistention of the lung rather than the pressure per se that drives pulmonary 
oedema formation. This was elegantly demonstrated in a study by Dreyfuss et al. 
who compared the efects of low and high VT ventilation in the presence of high and 
low peak airway pressures in rats [292]. Low VT–high PIP ventilation was achieved 
by thoraco-abdominal strapping of the animals, whereas high VT–low PIP ventilation 
was accomplished by using an iron lung. The authors concluded that it was the 
excessive VT and the resultant end-inspiratory lung volume and overdistention that 
caused pulmonary oedema, rather than excessively high inspiratory pressure per se, 
which led to the term volutrauma as opposed to barotrauma [293, 294]. These 
findings were also confirmed in rabbits and lambs using similar protocols [295, 296]. 
 Subsequent animal studies evaluated the efect of mechanical ventilation with 
overdistention on pre-injured lungs to resemble the clinical situation, particularly 
because VILI occurs less readily in ventilated patients with healthy lungs [297, 298]. 
In perfused rabbit lung models a combination of oleic acid pre-injury with relatively 
high tidal volume has been shown in a variety of studies to result in increased 
capilary filtration co-eficient and wet:dry weight ratio, whereas the two insults 
individualy did not [299, 300]. One of these groups also demonstrated that 
inactivation of surfactant by dioctyl-succinate enhanced the increase in capilary 
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filtration co-eficient caused by high-stretch ventilation [301]. Dreyfuss et al. 
demonstrated the synergistic efect of pre-existing lung injury and high-stretch 
ventilation in an in vivo rat model where lungs were damaged with alpha-
naphtylthiourea and ventilated with high VT (45ml/kg) [302]. The combination of the 
two insults resulted in more severe permeability oedema than that predicted by 
summing up their individual efects, indicating synergism.  
 One mechanism by which increased permeability occurs in high-stretch 
ventilation is the mechanical injury caused to the pulmonary endothelial and 
epithelial cels by excessive stretching forces, so caled stress-failure. During 
mechanical ventilation an internal tension develops in the alveolar structure with 
each inspiration that is equal to the transpulmonary pressure (airway pressure minus 
pleural pressure) and is also caled stress [303]. This stress is associated with 
elongation of the fibres of the extracelular matrix as wel as the cels (i.e. endothelial 
and epithelial) of the alveoli anchored to it, and this is caled strain. If stress exceeds 
the elastic properties of this structure it results in stress-failure. Fu et al. 
demonstrated in rabbit lungs that an increase in transpulmonary pressure from 5 to 
20cmH2O resulted in a significant increase in endothelial and epithelial ruptures 
[304]. This observation points out that while high peak inspiratory pressure per se 
may not be an important determinant of pulmonary oedema (see study by Dreyfuss 
et al. above), transpulmonary pressure (stress) is, and it is equaly important to 
volume (strain). 
 Beside the mechanical injury, high-stretch ventilation can also activate celular 
mechanisms (a concept often refered to as mechanotransduction) that may result in 
increased pulmonary permeability. For example, Parker et al. demonstrated in 
isolated perfused rat lungs that blockade of stretch-activated cation channels with 
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gadolinium administered to the perfusate prevented high-stretch induced increase in 
microvascular permeability [305]. Their findings suggested that increased 
microvascular permeability was mediated by active celular mechanisms dependent 
on intracelular calcium as opposed to passive mechanical injury to the alveolar-
capilary barier. Other active mechanisms, such as p38 MAPK-mediated alveolar 
cel apoptosis and actin polymerisation were also demonstrated to mediate alveolar-
capilary barier dysfunction associated with VILI [306, 307]. Several plasma 
membrane-associated molecules have been identified to sense mechanical stress 
(hence caled mechanoreceptors), including adhesion molecules, cytoskeleton and 
associated proteins and mechanosensitive ion channels, al of which can activate 
downstream signaling pathways [308]. 
Atelectrauma – Injury at low lung volumes 
In addition to volutrauma at high lung volumes there is great amount of evidence that 
lung injury can also occur during ventilation at low lung volumes (meaning low 
absolute lung volumes not low tidal volumes). This injury is thought to be related to 
the repetitive opening-closing of colapsed distal lung units. It is important to note 
that in a healthy lung, alveoli do not colapse at the end of expiration due to the low 
surface tension maintained by the surfactant lining and the physiological PEEP. In 
ARDS, however, because of surfactant dysfunction secondary to the interaction with 
pulmonary oedema fluid and the efects of mechanical ventilation (i.e. increased 
breakdown, impaired de novo synthesis), lungs are more susceptible to develop 
atelectasis. Once the airways colapsed, the amount of force required to reopen 
them is enormous and inversely proportional to their diameter, i.e. the more distal the 
airway the more force (pressure) is needed. Another aspect to this is that in normal 
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lungs, adjacent alveoli (except the ones adjacent to the pleura) are always 
surounded by other alveoli, and the forces exerted on one lung unit are transmited 
to those around it [309]. This support is caled interdependence, and helps to 
maintain the homogeneity of the lung. However, this also implies that if an alveolus 
colapses, the forces applied to its wals by the surounding open alveoli wil be 
greatly increased in order to help re-expansion. It has been calculated that at a 
transpulmonary pressure of 30cmH2O, re-expansion pressures can reach as high as 
140cmH2O, which results in a potentialy injurious stress at the interface of colapsed 
and expanded groups of alveoli [310]. Indeed, it has been shown in autopsies from 
ARDS patients that pseudocysts and cavities were predominantly around atelectatic 
areas [311]. Therefore, the repetitive opening and closing of smal airways leads to 
excessive shear-stress and subsequent injury to lung units, particularly if present in 
each breath [312]. 
 The main approach to minimise the deleterious efect of atelectrauma is by 
the application of PEEP. Webb and Tierney were the first to show that alveolar 
oedema was reduced by applying 10cmH2O of PEEP during ventilation of rats with 
45cmH2O PIP [286]. This was later replicated by  Dreyfuss et al., who also 
demonstrated that this positive efect of PEEP was associated with preservation of 
the alveolar epithelium [292]. 
While PEEP increases the end-expiratory volume and keeps lung units open, 
if the tidal volume applied is the same, PEEP wil also increase end-inspiratory 
volume thus favouring overdistention. Conversely, if application of PEEP is 
accompanied by reduction of VT and end-inspiratory volume is kept constant, 
oedema formation is reduced [313], as demonstrated by the studies of Webb and 
Tierney, and Dreyfuss et al. Therefore seting the right level of PEEP is very 
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important to avoid overdistension of lung units, in which the pressure/volume (P/V) 
curve can be helpful.  
The P/V curve has two characteristic points, namely the lower and upper 
inflection points (LIP and UIP, respectively). The LIP represents the recruitment 
pressure and lung volume at which lung units start to re-open and lung expansion 
rapidly begins, which is then folowed by linear increases in volume with increasing 
pressures until the UIP is reached, where the lung is near maximum capacity 
determined by elastic properties of its fibrous structure [312, 314, 315]. Beyond this 
point, however, no further recruitment occurs and lung units are endangered to over-
distension. Therefore in an ideal ventilation strategy tidal ventilation would take place 
on the steep portion of the static P/V curve, between the LIP and UIP [315, 316]. 
This may be achieved by seting the PEEP above the LIP, which should keep the 
alveoli open at end-expiration thus prevent repeated opening and closing and the 
associated shear stress in distal airways. This approach of seting PEEP is central to 
the protective, ‘open-lung’ ventilation strategy [317], which wil be discussed in more 
detail later under ‘Therapeutic approaches to Acute Lung Injury’. 
Biotrauma and Multiple System Organ Failure (MSOF) 
Beside some of the detrimental efects on respiratory physiology, mechanical 
stresses associated with ventilation can also initiate celular and molecular 
mechanisms that lead to an inflammatory response, termed biotrauma [318]. An 
increasing body of evidence from both experimental and clinical studies indicates 
that the degree of inflammation depends on the mode of mechanical ventilation [319-
322]. It has been also suggested that the inflammatory response is not limited to the 
lung but may also trigger and propagate a systemic inflammatory response, 
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contributing to MSOF [291], the major cause of death in this patient population [323-
326]. Therefore, understanding how mechanical ventilation influences these celular 
and molecular processes is crucial, as they may represent potential therapeutic 
targets in the batle against ARDS-associated mortality.  
 Most of the celular and humoral factors involved in the inflammatory response 
associated with ARDS have been already discussed earlier, but here we wil focus 
on them in relation to VILI.  
Pulmonary inflammation induced by mechanical ventilation 
1) Celular mechanisms 
The study by Hamilton et al. in 1983 was the first to demonstrate that injurious 
mechanical ventilation is associated with an increased inflammatory response. The 
authors compared the efects of high-frequency oscilation and conventional 
ventilation strategies in surfactant depleted rabbits [327]. The authors noted that the 
conventional ventilation strategy was not only associated with a significantly worse 
lung function and histological lung injury compared to HFO, but also with neutrophil 
infiltration to the alveoli and interstitial space [327]. To dissect out the role of 
neutrophils in lung injury associated with conventional injurious ventilation, in a 
subsequent study Kawano et al. subjected neutrophil-depleted rabbits to the same 
ventilation protocol, and found that in marked contrast to controls, the neutrophil-
depleted animals did not develop significant lung injury [328]. However, when 
neutrophils were re-introduced to neutrophil-depleted rabbits, this resulted in 
pulmonary dysfunction [328], indicating that lung injury due to surfactant dysfunction 
and VILI was mediated, at least in part, by neutrophils. Choudhury et al. later also 
demonstrated in mice that injurious high-stretch ventilation per se without any 
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underlying lung injury induces early pulmonary sequestration of neutrophils 
preceding the physiological signs of lung injury [106]. The authors also found that 
this phenomenon was associated with stretch-induced inflammatory events leading 
to neutrophil stifening and was mediated by L-selectin-dependent mechanisms 
[106]. In a subsequent study the authors also demonstrated that neutrophil 
accumulation in the lung secondary to pure mechanical-stretch is mediated, at least 
in part, by intra-alveolar TNF signaling [109]. 
 Although these and other studies clearly demonstrate that injurious 
mechanical ventilation strategies are associated with lung inflammation 
characterised by neutrophil margination, more recent evidence suggest that 
monocytes are also involved in VILI. Wilson and coleagues showed that healthy 
mice subjected to injurious mechanical ventilation (high VT and zero PEEP [ZEEP]) 
had  an increased  number  of the inflammatory  subset  Gr-1high monocytes in their 
pulmonary vasculature compared to control [116]. Pre-treatment with a subclinical 
dose of intravenous LPS (20ng) 2 hours prior to the start of high-stretch ventilation 
increased the number of marginated monocytes and significantly aggravated lung 
injury, whereas monocytes depletion with intravenously administered clodronate 
liposomes 24h prior to high-stretch ventilation significantly atenuated pulmonary 
oedema and dysfunction both in LPS-treated and non-treated mice [116]. 
 Alveolar macrophages (AMs) are also key players in VILI. Imanaka et al. 
showed an increased expression of ICAM-1 and CD11b on AMs recovered from rats 
exposed to high-pressure ventilation [107]. Moreover, Frank et al. demonstrated that 
depletion of AMs significantly atenuates permeability pulmonary oedema in a rat 
model of VILI [145]. Interestingly, the authors also found that interaction of AMs with 
alveolar epithelial cels was required for AM activation [145]. These studies clearly 
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indicate that AMs become activated during high-stretch ventilation and significantly 
contribute to VILI. 
2) Humoral factors 
Several clinical investigators have observed that conventional as compared to lung-
protective ventilation strategies can increase the level of pro-inflammatory mediators 
in the lung, such as IL-1-beta, IL-6, IL-8 and TNF [329-331] and that pulmonary 
inflammation is associated with poor outcome in ARDS patients [332, 333]. 
Experimental studies also confirmed that injurious mechanical ventilation results in 
production of a wide range of inflammatory mediators in the lung [109, 319, 322, 
334-337]. For example, Tremblay et al. examined the efects of injurious mechanical 
ventilation using an ex vivo isolated rat lung model [335]. The authors found that 
lungs from rats subjected to injurious ventilation strategies (high end-inspiratory 
and/or low end-expiratory lung volume) had increased levels of the inflammatory 
cytokines/chemokines TNF, IL-1-beta, IL-6, MIP-2, IFN-gamma and IL-10 in their 
lavage fluid, and showed an increased expression of mRNA for c-fos (an early 
response gene with a stretch sensitive promoter) and TNF in the lung homogenate 
[335]. Independently from this finding, the same year Takata et al. published similar 
observations in rabbits subjected to saline lavage folowed by HFO or conventional 
mechanical ventilation (CMV), demonstrating that CMV was associated with 
increased expression of TNF mRNA in lavage cels [322]. Experimental ‘blocking’ 
studies indicated that these inflammatory mediators are not only produced in 
response to high-stretch ventilation but also have a pathogenic role. For example, 
blockade of IL-1beta and TNF signaling significantly atenuated the inflammatory 
response (and in some cases lung dysfunction and pulmonary oedema as wel) 
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associated with VILI in diferent in vivo studies both with pre-injured and healthy 
subjects [109, 334, 338, 339]. 
Subsequent studies then aimed to identify the source and mechanisms by 
which these mediators are produced in the lung in response to stretch. Focus 
therefore turned to in vitro setups where individual cel types of the lung parenchyma 
could be exposed to stretch forces. For instance, isolated foetal rat lung cels 
exposed to cyclic stretch (5% elongation with 40cycles/min) produced MIP-2 within 1 
hour from the start of insult, and this was associated with cel injury (as shown by 
production of lactate dehydrogenase in the supernatant) but independent from 
stretch-activated cation channels as demonstrated by Mourgeon et al. [340]. Pugin et 
al. identified alveolar macrophages as the main source of TNF, IL-6, IL-8, IL-10 and 
matrix-metaloproteinase-9 (MMP-9) in response to prolonged (8 and 24h) cyclic 
stretch, whereas the alveolar type I cel-like A549 epithelial cels produced only a 
smal amount of IL-8 [341]. The authors also found that this response to stretch was 
associated with activation of NFkB in AMs and there was a synergistic efect 
between stretch and LPS, suggesting that mechanical ventilation is particularly more 
deleterious in pre-injured or infected lungs. In a similar study, Vlahakis and 
coleagues subjected A459 cels to cyclic stretch and measured the production of IL-
8 [342]. They found that when cels were stretched by 30% they released ~50% 
more IL-8 than the static controls, however when were stretched by only 20% the 
cels did not produce IL-8 [342]. This may give an explanation to the observation of 
Pugin and co-workers [341], as in their study cels were only stretched by 12-15% of 
their original surface area. 
Cyclic stretch of human pulmonary microvascular endothelial cels also results 
in production of IL-8, IL-6 and MCP-1 in a p38-dependent and Ca-channel 
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independent manner [343]. This finding is important because it suggests that high-
stretch ventilation may result in an increase of systemic cytokine/chemokine levels 
without any physical damage to the alveolocapilary barier, which may be highly 
relevant to the systemic inflammatory response associated with VILI (see below). 
Overal these findings indicate that a number of cel types of the lung parenchyma is 
capable to sense stretch (albeit by diferent mechanisms) and contribute to the 
inflammatory milieu associated with VILI. Although it remains contentious as to how 
much stretch each of these cel types is likely to be exposed to in vivo. 
In addition to the aforementioned inflammatory cytokines/chemokines, recent 
experimental studies identified other molecules that may also mediate VILI within 
animal models, such as angiotensin-converting enzyme [344, 345], ROS [346], lipid 
derived mediators and adenosine receptors [347-349], however these have as yet 
unknown clinical significance. 
Systemic inflammation and extra-pulmonary organ damage induced by mechanical 
ventilation 
It has been appreciated for a long time that in addition to exacerbating the pre-
existing lung injury, mechanical ventilation also has systemic efects such as 
compromising haemodynamics and thus leading to hypoperfusion of organs and 
consequent organ failure. More recent clinical and experimental observations, 
however also indicate that mechanical ventilation has other systemic sequelae 
unrelated to its efect on haemodynamics [350]. For example, Ranieri et al. showed 
that using a protective ventilator strategy in ARDS patients resulted in a significant 
reduction in the inflammatory response not only in the lungs but also in the systemic 
circulation, indicating that the systemic inflammatory response was triggered by 
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and/or originated from the lungs [330]. More importantly, after retrospective analysis 
the authors also found that protective ventilation strategy was associated with 
reduced prevalence of MSOF, particularly renal failure, after 72h of enrolment to the 
study, and there was a significant corelation between occurence of organ failure at 
72h and the plasma concentration of several inflammatory mediators at 36h [333]. 
Stuber et al. also found that a more conventional ventilatory strategy is associated 
with increased levels of cytokines both in BAL and the systemic circulation within 1 
hour from the start of ventilation [331]. Interestingly they also showed that changing 
the ventilatory strategy to a less injurious type can reverse the increase in plasma 
cytokines, but the efect on organ failure was not investigated [331]. 
Experimental studies lent further support to the idea that lung-borne 
inflammatory mediators can become decompartmentalised and spil over to the 
systemic circulation [336, 351-355]. Studies have shown that hyperventilation in 
isolated perfused lung models leads to increases in TNF and IL-6 in the perfusate 
[336] [355]. In addition to inflammatory mediators, live bacteria and bacterial 
products were also shown to decompartmentalise into the circulation from the 
alveolar space, folowing injurious mechanical ventilation in dogs, rats  and rabbits 
[356-358]. In a more chronic model Lin et al. exposed rats to either protective 
(VT=7ml/kg, PEEP=5cmH2O) or injurious (VT=21ml/kg and ZEEP) ventilation protocol 
for 1 hour before intratracheal administration of Pseudomonas aeruginosa, after 
which the mortality was assessed up to 48 hours [359]. The authors found that 
injurious mechanical ventilation was associated with a non-significant trend of 
increased mortality (40% vs. 28%), significantly higher rate of positive blood cultures 
and absolute bacteria count in blood, and an impaired host defence in the surviving 
animals by means of cytokine response [359]. Therefore, these data suggest that 
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more injurious ventilatory strategies not only lead to dissemination of the 
inflammatory milieu of the lung to the systemic circulation but may also alter host 
defence predisposing the body to further infectious/inflammatory insults, which may 
be another contributing factor in the development of MSOF. Munford and Pugin 
suggested that the body’s normal response to stress is to minimise systemic 
inflammation, and local inflammation is therefore accompanied by an anti-
inflammatory response systemicaly [360]. This is to help the body to concentrate its 
forces at the local injury site while preventing the potentialy deleterious inflammation 
in uninvolved sites. However, this is a double edged sword, as if the anti-
inflammatory response is too intense, it may lead to immunosuppression. This theory 
is supported by the observations of Plötz et al.  who found that ventilation of infants 
with healthy lungs (VT=10ml/kg, PEEP=4cmH2O) resulted in an increase of TNF and 
IL-6 in BALF after 2 hours, which was associated with a reduced capacity of cytokine 
production by their peripheral blood leukocytes and a decreased activity of natural 
kiler cels [361]. This notion was later confirmed in experimental setings using 
healthy rats [362]. 
Our group demonstrated that injurious mechanical ventilation in healthy mice 
is associated with margination of inflammatory leukocytes (i.e. neutrophils  and  Gr-
1high monocytes) to distal organs, such as the liver, spleen and kidney [363]. 
However, whether this response is associated with organ injury was not investigated, 
and it is stil unknown what stimulus or mediator directs leukocytes to these organs in 
response to mechanical ventilation. One possible mechanism, as demonstrated by 
Hegeman et al., is the activation of endothelium in these organs. They showed that 
high-stretch ventilation in healthy mice led to an increased expression of adhesion 
molecules E-selectin, VCAM-1 and ICAM-1 on endothelial cels in the hepatic and 
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renal tissue but not in the brain, suggesting a specific susceptibility of diferent 
organs [364]. Activation of endothelium in these organs was also associated with 
increased tissue level of cytokines/chemokines (IL-1beta, TNF, KC) and margination 
of neutrophils (as measured by MPO assay), but again organ dysfunction was not 
measured, and it remains unclear what stimulus or mediator caused the increase in 
adhesion molecule expression [364]. 
Imai et al. were the first to demonstrate a direct link between VILI and MSOF. 
Using an acid aspiration rabbit model, the authors showed that injurious mechanical 
ventilation led to significantly increased apoptosis of epithelial cels in the kidneys 
and smal bowels, which was associated with organ dysfunction as measured by 
serum creatinine, lactate dehydrogenase and aspartate transaminase [365]. In 
addition, plasma from animals ventilated with the injurious strategy was shown to 
induce apoptosis in kidney epithelial cel in vitro, which was prevented by blocking 
the pro-apoptotic mediator Fas ligand [365]. When the authors assessed samples 
from patients with ARDS they also found a significant corelation between changes 
in soluble Fas ligand and changes in creatinine. However, it remains unclear as to 
whether Fas ligand is produced in the lung and decompartmentalised to the systemic 
circulation in response to injurious ventilation. 
There is also evidence that mechanical ventilation may result in increased 
permeability of the intestines which would predispose to translocation of bacteria to 
the  systemic  circulation.  Guery et al. subjected rats to high or low tidal volume 
ventilation (30ml/kg vs. 10ml/kg) and found that high tidal volume ventilation led to 
pulmonary oedema and increased gut permeability, both of which could be 
abrogated by neutralising antibodies to TNF [366]. As Fas ligand and TNF share the 
same downstream signaling pathways, it is tempting to speculate that increased gut 
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permeability in this model was also secondary to epithelial apoptosis, such as that 
observed by Imai and coleagues [365]. Peripheral immunosuppression may also 
influence the gut immune system and predispose to bacterial translocation [367]. 
Overal these studies provide suficient evidence to suggest that mechanical 
ventilation propagates a switch from localised pulmonary inflammatory response to a 
systemic inflammatory process, which also afects extra-pulmonary organs and thus 
may influence MSOF and mortality in ARDS patients. 
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1.3 Therapeutic approaches to Acute Lung Injury  
Therapeutic approaches to ARDS can be grouped as ventilator and non-ventilatory 
approaches. While ventilator approaches are aimed at preventing or minimising the 
harmful efects associated with mechanical ventilation, non-ventilatory approaches 
are designed to restore the homeostasis of the lung by halting injury progression and 
facilitating resolution. Only those that have been tested clinicaly wil be discussed in 
this section. 
1.3 Ventilatory approaches 
Low versus high tidal volume ventilation – avoiding baro-/volutrauma 
The traditional approach to ventilating patients with ARDS in the 1970s and 1980s 
was to maintain normal arterial PCO2 and PO2. While adequate CO2 clearance was 
achieved by using high pressure and volume ventilation (VT often exceeding 20ml/kg, 
[368], despite a recommended standard 12-15ml/kg [369]), the key manoeuvre to 
improve PaO2 was to apply PEEP [3, 368]. However, it was soon realised that this 
approach is not without deleterious consequences to the lungs as pneumothorax and 
pulmonary hyperinflation were common complications [370, 371]. 
The milestone experimental studies by Webb and Tierney and then by 
Dreyfuss et al. demonstrating that high end-inspiratory lung volumes lead to 
increased permeability oedema (see in previous section) [286, 292, 372], greatly 
influenced future ventilatory care. Hickling et al. were the first to demonstrate that 
lowering tidal volume (VT= 4-7ml/kg) and peak airway pressures (PIP=30-40cmH2O) 
and alowing hypercapnia resulted in significantly reduced mortality in ARDS patients 
than predicted by APACHE I scores [373, 374]. Subsequently to these observations, 
five multicentre, randomised trials were conducted to investigate the efects of low 
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vs. high tidal volume ventilation on mortality in ARDS patients. Stewart et al. 
compared the efect of a volume- and pressure-limited ventilation strategy 
(VT<8ml/kg, PIP<30cmH2O) with conventional ventilation [375], and found no 
diference in mortality or organ failure and the incidence of renal failure was 
significantly higher in the ‘protective’ ventilation group [375]. The study by Brochard 
et al., limited end-inspiratory plateau pressure of up to 25cmH2O and a VT<10ml/kg 
[376]. There was no significant diference between the two groups in 60-day mortality 
or MSOF. The same year, however, Amato et al. reported beneficial efects with 
protective ventilation strategy (VT<6ml/kg and PEEP above the LIP) in 28-day 
mortality [377]. In a subsequent study Brower et al. also assessed the impact of low 
VT by limiting Pplat (<30cmH2O); however there was no diference in mortality 
between the groups [378]. 
To address the discrepancy in the findings of these studies, which was likely 
secondary to smal sample size, study design and lack of power to detect diferences 
between treatment arms in most of the studies, in 2000 the National Heart, Lung and 
Blood Institute (NHLBI) Acute Respiratory Distress Network (ARDS Network) 
conducted a multicentre phase II clinical trial enroling a total of 861 patients [329]. 
This study found a 22% reduction in mortality (from 39.8% to 31%) when VT was 
reduced to 6ml/kg from 12ml/kg predicted body weight and plateau pressure was 
limited to less than 30cmH2O. Patients in the protective arm also had more 
ventilator-free days (VFDs) and organ failure-free days (OFFDs) compared to 
controls. Interestingly, patients ventilated with lower VT also showed a greater 
decrease in their plasma IL-6 levels from Day 0 to Day 3, indicating atenuation in 
the systemic inflammatory response, which may have contributed to the beneficial 
efects of low VT on organ failure. 
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Although the ARDS Network trial is not without its critics [379, 380], most 
importantly, this was the first trial that was adequately powered to show a mortality 
benefit in ARDS and established a new standard of ventilatory management to which 
new treatment strategies should be compared.  
Lowering tidal volume has a beneficial efect on but does not completely 
abrogate mortality in ARDS patients, indicating that although VILI is a significant 
contributing factor, it may not be the only determinant of the outcome. One can 
argue, however, that some of the residual mortality seen in the Amato and ARDS 
Network studies (38% and 31%, respectively) is stil related to lung over-distension 
which may happen even at lower tidal volumes.  When conducting quantitative CT 
imaging  studies in  patients  with  ARDS,  Gatinoni et al. found that the amount of 
normaly aerated lung tissue, measured at end-expiration, was about 200-500g, 
equivalent to the normaly aerated lung tissue of a 5-6 years old healthy boy [381]. 
Based  on these  observations  Gatinoni  and  Pesenti  proposed that lung  over-
distension can occur even at lower tidal volumes, a phenomenon they termed the 
“baby lung” [368]. 
Another interesting finding of these studies was that the respiratory 
compliance corelated only with the size of the normaly aerated lung tissue, i.e. 
compliance reflected the size of the “baby lung”. The studies also revealed that the 
ARDS lung is not homogenously “stif”, as previously considered, but smal, and the 
elasticity of the “baby lung” is nearly normal. Based on this and the CT imaging, the 
authors initialy thought that the “baby lung” was a healthy anatomical structure, 
located in the non-dependent regions (ventral parts in the supine position) of the 
original lungs. This gave rationale to start using the prone position in order to 
increase perfusion of the anatomical “baby lung” and thus improve oxygenation. 
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Although oxygenation did indeed improve [382], CT imaging soon revealed that 
gravity-dependent densities shifted from dorsal to ventral regions within minutes 
when the patient was turned to prone position, indicating that the non-aerated 
regions represented colapsed alveoli and the “baby lung” is not a healthy anatomical 
but rather a functional structure, consisting of non-healthy aerated lung units [382]. 
The “baby lung” model therefore means that during positive pressure 
ventilation, even at low tidal volumes, the aerated lung regions receive 
disproportionaly greater volume of gas in ARDS patients, which can ultimately lead 
to volutrauma and consequent biotrauma. This would also suggest that reducing tidal 
volume even further may be beneficial and could potentialy further reduce VILI 
associated mortality. On the other hand, using significantly lower tidal volumes than 
6ml/kg could potentialy be harmful, as it could lead to hypoxaemia, hypercapnia, 
reduced cardiac output and consequent organ hypoperfusion [383]. Some of these 
limitations can be resolved by utilising extracorporeal CO2 removal and membrane 
oxygenation (ECMO), which would alow “lung rest” using low tidal volumes whilst 
maintaining gas exchange. The first multicentre, prospective, randomised trial of 
ECMO versus conventional support in ARDS patients was conducted in the late 
1970s and published by Zapol et al. [255]. This study was stopped early because of 
high mortality (90%) in both groups. Bleeding was the main complication associated 
with ECMO, which led to several blood transfusions which may have contributed to 
lung injury. Importantly, this study was performed 25 years before the ARDS 
Network trial and used high tidal volume ventilation in both groups. Subsequently, 
ECMO was used successfuly with high survival rates in new-born and paediatric 
patients with respiratory failure [384-386], and there have been encouraging results 
in adult patients [387-393] [394]. However, due to its associated high bleeding risk 
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(54%), ECMO is contraindicated in patients who are not suitable for anticoagulation 
due to other reasons (e.g. acute stroke, known bleeding disorder, etc.). Furthermore 
the benefits of ECMO decline after ARDS duration of more than 7 days [395]. 
Overal, ECMO may be a useful salvage therapy for patients with early and severe 
ARDS. 
Another possible way of reducing tidal volume to a minimum and thus avoid 
volutrauma is by the use of high frequency ventilation (HFV) strategies. The concept 
of HFV is to ventilate the lungs with very low tidal volumes in conjunction with high 
frequencies (3-7Hz) and high mean airway pressures to keep the lungs open. By this 
approach both overdistension and shear stress generated by repetitive opening 
closing of lung units can be potentialy avoided. There is experimental evidence that 
HFV can atenuate VILI [319-322], and it has been commonly and safely used in 
premature infants with surfactant deficiency, although a Cochrane Database review 
showed no evidence for a benefit over conventional ventilation strategies in this 
patient population [396]. In ARDS patients there were two smal randomised trials 
that compared HFV with conventional ventilation, each of which showed that this 
approach was safe and improved oxygenation, but were not powered to show a 
survival benefit [397, 398]. Outcome benefits of HFV are curently being evaluated 
by the randomised multicentre Oscilation for ARDS Treated Early (OSCILLATE) 
trial, until then HFV remains an experimental approach. 
Optimising PEEP - avoiding atelectrauma 
Another strategy to reduce the lung injury during mechanical ventilation is by the 
application of PEEP, which is used to improve oxygenation and reduce the chance of 
alveolar colapse at end-expiration and resultant atelectrauma [3, 286, 292]. 
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Optimising PEEP, however, might be chalenging as too high levels might be more 
injurious than beneficial as discussed earlier. One major dificulty is that the lung is 
heterogeneously injured/atelectatic in ARDS, and a set PEEP that is optimal to keep 
less aerated parts open may cause overdistention in beter aerated units (see “baby 
lung” theory above).  Moreover, high PEEP levels may have detrimental efects on 
haemodynamics by increasing intra-thoracic pressure consequently reducing venous 
return and cardiac output, which could ultimately lead to reduced organ perfusion. 
Amato et al. demonstrated reduced mortality in a smal trial with a combination of low 
tidal volume and titrating PEEP above the LIP on the P/V curve [377]. Subsequently, 
the ARDS Network conducted the ALVEOLI study, a prospective, randomised, 
multicentre trial comparing the efect of higher PEEP (13cmH2O) versus lower PEEP 
(8 cmH2O) in conjunction with lung-protective tidal volume (6ml/kg) on hospital or 60-
day mortality [399]. The study was discontinued prematurely after enroling 549 
patients, due to lack of eficacy. One can argue, however, that the beneficial efects 
of lung protective tidal volume may have masked those from higher PEEP. In some 
contrast, a more recent meta-analysis of three multicentre trials comparing the efect 
of higher (15±3cmH2O) versus lower (8±3cmH2O) PEEP showed a survival benefit in 
patients with moderate-severe ARDS (PaO2/FiO2 <200), whereas a trend towards 
increased mortality in mild ARDS (PaO2/FiO2 =200-300) with the use of higher PEEP 
[400]. These findings highlight the “double-edged sword” nature of PEEP, but also 
indicate that using high levels of PEEP may have a benefit in patients with the more 
severe forms of ARDS. 
Prone positioning 
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Prone positioning was tangentialy discussed above in the context of the “baby lung” 
phenomenon. The idea behind prone positioning is to aleviate the compressive 
gravitational forces expressed on the dorsal dependent regions thus facilitating more 
evenly distributed ventilation throughout the lung, which ultimately manifests in 
improved oxygenation (by a reduction in ventilation/perfusion mismatch and shunt) 
[401]. The more uniform distribution of tidal volume may also help to reduce 
excessive stretch at margins between atelectatic and aerated lung units in the dorsal 
regions, and atenuate atelectrauma by preventing repeated opening closing of smal 
airways [315]. However, prone positioning may result in adverse events, such as 
dislodgement of endotracheal tube, intravascular lines, facial oedema, eye damage 
and increased intra-abdominal pressure [315]. A large, multicentre, randomised trial 
of prone positioning for patients with ARDS was published in 2001 by Gatinoni et al. 
[402]. The PaO2/FiO2 ratio was significantly higher in the prone group compared to 
the supine group (N=152), but prone positioning did not improve survival. 
Importantly, however, there was no diference between the groups in the 
complications related to positioning, such as pressure sores and accidental 
extubation.            
  A meta-analysis and systemic review of ten clinical trials (total of 1867 
patients) published in 2010 demonstrated a significant reduction in mortality with 
prone positioning in patients with severe ARDS (PaO2/FiO2 <100) [403]. The meta-
analysis also revealed a significant increase in the risk of pressure ulcers, 
endotracheal tube blockade and chest tube dislodgement associated with prone 
positioning. More recently, Guerin et al. published the results of the PROSEVA trial 
(Efect of Prone Positioning on Mortality in Patients With Severe and Persistent 
Acute Respiratory Distress Syndrome) in the New England Journal of Medicine 
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[404].This this multicentre, prospective, randomised, controled trial, randomly 
assigned 466 patients with severe ARDS (defined as PaO2/FiO2 <150mmHg, at a 
minimum FiO2 of 0.6 and a minimum PEEP of 5cmH2O, VT~6ml/kg predicted body 
weight) to undergo prone-positioning sessions of at least 16 hours or to be ventilated 
in the supine position. The study demonstrated an impressive more than 50% 
relative reduction in 28-day hospital mortality (primary outcome, 16% in prone 
positioning vs. 32.8% in supine), and a similar efect in unadjusted 90-day mortality 
(23.6% vs. 41%). Also, the incidence of complications did not difer significantly 
between the groups, except for the incidence of cardiac arests, which was higher in 
the supine group [404]. Therefore, while prone positioning should not be used 
routinely for al ARDS patients, but it is reasonable to utilise this approach in patients 
with severe ARDS. 
Recruitment manoeuvres 
Low tidal volume ventilation may result in loss of lung volume and derecruitment of 
lung units, ultimately leading to impaired gas exchange.  This can be prevented by 
the delivery of intermitent breaths of large tidal volumes (sigh) [405]. In a clinical 
study by Pelosi et al. [406], application of intermitent sighs by increasing the plateau 
pressure by 10cmH2O every 20 seconds over a period of 1 hour resulted in a 26% 
reduction in shunting with a 50% increase in oxygenation. Two more recent meta-
analyses, including up to 40 clinical studies comparing recruitment manoeuvres (RM) 
to conventional ventilation strategy, found that RM resulted in a significant but 
transient increase in oxygenation with very few non-significant adverse events 
(barotrauma, hypotension, desaturation, arhythmias), but there was no significant 
diference in 28-day mortality, and there was not enough data on the length of 
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ventilation or hospital stay to pool the results [407, 408]. Therefore, given the 
uncertain benefit of transient oxygenation improvements in patients with ALI/ARDS, 
the routine use of RMs cannot be recommended, but should be considered for use in 
patients with ARDS who have life-threatening hypoxemia on an individualy judged 
basis. 
Strategies reducing patient-ventilator asynchrony (PVA) 
A ventilated patient’s own respiratory efort driven by their neural respiratory cycle is 
often only partialy suppressed and asynchronous to the ventilator, which can result 
in increased transpulmonary pressure, with a risk of barotrauma and VILI, and 
prolonged duration of ventilation [409]. This even happens with ventilators designed 
to detect the patients’ own respiratory efort, such as pressure support ventilation 
(PSV) and assisted spontaneous breathing. 
In a large clinical trial with ARDS patients, suppression of the patients’ own 
breathing efort using short-term, early neuromuscular blockade was shown to 
improve PVA and reduce 90-day adjusted mortality without significant complications 
[410]. 
Another way of improving PVA is by the use of proportional assist ventilation 
(PAV). It provides asisted pressure support ventilation by means of a complex 
algorithm based on the compliance and resistance of the airways [409]. However 
estimation of these parameters may prove to be dificult in clinical practice and PVA 
is only available on a limited number of ventilators, therefore it’s use is not widely 
adopted [409].        
A more recent development to this field is the use of neuraly adjusted 
ventilatory assist (NAVA), in which the electrical activity of the patient’s diaphragm is 
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measured by electrodes atached to a nasogastric tube, serving as a surogate of the 
patient’s neural respiratory efort resulting in a high level of patient-ventilator 
synchrony [409]. A smal clinical trial (N=14) by Colombo et al. comparing NAVA and 
PSV [411] showed that tidal volume and the incidence of patient-ventilator 
asynchrony was significantly higher in the PSV group, indicating that NAVA may 
improve patient-ventilator interaction and avoid overassistance. In a rabbit model of 
ALI induced by intratracheal HCl, NAVA provided the same level of lung protection 
as low-tidal volume ventilation when compared to high-tidal volume ventilation and 
was just as eficient in atenuating extra-pulmonary organ injury [412]. These findings 
suggest that NAVA may be a safe and efective tool to reduce VILI and MSOF, but 
large clinical trials are needed to establish its role in ARDS patients. 
1.3 Non-ventilatory approaches  
Haemodynamic management  
Pulmonary oedema formation is greatly influenced by Starling forces, even if not 
cardiogenic in origin, and experimental data suggest that even a smal decrease in 
hydrostatic pressure in the pulmonary vasculature can atenuate it [413]. Also, 
reduction in pulmonary artery wedge pressure is associated with improved survival in 
ARDS patients [414], likely secondary to a decrease in extravascular lung water 
[415]. This would suggest that a more conservative fluid management may confer 
benefits in this patient population, although one has to take into account that 
maintenance of organ perfusion should not be compromised to achieve this. To 
investigate this further, the ARDS Network conducted the Fluid and Catheter 
Treatment Trial (FACTT), a large, multi-centre, randomized trial comparing liberal to 
conservative fluid management strategy in patients with ARDS [416]. The study 
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found that compared to the liberal fluid management arm, those patients in the 
conservative fluid management group had significantly more ventilator-free days 
(VFDs), improvement in lung function and more ICU-free days without an increase in 
the incidence of non-pulmonary organ failures. However, 60-day mortality was not 
improved significantly. 
ARDS is associated with increased dead space fraction due to pulmonary 
microvascular vasoconstriction leading to shunt and ventilation-perfusion mismatch 
[35]. Restoration of pulmonary microvascular circulation therefore would theoreticaly 
improve gas exchange thus decrease ventilator-dependency and improve survival. 
Nitric oxide (NO) is a potent endogenous vasodilator predominantly produced by 
endothelial cels exogenous forms of which can be also delivered by inhalation to 
achieve selective vasodilation in the pulmonary vasculature without any systemic 
efect (due to rapid inactivation by haemoglobin [417]) [418, 419]. Indeed, when 
ARDS patients were treated with inhaled NO (iNO) in a smal observational pilot, 
they showed a significantly decreased pulmonary artery pressure without changes in 
systemic arterial pressure, and this was associated with a significant improvement in 
oxygenation and a decrease in pulmonary shunt [420]. Two subsequent, smal (30 
and 40 patients), randomized trials confirmed these positive findings, although these 
were found to be transient and did not manifest in improved survival [421, 422]. 
Unfortunately, this did not seem to be related to smal sample size, as three 
subsequent large, multi-centre, randomised, double-blinded, placebo-controled trials 
also failed to show a benefit in mortality or VFDs of using iNO in ARDS patients, 
despite the short-term improvement in oxygenation [423-425]. Moreover, Ader et al 
demonstrated in a mouse model of Pseudomonas aeruginosa pneumonia that iNO 
can increase pulmonary endothelial permeability [426]. Therefore, apart from using 
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as a rescue therapy for refractory hypoxaemia, iNO is generaly not recommended 
for the treatment of ARDS patients. 
Prostaglandins (PGs, e.g. PGI2, PGE1, PGE2), similarly to NO, are important 
endogenous vasodilators, which also inhibit platelet aggregation and activation of 
leukocytes [427], therefore seem atractive as a potential treatment tool for ARDS. 
When  aerosolised  PGI2 was given to ARDS patients [428], it confered selective 
pulmonary vasodilation and showed similar eficacy to iNO. However, no large 
randomised trial has been conducted with inhaled PGs. Systemic delivery of PGs for 
the treatment of ARDS was also tested. In animal models of ALI, such as that 
induced by bleomycin or pancreatitis [429, 430], intravenous infusion  of  PGE1 
reduced pulmonary neutrophil margination and vascular leak. The first clinical trial of 
PGE1 in 41 ARDS patients showed a trend toward mortality benefit and triggered 
larger studies [431]; however these could not show a significant improvement in 
survival [432, 433]. Interestingly, there was no significant efect on neutrophil activity 
either. In a subsequent study by Abraham et al. where neutrophils were targeted 
more specificaly by the use of liposomal PGE1 in 25 patients with ARDS, treatment 
led to a significant improvement in oxygenation, lung compliance and ventilator 
dependency [434]. However, large clinical trials conducted in North-America and 
Europe failed to confirm these positive findings [435, 436], and therefore systemic 
PGs are not recommended for treatment of ARDS patients.  
Enhancement of alveolar fluid clearance  
Resolution of alveolar fluid is critical for the recovery from ARDS [22, 35], and early 
resolution is associated with improved survival [270]. Experimental studies on ex 
vivo human lungs indicate that beta-agonists can accelerate alveolar fluid clearance 
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by cAMP-mediated up-regulation of ENaC and Na-K-ATPase with subsequent 
increase in sodium transport in type I AECs [437, 438]. There is also data to support 
that beta-agonists may atenuate alveolar-capilary permeability [439]. These efects 
are mediated through the beta2-adrenoceptor [440, 441], and a placebo-controled 
clinical trial in healthy volunteers who were at known risk of developing high-altitude 
pulmonary oedema (HAPO) showed that inhaled beta2-agonist salmeterol reduced 
the incidence of high-altitude pulmonary oedema [442]. 
These experimental data paved the way for a clinical trial using beta2-agonist 
salbutamol intravenously (15ug/kg/h for 7 days) in ARDS patients, the beta-agonist 
lung injury trial (BALTI) with an atempt to accelerate the resolution of pulmonary 
oedema [443]. This single-centre, randomised, double-blind, placebo-controled 
phase 2 trial enroled a total of 40 patients, and found a significant reduction in 
extravascular lung water (EVLW) and Pplat at Day7 in the treatment group, and a 
non-significant trend toward a reduced lung injury score (LIS), but no diference in 
VFD or survival. However, the positive results in the primary outcome caled for 
large, multi-centre, randomised trials. One was designed and performed in North-
America by the ARDS Network and named ALTA [14]. This study used aerosolised 
salbutamol (5mg every 4h for 10 days) partly because intrapulmonary delivery of 
beta-2-agonist reduced pulmonary oedema in a preclinical model of lung injury [444] 
and the amount of salbutamol achieved in the pulmonary oedema fluid by this 
method is suficient to stimulate AFC in ex vivo human lungs [445], and partly 
because of safety concerns (i.e. potentialy less systemic side efects, e.g. 
arhythmias). Unfortunately, the study was terminated for futility after 282 patients 
had been enroled. The reasons behind this lack of benefit are unclear, but the 
possibility of a sub-optimal drug delivery to the injury site was raised as an 
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explanation. Another possible explanation is that the ALTA study enroled patients 
with less severe ARDS with an overal 60-day mortality of 20% when compared to 
the BALTI trial (28-day mortality of 60%), and more severely il patients may have 
more significantly impaired AFC, and so are more likely to benefit from interventions 
that accelerates AFC [446].  
Paralel to the ALTA study, the BALTI-2 trial was run in 46 intensive care units 
across the UK evaluating the efects of intravenous salbutamol in ARDS patients 
with 28-day mortality being the primary outcome [447]. Unfortunately, similarly to the 
ALTA trial, the BALTI-2 trial also had to be stopped early because of safety 
concerns. Salbutamol treatment was associated with a significantly increased 28-day 
mortality compared to placebo (34% vs 23%, respectively), and other adverse efects 
such as tachycardia, arhythmias and lactic acidosis, and also reduced VFDs and 
OFFDs. Therefore intravenous beta-2 agonist therapy cannot be recommended for 
ARDS patients. 
Surfactant therapy  
The role of surfactant in lung homeostasis, alterations to the surfactant system in 
patients with ARDS and the success of exogenous surfactant therapy in pre-mature 
babies with neonatal respiratory distress syndrome (NRDS) [448-452] give a 
rationale for surfactant therapy in ARDS.  However, whilst in NRDS the main 
pathology is surfactant deficiency, in the case of ARDS the main problem is 
surfactant dysfunction associated with a much more complex pathology as described 
above, which is complicated only further by the heterogeneity arising from diferent 
aetiologies of the syndrome [453]. 
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Several animal studies demonstrated the eficacy of exogenous surfactant in 
diferent models of lung injury, such as acid-aspiration [454-456], bacterial and 
endotoxin-induced lung injury [457-462], hyperoxia [463-465] and in vivo lavage 
[466-470]. However, in adult patients with ARDS, despite the initial encouraging 
results in smal clinical studies, large controled clinical trials were unsuccessful, 
apart from a temporary improvement in oxygenation in some but not al studies [471] 
[472] [473, 474], [475]. This apparent lack of benefit can be partly explained in some 
of these trials by the low eficacy (secondary to low or no SP-B content) [476-480] of 
the material used and the delivery method (aerosolised vs. instiled) that may have 
also influenced the bioavailability of the drug [453].  
In summary, the treatment of ARDS in adult patients with exogenous 
surfactant has been unsuccessful. Future success of this approach may simply lie in 
optimising the drug components, the delivery method, and/or in using it in 
conjunction with other therapeutic methods [453]. 
Prevention/reversion of the overwhelming pro-coagulant state  
Alteration to the coagulation pathway and evolvement of a pro-coagulant state is 
characteristic to ALI/ARDS and is a significant contributor to the physiologic changes 
seen during the pathogenesis, such as increased vascular permeability and 
inflammation [22, 35]. 
Genetic  and  pharmacological targeting  of tissue factor (TF)  was  shown to 
atenuate endotoxin/sepsis-induced lung injury, extra-pulmonary organ injury and 
mortality in several animal models [481-485]. Despite these encouraging results, 
when TF pathway was blocked using a recombinant human tissue factor pathway 
inhibitor TFPI in a large multicentre randomised clinical trial in patient with sepsis, it 
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confered no benefits in mortality [486]. The reasons behind this lack of benefit are 
not known, but it highlights the complexity of the role of TF and the coagulation 
pathway in the pathogenesis of sepsis and ALI/ARDS.  
 In vitro studies indicate that activated protein C (APC) has anti-inflammatory 
and anti-apoptotic efects on PECs [487, 488]. It has been demonstrated in vitro that 
APC can inhibit thrombin-induced permeability in PECs [489]. Also, systemic 
administration of APC prevents LPS-induced pulmonary vascular injury in vivo  by 
inhibition of TNF production [490].  Conversely, during sepsis PECs shed 
thrombomodulin (TM) and endothelial protein C receptor (EPCR) from their surface 
[491, 492], which results in decreased ability to activate protein C and consequently 
propagates lung injury. These findings coupled with the clinical observations that 
sepsis/ARDS are associated with reduced APC levels, prompted clinical trials using 
recombinant human APC (rhAPC) with an atempt to improve clinical outcome. The 
first large, multicentre placebo-controled trial, the Prospective Recombinant Human 
Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study 
demonstrated a 6.1% absolute risk reduction in 28-day mortality in the treatment 
group [493]. More than 70% of the patients in both study arms had respiratory 
dysfunction, and the resolution of this was significantly quicker in the rhAPC-treated 
group [494]. A subgroup analysis suggested that the mortality benefit was limited to 
patients with an increased risk of death, therefore the FDA requested additional trials 
involving less severely il adults and children. These trials, the Administration of 
Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) [495] and the 
Resolution of Organ Failure in Pediatric Patients with Severe Sepsis (RESOLVE) 
[496], were terminated early for futility. Subsequent trials and analyses also caled 
into question the results of the PROWESS study [497], which led to the PROWESS-
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SHOCK study to test whether rhAPC would reduce mortality in patients with septic 
shock. This showed no benefit from the use of rhAPC in patients with sepsis, and 
therefore it is curently not recommended for clinical use and the manufacturer has 
withdrawn the product from the market [498]. 
 Several smal human studies indicated the efectiveness of AT II in reducing 
the mortality and organ dysfunction in patients with sepsis [499-501], which led to a 
large, randomised, double-blind, placebo-controled trial [502]. Disappointingly, this 
trial did not show any beneficial efect on mortality [502], however a subgroup 
analysis revealed that AT II treatment resulted in a 6.8% absolute risk reduction in 
56-day al-cause mortality in patients with severe sepsis and high risk of death [503]. 
Interestingly, this benefit was more prominent in patients who did not receive 
concomitant heparin, which warants for further prospective validation. 
 In summary, although the role of coagulation pathway in the pathogenesis of 
sepsis/ALI/ARDS is wel established in experimental models and clinical studies, 
therapeutic interventions aiming to restore the altered haemostasis showed very 
limited benefits and only to a very specific subpopulation, which only highlights the 
complexity of these pathways. 
Counteracting oxidative stress 
As the pathogenesis of ARDS is associated with excessive production of free 
radicals and depletion of antioxidant systems, it clearly delineates the two main 
therapeutic approaches to counteract oxidative stress during ARDS: 1) inhibit the 
production of free radicals, and 2) replenish antioxidant systems. 
 While NO is important in maintaining pulmonary vascular function, its 
derivatives (RNS) can also promote injury due to their high reactivity with other 
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molecules. Excessive production of NO during lung injury is a result of induced 
activity of iNOS in inflammatory cels, such as AMs [504]. Genetic inhibition of iNOS 
confers protection from lung injury of diferent aetiologies in animal models [505, 
506]. On the contrary, overexpression of eNOS atenuates VILI [507] and LPS-
induced [508] lung injury. This suggests that while excessive production of NO by 
iNOS may act as a free radical, maintenance of a baseline NO expression by eNOS 
is required for appropriate endothelial function, implicating that a specific blockade of 
iNOS may confer more benefits than total NOS inhibition. Indeed, selective targeting 
of iNOS with the inhibitor ONO-1714, has been demonstrated to atenuate hyperoxic 
[509], Candida- [510, 511], LPS- [512] and acid aspiration-induced [513] lung injury 
in animal models, but clinical trials using this agent are lacking. 
 ARDS is associated with reduced GSH and increased GSSG levels clinicaly 
[514].  Systemic  administration  of the  GSH  precursor  N-acetyl cysteine (NAC) 
atenuated LPS-induced alteration of pulmonary circulation, lung compliance, and 
production of inflammatory cytokines in sheep [515]. However, when trialed in 
human ARDS, even though it successfuly increased GSH levels [516], NAC failed to 
show any mortality benefit [517-520]. 
 Haem oxygenase (HO)-1, is a ubiquitous inducible enzyme catalysing the 
oxidative degradation of haem into bilirubin and biliverdin with the release of by-
products carbon monoxide (CO) and iron [521, 522]. Both bilirubin and biliverdin 
have antioxidant properties [523]. Moreover, overexpression of HO-1 confers 
increased resistance to hyperoxia in vitro and in vivo [524], [525] and LPS-induced 
lung injury [526] in vivo, partly via enhanced expression of IL-10 by AMs [526]. 
Exogenous administration of biliverdin has been also shown to provide protection 
from LPS- [527] and ischaemia-reperfusion [528, 529] induced lung injury. Although 
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clinical evaluation of HO-1 gene transfer and delivery of exogenous biliverdin is stil 
awaited, these may ofer an alternative therapeutic approach. CO also has anti-
inflammatory properties and exposure to low concentrations atenuated several 
models of lung injury including VILI [530-532], acid aspiration [533], ischaemia-
reperfusion injury [529, 534], injury associated with cardiopulmonary bypass [535-
538], mainly by atenuating the associated inflammatory response. However in other 
models of lung injury, such as LPS- and oleic acid-induced [539], it failed to show 
protection, or required doses that increased lung permeability and produced 
potentialy toxic levels of carboxyhaemoglobin [540]. With regards to clinical 
application, inhaled CO failed to exhibit anti-inflammatory efects during 
endotoxaemia in healthy volunteers [541], but was efective in reducing sputum 
neutrophils in COPD patients and improved bronchial responsiveness [542]. 
Therefore, further clinical trials are needed to establish the potential benefits of 
inhaled CO for the treatment of ARDS [543]. 
Albumin has antioxidant properties through its thiol groups and its 
administration to patients with sepsis or lung injury replenished plasma antioxidant 
capacity [544, 545] and improved gas exchange [546]. However it remains to be 
elucidated whether albumin administration to patients with ARDS could also improve 
survival. Supplementation of dietary antioxidants such as vitamin C- and E and 
carotenoids were also shown to be beneficial in preventing ozone-induced 
respiratory dysfunction and inflammation in healthy human subjects [547], and may 
be favourable to use in patients with acute lung injury.  
Anti-inflammatory drugs 
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Inflammation is a key to the pathogenesis of ARDS, and halting inflammatory 
processes is a prerequisite of successful resolution of injury. Therefore, anti-
inflammatory drugs as potential therapy have been widely tested. 
 Glucocorticoids  seemed to  be  an ideal  candidate  not  only  because they  are 
widely used in clinical practice, but also because they can inhibit or suppress many 
inflammatory mechanisms that are wel known to be involved in the development of 
ARDS. For example, glucocorticoids inhibit the expression of inflammatory cytokines 
IL-1, IL-6, IL-8, TNF  and  GM-CSF [548, 549] through the inhibition of transcription 
factors NFkB and AP-1 [550-552], suppress expression of adhesion molecules 
ICAM-1 and E-selectin [553, 554] and the synthesis of enzymes (e.g. PLA2, COX, 
iNOS) that are responsible for the production of other mediators such as 
prostanoids, PAF and NO [555].  Glucocorticoids  can  also induce the  breakdown  of 
colagen, thus preventing excessive colagen deposition in the lung that would lead 
to fibrosis. However, when clinical trials were conducted with methylprednisolone for 
the prevention [556-559] or treatment of either early [560] or late [561-566] phases of 
ARDS, these showed litle clinical benefits [565] and in one study even increased 
mortality [556]. 
 Ketoconazole is an antifungal agent with anti-inflammatory properties. It can 
inhibit synthesis and release of leukotrienes and TXA2 by AMs, which are important 
mediators of vasoconstriction, platelet aggregation and neutrophil activation in the 
pathogenesis of ARDS [567, 568]. While oral ketoconazole successfuly reduced the 
incidence of ARDS in surgical patients who were at high risk [569, 570],  it failed to 
show a mortality benefit or a positive impact on VFDs in patients who already 
developed the syndrome [571]. Therefore ketoconazole may be useful 
76 
prophylacticaly in some patient populations at risk of ARDS, but should not be used 
for ARDS therapy. 
 The xanthine derivative pentoxifyline is a competitive non-selective 
phosphodiesterase inhibitor, commonly used in vascular surgery to improve 
peripheral circulation [572]. Besides its haemorheologic efects, pentoxifyline and 
its derivative lisofyline have potent anti-inflammatory properties. For example, 
pentoxifyline has been shown to inhibit neutrophil chemotaxis and TNF release by 
macrophages in animal models of ARDS [573-575], and pre-treatment with 
pentoxifyline successfuly atenuated pulmonary oedema in saline lavage and acid-
aspiration models of ARDS [574, 576]. However, there is only one human pilot study 
in ARDS patients, in which pentoxifyline showed no positive efect on respiratory 
physiology [577]. Lisofyline can also atenuate production of pro-inflammatory 
cytokines, reduce neutrophil accumulation and pulmonary oedema formation and 
improve survival in animal models of sepsis [578-580]. However, similarly to 
pentoxifyline, i.v. lisofyline failed to confer benefits in ARDS patients [581]. 
 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine 
which plays an important role in pulmonary homeostasis by regulating AM function in 
innate host defence, preventing apoptosis in AECs in response to noxious stimuli 
and through its involvement in surfactant homeostasis [582, 583]. Animal models 
studying either administration or overexpression of GM-CSF indicated atenuation of 
lung injury [582, 584]. Similarly, beneficial efects of intravenously administered 
recombinant human (rh)GM-CSF were observed in a smal scale trial amongst septic 
patients [585], although a subsequent larger trial in patients with ARDS failed to 
confirm benefits [586], although showed a very subtle positive trend in 28-day 
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mortality and OFFDs. Thus larger trials are needed to establish the benefits, if any, 
of rhGM-CSF therapy in ARDS. 
  3-hydroxy-3-methylglutaryl  coenzyme  A (HMG-CoA) inhibitors,  or statins, 
have been used in primary and secondary prevention of cardiovascular disease for a 
long time [587-589], not only for their beneficial efect on lipid profile but also 
because of their immunomodulatory and anti-inflammatory efects [590, 591]. This 
pleiotropic efect has been utilised in diferent inflammatory conditions, such as 
rheumatoid arthritis and multiple sclerosis with good results [592, 593], and thus has 
also been the interest of ALI research. For example, in a mouse model of sepsis 
statin pre-treatment reduced plasma TNF and IL-1 that was associated with 
increased survival [594]. Also, mice pre-treated with statin had significantly 
atenuated pulmonary inflammation and injury folowing intratracheal LPS 
administration [595, 596], and in a model of VILI [597]. In healthy volunteers, pre-
treatment with 80mg simvastatin for 4 days significantly atenuated systemic and 
pulmonary inflammatory response folowing intravenous and inhaled LPS, 
respectively [598, 599]. Observational cohorts of patient with sepsis and ICU 
admission also demonstrated a mortality benefit in those patients who were on 
statins prior to their ilness [600-603], and patients on pre-hospital statin treatment 
who were admited to ICU were less likely to develop sepsis or ALI/ARDS than those 
who were not on statins [604].  These positive observations led to the randomised, 
double-blind, placebo controled trial of Hydroxymethylglutaryl-Coenzyme A 
Reductase inhibition for Acute Lung Injury (The HARP study) recruiting 60 patients 
with ALI, who either received 80mg of simvastatin or placebo daily until cessation of 
mechanical ventilation or up to 14 days [605]. By day 14 the statin group showed 
improvement in non-pulmonary organ dysfunction, significant reduction in pulmonary 
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and systemic inflammation and a non-significant trend for beter pulmonary function, 
but no diference in mortality although this was not the primary end-point and the 
study was not powered to detect diference in mortality (the HARP-2 study is 
curently recruiting a total of 540 patients to beter assess the potential benefits of 
simvastatin use in ALI patients [606]).  In a more recent, randomised, double-blind, 
multicentre, placebo-controled trail enroling 250 criticaly il patients, daily 
administration of 20mg atorvastatin did not show any significant reduction in plasma 
IL-6 (primary end-point), organ failure or mortality [607]. Interestingly, however, pre-
hospital statin users randomised to the placebo group had a greater 28-day mortality 
(28% vs. 5%) compared to those receiving atorvastatin, suggesting an important role 
for statins in regulating the inflammatory response in severe sepsis. 
 IL-1-beta, similarly to TNF is an early expressed cytokine, closely linked with 
the pathogenesis of ARDS as discussed earlier. IL-1-beta has two receptors, IL-1R1 
and IL-1R2, but exerts its biological efects only through IL-1R1 [608, 609]. Both IL-1-
beta and its natural antagonist IL-1Ra are elevated in the BALF of ARDS patients, 
and lung protective ventilation decreases BALF IL-1-beta levels, without afecting 
that of IL-1Ra, suggesting a contributory role for IL-1-beta in the pathogenesis of VILI 
[330]. Indeed, animal models confirmed these observations [335, 610], and genetic 
or pharmacological inhibition of IL-1-beta signaling successfuly atenuated VILI 
[338, 339, 611]. It has been demonstrated that deleterious efects of IL-1 on 
pulmonary permeability in VILI can be atributed to down-regulation of epithelial 
ENaC expression [612], neutrophil recruitment through up-regulation of KC, ICAM-1 
and iNOS, and associated epithelial cel injury [338]. However, when i.v. recombinant 
human (rh)IL-1Ra was given to sepsis patients in a large multi-centre trial, it proved 
unsuccessful to reduce mortality [613]. This lack of eficacy could be related to the 
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route of delivery (i.e. systemic instead of intrapulmonary), or the multifaceted role of 
IL-1 signaling in the pathogenesis of ARDS. For example, IL-1-beta is also involved 
in alveolar repair after injury [614]-[615], thus its blockade may even be deleterious. 
Overal these studies suggest that while anti-IL-1-beta treatment might be beneficial 
in the acute phase of ARDS, it might be harmful in the resolution phase. These 
important aspects need to be considered if clinical trials targeting IL-1-beta wil be 
atempted again in ARDS patients in the future. 
 Similarly to targeting IL-1-beta, clinical trials with i.v. anti-TNF therapies 
including anti-TNF monoclonal antibodies [616-622], soluble TNF receptor (sTNFR)-
immunoglobulin fusion proteins [623-625] and polyclonal  Fab IgG fragments 
targeting TNF [626] in septic patients with ARDS showed litle or no benefit in 
improving the clinical outcome. The possible reasons behind the lack of success with 
this therapy and the role of TNF signaling in ARDS/VILI wil be discussed in more 
detail later in this chapter. 
 In summary, while ARDS is clearly an inflammatory condition, anti-
inflammatory therapeutic approaches were so far unsuccessful. This only highlights 
the complex interplay of inflammatory mechanisms in the pathogenesis and indicates 
that beter understanding is an absolute necessity if one wants to achieve success. 
It is clear that the only therapy so far that has reduced the mortality associated with 
ARDS has been altering the approach to mechanical ventilation. However, the 
mortality remains unexpectedly high indicating that new therapies are required. The 
recognition of ARDS as an inflammatory condition directed researchers to explore 
potential therapeutic targets that regulate the inflammatory response. Despite 
extensive investigations there has been no significant breakthrough in treating 
ARDS. More recently new potential therapeutic approaches were suggested (e.g. 
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angiopoietin-1 [627-629], KGF [630-633], sphingosine-1 phosphate receptor 1 [129, 
634, 635], mesenchymal stem cels [273, 636-638]) based on experimental studies, 
however these were not yet tested clinicaly. 
One mediator that has been consistently implicated in ARDS/VILI in clinical 
and experimental studies is TNF [109, 322, 330, 334-337, 344, 347, 348, 639, 640]. 
TNF is an early response cytokine, upstream of many implicated mediators such as 
IL-1, IL-10, ROS and lipid mediators and influences the coagulation and apoptotic 
pathways and the surfactant system [641-648]. Thus, TNF signaling may represent 
an important common pathway and therapeutic target. Its roles in ARDS wil now be 
discussed in more detail. 
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1.4 Tumour necrosis factor-α  signaling in  Acute  Lung Injury  and  Ventilator-
Induced Lung Injury 
TNF  
TNF is the prototypic member of the TNF ligand family, comprising of 17 similar 
proteins with diferent functions, including: TNF, lymphotoxin-alpha (TNF-beta), 
CD40 ligand, receptor activator for NF-kappaB ligand (RANKL) and TNF-related 
apoptosis-inducing ligand (TRAIL) [644]. TNF is mainly produced by activated 
macrophages and monocytes, but also by many other cels including lymphocytes, 
fibroblasts, mast cels, cardiomyocytes, adipose tissue, neuronal tissue and 
endothelial cels [644, 649]. It is expressed as a 26kDa type I transmembrane 
protein aranged in a non-covalently bound homotrimer form [650]. This 
transmembrane form (mTNF) can be cleaved primarily by the metaloprotease TNF-
alpha converting enzyme (TACE or ADAM-17), but also by proteinase-3 to release 
the soluble TNF form (sTNF) [650-652]. The 51kDa trimeric sTNF tends to dissociate 
below the nanomolar range (forming three 17kDa protomers), thereby losing its 
bioactivity [649]. Historicaly, mTNF was only considered as a precursor to the 
bioactive sTNF with no active function, however it was later recognised that mTNF 
can also elicit celular responses independently of sTNF [653-656]. Large amounts of 
TNF is released in response to LPS and other bacterial products and IL-1[649], 
whereas IL-4, IL-10 and glucocorticoids are potent inhibitors of TNF release [657, 
658]. IL-10 inhibition of TNF release represents a negative feedback loop as its 
production is induced by TNF in monocytes [648]. 
TNF is a pleiotropic cytokine that mediates a vast spectrum of biological 
responses, some of which often seem conflicting. For example, in addition to its 
firstly recognised necrotising efect and cytotoxicity in some tumours and tumour cel 
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lines, TNF is also involved in cel proliferation and cel diferentiation [644, 649]. In 
concert with other cytokines, such as IL-1 and IL-6, TNF is a key player in the 
systemic inflammatory response syndrome [659]. It acts as a potent early-response 
pro-inflammatory mediator by inducing the expression of the chemokines MCP-1 and 
IL-8 (or its murine homologs MIP-2 and KC) and endothelial adhesion molecules E-
selectin, VCAM-1 and ICAM-1, thereby facilitating leukocyte migration to sites of 
inflammation [660-663]. It also augments the phagocytic function of macrophages, 
expression of other cytokines such as IL-1, IL-6 and IL-10, oxidants and the pyrogen 
prostaglandin-E2 [642, 648, 664-666]. TNF can also induce apoptotic cel death, 
tumourigenesis and viral replication [644]. 
Since its discovery, TNF has been shown to be a primary mediator in several 
pathophysiological processes and conditions. For example, while high amounts of 
TNF are produced in septic shock,  more prolonged exposure to TNF at low 
concentrations leads to wasting or cachexia such as that observed in cancer and 
chronic infection, hence its other name cachectin [667]. TNF has been also linked 
with atherosclerosis [668], and autoimmune conditions such as ankylosing 
spondylitis [669], rheumatoid arthritis [670], psoriasis [671] and inflammatory bowel 
disease [672], Alzheimer’s disease [673], major depression [674] and various 
pulmonary disorders [675], but wil be primarily discussed here in relation to ARDS 
and VILI.  
TNF in ALI/ARDS and VILI pathogenesis 
Role of TNF in clinical ARDS and VILI models 
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Multiple clinical studies investigated the relevance of TNF in ARDS pathology and 
demonstrated changes in its levels both in the alveolar compartment and the 
systemic circulation, although some of these are not consistent in their findings. 
In a smal study by Armstrong et al. enroling a total of 26 patients the authors 
found a tendency toward increased sTNF levels in BALF and AM supernatant of 
patients with ARDS (N=10) compared to at risk patients, without any diference in 
plasma levels [676]. The same authors later also demonstrated an increased 
expression of mTNF on AMs derived from ARDS patients compared to those 
isolated from at risk patients, and this mTNF was functionaly active in a cytotoxicity 
assay [677]. Despite increased mTNF expression the authors failed to show an 
increase in sTNF in BALF or AM supernatant. Pugin et al. showed up-regulation of 
sTNF in BALF but not in plasma obtained from ARDS patients, and this TNF was 
bioactive mainly in concert with IL-1-beta [102, 259]. 
In agreement with the findings of Pugin et al., Parsons and co-workers also 
failed to show an increase in plasma levels of sTNF during the course of ARDS, and 
plasma TNF levels had no value in predicting the development or clinical outcome of 
ARDS [678, 679]. In direct contrast, in the study by Meduri et al. plasma TNF levels 
were found to be significantly higher on day 1 of ARDS and remained persistently 
elevated in non-survivors compared to survivors, thus predicting the clinical outcome 
[680]. BALF TNF levels were also high and showed the same trend as plasma TNF 
levels, but more importantly, BALF:plasma ratio was also elevated, hinting toward a 
pulmonary origin of TNF. There is also clinical evidence that ventilation of ARDS 
patients with more conventional setings (i.e. higher VT) results in elevated BALF and 
plasma TNF levels and is associated with higher mortality [330]. 
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The role of TNF is also subject of debate when it comes to VILI, especialy in 
experimental studies. In in vivo saline-lavaged rabbit models conventional ventilation 
strategy up-regulates intra-alveolar TNF both at messenger and protein level as 
compared to protective HFV [322, 681], and administration of i.t. anti-TNF 
monoclonal antibodies atenuates VILI [334]. Also, Tremblay et al. demonstrated in 
an ex vivo isolated non-perfused rat lung model, that injurious ventilation up-
regulates intra-alveolar levels of TNF [335, 682]. Using an isolated-perfused mouse 
lung system, von Bethman et al. and Held et al. showed that over-inflation of the 
lungs results in increased perfusate levels of TNF, but they did not investigate BALF 
levels [336, 683]. In direct contrast, Verbrugge et al. showed no increase in BALF or 
serum levels of TNF in surfactant-depleted rats subjected to high-pressure 
ventilation [684]. Similarly, Ricard et al. found no TNF in BALF obtained from rats or 
isolated rat lungs ventilated with high VT [610]. 
Some of these inconsistencies may arise from the use of two-hit (i.e. pre-
injured lungs subjected to high stretch) vs. one-hit VILI models (‘pure’ VILI), 
diferences in the species used or in the timing of TNF measurements and kinetics. 
This was clarified, at least in part, by a study from our group using an in vivo mouse 
model of VILI without pre-existing lung injury [337]. We found that high-stretch 
mechanical ventilation resulted in a transient up-regulation of intra-alveolar TNF with 
an early-peak during the course of VILI with undetectable levels at later stages. This 
could therefore explain the previous conflicting of TNF up-regulation in one-hit pure 
VILI models. Bioactivity of TNF was however stil present at the end stages of injury 
progression as demonstrated by WEHI bioassay [337]. Our group later also 
demonstrated that this intra-alveolar TNF played a role in the pathogenesis of VILI 
by using mice deficient in TNF receptors and treating wild-type mice with anti-TNF 
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antibodies [109]. The authors found that blockade of total TNF signaling in receptor 
deficient mice and by i.t. administration of anti-TNF mAb significantly reduced the 
influx of neutrophils to the alveolar space. Importantly, intravenous administration of 
the same antibody was without efect, hinting towards the importance of intra-
alveolar TNF signaling at least in this aspect of VILI. 
TNF was also implicated in other experimental models of ARDS and even 
MSOF. For example, acid aspiration-induced lung and systemic organ injury can be 
atenuated by pharmacological blockade of systemic TNF signaling as demonstrated 
by  Goldman et al. [685]. Davidson and coleagues demonstrated similar protective 
efect of i.t. administered anti-TNF antibody on lung injury induced by acid aspiration 
[686]. 
TNF-mediated celular and molecular mechanisms in the pathogenesis of ARDS/VILI 
As discussed before, the pathogenesis of ARDS of al aetiologies involves a complex 
interplay of molecular and celular mechanisms, and TNF has been demonstrated to 
play a role in most, if not al of these processes. 
Increased permeability oedema is a key feature of ARDS [22], and TNF 
mediates alveolar-capilary barier dysfunction in diferent ways, but mainly involving 
cytoskeletal re-arangements and apoptosis of the cels. For instance, TNF can 
induce pulmonary vascular permeability in vivo and in vitro [687]. TNF treatment in 
pulmonary endothelial cel culture results in a decrease in F-actin and an increase in 
G-actin, and this imbalance between the two manifests in increased permeability 
[688]. Similarly, Petrache et al. showed that TNF induces phosphorylation of the 
myosin light chain (MLC), resulting in stress fibre formation, apoptosis of pulmonary 
endothelial cels and increased permeability [689]. The same investigators later 
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demonstrated that TNF-induced endothelial cel permeability is mediated by the 
destabilisation of tubulin-based microtubule network in a p38 MAPK-dependent 
manner, leading to an increase in actin stress fibres, intercelular gaps and 
compromise of VE-cadherin based adherens junctions [690]. This later is secondary 
to TNF-induced tyrosine phosphorylation of VE-cadherin leading to its redistribution 
on the endothelial cel surface which subsequently leads to intercelular gaps and 
increased permeability [691-693].  In addition to its role in regulating endothelial 
permeability, TNF also induces alveolar epithelial permeability in vitro by causing 
cytoskeletal re-arangement and consequent gap formation [694]. This is important 
as alveolar epithelial integrity is the main determinant of alveolar flooding in ARDS 
[67]. 
Margination of inflammatory leukocytes to the lung is another halmark of 
ARDS [22], and was shown to be mediated by TNF by at least three mechanisms. 
Firstly, TNF regulates the production of other inflammatory cytokines and 
chemokines such as MIP-2 and MCP-1 that leads to pulmonary sequestration of 
circulating inflammatory leukocytes [660, 661, 663]. Secondly, TNF induces the 
expression of adhesion molecules on both endothelial and epithelial cels, which 
could afect leukocyte margination and migration [695]. Thirdly, TNF triggers 
paracelular gap formation in the endothelial layer, thus facilitating leukocyte 
migration. This was elegantly demonstrated in vitro by Notebaum et al., who found 
that pre-treatment of endothelial cels with TNF was required for neutrophil- and 
leukocyte-induced dissociation of vascular endothelial receptor-type protein tyrosine 
phosphatase (VE-PTP) from VE-cadherin, which ultimately resulted in increased 
tyrosine phosphorylation of VE-cadherin, weakening of adherens junctions and 
enhanced leukocyte transmigration [48]. 
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Surfactant dysfunction is also characteristic to the pathogenesis of ARDS [22], 
resulting in deterioration of respiratory mechanics and increasing the need for 
mechanical ventilation, which impairs further the surfactant layer and function 
thereby generating a vicious cycle [183-189]. Moreover, surfactant dysfunction has a 
detrimental efect on host defence from airborne as wel as blood borne pathogens 
[696, 697]. TNF contributes to this pathology by suppressing the transcription of SP-
A and SP-B [641, 645], the surfactant proteins playing a crucial role in host defence 
[152, 153] and biophysical properties [151] of the surfactant system, respectively. 
TNF-induced suppression of SP-A transcription in lung epithelial cels is apparently 
mediated by the p38 MAPK pathway [645]. 
Intravascular and intra-alveolar coagulation in ARDS results in increased 
shunt fraction leading to hypoxia and is also linked with the initiation and propagation 
of the inflammatory response [38, 41]. TNF facilitates this process by activating pro-
coagulant factors and inhibiting those involved in fibrinolysis [646]. For example, TNF 
indirectly activates coagulation by inducing IL-6 production which then stimulates 
tissue factor (TF) expression [698]. Also, TNF down-regulates thrombomodulin (TM), 
a crucial mediator of thrombin-induced protein C activation, on the endothelial 
surface thus facilitating the coagulation cascade [699, 700]. TNF also exerts anti-
fibrinolytic efects by stimulating the release of plasminogen activator inhibitor (PAI)-
1 [701]. 
Production of reactive oxygen species by inflammatory cels and cels of the 
lung parenchyma facilitated by supplementary oxygen during mechanical ventilation, 
in conjunction with deprivation of endogenous antioxidants leads to a redox 
imbalance and oxidative injury to the lung during ARDS [206]. Glutathione (GSH) is 
one of the most important endogenous antioxidants [213], levels of which are greatly 
88 
reduced in the BALF and plasma of ARDS patients [215, 216]. Over-expression of 
TNF in transgenic  mice is  associated  with  decreased levels  of  GSH in their lungs, 
liver and kidney, suggesting that TNF can impair anti-oxidant capacity [702]. 
Exposure of human pulmonary artery endothelial cels to TNF in vitro also reduces 
intracelular GSH levels enhancing the susceptibility of cels to oxidative injury [703, 
704]. TNF is also involved in propagating oxidative stress by inducing production of 
ROS. For example, TNF treatment induces mitochondrial ROS production by 
HUVECs and human pulmonary microvascular endothelial cels in vitro [664, 705]. 
TNF was also shown to stimulate ROS production by neutrophils which altered 
pulmonary vasoreactivity in vivo [665]. This efect is likely to be related to ROS-
induced stifening of pulmonary endothelial cels as demonstrated by Wang et al. 
[705]. 
TNF also plays an important role in the resolution phase of ARDS by 
regulating alveolar fluid clearance, although some of the reports are conflicting in 
their findings [706-710]. 
Clearly TNF is involved in most aspects of the pathogenesis of ARDS, and its 
efects are mainly detrimental. However, clinical trials with anti-TNF therapy in 
sepsis/ARDS patients using agents that were efective in other TNF-mediated 
pathologies such as rheumatoid arthritis and inflammatory bowel disease, proved to 
be largely unsuccessful [616, 617, 620, 623-625]. The reasons as to why anti-TNF 
therapy failed in these trials are not fuly understood, but the answer may lie in the 
complexity of TNF biology and how its efects are mediated through its cel surface 
receptors. This wil now be discussed in more detail. 
TNF receptor subtype signaling  
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TNF receptors - overview 
Similarly to TNF-like ligands, the TNF receptor (TNFR) superfamily is also extensive, 
counting at least 41 members that share diferent level of homology in their cysteine-
rich extracelular sequence, including TNF receptors, CD40, Fas, nerve growth factor 
receptor (NGFR),  TRAIL receptors,  RANK  and  death receptors (DR) [644]. Most of 
the members are activated by one specific ligand, however TNF has the ability to 
bind to and exert its celular efects via two distinct cel surface receptors: the 55kDa 
TNF receptor p55 (also known as TNFR 1, CD120a, TNFRSF1A) and the 75kDa 
TNF receptor p75 (TNFR 2, CD120b, TNFRSF1B), both of which are also activated 
by lymphotoxin-alpha [644]. Both  TNFR  p55  and  p75  are  single  
transmembrane glycoproteins sharing 28% homology, mainly in their extracelular 
domains [644]. They share similarity in that they both contain an extracelular pre-
ligand-binding assembly domain (PLAD) that facilitates trimerisation of the receptors, 
particularly upon ligand binding [711]. In contrast, the diferences in their extracelular 
domain lend them diferent ligand binding and activation characteristics.  Moreover, 
their intracelular domains are largely unrelated, alowing for their diversity in 
signaling functions [712]. The main diference is that TNFR p55 contains a death 
domain (DD) in its intracelular portion, that plays a critical role in its cel-death 
inducing function [713], whereas TNFR p75 does not have a DD and recruits 
diferent adaptor molecules in order to exert its celular efects [644]. 
TNFR p55 expression 
TNFR p55 is considered to be expressed on al nucleated cels [649], including 
circulating monocytes [714-718], macrophages [719, 720], neutrophils [721, 722], T- 
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and B-lymphocytes [712, 716, 723], and parenchymal epithelial [656] and endothelial 
cels [53, 724, 725]. 
TNFR p55 can be cleaved from the cel surface by metaloproteases such as 
TACE [718, 721, 726]. Upon ligand binding it can also be internalised to initiate 
signaling pathways, but also to inhibit its long-term actions thus acting as a negative 
feed-back loop [726-728]. Surface expression of p55 receptor can also be up-
regulated on some cels by certain stimuli [719, 729, 730], but not as readily and 
dynamicaly as p75 (see below). 
In addition to its surface expression, there is also evidence that large amounts 
of TNFR p55 can be found localised in the perinuclear-Golgi  complex [731, 732]. 
From this intracelular reservoir, ful length p55 receptors can be released to the 
extracelular environment in exosome-like vesicles [733, 734], but there is no 
evidence that these Golgi-contained receptors would play a role in reconstitution of 
surface p55 expression. 
There are only few studies investigating the expression of TNFR p55 in the 
lung, and some of these studies are conflicting in their findings. For example, 
Nakamura et al. showed expression of both TNF receptors in lung tissue at mRNA 
level, but did not investigate their expression at the protein level [730]. The same 
study also used type I-like A549 cels that were found to express only TNFR p55 
both at gene and protein levels (the later assessed indirectly by ligand binding 
studies). Islam et al. demonstrated surface expression of TNFR p55 on human smal 
airway epithelial cels [734], whereas in another study by Liu et al. primary rat type I 
AEC and type I-like MLE-Kd cel line were found to express both receptors with 
some dominance of p55 [656]. In direct contrast, Ermert et al. using human and rat 
lung sections found no expression of p55 on the alveolar septum [735], while TNFR 
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p75 was expressed on nearly al cels,  including the alveolar epithelium, and both 
receptors were found on pulmonary endothelial cels, consistent with Grau et al. [53]. 
Some of these discrepancies may lie in the diferent techniques employed. For 
example, while Liu et al. and Grau et al. used quantitative flow cytometry, Ermert et 
al. used immunohistochemistry, and with such a qualitative/semi-quantitative 
method, the relative expression of the two receptors may be dificult to determine. In 
addition, none of these studies validated their staining technique with TNFR knock-
out animals. Therefore, the exact expression of TNFRs in lung tissue remains to be 
elucidated, and wil form one focus of this project. 
TNFR p55-associated signaling 
TNFR p55 is considered to be the major mediator of TNF signaling [649]. Both 
soluble and membrane-bound forms of TNF can activate TNFR p55 equaly wel 
[644]. As TNFRs do not possess a catalytic domain, they exert their signaling efects 
through adaptor molecules that are recruited upon ligand binding. Diferences in their 
cytoplasmic domain account for the diference in what adaptor molecules they recruit 
and what signaling pathways they activate, although considerable overlap exists 
between the receptors in this regard. 
TNFR p55 is a death receptor in the classical term owing to its intracelular 
DD, but can also mediate cel proliferation through activation of the NF-kB pathway. 
How activation of the same receptor in the same cel can mediate such opposing 
celular responses was elegantly explored and demonstrated by Micheau et al. [736]. 
According to their model, after binding of TNF to TNFR p55, a rapid assembly of 
TNFR p55-associated death domain (TRADD), receptor interacting protein-1 (RIP1) 
and TNFR-associated factor-2 (TRAF2) occurs forming Complex I. Complex I then 
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activates the NF-kB, promoting protein synthesis and cel survival. The formation of 
Complex I is however transient, as TRADD, RIP1 and TRAF2 dissociates from 
TNFR p55 within an hour while the receptor undergoes endocytosis. Folowing 
dissociation from TNFR p55, TRADD and RIP1 recruit Fas-associated death domain 
(FADD), caspase-8 and 10, forming Complex I that triggers apoptosis. According to 
a second model, upon ligand binding TNFR p55 wil become internalised in a 
receptosome where it associates with TRADD, FADD and caspase-8 to trigger 
apoptosis, whereas the lack of receptor internalisation promotes NF-kB activation, 
thus cel survival [728]. 
TNFR p55 can also activate the MAP kinases (MAPKs) p38, extracelular 
signal regulated kinase (ERK or p44/p42) and c-Jun N-terminal kinase (JNK) via 
TRAF2 and RIP-mediated activation of their upstream kinases (MAPKKK, MAPKK) 
[644, 649, 737, 738]. Activation of the MAPK pathways can mediate cel death, 
survival and inflammation.  
Activation of TNFR p55 can result in TRAF-2 mediated ROS production by the 
mitochondria [739]. Stimulation of TNFR p55 facilitates the interaction of apoptosis-
regulating kinase 1 (ASK1) with TRAF2 leading to the activation of ASK1 in a redox 
sensitive manner, in which thioredoxin (Trx) plays an essential role [740]. Under 
reducing conditions, the reduced form of thioredoxin binds and inhibits ASK1. When 
ROS are produced, thioredoxin becomes oxidised and dissociates from ASK1 which 
then forms a JNK-inducing complex with TRAF-2 [741], leading to JNK-activation 
and apoptosis. At the same time, TNF-induced ROS can inhibit the NF-kB pathway 
thus further facilitating apoptotic cel death [647]. On the contrary, there is also 
evidence that ROS can activate NF-kB and promote cel survival [742], adding to the 
complexity of TNF biology. It has been demonstrated by Yazdanpanah et al. that 
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TNFR p55 can also recruit riboflavin kinase via TRADD that that activates 
membrane-associated NADPH oxidase, lading to ROS production and cel death 
[743]. Overal, these findings point toward a mainly pro-apoptotic function of TNFR 
p55-induced ROS. 
In addition to the above mentioned signaling pathways, there is also evidence 
that TNFR p55 can bind other adaptor proteins to sites on its cytoplasmic domain 
that are distinct from its DD. For instance, it binds factor associated with neutral 
sphyngomyelinase activation (FAN), which facilitates the degradation of 
sphingolipids by neutral sphyngomyelinase into ceramide-containing signaling 
intermediates that are involved in a pro-apoptotic function [644, 649]. Another 
molecule that interacts with the juxtamembrane region of TNFR p55 is brain and 
reproductive organ-expressed (TNFRS1A modulator) (BRE), the role of which is to 
inhibit and dampen TNFR p55-mediated signaling  [644]. 
Physiological roles of TNFR p55 
In addition to its role in mediating cytotoxicity, TNFR p55 is also recognised as a 
major mediator of the pro-inflammatory response exerted by TNF and is involved in 
the pathogenesis of a number of pathological conditions. For example, TNF 
contributes to the insulin resistance seen in type I diabetes melitus, and this efect 
is mediated by TNFR p55 [744], and so is mTNF-induced arthritis [653]. The pro-
inflammatory role of TNFR p55 is best demonstrated in the autosomal dominant 
TNFR 1-associated periodic syndrome (TRAPS) where a mutation of TNFR p55 
leads to impaired shedding of the receptor and increased cel-surface expression, 
and is characterised by recurent high fevers, abdominal pain, rash and arthralgia 
[745]. 
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TNFR p55 mediates the generation of pro-inflammatory cytokines/chemokines 
IL-6, IL-8 (and its murine homologues MIP-2 and KC), MCP-1  and  GM-CSF [655, 
662, 746-748], and up-regulation of endothelial adhesion molecules (E- and P-
selectin, VCAM-1, ICAM-1) [662, 725, 749, 750], leading to leukocyte chemotaxis, 
entrapment and transmigration to sites of inflammation/infection, and also mediates 
the oxidative burst in neutrophils [722]. 
Transgenic mice deficient in TNFR p55 have greater sensitivity to infection by 
Listeria monocytegenes and Legionela pneumophila infection with associated high 
mortality, yet are resistant to TNF-, IL-1- and LPS-induced lethality in vivo [751, 752], 
indicating that while TNFR p55 is crucial in host defence against active bacterial 
infection, it can also be deleterious by activating an overwhelming inflammatory 
response. TNFR p55 has also been implicated in early acute graft-versus-host-
disease [753]. 
TNFR p75 expression 
Historicaly it was thought that while expression of TNFR p55 is ubiquitous, TNFR 
p75 is predominantly expressed on haemopoetic cels [754]. However, similarly to 
p55 it was found to be expressed on  B- and T-lymphocytes [716, 755], monocytes 
[714-718], macrophages [719, 720], neutrophils [722], endothelial [662, 724, 725] 
and epithelial cels [656].  
 Similarly to TNFR p55, surface expression of TNFR p75 can be down-
regulated to some extent by receptor internalisation [726, 727, 756], but it is more 
inclined to shedding by TACE and elastase [757, 758] compared to TNFR p55 [658, 
714, 726, 727, 747]. It has been suggested that TNFR p75 shedding is in part 
mediated by TNFR p55 [727, 747]. On the other hand, expression of TNFR p75 can 
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also be up-regulated and is more dynamicaly controled than that of p55 [754]. This 
suggestion is mainly based on in vitro experiments using haemopoietic cel lines, 
where cels exhibited increased p75 expression with unafected p55 levels in 
response to a variety of inflammatory stimuli (e.g. LPS, IL-2, mitogens, PMA) [723, 
759, 760], but whether this applies to the in vivo seting remains unclear. This readily 
changeable expression of TNFR p75 coupled to a largely unmodulated TNFR p55 
expression can rapidly alter the TNFR p55:p75 ratio on the cel surface and is likely 
to play an important physiological role in determining the overal TNF response in 
that particular cel [761-763], and suggests an important functional role for this 
receptor. 
TNFR p75-associated signaling 
In vitro studies in the early 1990s indicated that antagonistic TNF receptor specific 
muteins against p55 as wel as p75, at least to some extent, can inhibit sTNF-
induced cel death [764] in tumour cels and sTNF-enhanced adhesion molecule 
expression on endothelial cels [725, 764], suggesting that both receptors are 
involved in mediating these celular responses. However, when receptor agonistic 
muteins were employed, it revealed that only TNFR p55 activation is responsible for 
these TNF-induced bioactivities [724, 765-769]. The discrepancy between the 
findings of these receptor agonistic and antagonistic studies was historicaly 
explained by the ligand-passing theory [770]. According to this, TNFR p75 having a 
much higher afinity to sTNF than p55 (Kd 100pM and 500pM, respectively), as wel 
as a much more rapid dissociation rate (t½=10min and >3h, respectively), 
preferentialy binds sTNF, especialy at low ligand concentrations, and then passes it 
onto the p55 receptor in close proximity, thereby promoting its activity [770]. 
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However, the TNFR p55:p75 ratio seems to be very important, as artificialy high 
levels of p75 can reduce p55 activity by ligand depletion [770], whereas when the 
expression levels of p75 are very low, its contribution to TNF-induced cytotoxicity is 
negligible [765, 767, 768]. 
 More recently, however, a growing body of evidence indicated that TNFR p75 
can mediate distinct celular pathways, partly or completely independently from 
TNFR p55 [644]. Moreover, it has been also found that mTNF is the prime activator 
of TNFR p75 and it cannot be eficiently activated by sTNF [655], thus the in vitro 
studies may not accurately reflect the in vivo function of TNFR p75, which therefore 
may have been underestimated in the past [644]. 
 As TNFR p75 does not possess a DD, it mainly exerts its signaling via 
recruitment of TRAF adaptor proteins, more specificaly TRAF2 [644]. TRAF2 alows 
the recruitment of other factors, such as RIP and FADD through which TNFR p75 
can trigger apoptosis [755]. According to other studies employing sTNF and receptor 
agonistic antibodies, TNFR p75-induced apoptosis does not involve direct 
engagement with the apoptotic pathways, but relies on the induction of mTNF, which 
subsequently activates TNFR p55, as wel as on the concomitant depletion of TRAF2 
and TRAF2-associated protective factors [771, 772]. On the other hand, TNFR p75 
activation can also lead to recruitment of celular inhibitor of apoptosis (cIAP)-1 and -
2 via the TRAF2-TRAF1 heterocomplex [773], and in the absence of RIP it can also 
activate the NF-kB pathway [755] [774] alowing the transcription of anti-apoptotic 
and pro-inflammatory genes. There is evidence that this activation of the NF-kB 
pathway by TNFR p75 is distinct from its p55-mediated activation (thereby caled the 
alternative NF-kB pathway) and is restricted to TNFR p75 engagement with mTNF 
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[775]. Therefore it seems that while TNFR p75 activation by sTNF is mainly 
cytotoxic, mTNF mainly triggers protein synthesis and cel survival.  
 The above mentioned mechanisms indicate that TNFR p75 signaling 
significantly overlaps with that of TNFR p55, mainly because they recruit the same 
adaptor proteins, particularly TRAF2. However, in addition to these shared pathways 
TNFR p75 can also activate its own specific signaling molecules, similarly to BRE 
and FAN for TNFR p55. For example the endothelial/epithelial tyrosine kinase 
(Etk/Bmx) constitutively associates with the cytoplasmic domain of TNFR p75 in a 
ligand-independent manner and remains in its closed inactive form [776]. Upon 
ligand binding the receptor goes through trimerisation and conformational change 
leading to an open conformation of Etk which then becomes activated via 
phosphorylation [776]. The active form of Etk then activates downstream signaling 
molecules such as Akt (or protein kinase B -  PKB) [777], resulting in cel-specific 
responses, such as endothelial cel migration and angiogenesis in endothelial cels 
[776], and strengthening of intercelular junctions thus increasing trans-epithelial 
resistance in epithelial cels [778]. 
Physiological roles of TNFR p75 
Transgenic mice deficient in TNFR p75 show increased resistance to low dose TNF-
induced lethality and tissue necrosis [779], indicating an important role for this 
receptor in these biological responses. TNFR p75 can also facilitate p55-mediated 
apoptotic cel death by at least two distinct mechanisms: via ligand passing [770], 
and by TRAF2 depletion with concomitant up-regulation of mTNF and subsequent 
paracrine/autocrine TNFR p55 activation [771, 780]. It can also promote cel-death 
via caspase activation independent of TNFR p55 [755]. Beside cel death, TNFR p75 
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also mediates proliferation of kidney tubular cels, thymocytes and the production of 
GM-CSF independent of TNFR p55 [777, 781]. It is also involved in endothelial cel 
migration and angiogenesis via its distinct Etk/Bmx signaling pathway [776]. 
 In addition to mediating cel proliferation and cel death, TNFR p75 is also 
heavily involved in TNF-mediated inflammation and immune response. For example,  
TNFR p75 is required for the migration of activated Langerhans’ cels from the 
epidermis to the lymph nodes [782] and plays a minor role in mycobacterial immunity 
[783]. It has been also demonstrated that TNFR p75 plays a role in mediating TNF-
induced expression/production of E-selectin, VCAM-1, ICAM-1, IL-6, IL-8, KC, tissue 
factor  and  GM-CSF [655, 662, 747], mainly through enhancing signaling through 
TNFR p55.   However, a study using TNFR knock-out mice suggested that TNFR 
p75 is important for TNF-induced expression of E-selectin, VCAM-1 and ICAM-1 in 
aortic endothelial cels, and its expression on endothelial cels is essential for 
adequate leukocyte roling, adhesion and transmigration [749]. TNFR p75 also plays 
a pivotal role in the pathogenesis of cerebral malaria, as receptor deficient mice 
exhibit an absence of ICAM-1 induction on brain microvessels which is associated 
with brain protection and reduced mortality [784]. There is also evidence that TNFR 
p75 plays a role in the pathogenesis of CD4+-T-cel mediated hepatitis [785], 
glomerulonephritis [786], and multiorgan inflammation [787]. 
Soluble TNFRs (sTNFRs) 
As mentioned earlier both TNFRs can be shed from the cel surface by the action of 
proteases that cleave the receptor ectodomains. The physiological sheddases 
responsible for sTNFR production are TACE and elastase [757, 758]. TACE can 
cleave both cel-surface TNFRs, whereas elastase can only cleave TNFR p75, which 
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could account for the apparent increased susceptibility of TNFR p75 to be shed and 
its higher levels in biological fluids as compared to p55 [658, 714, 727, 747]. These 
cleaved monomeric receptor fragments (28 kDa and 40-42 kDa for TNFR p55 and 
p75, respectively) [726, 788], retain their ability to bind TNF although with lower 
afinities [649]. In the case of TNFR p55, uncleaved, ful-length receptor can be also 
released via exosome-like vesicles as discussed earlier [733, 734]. 
TNFRs are constitutively shed in vivo and in vitro [657, 658, 678, 716, 726, 
730, 788] and hence sTNFRs are present in many biological fluids under baseline 
conditions including the alveolar lining fluid, blood and urine, with sTNFR p55 
produced mainly by parenchymal cels and sTNFR p75 by leukocytes [746, 789]. 
Soluble TNFR release can also be enhanced by a range of inflammatory mediators 
including LPS, TNF, IL-1, IL-6, IL-10 and many others [658, 714-716, 718, 721, 726, 
730, 734, 746, 788, 790] and be inhibited by steroids, IL-4 and PKC inhibition [657, 
658, 714, 791]. The sTNFRs are mainly cleared from the circulation by renal 
excretion [792]. 
Soluble TNF receptors have been implicated in a variety of clinical conditions. 
For example, BALF sTNFR levels are elevated in patients with sarcoidosis [793, 794] 
and ALI [678], where their levels seem to corelate with mortality. Increased plasma 
levels are associated with sepsis/endotoxaemia [795-797], cancer [798] and 
autoimmune diseases such as inflammatory bowel disease [799], rheumatoid 
arthritis [800] and systemic lupus erythematosus [746], with as yet unknown 
significance. 
As they are unable to transduce signals from TNF, sTNFRs were originaly 
considered to have one biological role, namely to neutralise TNF actions as decoy 
receptors [200, 654, 788, 797, 798, 800-806], which mechanism was utilised in 
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sTNFR-based therapies. For example, sTNFR constructs such as p55-PEG (soluble 
p55 linked to polyethylene glycol) and etanercept (dimeric soluble p75:Fc fusion 
protein) atenuates arthritis in transgenic mice overexpressing mTNF [654]. Similarly, 
etanercept has been used as an anti-TNF drug with success in rheumatoid arthritis, 
ankylosing spondylitis, psoriasis, psoriatic arthritis and juvenile idiopathic arthritis 
[672, 807]. In contrast, it has been also proposed that sTNFRs may prolong the 
bioactivity of TNF via the formation of a sTNFR-sTNF complex that stabilises its 
structure and release bioactive sTNF over time, thus increasing its half-life and 
activity [808, 809]. 
The specific role of sTNFRs in a given biological scenario may depend on 
their relative levels to TNF. When the sTNFR:sTNF ratio is high, they could be 
antagonistic, but the net outcome depends on whether TNF plays a deleterious or a 
protective role in that particular biological process [746, 809]. When the level of 
sTNFRs is moderate they may serve as bufers by inhibiting the efects of high 
concentrations of TNF, but also facilitating TNF signaling in a controled manner 
[746]. 
Role of TNFRs in ALI/ARDS 
Both clinical and experimental studies implicated roles for each TNFR subtype in the 
pathogenesis  of  ALI/ARDS.  Grau  et  al.  showed that  cultured pulmonary 
microvascular endothelial cels (MVEC) isolated from patients with ARDS expressed 
higher levels of TNFR p75 (but not TNFR p55), VCAM-1 and ICAM-1 as compared 
to controls (lung cancer patients undergoing lobectomy) [53]. These cels also 
exhibited increased production of IL-6 and IL-8 upon TNF treatment compared to 
controls, indicating a role for TNFR p75. Upregulation of ICAM-1 was weaker in cels 
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from ARDS patients (approximately 2-fold increase from baseline as compared to a 
5-fold increase in controls), but this might have been secondary to an already high 
baseline expression and a saturated response to TNF. Nonetheless, the absolute 
level of TNF-induced ICAM-1 expression was stil significantly higher in cels from 
ARDS patients. It is important to point out, however, that culturing cels over several 
weeks (2-3 weeks in this particular study) can potentialy result in phenotypic and 
functional change of cels, and therefore the data may not reflect the in vivo 
expression of TNFRs and their function. 
Xu et al. showed that alveolar TNFR p55 mediated lung injury induced by 
adoptive transfer of CD8+ T-cels activated by intraalveolar viral antigens [748]. Liu et 
al. reported an important role for TNFR p75 in the same process [656]. The authors 
found that TNFR p75 deficient mice were nearly free from alveolar infiltration by 
inflammatory cels and had significantly reduced lung injury compared to wild-types. 
They suggested that this protection from lung injury might be due to a reduced MCP-
1 production by type I AECs in response to CD8+ T-cel derived sTNF, because 
primary type I AECs isolated from TNFR p75 knockout mice produced no MCP-1 in 
response to sTNF. On the other hand, lack of TNFR p55 had the same efect, in 
agreement with the finding by Xu et al. [748]. Lung injury secondary to Pneomocystis 
carini infection is also mediated by CD8+ T-cels and involves both TNFRs as 
demonstrated by Pryhuber et al. [789]. Using a chimera model in which bone marow 
from wild-type mice was injected to mice lacking both TNFRs (TNFR double knock-
outs (DKO), the recipients had significantly lower number of inflammatory 
leukocytes in their BALF than wild-type  wild-type chimeras, indicating a role for 
parenchymal TNFRs in the development of lung injury via the recruitment of 
damaging inflammatory cels, in support of the findings of Liu et al. [656] and Xu et 
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al. [748]. However, the individual role of each TNFR was not investigated in this 
study.  
Mizgerd et al. showed in vivo that TNFR-DKO mice inoculated with i.t. E. coli 
exhibit increased neutrophil infiltration to their lung and an impaired bacterial 
clearance from the alveolar space compared to their wild-type control with no 
diference in pulmonary oedema or NF-kB activation [810]. Later the same group 
using the same model but employing TNFR p55/IL-1R1 knock-out mice 
demonstrated, that these animals had significantly reduced pulmonary oedema, 
BALF neutrophils and KC levels compared to wild-types [811]. Interestingly, in mice 
lacking the IL1R1 alone, neither the number of alveolar neutrophils nor the amount of 
pulmonary oedema were reduced, indicating an important role for TNFR p55 in 
pulmonary neutrophil traficking and oedema formation [811].  Although the authors 
did not investigate the role of TNFR p75 individualy in this model, the seemingly 
contradicting findings of their two studies can potentialy be reconciled by a 
protective role for this receptor in this particular biological scenario. 
Neumann et al. reported a crucial role for TNFR p55 in mediating i.p. TNF-
induced E-selectin, VCAM-1 and ICAM-1 expression and leukocyte migration to the 
lungs and other organs, but did not investigate the role of TNFR p75  [695]. Calkins 
et al. investigated the role of individual TNFRs in pulmonary chemokine production 
and neutrophil sequestration in response to intraperitoneal LPS [812], and found that 
p55, but not p75, was responsible for LPS-induced KC and MIP-2 production and 
neutrophil infiltration to the lungs.  
Ferero et al. investigated the role of individual TNFRs on endothelial 
permeability in vitro and in vivo [813]. They found that TNFR p55 was responsible for 
TNF–mediated cytoskeletal re-arangement of endothelial monolayers associated 
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with increased permeability, mediated by the p38 MAPK [813]. This suggests that 
p55 promotes endothelial barier dysfunction and potentialy pulmonary oedema 
formation in ARDS.   However, in vivo blockade of TNFR p75 by antagonist 
antibodies partialy inhibited TNF-induced vascular leak in the liver, indicating some 
role for this receptor [813].  
Diferential TNFR signaling 
Although the biological functions of the TNFRs often overlap despite their ability to 
activate distinct signaling pathways, there is a growing body of evidence which 
indicates that they can also act in direct opposition in a variety of physiological 
scenarios including acute lung injury of diferent aetiologies.  
In a model of ‘pure’ VILI using TNFR single and double knockout (KO) mice, 
our group has previously shown that while p55-KO mice were completely protected, 
p75-KO mice were more susceptible to develop pulmonary oedema [639]. 
Importantly, absence of al TNF receptor mediated signaling in receptor double 
knock-out animals led to a similar amount of injury compared to wild-types [639]. 
Moreover, protection from pulmonary oedema in p55-KO mice was not associated 
with decreased pulmonary neutrophil infiltration, as demonstrated by similar MPO 
activity compared to wild-types. 
We then investigated whether such phenomenon also applies to ALI of 
diferent aetiology, and tested in a mouse model of acid aspiration-induced lung 
injury [814]. We found that TNFRs played a very similar role to that in the VILI model, 
i.e. p55-KO mice were protected from pulmonary oedema, whereas lack of p75 
receptor may have exacerbated it. Further studies investigating the individual roles of 
TNFRs in this model indicated that acid aspiration-induced lung injury in wild-type 
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mice was associated with pulmonary inflammation (i.e. increased alveolar 
neutrophils, IL-6, KC, MIP-2) and markers of epithelial cel apoptosis (i.e. increased 
caspase-8, TUNEL staining) and dysfunction (i.e. reduced alveolar fluid clearance) 
[815]. Pulmonary inflammation was exacerbated by absence of the p75 receptor, 
while absence of p55 was without efect. In contrast, the p55 receptor contributed to 
epithelial apoptosis by activating caspase-8. Moreover, specific pharmacological 
inhibition of caspase-8 led to significant improvements in alveolar fluid clearance and 
oxygenation. These data suggest that p55 receptor is the main mediator of epithelial 
cel death and dysfunction contributing to lung injury, whereas p75 receptor may be 
protective via suppressing the inflammatory response.  
Similar studies have been done in other areas, such as retinal ischaemia, 
heart failure, sepsis and colitis models, suggesting that such diferential efects may 
be a universal phenomenon taking place in other organs and disease processes. For 
example, Fontaine et al. investigated the roles of TNFRs in a model of retina 
ischaemia-reperfusion damage using TNFR knock-out mice [729]. The authors found 
that while TNF deficiency (i.e. total TNF-signaling blockade) did not afect overal 
cel loss, TNFR p55-KO exhibited a significant reduction in neurodegeneration, 
whereas lack of p75 enhanced this process [729]. Higuchi et al. showed that in mice 
that overexpress myocardial TNF, and thus develop heart failure, the absence of 
TNFR p55 improved survival significantly, whereas TNFR p75-KO animals were 
more prone to develop heart failure and had reduced survival compared to mice 
expressing both TNFRs [816]. Ebach and co-workers demonstrated in a caecal 
ligation and puncture (CLP) model of sepsis that mice lacking TNFR p55 had 
prolonged survival and less hypothermia compared to wild-types [817]. In direct 
contrast, TNFR p75 deficiency led to significantly shortened survival and more 
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severe hypothermia compared to wild-types [817]. Furthermore, the level of free 
sTNF in the serum and peritoneal fluid was markedly elevated in TNFR p75-KO mice 
[817], indicating a role for this receptor in controling sTNF levels. In a mouse model 
of inflammatory bowel disease the same group has demonstrated a protective role 
for TNFR p55, whereby mice lacking this receptor lost more weight, became 
hypothermic and had reduced survival compared to their wild-type control [818]. 
TNFR p75 deficiency on the other hand resulted in less weight loss, normal 
temperature and improved survival [818]. Similarly to their other model, TNFR p75-
KO mice had increased levels of TNF [818]. 
With the exception of the colitis model, al these experiments demonstrate a 
deleterious efect for p55 and a protective role for p75. This diferential, opposing 
signaling mechanism may explain why total TNF blockade has been unsuccessful in 
the treatment of ARDS, and indicates that specific targeting of TNFR p55 signaling 
is necessary to provide protection in these clinical entities. However, we have to be 
cautious when interpreting these findings for a couple of reasons. Firstly, genetic 
modifications in knock-out animals may cause chronic compensation as wel as non-
predictable changes in the expression of other, not directly targeted genes. 
Secondly, we don’t know precisely where the locus of TNF signaling during VILI or 
acid aspiration occurs, be it intrapulmonary (alveolar) - or extrapulmonary (vascular), 
and what is the relative role of the receptor subtype signaling in diferent 
compartments of the lung. These cannot be elucidated solely by using knock-out 
animals that lack both alveolar and vascular expression of TNF receptors. In order to 
achieve success in the treatment of ARDS by targeting specific TNF receptor 
subtype signaling, the precise location where the key TNF-mediated signaling takes 
place in vivo has to be fuly uncovered.  Moreover, as the function of the individual 
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TNFRs shows corelation with their surface expression that may change dynamicaly 
leading to a varying p55:p75 ratio and net physiological outcome, it is an absolute 
necessity to explore the expression profile of TNFRs on each side of the 
alveolocapilary barier in the context of ALI/ARDS. Previous work in our group has 
indicated that alveolar expression of TNFR p55 is wel preserved during lung 
inflammation, whereas TNFR p75 is prone to shedding [819]. However, 
characterisation of TNFR expression and signaling on the endothelial side remains 
to be fuly elucidated as previous studies are contradicting in their findings and rely 
on semi-quantitative methods and extrapolation of findings in phenotypicaly diferent 
endothelial cels. Therefore this wil form one major aim of the curent study. 
Domain antibody technology 
Although diferential TNFR signaling in animal models of acute lung injury suggests 
that specific targeting of p55 receptor signaling may confer more benefits than total 
TNF blockade, monoclonal antibodies may not be optimal for this purpose for a 
couple of reasons. Firstly, monoclonal antibodies have two antigen binding 
fragments (Fab) which can result in cross-linking of the target antigens, leading to 
receptor activation instead of the desired neutralising efect, which has been 
demonstrated in a cel-lysis assay and neutrophil respiratory burst in vitro [820, 821]. 
Additionaly, monoclonal antibodies may bind non-specificaly through their 
crystalisable domain (Fc) to celular Fc receptors, leading to their endo- or 
phagocytosis folowed by recycling to the cel surface or extracelular space [822, 
823]. This may, on one hand, limit their biodistribution (i.e. may not get to their target 
antigen), while on the other hand leads to a long half-life, which may not be practical 
in the clinical seting.         
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 A  novel  development from  GlaxoSmithKline,  caled  domain  antibody 
technology may overcome these limitations. Domain antibodies (dAbs) comprise the 
variable domains of either the heavy (VH) or light chain (VL), and are thus the 
smalest functional antigen-binding  portions  of the IgG  molecule [824, 825].  Their 
smal  size (~12kDa  as  opposed to  150kDa for IgG)  means they  have  high tissue 
penetration and can be delivered at much higher concentrations per unit mass than 
monoclonal antibodies or conventionaly produced antigen-binding fragments (Fab); 
their lack of Fc portions means they are less likely to be recycled in cels (therefore 
have shorter half-life) or to induce Fc efector responses such as complement-
dependent cytotoxicity (CDC) or antibody-dependent cytotoxicity (ADCC). They have 
monovalent antigen binding characteristics, thus avoiding the potential for receptor 
cross-linking and activation. 
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1.5 Hypothesis and Aims 
This project had the main hypothesis that the two TNF receptor subtypes have 
diferent expression kinetics and roles on the two sides of the alveolar-capilary 
membrane and can mediate opposing efects in the pathogenesis of ALI; specificaly 
p55 TNF receptor mediates lung injury whereas p75 signaling has a protective role, 
therefore specific blockade of p55 signaling is necessary to atenuate ALI. This PhD 
thesis has been divided into two main parts. Firstly, this thesis wil investigate the 
expression profile and roles of TNF receptor subtypes on the pulmonary 
endothelium. Secondly, this thesis wil aim to modulate ALI progression by 
specificaly targeting individual TNF receptors on the epithelial and/or endothelial 
side of the alveolar-capilary membrane in mouse models of ALI. These 2 main aims 
have the folowing sub-divisions and specific hypotheses: 
1. Characterisation of TNF receptor expression and signaling on pulmonary 
endothelial cels: 
• Investigate the expression levels of individual TNF receptors on pulmonary 
endothelial cels under control and inflammatory conditions. We 
hypothesise that the expression level of the two TNFRs is diferentialy 
regulated on the pulmonary endothelium under control and/or 
inflammatory conditions. 
• Investigate the roles of individual TNF receptor subtype signaling in TNF-
mediated pulmonary endothelial cel activation using TNF receptor knock-
out animals and pharmacological inhibition of TNF receptor signaling in 
vivo and in vitro. I hypothesise that p55 and p75 TNF receptors have 
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diferential or even opposing roles in TNF-induced pulmonary endothelial 
cel activation. 
2. Diferential TNFR signaling in ALI: 
• Investigate the efects of pharmacological TNFR p55 signaling blockade 
on the epithelial and/or endothelial side of the alveolar-capilary membrane 
on the progression of lung injury, using in vivo mouse models of VILI and 
acid-aspiration induced lung injury. I hypothesise that TNFR p55 promotes 
pulmonary oedema and inflammation during the pathogenesis of ALI and 
its blockade therefore atenuates lung injury. 
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This chapter wil describe the various methodologies applied in this project, including 
diferent animal models of ALI, lung histology, flow cytometry and in vitro cel culture. 
 The majority of this project has been based upon the use of in vivo mouse 
models. A custom-made mouse mechanical ventilation system is described that has 
been used to model ALI  induced by use of injurious high VT ventilation or 
intratracheal instilation of hydrochloric acid (in colaboration with Dr Kenji 
Wakabayashi and Dr Brijesh Patel). I have also used in vivo mouse models of 
systemic inflammation induced by i.v. administration of bacterial toxins or TNF in 
non-ventilated mice. Protocols for each of these models are described below. 
Sampling/harvesting of BALF, plasma and lung tissues from animal models is 
described with specific assays, and in vitro culture of primary mouse lung endothelial 
cels (in colaboration with Dr Justina O Dokpesi) to investigate TNF receptor 
subtype-mediated adhesion molecule expressions is also described.  
A flow cytometry method for quantifying the expression of cel-surface TNFRs 
in normal lung tissue was utilised (in colaboration with Dr Anthony D Dor) to study 
TNFR expression on pulmonary endothelial cels under baseline and inflammatory 
conditions. The principles of this technique wil be discussed in detail below, 
including protocols for identification of pulmonary endothelial cels, and validation of 
specific TNFR staining. In addition, a lung histology protocol used for qualitative 
assessment and demonstration of lung injury is described. Beside the methods 
described in this chapter, specific protocols wil be outlined where appropriate in 
subsequent chapters. 
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2.1 Animal models 
Animals 
Al experimental protocols were approved by the Ethical Review Board of Imperial 
Colege London as wel as the GSK  Policy  on the  Care, Welfare  and  Treatment  of 
Laboratory Animals (where appropriate), and caried out under the authority of the 
UK Home Ofice in accordance with the Animals (Scientific Procedures) Act 1986. 
Experiments were performed using male wild-type C57BL6 mice aged 9-12 weeks, 
or age and sex-matched mice lacking p55 (p55KO) or p75 (p75KO) or both (DKO) 
TNF receptors (generous gifts from Amgen, Thousand Oaks,  CA) [826]. DKO mice 
were bred by crossing mice heterozygous for p55 and p75 (p55+/- and p75+/-, 
respectively). p55KO mice were C57BL6 inbred, whereas the p75KO and DKO mice 
were backcrossed onto their wild-type C57BL6 strain for five generations. 
Genotyping  of  knock-out mice was regularly performed by Surey Diagnostics to 
confirm TNFR deficiencies. 
 
In vivo systemic inflammation models 
Intravenous instilation method was used to deliver inflammatory agents systemicaly 
targeting pulmonary endothelial cels and to monitor their specific response to these 
insults. 
 Mice were transfered from their cage into a plastic chamber and placed 
under direct heat from a light bulb for approximately 1 minute in order to facilitate 
vasodilation in the tail, but not to an extent to cause harm or excessive stress to the 
animals. Then mice were transfered to a cone mouse restrainer, the tail disinfected 
with 70% ethyl alcohol, and then the agent of interest was injected via the tail vein. 
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Mice were then marked appropriately and transfered back to their cage alowing 
access to food and water ad libitum. At desired time points, mice were euthanised by 
isoflurane overdose for sampling and harvesting. 
TNF-induced pulmonary microvascular inflammation 
In order to trigger TNF-mediated celular response in pulmonary endothelial cels and 
to investigate the specific roles of individual TNF receptor subtypes, wild-type mice 
and mice lacking either one (p55KO and p75KO) or both (p55/p75 double KO) TNF 
receptors were injected intravenously with 500ng recombinant mouse TNF (R&D 
Systems Europe Ltd., Abingdon, UK) via the tail vein. Untreated mice served as 
controls. This produced distinct celular response by pulmonary endothelial cels in 
terms of adhesion molecule expression at the defined time points, depending on the 
TNFR genotype. 
Lipopolysaccharide-induced pulmonary microvascular inflammation 
To investigate the efect of systemic inflammation on the TNF receptor expression 
profile on pulmonary endothelial cels, wild-type mice were injected intravenously 
with 20µg lipopolysaccharide (Ultra-pure LPS from E. coli O111:B4, Source 
BioScience UK Ltd, Notingham, UK) and incubated for selected periods of time, 
after which the expression level of the individual TNF receptors was quantitatively 
assessed by flow cytometry and compared to control values. Systemic administration 
of LPS had diverse efects on the receptor subtypes that changed dynamicaly over 
time. 
 
In vivo mechanical ventilation in mice 
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The mechanical ventilation system used in this project has previously been 
described in great detail [106, 109, 116, 337, 639]. In this study, mechanical 
ventilation was used to either deliberately produce lung injury by applying high VT 
ventilation (VILI) with or without co-administration of i.t. LPS, or in a non-injurious 
manner either to serve as control in these models or to maintain animals after i.t. 
administration of acid during acid-aspiration induced ALI. 
The ventilation system 
This is a positive pressure ventilation system utilising a custom-made flow-controled 
ventilator [827] supplied by dry gas from a cylinder. The gas enters the system 
through a flow regulator enabling the investigator to control the flow and thus the 
actual VT (Figure 2.1.). ‘Inspiration’ and ‘expiration’ are regulated by two electronicaly 
controled valves, the solenoids. When the inspiratory valve opens, it alows gas to 
enter the lungs. Then it closes whilst the expiratory valve opens simultaneously to 
facilitate gas flow out of the lungs. This ‘expiration’ is passive and entirely relies on 
the elastic properties of the chest wal and the lungs. The gas leaving the system 
through the expiratory pipe can either enter the atmosphere freely or can be led 
through an adjustable water column to apply positive end-expiratory pressure 
(PEEP). Then the expiratory valve closes and the respiratory cycle starts again. The 
respiratory rate is controled electronicaly with a fixed inspiratory to expiratory time 
ratio of 1:2. 
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Figure 2.1 - Photograph and schematic diagram of the in vivo mouse ventilation system. High-
pressure gas from the gas cylinder passes through a flow regulator (1), which can be adjusted to give 
a desired constant VT throughout the experiment. When open, gas flows through the inspiratory 
solenoid (2), through the pneumotachograph (3) and into the mouse via the endotracheal tube (4). 
After inspiration, the inspiratory solenoid closes, the expiratory solenoid (5) opens and the mouse 
exhales passively against either atmospheric pressure or a set positive end-expiratory pressure 
(PEEP) regulated by a water column. A pressure transducer (6) for measurement of airway pressure 
and a diferential pressure transducer (7) for monitoring of airway flow, enable determination of 
respiratory mechanics. There is also an arterial line (8) for blood pressure and blood gas analyses 
and for maintenance fluid infusion, and an i.p. line for maintenance of anaesthesia (9). The mouse is 
positioned supine on a heating pad to maintain physiological temperature (36-37ºC) monitored by a 
rectal probe. Al information from the transducers is colected by a PowerLab data acquisition system 
and analysed by Chart software (AD Instruments, Chalgrove, UK). 
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Animal preparation 
Mice were anaesthetised by intraperitoneal (i.p.) injection of ketamine (60mg/kg) and 
xylazine (6mg/kg). Anaesthesia was maintained throughout experiments via an i.p. 
line, and body temperature maintained between 36-37ºC using a heating pad and 
monitored with a rectal temperature probe (Figure 2.1). After induction of 
anaesthesia, mice were laid supine on a plastic perforated tray and fixed in this 
position with tapes applied on the limbs. Then the neck region was disinfected with 
70% ethyl alcohol and a tracheostomy was performed to alow insertion of an 
endotracheal tube. Mice were connected to the ventilator via the endotracheal tube 
and ventilated using low VT of 8-10 ml/kg, a PEEP of 3 cmH2O and a respiratory rate 
of 120/min using 100% oxygen.  
The left carotid artery was exposed and cannulated for constant monitoring of 
arterial blood pressure and administration of normal saline with 10U/ml heparin (to 
maintain patency of cannula) at a rate of 0.3-0.4 ml/h to compensate for increased 
fluid loss through the airways secondary to dry gas ventilation. The arterial line was 
also used for arterial blood gas monitoring at predetermined time points 
(~70µl/sample, folowed by bolus saline to replace fluid loss). In some experiments 
the right internal jugular vein was also cannulated for continuous infusion of 
antibodies.  
Airway pressure and gas flow were monitored real-time via transducers 
connected to a PowerLab data acquisition system (AD Instruments, Chalgrove, UK), 
and the data analysed using Chart software (version 5.5.6, AD Instruments). Plateau 
pressure (Pplat), respiratory system elastance (Ers) and resistance (Rrs) were 
determined at 20 min intervals by the end-inflation occlusion technique [827], which 
is incorporated in this custom-made ventilator system. During this manoeuvre an 
117 
inspiratory pause is generated by closing the inspiratory solenoid with the expiratory 
solenoid stil being in a closed state. Therefore, zero flow is achieved in the 
pneumatograph while the lungs remain inflated with a given VT. Tidal volume is 
calculated by calculating the area under the curve on the flow chart (Figure 2.2) after 
corection for the frequent zero drift in the flow transducer.  
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Figure 2.2 - Measurement of respiratory mechanics in vivo using end-inflation occlusion 
technique. Using pressure transducers, pressure and flow traces are obtained similar to those shown 
above. Using end-inflation occlusion and the gas flow trace, zero drift can be corrected and VT 
accurately measured by integrating the area under the curve (AUC). Using the pressure trace, peak, 
plateau (Pplat) and positive end-expiratory pressures (PEEP) can be accurately measured.  Lung 
mechanics, such as respiratory system resistance (Rrs) and elastance (Ers) can thus be calculated and 
monitored throughout experiments. 
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Al of the ventilation models used in this project involved bolus intratracheal 
fluid administration at some point during the protocol. For this, mice were 
disconnected from the ventilator and the agent of interest was instiled through a fine 
cannula inserted in the endotracheal tube. In some experiments, bolus technique 
was substituted to a MicroSprayer delivery method (Penn-Century, Inc., PA, US). 
Then mice were reconnected to the ventilator, and to help the fluid distribute in the 
lungs, 4 subsequent sustained inflations with a pressure of 35cmH2O for 5sec were 
given in 30sec intervals. Further single sustained inflations were also applied in 
every 20min to avoid development of atelectasis.  
Upon termination of experiments, mice were overdosed with anaesthetic 
administered via the arterial line and exsanguinated by cardiac puncture prior to 
tissue sampling. 
In vivo mouse model of ventilator-induced lung injury 
Our in vivo mouse model of VILI is based upon previously published models [106, 
109, 116, 337, 639]. In these, lung injury is produced within 2 hours solely by over-
stretching healthy lungs with excessive VT. However, as our model involves 
intratracheal administration of agents to the lungs in a fluid phase it has an intrinsic 
efect on respiratory mechanics. It is likely that the fluid interferes with the surfactant 
layer, hence changing the elastic properties of the lung and introducing significant 
heterogeneity into the system. As one of our main interests was to investigate the 
efect of p55 receptor blockade on the respiratory mechanics, we had to establish a 
model which can be wel standardised and therefore has reasonably smal variability 
in respiratory mechanics. We also had to take into account that if the p55 receptor 
blocking antibody used has any protective efect on VILI in terms of respiratory 
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physiology, it could be moderate to mild; therefore a model which causes a too harsh 
injury may not be feasible to reveal these efects. Therefore, a couple of 
modifications had to be introduced to the previously established VILI models. This 
wil be discussed in more detail as part of a model development section in the 
relevant chapter, whereas the main steps of the final protocol are outlined here. 
 Mice receiving low VT (low-stretch) were ventilated with 100% oxygen, whilst 
those receiving high VT (high-stretch) were ventilated with oxygen supplemented with 
4% CO2 to avoid hypocapnia. 
 Surgery was folowed by a 5 min equilibration period, after which baseline 
readings were taken and high-stretch ventilation started or low-stretch setings 
maintained (in some control animals). Immediately after seting high-stretch 
parameters, mice received an intratracheal bolus of either anti-p55 or anti-TNF 
antibody or their appropriate controls with or without a subclinical dose of LPS, and 
ventilated for 240 min or until BP dropped below 45 mmHg (indicative of cardio-
respiratory colapse [337]), whichever occured earlier. The dose of anti-TNF 
monoclonal antibody (50µg) derived from a previously published work from our group 
where it eficiently reduced high stretch induced neutrophil influx to the lungs [109], 
whereas the anti-p55 dAb dose (25µg) was selected based on previous mouse 
models of smoke inhalation and LPS-induced lung injury, where it significantly 
reduced the inflammatory response (interpersonal  communication  with  GSK). In 
some experiments, mice also received a continuous intravenous infusion of either 
control or p55 specific blocking antibody via the jugular vein during high-stretch 
ventilation. Mice received sustained inflations in every 20 min to avoid atelectasis.  
Development of lung injury was assessed by an increase in Pplat, Rrs and Ers 
compared to their value at the start of high-stretch (expressed as % change in the 
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case of Rrs and Ers). Deterioration in gas exchange, i.e. changes in PO2 and PCO2, 
was also monitored at predetermined time points as indicator of lung injury.  
 After termination, BALF, plasma and lungs were harvested and either used for 
immediate analysis or stored at -80ºC. 
In vivo mouse model of acid aspiration 
Experiments with the in vivo VILI model demonstrated that blockade of 
intrapulmonary p55 TNF receptor signaling by a domain antibody can atenuate VILI 
as wil be described later. Therefore, we went on to investigate whether this 
approach would be also beneficial in another model of ALI, namely in acid induced 
lung injury. This work was done in colaboration with Dr Brijesh Patel and Dr Kenji 
Wakabayashi. The model is based on previously published models [365, 814, 828] 
and uses in vivo mechanical ventilation system for the maintenance of treated mice 
and the assessment of injury development. As with the VILI model this model also 
required fine-tuning secondary to the efects of intratracheal fluid instilation on 
respiratory mechanics and lung homeostasis. Also, as the antibody bolus could not 
be co-administered with the injurious insult (i.e. hydrochloric acid); this model 
involved two separate i.t. fluid instilations. A detailed model development wil be 
described in Chapter 6, while here we outline the main steps of the final protocol. 
 After surgery and a 5 min equilibration period, mice received an i.t. bolus of 
25µg of either dummy or p55 receptor specific domain antibody in a volume of 50µl 
as described earlier and ventilated with low-stretch setings (i.e. VT= 8-9ml/kg). After 
60min, mice also received an i.t. bolus of 65µl of 0.075M hydrochloric acid or normal 
saline and ventilated for further 180min or until BP dropped below 45mmHg, 
whichever happened earlier. Mice received a series of sustained inflations 
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(35cmH2O for 5sec, 4 times with 30sec intervals) after each bolus instilation, and 
single sustained inflations every 20min thereafter to prevent atelectasis. Al animals 
were ventilated with 100% oxygen to avoid hypoxia.  
 In this model, acid instilation produced significant lung injury by 3 hours, 
characterised by pulmonary oedema and recruitment of leukocytes to the pulmonary 
microvasculature and alveolar space. Upon termination, saline lavage was 
performed, plasma and lungs were harvested and either used for immediate analysis 
or stored at -80ºC. 
 
2.2 In vivo/Ex vivo sampling 
Bronchoalveolar lavage 
Bronchoalveolar lavage fluid (BALF) was obtained as described previously [337]. 
Sterile saline (750μl) was flushed into the lungs via the endotracheal tube and gently 
sucked out. This was repeated twice with the same saline. Samples were 
immediately centrifuged at 1500rpm for 5min at 4°C. Supernatants were aliquoted 
and stored at -80°C for analysis by ELISA or protein assay, and cel pelets 
resuspended in  350μl  sterile  saline.  Cels  were  analysed  by flow  cytometry  and/or 
diferential cytology using a Dif-Quik  staining  kit (Medion  Diagnostics  AG, 
Duedingen, Switzerland). 
 
Plasma 
Plasma samples were obtained by cardiac puncture with a heparinised needle and 
syringe. Heparinised blood was centrifuged at 4000rpm for 5min at 4ºC. Plasma was 
removed and aliquoted for storage at -80ºC for analysis by ELISA. 
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Lung wet:dry weight ratio 
Folowing exsanguination of mice, lungs were excised and briefly rinsed in saline 
then bloted on tissue paper. Lungs were weighed and placed in an oven at 60-65ºC 
to dry overnight. Lungs were re-weighed and wet:dry weight ratios calculated. 
 
2.3 In vitro pulmonary endothelial cel culture 
The in vivo experiments with TNF receptor knock-out animals investigating the roles 
of individual TNF receptor subtypes in TNF-mediated activation of pulmonary 
endothelial cels showed interesting results as wil be described in Chapter 3. 
However, genetic modifications in knock-out animals may cause chronic 
compensation as wel as non-predictable changes in the expression of other, not 
directly targeted genes which may influence a specific biological response. Also, lack 
of TNFR signaling on cels other than PECs (e.g. circulating leukocytes) may also 
indirectly impact on TNF-mediated activation of PECs. Therefore to verify our in vivo 
findings, we used an in vitro pharmacological approach in colaboration with Dr 
Justina O Dokpesi utilising wild-type primary mouse pulmonary endothelial cel 
(PEC) culture. 
Isolation and culture of primary mouse pulmonary endothelial cels 
Wild-type  mice  were  sacrificed,  and  1ml  of  1mg/ml  Dispase (Gibco, Invitrogen  Ltd, 
Paisley, UK) was instiled through tracheostomy into the lungs and left for 5 min, 
after which lungs were excised and washed in Hank’s Balanced Salt Solution 
(HBSS) (Sigma-Aldrich) containing 0.5% FCS.  Samples were finely minced with a 
pair of scissors, digested in 1mg/ml Dispase at 37°C for 45 min, and then 
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mechanicaly dissociated by triturating and filtered through a 40-µm nylon mesh (BD, 
Oxford, UK) to form a single cel suspension.  PECs were isolated from the 
suspension by a magnetic labeling method, using the midiMACS separation unit 
(Miltenyi Biotec Ltd., Bisley, Surey, UK) according to the manufacturer’s 
instructions.  In brief, depletion of CD45+ (pan-leukocyte marker, clone: 30-F1, 
Biolegend, Uithoorn, The Nederlands) cels was folowed by 2 repeated steps of 
enrichment of CD31+ (PECAM-1, endothelial cel marker, clone: MEC 13.3, BD 
Pharmingen, Oxford, UK) cels. By this method I could obtain 6 milion pulmonary 
endothelial cels on average per mouse (determined by flow cytometry using 
microsphere counting beads (Caltag Medsystems, Towcester, UK) with a purity of 
95% (Figure 2.3).  
Cels were then cultured at 37°C in 5% CO2 in DMEM supplemented with 1% 
non-essential amino acids (Sigma), 1% sodium pyruvate (Sigma), 12U/ml heparin 
(Leo Laboratories Ltd, Princes Risborough, UK), 25mM HEPES (VWR, Luterworth, 
UK), 10% heat inactivated FCS, 2mM glutamine, 100µg/ml streptomycin, 100U/ml 
penicilin (al from Gibco), and 50µg/ml endothelial cel growth supplement (Sigma) in 
flasks coated with 1% type B gelatin (Sigma).  After overnight culture, cels were 
washed to remove non-adherent cels and fresh medium was added. Once the cels 
reached confluence, they were re-plated using trypsin-EDTA (Sigma), and used for 
experiments between passage 3 and 8. 
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 Figure 2.3 – Analysis of purification of mouse primary pulmonary endothelial cels by flow 
cytometry. Primary PECs were isolated from wild-type mice by enzymatic digestion and mechanical 
dissociation folowed by depletion of CD45+ cels and enrichment of PECAM-1+ cels by a magnetic 
labeling method, using the midiMACS separation unit. This provided a 95% purity of PECs for culture. 
Dot plots represent composition of cel suspension before and after CD45+ cel depletion and after 
PECAM-1+ cel enrichment. 
In vitro TNF-induced adhesion molecule expression by primary PECs 
Cultured PECs were seeded at a density of 105 cels/wel in a 24-wel plate coated 
with 1% type B gelatin. After overnight culture, the medium was replaced with RPMI 
containing 10% FCS, and triplicate wels were alocated into one of four groups: no 
treatment (control); 10ng/ml recombinant mouse TNF for 4 h; and pre-incubation with 
anti-p55 (90µg/ml; 55R-170, BD Biosciences) or anti-p75 (20µg/ml; TR75-32, BD 
Biosciences) neutralizing antibody for 1 h before TNF treatment.  The anti-TNF 
receptor antibodies are validated by the manufacturer as having no cross-reactivity 
between receptor subtypes.  Cels were recovered/detached with 1% trypsin-EDTA 
at 37°C for 1 min and processed for flow cytometry.  
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2.4 Enzyme-linked imunosorbent assay (ELISA) 
Colorimetric sandwich ELISA was used to quantify soluble mediators in BALF and 
plasma, in accordance with manufacturer’s instructions. ELISA kits were purchased 
for murine interleukin-6 (IL-6), monocyte chemoatractant protein-1 (MCP-1), 
macrophage inflammatory protein-2 (MIP-2), keratinocyte-derived chemokine (KC) 
and TNF (R&D Systems, Abingdon, UK), and analysed using a colorimetric plate 
reader (MRX I absorbance reader, Dynex Technologies, Magelan Biosciences, 
Worthing, UK). 
 
2.5 Protein assay 
Protein concentration in lavage fluid was determined by the Bradford method [829] 
using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hemel Hempstead, UK) 
with bovine serum albumin (Sigma-Aldrich, Gilingham, UK) as a standard. Samples 
were diluted with distiled water so that predicted protein concentrations would fal 
within the limits of the standard curve. Standard preparations of bovine serum 
albumin (BSA) were prepared by serial dilution (range 0.0156 mg/ml – 1 mg/ml, 
linear range 0.05 mg/ml – 0.5 mg/ml). Both samples and standards were plated in 
triplicate. Bradford reagent was added to each wel and gently mixed. Plates were 
analysed using a colorimetric plate reader. 
 
2.6 Lung histology  
In some experiments, upon termination the lungs and heart were removed en bloc 
from the thoracic cavity, and lungs were instiled via the endotracheal tube with 
approximately 1 ml of melted (42ºC) 1 % low-melting point agarose in 4 % 
paraformaldehyde until moderate distension was gradualy achieved (i.e. margins of 
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lobes became sharp, Figure 2.4). Lungs then were immersed in plastic tube 
containing 4 ºC cold 4 % paraformaldehyde to facilitate hardening of agarose gel and 
hence to maintain opened alveolar structure of lungs. After overnight incubation, 
samples were embedded in parafin, and 5µm thick sections were cut using a 
microtome. Sections were mounted on glass slides and dried overnight before 
staining with haematoxylin and eosin (H&E) for histological evaluation [830]. 
 
 
 
Figure 2.4 - Photographs of agarose instiled mouse lungs. For lung histology, lungs were excised 
from the thoracic cavity with heart en bloc and instiled with warm (42ºC) 1% low-melting point 
agarose in 4% paraformaldehyde via the endotracheal tube until gradual distension of lungs was 
achieved. Then lungs were immediately immersed into cold (4ºC) 4% paraformaldehyde to induce 
geling of agarose in lung, thus fixing alveolar units in an open/inflated state (please note sharp edges 
of the lungs). Lungs were then kept in 4% paraformaldehyde at 4 ºC until processed for H&E staining. 
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2.7 Flow cytometry 
Flow cytometry is a sensitive technique using immunofluorescence to measure 
expression of cel-associated antigens on a per cel basis. It is arguably the most 
quantitative way to assess this, because fluorescent signals are converted to 
numerical values. Cels are stained with antibodies specific for antigens of interest, 
conjugated to fluorescent dyes. A number of dyes can be used simultaneously, 
enabling co-staining for multiple antigens. Diferent cel types are identified based on 
their antigen expression and by their size and granularity. A disadvantage of flow 
cytometry is that samples have to consist of single cels, thus solid tissues have to 
be processed into single cel suspensions prior to scanning. Therefore, diferent 
tissue processing techniques may have to be employed depending on the antigen of 
interest. 
We used flow cytometry to characterise TNFR expression profile and 
signaling on pulmonary endothelial cels under control and inflammatory conditions 
both in vivo and in vitro, and to identify and quantify inflammatory leukocytes in the 
lungs in diferent in vivo models of acute lung injury.  
Preparation of lung single cel suspension 
Lung single cel suspensions were prepared slightly diferently depending on whether 
the number of leukocytes, the expression of adhesion molecules or TNF receptors 
was to be studied. For leukocyte counts and adhesion molecule expression, 
mechanical disruption and enzymatic digestion of excised lungs was caried out 
using an established technique, described and validated by our group previously 
[115]. Briefly, after harvest the lung was rinsed in saline and finely minced in a Petri 
dish by manual chopping using a surgical blade. The tissue was resuspended in 
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saline and incubated in 0.5mg/ml Colagenase (type IV, Sigma) at 37°C for 30 min. 
The resultant digest was then pushed through a 40-µm nylon mesh sieve (BD 
Falcon, Oxford, UK) with a syringe plunger and flushed through using FACS wash 
bufer (2% FCS, 1% sodium azide and 5mM EDTA), to produce the single cel 
suspension. Although it is possible that such a short warming period during the cel 
isolation procedure (i.e. colagenase digestion) could induce non-specific efects on 
PECs, we found in pilot studies that varying the incubation time between 15 to 45 
minutes had no significant influence on adhesion molecule expression (Figure 2.5). 
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Figure 2.5 – Effect of colagenase digestion on adhesion molecule expression on PECs. Lung 
tissues were exposed to various length of colagenase digestion (15, 30 and 45min) at 37ºC then 
processed for flow cytometry to measure VCAM-1, E selectin and ICAM-1 expression on PECs 
(PECAM-1+ cels, see below in ‘Staining protocols’). Staining with respective antibody (dashed, single 
or doted line as per digestion period) and isotype control (grey fil) are shown on histograms. 
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The tissue processing method was adapted slightly for assessment of TNF 
receptors.  These molecules are highly sensitive to protease-induced shedding 
(much more so than adhesion molecules), and pilot experiments indicated that even 
a very short enzymatic digestion step had a major adverse efect on surface 
expression of the receptors (Figure 2.6).  Therefore, to maximize cel yield whilst 
maintaining receptor expression, when mice were sacrificed, 1ml of ice-cold inhibitor 
cocktail was instiled through tracheostomy into the lungs.  The cocktail consists of 
serine/cysteine protease inhibitor (1mM PMSF, Sigma-Aldrich Ltd., Poole, UK) and 
metaloprotease inhibitor (10µM BB94, British Biotech, Abingdon, UK) in PBS with 
2% FCS, 1% sodium azide and 5mM EDTA. Lungs were then excised and chopped 
(without colagenase, in the inhibitor cocktail described above) using a gentleMACS 
tissue dissociator (Miltenyi Biotec Ltd., Bisley, UK), after which they were also filtered 
and flushed through a sieve. This ‘non-colagenase’ method resulted in beter 
preservation of TNFR expression on PECs (Figure 2.6). In some technique validation 
experiments the liver was also processed the same way.  
The lung single cel suspension was finaly centrifuged at 1300rpm for 7 min, 
the supernatant discarded and the pelet resuspended in 900µl of flow cytometry 
washing bufer or inhibitor cocktail as appropriate. The samples were kept on ice 
throughout the procedure (except the short colagenase incubation period where 
utilized) until analyzed by flow cytometry. 
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Figure 2.6 – Effect of diferent tissue processing methods on TNFR expression on PECs. Pilot 
studies indicated that even a short (15 minutes) exposure of lung tissue to colagenase results in 
shedding of TNFRs from PECs (PECAM-1+ cels), whereas their expression is beter preserved by the 
use of protease inhibitors and maintaining the working temperature close to 4ºC  (‘non-colagenase 
method’). Staining with respective antibody (dashed and single line for colagenase and non-
colagenase methods, respectively) and isotype control (grey fil) are shown on histograms. 
 
Staining protocols  
Cels from BALF samples, in vitro culture and lung cel suspension were stained for 
flow cytometry as previously described [106, 114-116]. Cel-surface TNF receptor 
and adhesion molecule expression were quantified using fluorophore-conjugated 
antibodies for TNF receptor p55 (clone: 55R-286), p75 (clone: TR75-89), or their 
isotype controls (AbD Serotec, Kidlington, UK), and for adhesion molecule VCAM-1 
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(CD106, clone: 429), ICAM-1 (CD54, clone: 3E2) and E selectin (CD62E, clone: 
10E9.6) or their isotype controls (antibodies al from BD Biosciences), respectively. 
 Diferent cel populations were identified based on size, granularity and 
expression of surface markers using the folowing antibodies: PECAM-1 (CD31, 
clone: MEC13.3), Endoglin (CD105, clone: MJ7/18), VE-cadherin (CD144, clone: 
BV13), ICAM-2 (CD102, clone: 3C4), Mucosialin (CD34, clone: RAM34) (BD 
Pharmingen, Oxford, UK), Grifonia simplicifolia lectin (Sigma), F4/80 (clone: CI:A3-
1, AbD Serotec), CD11b (clone: M1/70), Gr-1 (clone: RB6-8C5), CD11c (clone: HL3) 
(BD Pharmingen), CD45 (clone: 30-F1, Biolegend, Uithoorn, The Nederlands).  
 Cels were stained in the dark at 4ºC for 30min and then washed with flow 
cytometry wash bufer to remove unbound antibodies. In some experiments, cel 
numbers were determined using microsphere beads (Caltag Medsystems, 
Buckingham, UK) as previously described [114-116]. 
 Samples were run on a FACSCalibur flow cytometer (BD) and analysed by 
FlowJo software (Tree Star, Ashland, OR, USA). 
Identification of cel types 
Pulmonary endothelial cels 
Pulmonary endothelial cels were identified in lung cel suspensions using their 
characteristic expression of PECAM-1 (Figure 2.7), as previously described [115]. 
PECAM-1 positive cels were further characterised as endothelial cels by positive 
staining for Endoglin (CD105), VE-Cadherin (CD144) and ICAM-2 (CD102), 
confirming the endothelial origin of these cels. Additionaly, cels were stained for 
mucosialin (CD34) and with lectin from Grifonia simplicifolia.  Positive staining for 
both of these markers suggests that the vast majority of endothelial cels analysed 
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were microvascular in origin [831-833], although some contamination by 
macrovascular cels cannot be entirely excluded. 
 
 
Figure 2.7 - Identification of pulmonary endothelial cels (PECs) in lung single cel suspension 
by flow cytometry. In characterization studies PECs were identified as PECAM-1+ events (R1) and 
their endothelial phenotype was confirmed by positive staining for endothelial cel markers, i.e. 
Endoglin (CD105), VE-Cadherin (CD144), ICAM-2 (CD102), Grifonia simplicifolia Lectin and 
Mucosialin (CD34). Staining with the respective antibody (black line) and isotype control (unstained in 
the case of lectin) (grey fil) is shown on histograms. 
 
During the in vitro studies where cultured PECs were utilised, before each set 
of experiments, cels were also stained for a variety of these endothelial cel markers, 
to confirm both that they stil retained their phenotype across passages, and that 
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measurement of adhesion molecule expression did not include the presence of any 
contaminating non-endothelial cels (Figure 2.8) 
 
       
Figure 2.8 – Characterization of mouse primary pulmonary endothelial cels by flow cytometry. 
Before experiments (as wel as at time of purification), PECAM-1+ cels were characterized by staining 
for Endoglin, VE-Cadherin and ICAM-2 to ensure their endothelial phenotype was maintained from 
passage to passage. Staining with the respective antibody (black line) and isotype control (grey fil) is 
shown on histograms in passage #6 cels. 
 
 
136 
Lung leukocytes 
Our group has previously demonstrated that neutrophils and inflammatory subset of 
monocytes (i.e.  Gr-1high monocytes) marginate from the bone-marow to the 
pulmonary microvasculature in response to high-stretch ventilation and inflammatory 
stimuli such as LPS [106, 109, 114-116]. Leukocytes were identified in lung cel 
suspensions and BALF as previously described [114]. Lung-marginated and BALF 
neutrophils were identified by their high expression of CD11b and Gr-1 and absence 
of F4/80 expression (Figure 2.9/A-B). Lung-marginated monocytes were identified by 
their  expression  of  CD11b  and  F4/80 (Figure  2.9/A).  Monocyte  Gr-1high and low 
subpopulations were identified based on the relative expression of this antigen. 
Monocyte subpopulations were not present in BALF. Alveolar macrophages in BALF 
were identified as forward/side-scaterhigh, F4/80+, CD11c+ events (Figure 2.9/C). 
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Figure 2.9 - Flow cytometric analysis of leukocyte subsets in the lungs and lavage fluid – 
representative sample from i.t. LPS + VILI model. (A) In lung single-cel suspensions monocytes 
were identified as CD11b+, F4/80+ events, and their subsets were defined as either Gr-1low (R1) or Gr-
1high (R2), diferentiated from CD11b+, F4/80-, Gr-1very high neutrophils (R3). (B) Neutrophils in lavage 
fluid were similarly identified as CD11b+, F4/80-,  Gr-1very high events (R4), and their number varied 
model specificaly (i.e. higher in i.t. LPS+VILI model than in ‘pure’ VILI), whereas monocytes were not 
present in BALF in any of the models investigated. (C)  Alveolar macrophages in lavage fluid were 
recognised as forward/side-scaterhigh, F4/80+, CD11c+ events (R5). 
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2.8 Data analysis 
Data are expressed as means±SD. Normality was tested across the whole data set 
using Shapiro-Wilk test. Where data were not normaly distributed, data 
transformation (folowed by parametric tests, i.e. t-tests or ANOVA with Bonferoni 
tests where appropriate) or non-parametric analysis (i.e. Mann-Whitney U-test or 
Kruskal-Walis with Dunn’s post-test analysis) was caried out. A P value <0.05 was 
considered significant. Al statistical analyses were performed using Prism software 
(version  5.0,  GraphPad,  La  Jola,  USA) or SPSS (for normality assessment, IBM 
SPSS statistics 19.0, IBM Corporation, USA). 
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3. Characterisation of TNF receptor 
subtype expression and signaling on 
pulmonary endothelial cels 
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Both clinical and experimental evidence supports the pivotal role of TNF in the 
pathogenesis of ALI/ARDS. Celular efects of TNF are mediated via two cel surface 
receptors, the p55 and p75. Using TNF receptor knock-out mice our group has 
demonstrated that signaling through the two receptors can have directly opposing 
roles during the progression of ALI/ARDS of diferent aetiologies [639, 814]. 
Specificaly, signaling through the p55 receptor promoted pulmonary oedema, 
whereas p75 signaling opposed this, indicating that specific targeting of p55 
signaling as opposed to total TNF blockade could be more beneficial in atenuating 
ALI.  
However, due to the nature of using knock-out models, it remains unclear 
where these important signaling mechanisms take place, the endothelial or epithelial 
side of the alveolar-capilary membrane, thus where p55 signaling should be 
targeted. Therefore, over the past few years our group has been trying to further 
characterise the role of individual TNF receptors in the lung by assessing their 
expression levels on diferent cels and identifying receptor-specific celular 
mechanisms using in vivo and ex vivo mouse models. As part of this on-going 
investigation, Dr Anthony D Dor developed a flow cytometric technique during his 
PhD project that alows us to quantitatively assess the expression profile of TNF 
receptors on diferent cels in the mouse lung. This work, however, mainly focussed 
on the pulmonary epithelium and therefore the kinetics and roles of individual TNF 
receptors in the pulmonary microvasculature during ALI remains unknown. 
Using this flow cytometric technique and developing it further we 
characterised the expression profile of TNF receptors on the surface of freshly 
harvested pulmonary endothelial cels (PECs) from mice, and found expression of 
both receptors with dominance of p55.  
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Then we treated wild-type and TNF receptor knockout mice with intravenous 
TNF and determined surface expression of adhesion molecules (E-selectin, VCAM-
1, ICAM-1) on PECs by flow cytometry to characterise the specific role of each 
receptor. We found that TNF-induced upregulation of al adhesion molecules was 
substantialy atenuated by absence of p55, whereas lack of p75 had a similar but 
smaler efect that varied between adhesion molecules. By pharmacological inhibition 
of individual TNF receptor signaling in wild-type primary PEC culture, we then 
confirmed that the in vivo findings were a result of direct TNF receptor inhibition on 
pulmonary endothelium and not on other cels (e.g. circulating leukocytes).  
The role of TNF receptors has been shown to corelate with their surface 
expression in other models of TNF-mediated organ injury such as kidney and heart 
failure. Moreover, surface expression of TNF receptors may change dynamicaly in 
response to inflammatory stimuli. Therefore, we tested whether this also applies to 
the pulmonary endothelium in a scenario of generalised inflammation such as 
sepsis, a common cause of ALI/ARDS. We found that PEC surface expression of 
p55 dramaticaly decreased in the early stages of endotoxaemia folowing 
intravenous LPS, while no change in p75 expression was detected. 
These data demonstrate a crucial in vivo role of p55 and an auxiliary role of 
p75 in TNF-mediated adhesion molecule up-regulation on PECs, however their 
overal roles may vary at diferent stages of pulmonary microvascular inflammation 
folowing changes in their relative expression. 
 
3.1 Background 
As discussed in Chapter 1, activation of the pulmonary endothelium is one of the key 
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features of the pathogenesis of ALI/ARDS, and involves the production of 
inflammatory cytokines/chemokines and upregulation of adhesion molecules on 
PECs. As a result, inflammatory leukocytes wil marginate to the pulmonary 
microvasculature, become activated through cel-to-cel interactions with PECs and 
migrate into the lung interstitium and alveolar space, where they release their ROS 
and proteases to fight invading pathogens and to trigger further amplification of the 
inflammatory response [675]. There is mounting evidence that the pro-inflammatory 
cytokine TNF plays a key regulatory role in this process [109, 675, 686, 826]. 
Celular efects of TNF are mediated via two cel surface receptors, TNFR p55 
and p75 [649]. While early studies in the 1990s suggested that p55 is the major 
efector of TNF-mediated responses and p75 plays merely an auxiliary role by 
colecting and passing ligand to p55 (hence the name ‘ligand-passing’), more recent 
evidence indicated that p75 can also mediate celular responses partly or completely 
independently from p55 [643, 649, 737, 777]. For example, activation of p75 by 
receptor-specific muteins leads to activation of JNK (but not ERK or p38) MAPK in 
human rhabdomyosarcoma and cervical epithelial cel lines, and is suficient to elicit 
cel death [737]. Also, receptor-specific activation of p75 in renal tubular epithelial 
cels results in activation of Etk/Bmx, leading to cel proliferation as opposed to 
apoptosis elicited by p55 via activation of apoptosis signal-regulating kinase 1 
(ASK1) [777]. Additionaly, it has been demonstrated that the two receptors can even 
act in a directly opposing manner in some acute inflammatory conditions including 
retinal ischaemia, sepsis, VILI and acid aspiration-induced lung injury [639, 729, 814, 
817]. What is common in these models is that p55 seems to play a deleterious role, 
while p75 signaling is protective. Consequently, tissue specific expression of each 
individual TNF receptor may be a major determinant of an organ’s inflammatory 
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response to TNF stimulation. 
Indeed, Al-Lamki et al. demonstrated that TNFRs are diferentialy expressed 
on diferent cel-types of the myocardium and these expression paterns are changed 
in heart alograft rejection [834]. They found that in normal heart p55 but not p75 is 
predominantly expressed on cardiomyocytes, whereas cardiac alograft rejection was 
associated with a strong induction of p75 and diminished expression of p55 on these 
cels. The authors also demonstrated in wild-type mouse heart organ culture that 
TNF up-regulated p75 expression and activated both ASK1 and Etk/Bmx, causing 
both apoptosis and cel cycle entry. TNF treatment in heart tissue from p55 knock-
out mice led to diminished apoptosis, activation of Etk and increased entry into cel 
cycle. In contrast, heart tissue from p75 knock-out mice showed increased ASK1 
activation, apoptosis and lower level of cel cycle entry in response to TNF. The 
authors concluded that diferential activation of ASK1 and Etk by regulated 
expression of TNFRs is an important determinant of the outcome of the heart 
alograft rejection process.  
With regards to the roles of individual TNFRs in endothelial cels, the majority 
of previous studies have indicated that p55 receptor almost exclusively regulates 
TNF-induced inflammatory gene activation such as adhesion molecule expression 
[662, 724, 725, 750, 835], although such studies were primarily based on in vitro 
human umbilical vein endothelial cel (HUVEC) cultures. In direct contrast, 
Chandrasekharan et al. observed a critical role for p75 in regulating TNF-induced 
expression of adhesion molecules in aortic endothelial cels [749]. The authors found 
that when these cels were isolated from p75 knock-out mice, the TNF-induced up-
regulation of E-selectin, VCAM-1 and ICAM-1 was completely abrogated compared 
to wild-type cels. 
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Such discrepancies underscore the crucial importance of endothelial cel 
heterogeneity across the diferent vascular beds [836]. Endothelial heterogeneity is 
present at structural, functional and gene expression level. For example, the 
endothelium of arteries and veins form a continuous uninterupted layer of cels, held 
together by tight junctions, whereas the endothelial layer of capilaries might be 
fenestrated (e.g. in glomeruli, endocrine glands, choroid plexus or the intestinal 
mucosa) or discontinuous (e.g. in the liver sinusoids) according to the function of the 
underlying tissue [837]. 
Diferential regulation of vascular permeability and haemostasis across 
vascular beds secondary to diferential expression of junction proteins and 
coagulation factors, respectively, are great examples of functional heterogeneity. For 
instance, mice deficient for the tight junction protein claudin-5 have selective 
impairment in blood-brain barier function [838], whereas systemic administration of 
anti-VE-cadherin antibodies to wild-type mice leads to increased vascular 
permeability preferentialy in the lung and heart [44]. With regards to haemostasis 
regulation, while the anti-coagulant mediator endothelial protein C receptor (EPCR) 
is primarily expressed by large vessels [839], tissue factor pathway inhibitor (TFPI) is 
mainly produced in microvessels [840], whereas tissue-type plasminogen activator 
(t-PA) is predominant in pulmonary and cerebral arteries [841]. Moreover, in 
response to systemic inflammation, the expression of these factors changes in ways 
that difer across vascular beds, which may lead to diferences in local thrombotic 
phenotype, such as that observed in sepsis [837]. These examples highlight the 
danger of extrapolating findings obtained in one vascular bed (e.g. HUVECs) to 
endothelial cels in other tissues.   
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The lung microvasculature in particular is known to be functionaly and 
phenotypicaly distinct from most other vascular beds, for example in how leukocyte 
extravasation is regulated [86]. In the systemic circulation, binding of endothelial E- 
and P-selectin to their leukocyte ligands promotes roling of leukocytes on the 
endothelium, whereas binding of VCAM-1 and ICAM-1 to leukocyte integrins 
mediates firm adhesion. Transmigration involves endothelial PECAM-1 (or CD31) 
and junctional adhesion molecule-1. Preferential expression of E-selectin, P-selectin, 
VCAM-1, and ICAM-1 in postcapilary venules means that leukocyte extravasation 
predominantly occurs at this site of the vascular tree [836, 842]. In direct contrast, in 
the pulmonary circulation leukocytes primarily extravasate in alveolar capilaries by a 
roling- and E-selectin-independent but ICAM-1 dependent mechanism that involves 
trapping of poorly deformed activated leukocytes by the activated endothelium [86]. 
Haemostatic phenotype of the pulmonary microvasculature is also distinct from that 
of other tissues. For example, LPS- and TNF-induced pro-coagulant activity is higher 
in lung than in brain microvascular endothelial cels, reflected by diferential 
expression of thrombomodulin, t-PA and  PAI-1 [251]. In addition, pulmonary 
microvascular endothelial cels isolated from ARDS patients have a lower t-PA/PAI-1 
ratio compared to controls, indicating a pro-coagulant phenotype [251]. 
While a smal number of studies have atempted to investigate the specific 
role of pulmonary endothelial TNF receptors, they may be considered somewhat 
limited due to the methodologies used. Ermert et al. investigated the expression 
profile of TNFRs on rat and human pulmonary parenchymal cels using 
immunohistochemistry, and showed moderate to strong expression of p55 and a 
moderate levels of p75 receptor on endothelial cels [735]. However, they did not 
validate their staining technique in receptor knock-out animals; therefore the 
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possibility of non-specific staining for TNFRs cannot be ruled out with absolute 
certainty, which may have biased their results.  
Neumann et al. investigated the role of p55 receptor in mediating TNF-
induced up-regulation of adhesion molecules on endothelial cels in diferent organs, 
including the lungs, utilising p55 receptor knock-out mice and immunohistochemistry 
[695]. They demonstrated a crucial role for p55 in mediating TNF-induced E-selectin 
and VCAM-1 expression on pulmonary endothelial cels, but any conclusion 
regarding ICAM-1 was impossible to make using this technique, due to dificulties in 
detecting changes to its already high basal expression level. Moreover, the role of 
p75 receptor was not investigated.  
The only study that quantitatively assessed the expression profile of individual 
TNFRs  on  pulmonary  microvascular  endothelial  cels  was that  by  Grau et al. [53]. 
The authors isolated and cultured pulmonary microvascular endothelial cels (PECs) 
from patients who died with ARDS and those who had lung cancer and underwent 
pulmonary lobectomy serving as controls, and used flow cytometry to measure 
surface TNFRs expression and adhesion molecules (E-selectin, VCAM-1 and ICAM-
1) [53]. They found a constitutively up-regulated p75 and ICAM-1 on PECs from 
ARDS patients, and higher expression of IL-6 and IL-8 compared to controls, both 
under resting conditions and in response to TNF stimulus, but did not investigate the 
individual role of TNFRs [53].  More importantly, they assessed PECs after 2-3 
weeks of culturing, which may result in changes in the phenotype of primary cels.  
This is because endothelial cels actively sense and respond to the 
extracelular milieu, and diferences in this wil determine their phenotype and 
function [843]. Once they are removed from their native tissue, they lose these 
important extracelular cues and may undergo phenotypic changes [843]. Therefore 
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reconciliation of in vitro results with in vivo findings is essential to define the role of 
each TNF receptor during the activation of pulmonary endothelium. Thus, the relative 
expression of each TNF receptor within the pulmonary circulation and their precise 
roles in pulmonary microvascular inflammation in vivo stil remain unclear.  
 
3.2 Aims 
In this study, we atempted to characterise the expression profile of TNF receptor 
subtypes on pulmonary endothelial cels and their specific roles in TNF-mediated 
celular response. We used both in vivo and in vitro models utilising geneticaly 
modified animals as wel as a pharmacological approach. There were two main aims: 
1. Quantitatively assess the expression profile of TNF receptors on pulmonary 
endothelial cels both under control and inflammatory conditions. 
2. Characterise the roles of individual TNF receptor subtypes in TNF-mediated 
activation of pulmonary endothelial cels.       
                                                          
3.3 Protocols 
TNF receptor expression on PECs in vivo 
Wild-type mice were sacrificed, and 1ml of ice-cold protease inhibitor cocktail was 
instiled through tracheostomy into the lungs to minimize TNF receptors shedding 
during lung tissue processing.   Lungs were then excised to prepare a single cel 
suspension as described in Chapter 2, and TNF receptor expression on PECs was 
assessed by flow cytometry. In some animals the liver was processed and assessed 
by flow cytometry the same way for technique validation purposes.  
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In a separate series of experiments, mice were injected with 20µg LPS via the 
tail vein.  After 2, 4, 8 or 24 h animals were sacrificed and the lungs processed for 
flow cytometry the same way. 
Adhesion molecule expression on PECs in response to TNF in vivo 
 Wild-type or TNF-receptor knockout mice were injected with 500ng recombinant 
mouse TNF via tail vein. Two or four hours later animals were euthanised by 
isoflurane overdose, exsanguinated by cardiac puncture, the lungs were excised, 
and a single cel suspension prepared for flow cytometric analysis of adhesion 
molecules. Untreated animals served as controls. 
Adhesion molecule expression on PECs in response to TNF in vitro 
Primary pulmonary endothelial cels were isolated from wild-type mice and cultured 
under standard conditions. Cels were treated with TNF (10ng/ml for 4h) in the 
presence or absence of monoclonal neutralising antibodies for either the p55 or the 
p75 TNF receptor (chapter 2), and the expression of adhesion molecules VCAM-1, E 
selectin and ICAM-1 was quantitatively assessed by flow cytometry.  
 
3.4 Declaration 
The data contained within this chapter have been published in the American Journal 
of Physiology – Lung Celular and Molecular Biology by Bertok et al. [1] and can be 
found in Appendix I. Where indicated, the figures in this chapter are taken from this 
manuscript. The investigation was a colaborative efort: Anthony D Dor must be 
credited for developing the flow cytometry technique looking at surface TNF 
receptors on PECs, Justina O Dokpesi for the development of primary PEC culture, 
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Kieran O’Dea for his constant advice and guidance with flow cytometry, and Michael 
R Wilson and Masao Takata for designing and supervising the study. 
 
3.5 Results 
Basal expression of p55 and p75 receptors on PECs 
Our first aim was to clarify the expression of individual TNF receptors on PECs in 
vivo. For this, we developed a quantitative flow cytometry technique which alows us 
to assess the expression of the two receptor subtypes in single cel suspensions 
freshly prepared from the excised lungs of mice (Chapter 2).  PECs were identified 
based on positive staining for a wide range of endothelial markers, including 
Grifonia simplicifolia lectin and mucosialin (CD34) which are considered to be 
specific to endothelial cels of microvascular origin [831-833]. 
We found that under control conditions, both TNFRs were expressed on 
PECs, but expression of p55 was significantly higher compared to that of p75 (Figure 
3.1/A). In order to rule out the possibility that the relative level of expression of the 
individual receptors was not due to diferential susceptibility to shedding during 
tissue processing, we determined TNF receptor levels on endothelial cels harvested 
from the liver using the same methodologies. We found that these cels had similar 
p55 expression as pulmonary endothelial cels, but p75 expression was much higher, 
suggesting that the relative TNFR expression levels observed with PECs are unlikely 
to be an artefact of tissue processing (Figure 3.1/B).  
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Figure 3.1 - Flow cytometric analysis of TNF receptor expression on pulmonary and liver 
endothelial cels using the same tissue processing methodologies (i.e. ice-cold protease 
inhibitors and gentleMACS tissue dissociator). A. In control condition PECs showed greater 
expression of p55 (white fil) than p75 (black fil). Mean+SD, N=4 B. Liver endothelial cels expressed 
similar amount of the p55 (white fil) and p75 (black fil) receptors. Mean+SD, N=3, ***p<0.001 by 
paired t-test. Source – Bertok et al.[1] 
 
We then assessed TNFR expression on PECs from geneticaly modified 
animals lacking TNF receptors, as a final validation of the flow cytometry technique 
(Figure 3.2). In p55KO mice we found no p55 signal, while p75KO animals showed 
efectively zero signal for p75 with a very smal degree of non-specific staining with 
this antibody, indicating that the low level p75 expression on wild-type PECs was a 
genuine signal.  Importantly, the histogram paterns of p55 or p75 staining in wild-
type animals are consistent with normal distribution, suggesting that there were no 
subpopulations of TNFR positive and negative cels, but al PECs are expressing a 
moderate (p55) or low (p75) level of receptors. 
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Figure 3.2 - Flow cytometric analysis of TNF receptor expression on pulmonary endothelial 
cels in wild-type and TNF receptor knock-out mice. Validation of flow cytometry technique using 
wild-type and p55 and p75 knockout animals (TNFRp55KO and TNFRp75KO, respectively) indicated 
smal non-specific binding of the p75 antibody. Staining with the respective antibody (black line) and 
isotype control (grey fil) is shown on histograms. Source – Bertok et al. [1] 
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p55 and p75 TNF receptors both influence upregulation of adhesion molecules 
on PECs in vivo 
Having characterised the surface TNFR expression profile of PECs, we then turned 
to investigate the individual roles of the receptors in pulmonary endothelial activation. 
For this, wild-type and TNF-receptor knockout mice were treated with i.v. TNF and 
the surface expression of leukocyte adhesion molecules VCAM-1, E-selectin and 
ICAM-1 was quantitatively assessed on PECs by flow cytometry as surogate 
markers of cel activation.  Although the cel harvesting process involved a short 
period of colagenase digestion, we confirmed that PECs had the same phenotypic 
characteristics – i.e. positive expression of ICAM-2, Endoglin and Mucosialin (Figure 
3.3) when compared to the cels isolated during the TNFR expression studies.  
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Figure 3.3 - Characterisation  of  pulmonary  endothelial  cels (PECs) in lung  single  cel 
suspension by flow cytometry using the colagenase method. PECs had the same phenotypic 
characteristics  – i.e. positive expression of ICAM-2, Endoglin and Mucosialin as in the TNFR 
expression studies (see Chapter 2). Staining with the respective antibody (black line) and isotype 
control (grey fil) is shown on histograms. 
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In preliminary time course experiments using wild-type mice, we found that E-
selectin had a peak expression on PECs at 2 h after TNF treatment, while VCAM-1 
and ICAM-1 expression was greater at 4 h (Figure 3.4).  Therefore, in subsequent 
experiments we compared E-selectin expression between strains at 2 h, and VCAM-
1 and ICAM-1 expression at 4 h. 
      
Figure 3.4  – Time course of adhesion molecule expression on PECs in wild-type mice 
folowing intravenous TNF. Pilot studies in WT mice indicated a peak expression for E selectin at 2 
hours post-TNF i.v. (500ng), whereas it was 4 hours for VCAM- and ICAM-1. Therefore, in 
subsequent experiments these peak time points were  used. Idealy time-matched controls should 
have been used for these experiments, however this would have significantly increased the number of 
animals required which was dificult to justify. Mean+SD of Mean Fluorescence Intensity (MFI), N=3-
6/group. 
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PECs from al mouse strains had a moderate basal expression of VCAM-1, 
which was somewhat variable across the strains but in none of them was 
significantly diferent compared to wild-types   (Figure 3.5/A). TNF treatment 
substantialy up-regulated surface expression of VCAM-1 in wild-type mice, which 
was reduced in p75KO animals compared to wild-type mice, and decreased to an 
even greater extent in p55KO and DKO mice.   In contrast to VCAM-1, E-selectin 
was not expressed under resting conditions (Figure 3.5/B), but it was induced in wild-
type mice by i.v. TNF treatment. This TNF-induced response tended to be reduced 
(albeit not significantly) in p75KO mice compared to wild-type animals, whereas both 
strains of mice lacking the p55 receptor (i.e. p55KO and DKO) showed efectively no 
E-selectin expression.  In contrast to VCAM-1 and E-selectin, ICAM-1 is expressed 
on PECs at a high basal level in al strains (Figure 3.5/C), and was further up-
regulated upon TNF treatment in wild-type mice. While p75KO mice showed some 
tendency to decreased ICAM-1 expression, this was not significant.  In contrast, 
animals lacking the p55 receptor (i.e. p55KO and DKO mice) had significantly lower 
ICAM-1 expression after TNF stimulation compared to wild-types. 
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Figure 3.5  – Effects of chronic absence of TNF receptor subtype signaling on TNF-induced 
expression of adhesion molecules on pulmonary endothelial cels in vivo. Surface expression of 
VCAM-1 (A), E-selectin (B) and ICAM-1 (C) assessed by flow cytometry on pulmonary endothelial 
cels in diferent mouse strains either 2 (E selectin - B) or 4 h (VCAM-1, ICAM-1- A and C) after i.v. 
TNF injection (500ng). WT= wild-type, p75KO= TNFRp75 knockout, p55KO= TNFRp55 knockout, 
DKO= TNFRp55/p75 double knockout. Mean+SD of Mean Fluorescence Intensity (MFI), N=3-
6/group, **p<0.01, ***p<0.001 vs TNF-treated WT by one-way ANOVA with Bonferoni post-tests (A 
and C) and by Kruskal-Walis test with Dunn’s post-hoc analysis (B) . Source – Bertok et al.[1] 
 
 
 
157 
Diferences in adhesion molecule expression are due to TNF receptor 
signaling specificaly on pulmonary endothelial cels 
Because of the nature of using knock-out animals it was unclear, whether our in vivo 
findings reflected the importance of TNF receptors on endothelial cels per se, or the 
lack of TNFR signaling on other cels may have also influenced our observations. 
For example, leukocytes express both TNFRs [726],  and  Gr-1high monocytes in 
particular are known to activate PECs in a TNF-dependent manner [115]. To dissect 
this out, we took an in vitro approach and used acute pharmacological TNFR 
blockade in primary PEC culture isolated from wild-type mice. Cels were treated with 
TNF in the presence or absence of antagonistic antibody for p55 or p75 receptors, 
and surface expression of adhesion molecules was quantified by flow cytometry as 
in vivo.  The antagonistic TNFR antibodies used for this study were monoclonal 
antibodies (mAb) as opposed to domain antibodies (dAb) because anti-p75 dAb was 
not available at the time, and comparing the efect of anti-p55 dAb to that of anti-p75 
mAb in our assay may have led to scientific biases. Although these monoclonal 
antibodies may not be as potent as their domain antibody counterparts, they were 
both shown to inhibit TNF-induced cytotoxicity in vitro to variable extent (>95% and 
up to 60% for anti-p55 and anti-p75 mAb, respectively) in a concentration dependent 
manner, as wel as TNF-induced skin necrosis in vivo, whereas anti-p75 efectively 
inhibited TNF-mediated proliferation of T-cel-like CT6 cels [844]. Therefore, to 
achieve a good eficacy in blocking TNF activity in our model, we applied these 
antibodies in vast excess to TNF.  
 We found that p75 blockade, consistent with the in vivo findings, resulted in 
significant reduction of TNF-induced VCAM-1 and E-selectin expression by 28% and 
23%, respectively (p<0.05), but did not influence ICAM-1 expression (Figure 3.5/A). 
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In contrast, p55 blockade significantly decreased the expression of al adhesion 
molecules (p<0.01) (Figure 3.5/B) in keeping with the in vivo results, although did not 
completely abolished the TNF-response. 
 
 
 
Figure 3.5 – Effects of acute TNF receptor inhibition on TNF-induced expression of adhesion 
molecules in primary pulmonary endothelial cel culture. Fold changes (compared to untreated 
cels in the same experiment) of adhesion molecule expressions on wild-type primary mouse lung 
endothelial cels folowing 4 h TNF treatment (10ng/ml) in the presence or absence of (A) p75 
(20μg/ml) or (B) p55 (90μg/ml) receptor neutralising mAb. p55 and p75 blockade experiments were 
conducted separately. Mean+SD. N=3-4, * p<0.05, ** p<0.01, ***p=0.001 vs TNF by paired t-test. 
Source – Bertok et al. [1] 
p55 receptor expression decreases, while p75 remains stable during acute 
endotoxaemia 
Finaly, we determined the influence of acute inflammation on the relative levels of 
TNFR expression. Historicaly, p75 was shown to be more readily up-regulated than 
p55 on monocytes and synovial fluid macrophages in response to LPS and IL-10 
[53, 714], while both receptors also show a propensity to be shed from the surface of 
159 
neutrophils and monocytes in response to TNF and LPS [718, 721, 726], but such 
data for PECs have been lacking. This could be quite important, as dynamic 
changes in the relative level of TNFR expression could potentialy influence the 
overal celular response to TNF.         
 We found that p75 expression on PECs did not change substantialy over 24 
hours folowing i.v. LPS administration.  In marked contrast, there was a dramatic 
decrease in p55 expression at 2 hours after LPS, which started to recover after 4 
hours and reached nearly 80% of its baseline levels by 24 hours post-LPS (Figure 
3.6).  
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Figure 3.6 – Changes in TNF receptor expression on pulmonary endothelial cels during 
endotoxemia in vivo. Mice were injected with i.v. LPS (20µg), and after 2, 4, 8, and 24 h the lungs 
were processed for flow cytometric analysis. Untreated animals served as controls. Idealy time-
matched controls should have been used for these experiments, however this would have significantly 
increased the number of animals required which was dificult to justify. Surface expression of TNF 
receptor p55 and p75 was quantified on PECAM-1+ events as described before. Mean±SD of MFI, 
N=4-5/each time point, ***p<0.001 vs control for p55 expression by one-way ANOVA with Bonferroni 
post-tests. Source – Bertok et al. [1] 
3.5 Discussion 
Although TNF plays an important role in the pathogenesis of sepsis/ALI and elevated 
levels in plasma and/or BALF are associated with poorer outcome [332, 678, 680, 
795, 845], blockade of total TNF signaling in septic patients using anti-TNF 
monoclonal antibodies [616, 617, 620, 846] or TNFRp55-IgG fusion  protein [623-
625] proved to be clinicaly inefective, suggesting that TNF signaling during 
sepsis/ALI could be more complex than originaly considered.  
Indeed, recent evidence indicates that the two TNFRs can play diferential 
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and even opposing roles in a variety of acute inflammatory conditions, including 
sepsis [729, 817, 818]. For example, in a mouse model of sepsis induced by caecal 
ligation and puncture, Ebach et al. demonstrated that while p55 knock-out mice had 
prolonged survival compared to wild-type controls hence indicating a deleterious role 
for p55, p75 knock-out animals had increased mortality [817]. In contrast, the same 
group showed a protective role for p55 receptor and a deleterious role for p75 in a 
mouse model of T-cel mediated colitis [818], suggesting that the roles of individual 
TNFRs are model and/or disease specific.  
Moreover,  our group previously demonstrated that such opposing TNFR 
signaling also exists in ALI induced by high-stretch ventilation [639] and acid 
aspiration [814]. Using TNFR knock-out mice, we found in both models that 
signaling through p55 receptor promoted the development of pulmonary oedema 
and respiratory failure, whereas signaling through TNFR p75 opposed this, 
suggesting that selective targeting of p55 receptor signaling as opposed to total TNF 
blockade might be more efective in atenuating lung injury. Furthermore, these 
studies also indicate that the relative expression of p55 and p75 within the lung is 
criticaly important in determining the consequences of TNF signaling during the 
pathogenesis of ALI/ARDS. Whether such opposing TNFR signaling is involved in 
mediating pulmonary endothelium activation, an important step in the pathogenesis 
of ARDS, and the exact roles of TNFR subtypes in this process is unclear.  
To address this, in this chapter we quantitatively assessed the expression 
profile of TNF receptors on the surface of freshly harvested mouse PECs, and 
explored their roles in mediating TNF-induced expression of adhesion molecules as 
surogate markers of endothelial activation using flow cytometry. In control 
conditions, both receptors were expressed on PECs, with substantialy higher 
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expression of p55 than p75.  Both TNFRs played some role in mediating TNF-
induced expression of adhesion molecules, but p55 receptor had a much greater 
impact than the p75 receptor in vivo.   Finaly, we demonstrated that in acute 
endotoxaemia p55 expression on PECs was rapidly down-regulated, but no change 
in p75 expression was observed, which may have important consequences for TNF 
signaling during pulmonary microvascular inflammation. 
Expression of TNFR subtypes on PECs 
Most of our curent knowledge of TNF receptor expression on endothelial cels 
comes from studies using human umbilical vein endothelial cels (HUVEC). While 
TNF binding studies suggested marginaly higher p55 expression on these cels 
[662, 847, 848], flow cytometric analysis showed similar expression of the two 
receptors or a slightly higher expression of p75 [724, 725]. TNFR expression profile 
on pulmonary endothelial cels is not clear.  Previous studies suggested relatively 
similar expression of p55 compared to p75 on PECs of rats and humans, although 
these findings rely on data from prolonged in vitro cultures [53] which may 
significantly influence endothelial cel phenotype and function [843], and semi-
quantitative immunohistochemistry technique [735]. Therefore quantitative in vivo 
analysis of TNF receptors on PECs has been lacking.  
To address this, we established a flow cytometry method that enabled 
quantitative evaluation of TNFR expression on PECs in a single cel suspension. 
Positive cel staining for a panel of endothelial cel markers, including mucosialin and 
Grifonia simplicifolia lectin suggest that the PECs analysed were primarily 
microvascular in origin.  This distinction is important, because phenotypic and 
functional heterogeneity has been described among pulmonary endothelial cels of 
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microvascular and macrovascular origin [685, 849, 850]. We found that TNFRs were 
labile and sensitive to conditions of tissue processing; however by using a mixture of 
protease inhibitors and keeping the working temperature close to 4°C, we managed 
to preserve their cel surface expression on PECs. 
We found that both TNFRs were expressed on PECs, but expression of p55 
was substantialy higher than that of p75.  Using receptor knockout, we 
demonstrated that the antibody-binding was specific to each receptor, with only a 
smal non-specific signal for p75. We also measured the relative expression of TNF 
receptors on liver endothelial cels using the same tissue harvesting and processing 
technique, and found that while p55 expression was comparable to that found in 
PECs, p75 expression was greater and even exceeded the levels of p55. These data 
strongly support that the low signal of p75 on PECs is not due to processing 
artefacts, and more importantly, highlight the potential risks of extrapolating between 
endothelial cels from diferent sources.  
Roles of TNFR subtype signaling in TNF-induced activation of PECs 
A previous in vivo study by Neumann et al. using knockout mice suggested a crucial 
role of p55 in TNF-induced expression of E-selectin and VCAM-1 (measured by 
immunohistochemistry) and recruitment of leukocytes within the lung [695], however 
this study did not investigate the involvement of p75. To characterise the roles of the 
receptor subtypes, we injected TNF intravenously to wild-type and TNFR single and 
double knockout mice, and quantitatively evaluated E-selectin, VCAM-1 and ICAM-1 
expression on PECs using flow cytometry. We found that p55 receptor signaling was 
necessary for the up-regulation of each adhesion molecule (in keeping with the study 
by Neumann) while p75 signaling contributed to VCAM-1 up-regulation, but any 
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efects on E-selectin and ICAM-1 expression were unclear. To rule out that our 
observations from geneticaly modified mice were not influenced by the lack of TNFR 
signaling on other cels, such as circulating leukocytes, we used in vitro receptor 
blockade experiments. We found that the consequences of individual TNF receptor 
signaling observed in vivo were very likely due to direct efects on PECs, and 
confirmed that p75 signaling influenced VCAM-1 and E-selectin expression.  The 
influence of p75 signaling on ICAM-1 was however less clear, which may indicate 
some diferential efect of p75 on the diferent adhesion molecules, or may reflect a 
relative lack of sensitivity due to already high basal expression of ICAM-1.  
Our findings indicating a minor role for p75 in TNF-mediated adhesion 
molecule expression may be consistent with the ligand-passing theory of TNF 
signaling on PECs, whereby p75 functions primarily to modulate signaling through 
p55. Alternatively, it could be a reflection of the relative level of receptor expression 
(i.e. p55>p75) on PECs, and p75 may be more important in other organ beds, such 
as the liver, or conditions where the relative expression of the receptors are 
changed. Our finding that the p75 receptor does not contribute much to ICAM-1 up-
regulation is in contrast with a previous study by Chandrasekharan et al. [749]. 
Isolating aortic endothelial cels from TNF receptor knockout animals the authors 
reported that p75 receptor signaling was the main determinant of TNF-induced 
ICAM-1  up-regulation, although they did not assess the relative levels of TNF 
receptor expression on these cels, and therefore it is unclear whether their findings 
may be due to a significantly higher expression of p75. This suggests that the role of 
p75 in signaling varies between vascular beds, which would  argue against a 
generalised ligand-passing concept for this receptor.  
Diferential regulation of TNFR expression on PECs in inflammatory conditions  
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Expression of the TNF receptors is regulated by protein synthesis both at the 
transcriptional/translational level, by the action of sheddases such as TNF-alpha 
converting enzyme (TACE) [649, 758, 851] and by internalization mechanisms [727]. 
Both p55 and p75 may be shed or internalised from the surface of cels, and under 
certain circumstances both can be upregulated, p75 more dynamicaly than p55 
[658, 712, 718, 721, 722, 727].   However, the vast bulk of this knowledge comes 
from hematopoietic cels and cancer cel lines, which may not be applicable to 
endothelial cels.  To assess the changes in TNF receptor expression on PECs 
folowing an inflammatory stimulus, we treated mice with LPS and determined the 
expression of the two receptors over 24 h.  For the first time in freshly harvested 
PECs, we showed that surface p75 expression was efectively unchanged while 
expression of the p55 receptor decreased greatly folowing LPS.  Such a loss of 
surface p55 is likely to represent a regulatory mechanism to limit ongoing stimulation 
of the receptors folowing the initial ligand-receptor interaction. Indeed, TNF-induced 
TNF receptor shedding leading to deactivation of cels has been observed and 
investigated extensively in leukocytes [365, 721, 819], and impaired shedding of p55 
leads to an exaggerated inflammatory state in humans and mice [850, 852]. 
Although mice lacking the p55 receptor show atenuation in pulmonary neutrophil 
accumulation folowing systemic LPS chalenge [812], suggesting that TNF likely 
signals through the p55 receptor before shedding occurs,  the subsequent 
downregulation of p55 receptors on endothelial cels may have significant long-term 
consequences (e.g. endothelial hyporesponsiveness to further TNF stimuli) beyond 
the efect on adhesion molecules we observed here. 
Our findings regarding the changes in TNF receptor expression during 
inflammation  are  apparently inconsistent  with those reported  by  Grau et al. 
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investigating the functional characteristics of PECs isolated from patients who died 
with ARDS [53]. They demonstrated greater p75 expression on PECs from the 
patients than controls, which appeared to positively corelate with the duration of the 
disease, while no diference in p55 was observed. However their study investigated 
TNF receptor expression on PECs in vitro after 2-3 weeks culture, which may not 
reflect the phenotype at the time of isolation. Both our study and that by Grau et al. 
do however indicate a change in the ratio of p55:p75 receptors on PECs during 
ALI/inflammation.  The downstream consequences of such changes in the p55:p75 
expression ratio remain unclear. As the curent data indicate that p75 plays a similar 
role to p55 signaling in regards to adhesion molecule upregulation (albeit of lesser 
magnitude), it may be concluded that a relative shift in the contribution of signaling 
through p75 vs. p55 would have litle impact. However, adhesion molecule 
upregulation is but one consequence of TNF receptor activation, and it is now clear 
that the two TNF receptors are able to signal independently. For example, TNF has 
been shown in neurons to mediate pro-apoptotic signaling through p55 but anti-
apoptotic signaling through p75 [853].  Changes in the relative levels of TNFR 
expression may therefore have substantial consequences not apparent from the 
curent observations. 
In mouse models of VILI and acid aspiration-induced lung injury, our lab 
previously found that p75 signaling opposed, rather than complemented that of p55 
during the development of high stretch-induced pulmonary oedema [639, 814]. One 
possible interpretation is that the ‘protective’ role of p75 signaling observed in our 
previous study is not related to endothelial cel adhesion molecule up-regulation (as 
we found p75 signaling plays a similar ‘injurious’ role to that of p55, albeit less 
potent), but a diferential regulation of endothelial/epithelial cel permeability [689, 
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690, 694, 854] and fluid reabsorption [707-709]. 
 In summary, the present study provides invaluable new data of individual TNF 
receptor expression and signaling on pulmonary endothelium in vivo, by quantitative 
assessment of TNF receptors and TNF-induced expression of adhesion molecules 
on freshly harvested PECs using flow cytometry.  The results highlight the potential 
risks in extrapolating data obtained in cel lines/endothelial cels from other vascular 
beds or using semi-quantitative methods.  Our findings add crucial pieces of 
information to our knowledge base of endothelial cel biology within the lung, which 
would lead to novel insights into TNF-mediated pathophysiology within the 
pulmonary microvasculature. Further work wil need to be dedicated to elucidate the 
functional consequences of individual TNF receptor signaling during pulmonary 
inflammation. 
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4. Selective targeting of intraalveolar 
p55 TNFR signaling during 
ventilator-induced lung injury 
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Having characterised the expression profiles and roles of TNFRs on pulmonary 
endothelium, we then turned to investigate if specific targeting of TNFR subtype 
signaling could confer benefits in atenuating ALI of diferent aetiologies. 
Studies in geneticaly modified mice show that the two TNF receptors play 
opposing roles during injurious high-stretch mechanical ventilation, with p55 
promoting but p75 preventing pulmonary oedema [639], but it remains unknown by 
what mechanisms and in which pulmonary cels. 
Evidence in the literature indicates that function of the TNF receptor subtypes 
corelates, at least in part, with their level of surface expression on cels [777, 834], 
which can change dynamicaly in certain conditions, especialy during inflammation 
[658, 712, 718, 721, 722, 727]. Indeed, in Chapter 3 we have demonstrated that 
expression of p55 receptor on pulmonary endothelial cels rapidly decreases during 
systemic inflammation, whereas expression of p75 receptor remains unchanged. 
These findings suggest that targeting p55 receptor signaling during ALI from the 
intravascular space may not be beneficial. On the other hand there is evidence that 
surface expression of p55 in the alveolar space is wel preserved during pulmonary 
inflammation [819]. Moreover, TNF is up-regulated within the alveolar space early in 
the course of ventilator-induced lung injury [337]. Therefore pharmacological 
blockade of intraalveolar p55 TNFR signaling could be a reasonable approach to 
atenuate VILI. 
In this chapter, we investigated the efects of an intratrachealy delivered, p55 
TNFR targeting domain antibody in in vivo mouse models of VILI.  We found that 
selective blockade of intra-alveolar p55 signaling reduced alveolar-epithelial barier 
permeability and pulmonary inflammation, which suggests potential for new 
treatments of VILI and ALI. 
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4.1 Background 
Mechanical ventilation is essential for the treatment of patients with acute lung injury 
(ALI)/acute respiratory distress syndrome (ARDS), although this can often result in 
ventilator-induced lung injury (VILI) [329]. Although the initiating trigger is unique (i.e. 
mechanical stretch), the final pathophysiology of VILI is indistinguishable from that of 
ALI of other aetiologies, i.e. characterised by pulmonary oedema and inflammation 
[313, 330].   As the start of mechanical ventilation and thus VILI is predictable and 
physician-controled, VILI may be particularly amenable to early pharmacologic 
intervention.  
The pro-inflammatory cytokine tumour necrosis factor-( (TNF) has been 
consistently implicated in the pathogenesis of ALI/VILI both clinicaly and in 
experimental models [322, 330, 334, 678].  Clinical trials of anti-TNF therapy in 
sepsis/ALI patients [616, 617, 624, 625] were unsuccessful, and in some cases may 
have led to increased morbidity.  The reasons behind such a lack of benefit are 
unclear, but are likely to include issues relating to the site where TNF signaling was 
targeted (i.e. systemic vs. alveolar) and the complicated biology of TNF signaling.  
TNF signals through two cel surface receptors, p55 and p75, and recent 
evidence suggests that signaling through these individual receptors may have 
diferential, even opposing roles in a number of pathological conditions, including 
retinal ischaemia, heart failure and myocardial infarction [729, 834, 855]. In these 
models p55 receptor signaling was shown to be deleterious, whereas p75 receptor 
was protective. Using TNFR knockout mice our group demonstrated similar opposing 
roles for the two TNFRs during VILI and acid aspiration lung injury: p55 receptor 
knockout mice were protected while p75 receptor knockout animals were more prone 
to pulmonary oedema [639]. Moreover, we previously also demonstrated that 
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biologicaly active TNF is up-regulated within the alveolar space early during the 
development of VILI [337].  
Dor et al. showed that intrapulmonary inflammation induced by intratracheal 
administration of LPS (20ng and 20µg) in mice leads to increased levels of soluble 
p75 receptor in the alveolar space by 2 hours after chalenge, while levels of soluble 
p55 do not change even after 6 hours, suggesting that surface expression of p55 in 
the alveolar compartment is wel preserved [819]. In contrast, as we demonstrated in 
Chapter 3, folowing systemic administration of LPS (20µg) p55 receptor is rapidly 
shed from the surface of pulmonary endothelial cels by 2 hours post-LPS. 
Combining the findings of these two studies it is conceivable to think that targeting 
intraalveolar p55 signaling in ALI could be beneficial. We decided to test this 
hypothesis first in a VILI model. 
However, conventional antibody technologies are not optimal for this purpose 
for a variety of reasons, but most importantly because monoclonal antibodies against 
TNFRs can induce receptor cross-linking, thereby activating rather than inhibiting 
TNFR signaling [820, 821]. For example, the anti-p55 mAb (clone 55R-170) used in 
our in vitro studies in Chapter 3 was shown to induce cel lysis in L929 cel line when 
cross-linked with anti-hamster IgG [844]. This may not be an issue for the in vitro 
studies where the presence of immunoglobulins can be controled, but in vivo this 
would be impossible. In the lungs in particular, high levels of IgA is secreted into the 
mucous lining of the airways, which could possibly cross-link anti-TNFR monoclonal 
antibodies, and consequently lead to receptor activation. Indeed, when the anti-p55 
mAb used in Chapter 3 was previously tested in a mouse VILI model in our lab, it 
caused more significant lung injury than its isotype control (interpersonal 
communication with Dr Wilson). It is important to note that as anti-TNFR mAbs 
172 
possess two antigen-binding fragments and can bind two TNFRs at once, their 
TNFR cross-linking ability does not necessarily require their own cross-linking by 
other immunoglobulins.  
Therefore, to investigate the possibility of pharmacological inhibition of p55 
signaling,  we  utilised  a  novel IgG fragment  known  as  a  domain  antibody 
(GlaxoSmithKline, Stevenage, UK) that was selected to specificaly bind and inhibit 
mouse p55 TNF receptor.  As domain antibodies (dAbs) comprise only the variable 
domains of  either the  heavy or light chain of IgG [824, 825], they have monovalent 
ligand binding characteristics and lack the Fc portions ensuring high antigen 
specificity without the risk of receptor cross-linking. Their smal size (~12kD) enables 
beter tissue penetration, delivery at much higher concentrations per unit mass, and 
potentialy less long-term adverse efects (e.g. immunosuppression) due to more 
rapid excretion. Nonetheless, they are suitable for local pulmonary delivery such as 
inhalation. 
 
4.2 Aims 
In this chapter we aimed to investigate the efects of an intratrachealy delivered 
domain antibody that is targeted against mouse p55 TNF receptor on pulmonary 
oedema and inflammation during VILI using an in vivo mouse model. We had two 
main aims: 
1. To develop a robust, reproducible in vivo mouse model of VILI that is suitable 
for intratracheal administration of antibodies in a fluid form. 
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2. To investigate the efects of blocking intraalveolar p55 TNF receptor signaling 
by domain antibodies on pulmonary oedema and inflammation in relation to 
VILI. 
 
4.3 Model development and Protocols 
The most chalenging step of this project was to set up the high-stretch ventilation 
protocol. As we deliver our drug intratrachealy in liquid form, it has an intrinsic efect 
on respiratory function as wel as mechanics. It is likely that the fluid interferes with 
the surfactant layer, hence changing the elastic properties of the lung and 
introducing significant heterogeneity into the system. This is a very important point, 
because in these experiments, the degree of mechanical stress to produce VILI was 
standardised based on airway pressure, therefore any fluctuation of the baseline 
respiratory mechanics before introducing high-stretch ventilation may cause a 
substantial variability of the actualy applied VILI stress. We also had to take into 
account that if the p55 receptor blocking antibody used has any protective efect on 
VILI in terms of respiratory physiology, it could be moderate to mild; therefore a 
model which causes a harsh injury may not be feasible to reveal these efects. 
After investing a lot of time and efort, we managed to develop a robust model 
that can overcome the dificulties arising from the nature of intratracheal fluid 
intervention. Once the model was optimised great progress was made with some 
very exciting results. 
This section wil describe our main steps towards model development, 
whereas the main results achieved by the finalised protocol wil be described in more 
detail in the subsequent ‘Results’ section. 
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Assessment of potential adverse effects of vehicle, p55 and dummy dAb  
We first evaluated whether either of our agents per se would have any adverse 
efects on pulmonary physiology. For this, animals were given an intratracheal bolus 
(50µl) of vehicle, dummy or p55 specific dAb (1mg/kg) and ventilated for 3 hours with 
low stretch (8-10ml/kg, 100% O2). None of the groups showed sign of pulmonary 
oedema formation as assessed by changes in PIP (Figure 4.1/A) and wet:dry lung 
weight ratio (Figure 4.1/B), nor caused inflammation as measured by percentage of 
neutrophils (PMN) in bronchoalveolar lavage fluid (Figure 4.1/C) after diferential 
staining. 
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Figure 4.1 – Peak inspiratory pressure changes (A), lung  wet:dry  weight ratio (B)  and 
percentage  of lavage fluid  neutrophils (C)  during/after  3  hours low-stretch ventilation in 
vehicle,  dummy  dAb  and  p55  dAb treated  mice. Mice were instiled intratrachealy with 50µl of 
either vehicle or dummy dAb or p55 dAb and ventilated with low-stretch setings (VT=8-9ml/kg, 
PEEP=3cmH2O) for 3 hours. N.B. any values below 5 of lung wet:dry ratio does not indicate 
pulmonary oedema, also lavage PMN below 5% suggest no real inflammation. N=2-3/group.  
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Establishing high-stretch protocol using vehicle 
In this model development stage the dAb and vehicle were given as intratracheal 
instilations 1 hour prior to the start of high-stretch ventilation.  The rationale behind 
this was two-fold; firstly we considered that the dAb may need to be given 
prophylacticaly to have eficacy, and secondly (more importantly) that by carying 
out the instilations in advance, the fluid would have time to dissipate and be 
absorbed, hopefuly minimising its influence on respiratory mechanics thereby 
reducing the noise in our system.  For these preliminary experiments, animals were 
given vehicle (100mM Na-citrate in 0.9% NaCl - to preserve dAb structure and 
function in solution) as a bolus (50µl) and ventilated with low stretch (VT=8-9ml/kg, 
PEEP=5cmH2O) for 60 min after which ventilation was set to produce high-stretch 
using diferent levels of peak-inspiratory pressure (PIP) and zero PEEP (ZEEP). This 
was achieved by increasing the gas flow in the ventilatory system until the desired 
PIP was reached, which was continuously measured during ventilation. Mice were 
then ventilated with this seting for up to 120min or until increase in PIP reached 30 
per cent (indicating significant pulmonary oedema in our experience), whichever 
happened earlier. This 120min time frame was chosen to be consistent with our 
previous experiments showing protection from high-stretch-induced pulmonary 
oedema in TNFR p55 knockout mice [639].   We found that seting PIP below 32.5 
cmH2O at the start of high-stretch ventilation caused no significant lung injury, 
whereas any PIP above 33 cmH2O resulted in rapid pulmonary oedema formation 
and mortality within 90min of high-stretch ventilation (Figure 4.2). Therefore in future 
experiments a target PIP of 32.5-33 cmH2O (coresponds to VT ~30ml/kg) was 
chosen to set high-stretch ventilation, as mice ventilated with these setings 
completed the 120min protocol and developed decent pulmonary oedema (Figure 
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4.2). Note that during these experiments pulmonary oedema formation was solely 
monitored by changes in respiratory mechanics (i.e. increase in PIP). 
 
 
Figure 4.2 – Peak inspiratory  pressure (PIP)  changes in  vehicle treated  mice  ventilated with 
high-stretch standardised by PIP. Mice were instiled with vehicle (50µl) intratrachealy via the 
endotracheal tube and ventilated with low-stretch setings (VT=8-9ml/kg, PEEP=3cmH2O) for 60 
minutes after which ventilation was set to produce high-stretch by increasing the gas flow to achieve 
predetermined PIP levels (between 30-35cmH2O, with ZEEP). Seting PIP between 32-33cmH2O 
produced substantial injuries over 120min without compromising the protocol length. ‘Start’=start of 
high-stretch. N=1/each PIP level  
 
Using these ventilatory setings we went on to test the p55 dAb using dummy 
dAb as control. Mice were instiled intratrachealy with 50µl of either vehicle or 
dummy dAb or p55 dAb during low-stretch ventilation (VT=8-9ml/kg, PEEP=5cmH2O) 
and ventilated for 60min, after which setings were changed to produce high-stretch 
using a PIP of ~32.5cmH2O (coresponding to a VT of ~30ml/kg) and ZEEP. Again, 
experiments were stopped when PIP increased by 30% or at 120min, whichever 
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happened earlier. We found that experiments with p55 dAb-treated mice tended to 
last longer (meaning slower injury progression) as compared to dummy group, and 
seemed to have lower PIP (less oedema) at the 90min time point (Figure 4.3).  
 
 
Figure 4.3 – (A)  Peak inspiratory  pressure (PIP)  and (B) respiratory  system  elastance (Ers) 
changes, (C)  PIP  values  at  90  minutes  and (D) length  of  high-stretch ventilation in  vehicle, 
dummy and p55 dAb treated mice ventilated with high-stretch standardised by PIP. Mice were 
instiled intratrachealy with vehicle, dummy dAb or p55 dAb (25µg in 50µl) and ventilated with low 
stretch (VT=8-9ml/kg, PEEP=3cmH2O) for 60 minutes. Then ventilation was changed to produce high-
stretch by seting a PIP of 32.5cmH2O with ZEEP.  Changes in Ers are expressed as percentage 
increase in relation to ‘Start’ values. N=3/group 
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However, the respiratory mechanics were highly variable, and hence diferences 
between the groups were not clear. We also found that dummy dAb-treated mice 
were more injured than vehicle-treated mice. One possible explanation for this is that 
as domain antibodies are proteins, they may have presented oncotic forces thus 
caused slower fluid absorption/clearance from the airways compared to vehicle. The 
presence of fluid within the lung, somewhat moving along the major airways during 
the respiratory cycle results in variable airway resistance especialy at high gas flow, 
which wil ultimately produce more variability in peak pressure. Therefore we decided 
to fine tune the protocol using dummy dAb as control, and to use plateau pressure 
(Pplateau) instead of PIP to standardise stretch because Pplateau is not influenced by 
airway resistance and is a surogate for end-inspiratory alveolar pressure thus 
stress. Making these changes should consequently reduce some of the ‘noise’ in the 
model. 
Fine tuning VILI using dummy as control and standardising with Pplateau 
Mice were instiled with dummy dAb and ventilated for 60min with low-stretch (VT= 9-
10ml/kg, PEEP=5 cmH2O) folowed by 120min high-stretch standardised by Pplateau 
(~25cmH2O, coresponding to a VT of ~30ml/kg) and ZEEP. We found that seting 
Pplateau at 25-25.5cmH2O produced substantial injury by the end of 120min high-
stretch ventilation in dummy dAb-treated mice and only 2 out of 6 animals reached 
the 30% increase in PIP before 120min (Figure 4.4). However, variability in 
respiratory system elastance (Ers) was stil high. 
Regretably, when mice were given the p55 dAb using these setings, they 
showed no sign of protection compared to dummy, in fact these animals showed 
more rapid injury progression, meaning that none of the animals completed the 
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120min high-stretch protocol (Figure 4.4). Although these results may have reflected 
a true lack of eficacy of p55 dAb in atenuating VILI, the possibility that the model 
was too harsh to reveal any potential protective efect of the p55 dAb could not be 
ruled out. Nonetheless, the variability of respiratory physiology was stil high and 
needed to be further reduced. 
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Figure 4.4 – (A) Plateau pressure (Pplateau) and (B) respiratory system elastance (Ers) changes, 
and (C) length of high-stretch ventilation in dummy and p55 dAb treated mice ventilated with 
high-stretch standardised by Pplateau. Mice were instiled with dummy dAb and ventilated for 60min 
with low-stretch (VT= 9-10ml/kg, PEEP=5 cmH2O) folowed by 120min high-stretch standardised by 
Pplateau (~25cmH2O, corresponding to a VT of ~30ml/kg) and ZEEP. Changes in Ers are expressed as 
percentage increase in relation to ‘Start’ values. ‘Start’ = start of high-stretch. N=5-6/group 
Modification of the model – longer incubation period  
Our first atempt to increase the reproducibility of the protocols involved increasing 
the period between instilation and high-stretch ventilation.  In this set-up mice were 
instiled intratrachealy with 50µl of either dummy dAb or p55 dAb during low-stretch 
ventilation (VT=8-9ml/kg, PEEP=5cmH2O) and ventilated for 120min (as opposed to 
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60min), after which setings were changed to produce high-stretch standardised by 
Pplateau (~25cmH2O, coresponding to a VT of ~30ml/kg), and zero PEEP. 
Experiments were stopped when Pplateau increased by 30% (indicating significant 
injury/oedema) or at 120min, whichever happened earlier. Only 1 out of the 4 
dummy-treated mice completed the 120min high-stretch protocol, whereas p55 dAb-
treated animals showed even more rapid injury progression indicating no sign of 
protection (Figure 4.5). This longer pre-incubation, however, somewhat reduced the 
variability in physiology. 
 
 
 
183 
 
Figure 4.5 – (A) Plateau pressure (Pplateau) and (B) respiratory system elastance (Ers) changes, 
and (C) length of high-stretch ventilation in dummy and p55 dAb treated mice ventilated with 
high-stretch standardised by Pplateau after 120min incubation period. Mice were instiled 
intratrachealy with 50µl of either dummy dAb or p55 dAb during low-stretch ventilation (VT=8-9ml/kg, 
PEEP=5cmH2O) and ventilated for 120min, after which setings were changed to produce high-stretch 
standardised by Pplateau (~25cmH2O, corresponding to a VT of ~30ml/kg), and zero PEEP. 
Experiments were stopped when Pplateau increased by 30% (indicating significant injury/oedema) or at 
120min, whichever happened earlier. Changes in Ers are expressed as percentage increase in relation 
to ‘Start’ values. N=3-4/group 
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Trials with diferent instilation methods - bolus vs microsprayer 
Although longer incubation after dAb instilation helped, we felt that the protocol was 
stil not ideal and had to be further refined.  One area we tested was using a 
microsprayer (PennCentury) to nebulise the instilate. During this technique, mice 
were disconnected from the ventilator, placed in an upright position and the 
microsprayer probe was inserted into the endotracheal tube (ETT) until it just passed 
the inner orifice of the ETT (i.e. just above the tracheal bifurcation), then the instilate 
was rapidly injected. Then mice were reconnected to the ventilator and sustained 
inflations were applied to re-establish lung volume. While we found that this method 
substantialy decreased variability compared to the bolus technique (Figure 4.6), its 
usage resulted in intratracheal haemorhage (Figure 4.7). One possible explanation 
as to why the microspraying resulted in intraalveolar haemorhage is that the ETT 
practicaly sealed around the microsprayer probe, preventing any leak of air during 
instilation, which may have led to excessively high airway pressures and 
consequently barotrauma. As this issue could not be solved, in subsequent 
experiments the bolus method was used for drug delivery. 
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 Figure 4.6 – Percentage  of  standard  deviation (SD)  of  different respiratory  mechanics  at  40 
minutes post intratracheal instilation by the bolus method and the microsprayer technique. 
After finishing surgical preparation, mice were disconnected from the ventilator during low-stretch 
ventilation (VT=8-9ml/kg, PEEP=3cmH2O), placed in an upright position and the microsprayer 
(PennCentury) probe was inserted into the endotracheal tube (ETT) and the instilate was rapidly 
injected. Then mice were reconnected to the ventilator and sustained inflations were applied to re-
establish lung volume, after which low-stretch ventilation continued for 3 hours. Values are 
normalised to that of the bolus method (average of N=4/group). Crs=respiratory system compliance, 
Rrs=respiratory system resistance, PIP=peak inspiratory pressure, Paw=airway pressure.  
 
Figure 4.7 – Photomicrographs of cytospin slides showing lavage cels after Diff-Quick 
staining from mice instiled with dummy dAb using the bolus and microsprayer methods. 
Animals instiled with the microsprayer showed intrapulmonary haemorrhage and substantialy 
increased neutrophil numbers compared to those in which the bolus method was utilised. 
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Conclusion 
Our overal conclusions regarding model development at this stage were that the 
model was both too harsh (i.e. too rapid oedema development due to short protocol), 
and too variable to reveal any efects of the dAb on respiratory physiology and lung 
injury development. This variability in physiology, although somewhat reduced during 
model development, remained an issue that had to be appropriately addressed.  
As mentioned previously, intratracheal fluid instilation has a great impact on 
the elastic properties of the lung, and because our standardisation of high-stretch is 
based on respiratory mechanics, such an impact must introduce substantial noise 
into the system. To avoid this, we decided to set high-stretch ventilation before any 
intrapulmonary fluid administration, as wel as reducing the degree of stretch to make 
the model less harsh. By definition this means that the dAb would not have a pre-
incubation period if prophylaxis was required, but we felt that it was more important 
at this stage to consider reducing model variability. Another major change to the 
previous model was to apply PEEP during high-stretch ventilation. This was 
necessary because of the increased propensity of the lungs to develop atelectasis 
and atelectrauma due to the efect of fluid instilation on lung mechanics. Moreover, 
in practice this increased susceptibility to airway colapse could have also squeezed 
some of the instilate out of the lungs straight away after instilation in an 
unpredictable manner, which would have likely introduced noise to the system. 
Please note, during model development when the antibodies were instiled during 
low-stretch ventilation, a PEEP of 5cmH2O was applied, which was only changed to 
zero PEEP during high-stretch, by which time the instilate had been presumably 
absorbed, thus did not implicate such issues.  
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Finalised VILI protocol  
Folowing surgical preparation for the in vivo mouse mechanical ventilation system 
(during which animals were ventilated with 8-9 ml/kg) and baseline measurements, 
ventilation was then set to produce VILI (‘pure’ VILI model), standardised by Pplateau 
of 14 cmH2O coresponding to VT of ~22 ml/kg, with 3 cmH2O PEEP, 90/min 
respiratory rate, and 96%oxygen+4% CO2 (to prevent hypocapnia). Immediately 
folowing this, mice received an intratracheal bolus of either dummy dAb or p55 dAb 
(25µg), or either mouse anti-TNF monoclonal antibody (50µg) or its isotype control in 
a total volume of 50µl.  In a separate series of experiments, a subclinical dose of 
LPS (20ng) was co-administered intratrachealy with the dAb bolus to enhance the 
inflammatory component of the model. In this LPS+VILI model, slightly lower Pplateau 
(13 cmH2O) and VT (~20 ml/kg) were used because LPS was expected to enhance 
the degree of VILI [116]. 
Ventilation using the same constant high VT was continued in al groups for 
240 minutes or until mean BP dropped below 45 mmHg [337]. A smal number of 
animals displayed very rapid haemodynamic deterioration: in the ‘pure VILI’ model, 3 
dummy dAb, 1 p55-specific dAb, 1 isotype control and 2 anti-TNF treated; in the 
‘LPS+VILI’ model, 1 dummy dAb treated mouse.  These prematurely terminated 
experiments were excluded from analyses. Pplateau, Ers and Rrs were calculated every 
20 minutes, folowed each time by sustained inflation (35cmH2O, 5 seconds) to avoid 
the  development  of  atelectasis.   Arterial  blood  gases (ABG) were assessed at 
predetermined points throughout the protocol (Figure 4.8). 
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 Figure 4.8 - Scheme of ventilation protocol. Mice were anaesthetised, tracheostomised and 
ventilated with non-injurious ventilation for approximately 15-20min during instrumentation (doted 
line). Injurious ventilation parameters using high tidal volumes (VT) were then introduced, folowed 
immediately by instilation of the antibody of interest. As a model of VILI with enhanced inflammation, 
a subclinical dose of LPS (20ng) was co-administered with the domain antibody bolus.  After 
instilation of the reagents, 4 sustained inflations (35cmH2O, 5 seconds) were applied to help the fluid 
distribute within the lungs. Respiratory mechanics were assessed every 20min, folowed each time by 
sustained inflation.  Arterial  blood  gases (ABG)  were  assessed  at  predetermined time  points (Start, 
120min, End). Source – Bertok et al. [2] 
Upon termination of experiments, mice were euthanized by anaesthetic overdose 
and cardiac puncture and saline lavage performed, as described in Chapter 2. 
Samples were centrifuged and BALF supernatants aliquoted and stored at -80°C 
These were later quantified for total protein as a further indicator of pulmonary 
oedema/alveolar barier dysfunction, and for IL-6, KC, MIP-2 and MCP-1 by 
colorimetric sandwich ELISA in the LPS+VILI model as indicator of intraalveolar 
inflammation. In the LPS+VILI model, lungs were excised and processed for flow 
cytometry along with cel pelets from BALF samples to assess the degree of 
leukocyte infiltration and activation state of alveolar macrophages. Alternatively, non-
lavaged lungs were instiled with 1% low-melting point agarose in 4% 
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paraformaldehyde and processed for histological evaluation by H&E staining as 
described in Chapter 2. 
4.4 Declaration 
The data contained within this chapter have been published in Thorax by Bertok et 
al. [2] and can be found in Appendix I. Where indicated, the figures in this chapter 
are taken from this manuscript. The investigation was a colaborative efort: Peter 
Morley, Ruud de Wildt, Andrew Baylife, Michael Wilson and Masao Takata must be 
credited for the conception and design of the study as wel as for the analysis and 
interpretation of results, whereas Alicia Waite for her assistance with some of the 
flow cytometry measurements. 
4.5   Results 
Anti-p55 domain antibody atenuates pulmonary oedema in the ‘pure VILI’ 
model 
Mechanical ventilation with the high-stretch protocol resulted in a substantial 
deterioration of lung function in dummy dAb treated animals, consistent with the 
development of pulmonary oedema.  This was represented by a rapidly increasing 
Pplateau, Ers and Rrs towards the end of the 4h ventilation protocol (Figure 4.9/A-C). In 
striking contrast, no deteriorations were seen in respiratory mechanics in p55 dAb-
treated mice. 
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 Figure 4.9 - (A)  Plateau pressure (Pplateau), (B) respiratory  system  elastance (Ers)  and (C) 
resistance (Rrs), (D)  mean  arterial  pressure  were  determined in  ventilated  animals treated 
intratrachealy with either dummy or p55-specific domain antibody (dAb). After finishing surgical 
preparation during low-stretch ventilation (VT=8-9ml/kg, PEEP=3cmH2O), high-stretch was initiated 
standardised by Pplateau (14cmH2O, VT~22ml/kg, PEEP=3cmH2O). Immediately after seting high-
stretch, mice were instiled intratrachealy with either dummy or p55 dAb (25µg in 50µl) and ventilation 
continued with regular sustained inflations to prevent atelectasis for up to 240 minutes .  Changes in 
Ers and Rrs are expressed as percentage increase in relation to ‘Start’ (before instilation) values. 
Pplateau, Ers and Rrs changes over time during ventilation were significantly diferent between treatment 
groups (# P<0.05 for interaction between ‘treatment’ and ‘ventilation time’ by 2-way ANOVA).  N=8-
11/ group. Source – Bertok et al. [2] 
Arterial PO2 and PCO2 levels were similar across the treatment groups at the 
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start and 120 minutes after drug instilation (Figure 4.10/A-B).  By the end of the 
protocol, oxygenation tended to deteriorate in the dummy dAb group 
(365±146mmHg), while PCO2 increased.  In contrast, PO2 was beter maintained in 
the p55 dAb group (440±41mmHg), and PCO2 was unchanged from the 120 minute 
level. To assess alveolar epithelial permeability, we measured the protein content in 
BALF. High-stretch ventilation resulted in substantial protein levels in the dummy 
dAb group as compared to non-ventilated controls (2.82±1.73 vs 0.21±0.03mg/ml), 
and this was significantly atenuated by p55 dAb treatment (1.34±0.4mg/ml) (Figure 
4.10/D).  To confirm that high-stretch ventilation was associated with intraalveolar 
TNF production in dummy dAb treated mice, we measured BALF TNF at the end of 
the protocol, and found it to be up-regulated (147±144pg TNF, N=11) compared to 
untreated mice (undetectable). 
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Figure 4.10  - (A)  Arterial  PO2, (B)  PCO2, (C)  bicarbonate (HCO3-)  and (D) lavage fluid  protein 
were determined in ventilated animals treated intratrachealy with either dummy or p55-
specific domain antibody (dAb). Arterial PO2 showed a tendency to deteriorate in animals treated 
with the dummy dAb but not in mice given the p55-specific dAb.  Changes in PCO2 over time were 
significantly diferent between treatment groups (# P<0.05 for interaction by 2-way ANOVA), while 
changes in bicarbonate levels were similar across groups. Lavage fluid protein was significantly 
atenuated in the p55-specific dAb group († P<0.05 by unpaired t tests). Doted line represents mean 
value in non-ventilated control animals. N=8-11/group. Source – Bertok et al.. [2] 
 
Finaly, we found on lung histology that VILI led to a moderate degree of injury 
in dummy dAb treated animals, characterised by neutrophil infiltration and protein-
rich material in the alveolar space (Figure 4.11/A-B), that was substantialy reduced 
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folowing p55 dAb treatment (Figure 4.11/C-D). 
  
Figure 4.11 - Photomicrographs of lung tissue. Sample from dummy-dAb treated mouse (A, B) 
showed marked celularity, alveolar wal thickening (arrow), hyaline membrane formation and 
intraalveolar debris (arrowhead), whereas minimal changes were seen in p55-dAb treated animal (C, 
D). Hematoxylin-eosin stain. Magnification x100 (A and C), x400 (B and D). 
Blockade of total TNF-signaling by anti-TNF monoclonal antibody does not 
atenuate high-stretch induced pulmonary oedema 
Having demonstrated that blockade of p55 TNF receptor signaling atenuated VILI, 
we investigated whether total TNF signaling blockade would be similarly efective. 
To address this, we treated mice with an anti-TNF monoclonal antibody (or isotype 
control) using the same instilation strategy and ventilation protocol as for the domain 
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antibody experiments. We previously demonstrated that this particular anti-TNF 
antibody, given the same route and dose, efectively reduced alveolar neutrophil 
infiltration associated with VILI [109].  
We found that changes in respiratory mechanics in the isotype control treated 
group folowed a very similar patern as observed for the dummy dAb group (Figure 
4.12/A-C). However, in marked contrast to the beneficial efect of p55 dAb, the anti-
TNF mAb did not atenuate the changes seen in isotype-treated mice.  Likewise, 
anti-TNF treatment had no beneficial efect on blood gases (Figure 4.13/A-C) or 
alveolar epithelial permeability (Figure 4.13/D).  
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Figure 4.12 - (A)  Plateau  pressure (Pplateau), (B) respiratory  system  elastance (Ers)  and (C) 
resistance (Rrs), (D)  mean  arterial  pressure in animals treated intratrachealy with either 
isotype or mouse anti-TNF monoclonal antibody (mAb). After finishing surgical preparation during 
low-stretch ventilation (VT=8-9ml/kg, PEEP=3cmH2O), high-stretch was initiated standardised by 
Pplateau (14cmH2O, VT~22ml/kg, PEEP=3cmH2O). Immediately after seting high-stretch, mice were 
instiled intratrachealy with either isotype or anti-TNF mAb (50µg in 50µl) and ventilation continued 
with regular sustained inflations to prevent atelectasis for up to 240 minutes. Changes in Ers and Rrs 
are expressed as percentage increase in relation to ‘Start’ (before instilation) values. N=6/group. 
Source – Bertok et al. [2] 
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 Figure 4.13 - (A) arterial PO2, (B) PCO2, (C) bicarbonate (HCO3-) and (D) lavage fluid protein in 
animals treated intratrachealy with either isotype or mouse anti-TNF monoclonal antibody 
(mAb) and ventilated with high-stretch ventilation for 240min. Doted line represents mean value 
in non-ventilated control animals. N=6 /group. Source – Bertok et al. [2] 
Anti-p55 domain antibody reduces pulmonary inflammation secondary to 
LPS+VILI 
Finaly, we investigated if the p55-specific dAb would also have a beneficial efect on 
pulmonary inflammation associated with VILI. It was previously demonstrated by our 
group and others [856] that pure mechanical ventilation induces a relatively limited 
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degree of alveolar neutrophil infiltration (at least within the time frame of ventilation 
used curently), one of the halmarks of clinical ALI.  Therefore to enhance the 
degree of inflammation within the model we included a ‘subclinical’ dose of LPS 
(20ng) mixed with the dummy or p55 domain antibodies at the start of mechanical 
ventilation.  Our preliminary experiments showed that this dose of LPS did not 
induce changes in respiratory mechanics with low tidal volume ventilation. 
Similarly to the ‘pure VILI’ model, LPS+VILI induced substantial changes in 
respiratory mechanics which were significantly atenuated by p55 dAb (Figure 
4.14/A-C).   
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Figure 4.14 - (A)  Plateau  pressure (Pplateau), (B) respiratory  system  elastance (Ers)  and (C) 
resistance (Rrs), (D)  mean  arterial  pressure in the  LPS+VILI  model. After finishing surgical 
preparation during low-stretch ventilation (VT=8-9ml/kg, PEEP=3cmH2O), high-stretch was initiated 
standardised by Pplateau (13cmH2O, VT~20ml/kg, PEEP=3cmH2O). Immediately after seting high-
stretch, mice were instiled intratrachealy with either dummy or p55 dAb (25µg) mixed with LPS 
(20ng) in a total volume of 50µl, and ventilation continued with regular sustained inflations to prevent 
atelectasis for up to 240 minutes.Changes in Ers and Rrs are expressed as percentage increase in 
relation to ‘Start’ values. Changes in Pplateau, Ers and Rrs over time were significantly diferent between 
treatment groups (# P<0.05 for interaction between ‘treatment’ and ‘ventilation time’ by 2-way 
ANOVA). N=8-11/group. Source – Bertok et al. [2] 
Likewise, p55 dAb treatment prevented the deterioration of oxygenation 
(Figure 4.15/A), and tended to atenuate the rise in PCO2 (Figure 4.15/B). There was 
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also a trend toward decreased protein levels in lavage fluid in p55 dAb-treated 
animals (2.94±1.62 vs 2.06±1.45mg/ml, for dummy and p55 dAb respectively), 
although this did not reach statistical significance (Figure 4.15/D).  
 
Figure 4.15 - (A) arterial PO2, (B) PCO2, (C) bicarbonate (HCO3-) and (D) lavage fluid protein in 
the LPS+VILI model. Arterial PO2 and bicarbonate over time were significantly diferent between 
treatment groups (# P<0.05 for interaction between ‘treatment’ and ‘ventilation time’ by 2-way 
ANOVA). The p55-specific dAb tended to atenuate the rise in PCO2, but this did not reach statistical 
significance (P=0.055 for interaction by 2-way ANOVA). Lavage fluid protein levels tended to be 
reduced in p55-specific dAb treated animals, but not significantly. Doted line represents mean value 
in non-ventilated controls. N=8-11/group. Source – Bertok et al. [2] 
Neutrophils  and inflammatory  subset  Gr-1high monocytes in lung single cel 
suspension and lavage fluid were identified based on characteristic antigen 
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expression using flow cytometry as discussed in Chapter 2, and their number or 
activation state quantitatively assessed. LPS+VILI significantly increased the number 
of lung-marginated neutrophils as compared to non-ventilated controls 
(2.32±0.57x106 vs 0.13±0.05x106, respectively), which was significantly atenuated 
by p55 dAb treatment (1.25±0.31x106, P<0.01 vs dummy) (Figure 4.16/A). A similar 
trend  was found  with  Gr-1high monocytes, although this was not significant (Figure 
4.16/A). Transmigration of neutrophils to the alveolar space was also greatly 
increased by LPS+VILI, and substantialy atenuated by p55 dAb treatment (Figure 
4.16/B), whereas Gr-1high monocytes were not detected in BALF in any of the groups. 
Alveolar macrophages in BALF of dummy dAb treated mice showed up-regulated 
ICAM-1 expression compared to non-ventilated controls, indicating cel activation 
[107], which was also markedly reduced in the p55 dAb group (Figure 4.16/C). 
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Figure 4.16 – Number of leukocyte subsets in the lungs and lavage fluid and ICAM-1 
expression by alveolar macrophages of dummy-dAb and p55-dAb treated mice in LPS+VILI 
model assessed by flow cytometry. Treatment with p55-specific dAb atenuated the number of (A) 
lung-marginated and (B) intraalveolar neutrophils and (C) the activation state of alveolar 
macrophages by means of ICAM-1 expression (mean fluorescence intensity (MFI) after isotype 
subtraction). Doted line represents mean value in non-ventilated control animals. *P<0.05, **P<0.01 
by unpaired t-test (as lavage fluid neutrophil number data were non-parametric, these were 
transformed prior to t-test then transformed back for presentation). N=8-11/group. Source – Bertok et 
al. [2] 
Finaly, BALF levels of IL-6 and MCP-1 were also significantly decreased in 
p55 dAb treated mice, with similar trends for KC and MIP-2 (Figure 4.17). 
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Figure 4.17 - Levels of lavage fluid (A) IL-6, (B) MCP-1, (C) KC and (D) MIP-2 in LPS+VILI model. 
Doted line represents mean value in non-ventilated control animals (undetectable levels for IL-6). 
*P<0.05, **P<0.01 by unpaired t-test (A, B, C) and Mann-Whitney U-test (D). N=8-11/ group. Source – 
Bertok et al. [2] 
 
Although the findings of the ‘pure’ VILI model would suggest that p55 dAb can 
atenuate high-stretch ventilation induced lung injury, the findings of this model (i.e. 
LPS+VILI) may represent an atenuation of the LPS efect primarily perpetuated by 
mechanical ventilation, rather than an efect on mechanical ventilation per se. 
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4.5   Discussion 
Mechanical ventilation is an essential tool in the management of patients with 
ALI/ARDS, however this can exacerbate underlying lung injury and cause VILI. VILI 
can progress to systemic inflammation and multiple system organ failure (MSOF), 
which is a major cause of death amongst ARDS patients [291, 323]. Although low 
tidal volume ventilation in conjunction with other interventions reduced mortality in 
this patient population, it is not possible to eliminate completely the consequences of 
VILI in this manner.  Manipulation of the inflammatory response to ventilation is 
considered to be the strategy most likely to be successful for the therapeutic 
treatment of VILI. In this chapter we investigated the use of a novel therapeutic 
technology, domain antibodies, for the first time in the area of acute lung injury, and 
showed that intratracheal administration of dAb targeting the p55 TNF receptor 
atenuated both pulmonary dysfunction and inflammation associated with VILI.  
Model development 
In order to test our hypothesis that intraalveolar targeting of p55 signaling could 
atenuate VILI, we first had to establish a robust model that alowed us to deliver the 
antibodies in fluid form into the alveolar space without significantly influencing 
respiratory mechanics. This was quite important for at least two main reasons. 
Firstly, standardisation of high-stretch was based on airway pressures wich are 
greatly influenced by respiratory mechanics, therefore high variability in these 
parameters could potentialy introduce a lot of noise in the system and compromise 
standardisation. Secondly, our assessment of lung injury development relied, in part, 
on measuring respiratory mechanics, such as plateau pressure, resistance and 
elastance, and high variability in these parameters could potentialy prevent us from 
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detecting a subtle efect of the antibody. Indeed, initial experiment in which high-
stretch ventilation was initiated folowing some incubation period with intratrachealy 
administered antibodies, failed to show any benefits of p55 dAb. We felt that this 
might be because intratracheal fluid instilation interfered with the surfactant layer of 
the lung hence changing its elastic properties. Also, fluid movements in the airways 
during respiration could result in variable airway resistance, particularly during high 
gas flow, which substantialy influences peak inspiratory pressures.   
 To overcome these issues presented by fluid instilation to the airways, we 1) 
decided to standardise high-stretch by plateau pressure which is not influenced by 
airway resistance, 2) increased the incubation period before high-stretch ventilation 
and 3) tried microspraying to aid beter fluid dissipation and absorption. Although, al 
these modifications somewhat helped to beter standardise high-stretch ventilation 
and reduced the variability in respiratory mechanics, we stil could not detect any 
positive efect of p55 dAb. We came to the conclusion that it was crucial to set high-
stretch prior to antibody delivery to eliminate any influence of fluid instilation on 
model standardisation.  We also decided to prolong the ventilation protocol, as too 
rapid injury development may have also masked any beneficial efects of p55 dAb. 
Having made these changes to the model design, we managed to produce a robust 
and reproducible VILI model, which alowed us to show some very encouraging and 
potentialy clinicaly significant results.       
 The tidal volumes used in the finalised protocol (VT 20-22ml/kg), although 
higher than used clinicaly in humans, would have induced only a moderately high 
degree of lung stretch in untreated healthy mice as mouse lungs are much more 
compliant than those of humans [857]. This was elegantly demonstrated by Wilson et 
al. who ventilated healthy mice with diferent level of VT (10, 20, 30 or 40ml/kg), and 
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measured respiratory system compliance and arterial blood gases to evaluate 
physiological variables of lung injury, whereas lung wet:dry weight ratio, BALF 
protein and cytokines were measured to assess pulmonary oedema and 
inflammation [858]. They found that each ventilator seting reduced respiratory 
system compliance, but in mice ventilated with VT of 10, 20 and 30 ml/kg, this was 
largely reversible by recruitment manoeuvre at the end of protocol, and only mice 
ventilated with 40ml/kg developed pulmonary oedema and inflammation [858]. The 
authors concluded that tidal volumes up to 20 mL/kg are unlikely to induce 
substantial lung overstretch in models using healthy mice, therefore signs of lung 
injury/inflammation using such models are likely to result from other factors, 
particularly alveolar derecruitment and atelectasis. However, in the curent model 
due to the impact of the intratracheal fluid instilation, such setings were suficient to 
induce injury within 4 hours ventilation. Since atelectasis was minimised by the use 
of PEEP and regular sustained inflations, the major component of the observed 
physiological changes can be ascribed to the development of stretch-induced 
pulmonary oedema.         
 While the timeframe of the curent experiment is much shorter than ALI 
patients would be ventilated, it is comparable with the majority of published rodent 
studies of VILI and ALI.  
Specific targeting of intraalveolar p55 signaling by dAb atenuates VILI 
We found that high-stretch induced changes in respiratory mechanics and blood 
oxygenation, as wel as production of pulmonary oedema were substantialy 
improved when p55-specific blocking dAb was given intratrachealy at the start of the 
4 h high-stretch ventilation in the ‘pure VILI’ model. In complete contrast, total 
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blockade of intrapulmonary TNF signaling by a mouse anti-TNF mAb failed to exert 
protection.  
Having demonstrated that intratrachealy delivered p55 dAb atenuated the 
respiratory physiology in VILI, we questioned whether it could improve its 
inflammatory aspect. It is clear that ventilated patients are quite rarely without 
underlying inflammation the main causes of which are pneumonia and sepsis [22], 
and mechanical ventilation can exacerbate the inflammatory response [291, 859, 
860] which may eventualy lead to multiple organ failure (MOF), the main cause of 
high mortality amongst these patients.  
Therefore to investigate the efects of p55-blocking dAb we chose a 2-hit 
model of VILI, which may beter represent the clinical scenario. This comprised of an 
i.t. delivered LPS (subclinical dose) folowed by 4h high-stretch ventilation 
(LPS+VILI). We found that in addition to the improvements in respiratory physiology, 
p55-dAb significantly reduced the number of marginated and transmigrated 
neutrophils, and decreased the levels of pro-inflammatory cytokine IL-6 and 
monocyte/neutrophil chemoatractant MCP-1 in lavage fluid, and showed strong 
trends towards decreases in the chemokines MIP-2 and KC.  
While the precise sources of these inflammatory mediators in VILI remains 
uncertain, alveolar macrophages are likely contributors, and indeed we observed 
that alveolar macrophage activation (surface ICAM-1 expression [107]) was 
significantly atenuated by dAb treatment.  Presumably as a consequence of this 
reduced intra-alveolar inflammation, margination and migration of neutrophils within 
the lung was also atenuated. The pivotal role of neutrophils and chemokines in the 
pathogenesis of VILI is wel documented [105-109]. Recent evidence also indicates 
that margination of neutrophils to remote organs (including the lungs, heart and 
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kidney) during sepsis and thus their involvement in MOF is potentialy triggered by 
induced expression of the MCP-1 receptor CCR-2 on neutrophils, which is mediated 
by Tol-like receptor signaling [861]. Therefore, reduction of intraalveolar MCP-1 by 
intratracheal p55-dAb treatment likely contributed to atenuated lung neutrophil 
numbers and injury in our study. However further investigations are needed to 
elucidate what significance of this reduced pulmonary inflammation may have in 
relation to other organ injury during VILI. 
From the curent data, it is not possible to precisely determine why the p55-
specific dAb was clearly more efective in atenuating VILI than the anti-TNF mAb. 
One possibility is that this diference purely reflects greater biodistribution of the dAb 
compared to mAb due to diferences in their biophysical properties. For example, in 
contrast to dAbs, mAbs possess an Fc fragment and are likely subject to elimination 
from the lung by diferent Fc-FcR mediated mechanisms. Spiekermann et al. 
investigated the mechanisms by which IgG crosses epithelial surfaces in the mouse 
lung [822]. They identified an FcRn-mediated active celular transport by bronchial 
epithelial cels, and using an erythropoietin-Fc fusion protein demonstrated that 12-
15% of the intra-nasaly delivered dose was absorbed to the systemic circulation. 
Although they ascribed this mechanism solely to bronchial epithelial cels based on 
their strong expression of FcRn, it cannot be excluded that alveolar epithelium 
contributed to the transport despite they are low FcRn expresser cels. 
Another possibility by which intrapulmonary delivered monoclonal antibodies 
may be eliminated is their tendency to bind to surfactant proteins and being 
phagocytosed by alveolar macrophages, a mechanism which is also related to Fc-
FcR interaction as shown by Lin et al. [823]. The authors demonstrated that 
surfactant protein-A (SP-A) binds to the Fc portion of IgG and increases the uptake of 
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IgG-coated particles by alveolar macrophages. However, this interaction of IgG with 
SP-A did not afect the antigen binding afinity in their study. Therefore, if any of 
these aforementioned mechanisms are involved, it is tempting to speculate that the 
poor results of anti-TNF treatment in our experiments were more likely due to a 
quicker elimination of the antibodies by bronchial epithelial cels or alveolar 
macrophages before the high-stretch induced production of TNF occured, rather 
than to impaired binding of TNF.  
This lack of eficacy of anti-TNF treatment to atenuate the physiological 
manifestations of VILI are somewhat at odds with a previous study by Imai et al. 
showing a positive efect of anti-TNF in a rabbit model of saline lavage folowed by 
injurious ventilation [334]. One possible explanation for this is that in their 2-hit model 
pulmonary inflammation (e.g. marginated neutrophils) played a more significant role 
in lung injury progression than in our 1-hit model, and this was significantly 
atenuated by anti-TNF mAb. Our results do, however, reflect the disappointing 
results from clinical trials of sepsis/ARDS patients [616, 617, 624, 625, 862]. 
In addition to the biophysical properties of the respective antibodies, we 
believe that target antigen specificity is vitaly important and propose that the 
ineficacy of anti-TNF mAb in this model is potentialy due to diferential TNF receptor 
signaling. Our group previously showed using knockout mice that signaling through 
p55 promoted the development of high stretch-induced pulmonary oedema, while 
signaling through p75 protected against oedema formation, and that these opposing 
efects seemed to be independent of TNF-mediated leukocyte recruitment [639]. 
Importantly, mice lacking both TNF receptors showed no protection from oedema, a 
finding consistent with that of Yoshikawa et al. [863].  These data from TNFR 
knockout animals suggest that non-selective anti-TNF treatment would not be 
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efective to atenuate pulmonary oedema during VILI.  Interestingly, in an earlier 
study, we showed that the monoclonal anti-TNF antibody used curently atenuated 
alveolar neutrophil accumulation in VILI [109].  Similarly, Wolthuis et al., found that 
inhibition of total TNF signaling by a p75 receptor-Fc fusion protein (Etanercept), 
failed to atenuate high  stretch-induced pulmonary oedema but reduced neutrophil 
influx and BALF cytokine levels [640].   Taken together, these data suggest that 
while therapy designed to block TNF per se may be efective in reducing pulmonary 
inflammation associated with VILI, it has litle impact on pulmonary oedema, 
presumably as any beneficial efects of signaling through the p75 receptor on 
pulmonary fluid balance are inhibited. For example, it was demonstrated in vitro that 
activation of p75-associated Etk/Bmx tyrosine kinase [776] in epithelial cels results 
in cytoskeletal re-arangement thus increased transepithelial resistance, protecting 
from hypoxia–induced permeability [778].  TNF receptor p75 may also protect from 
TNF-induced apoptosis in endothelial/epithelial cels, thus help to maintain alveolo-
capilary barier integrity and function [729]. 
Our study may look somewhat limited by not comparing the efects of p55 
receptor inhibition by a dAb to that by a mAb. This was for two main reasons: First, 
as mentioned before, the use of monoclonal antibodies against the p55 receptor can 
result in receptor activation instead of inhibition due to receptor cross-linking as 
indicated in diferent celular assays [820, 821, 844]. These findings are consistent 
with our previous preliminary studies where intratrachealy given mouse anti-p55 
mAb worsened VILI. Second, monoclonal antibodies are not suitable for pulmonary 
delivery for various reasons as described above, whereas previous data strongly 
suggest that TNF signaling should be inhibited in the alveolar space in order to 
improve VILI.  We also aimed to further explore the role of diferential TNF receptor 
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signaling in VILI. However, as neither anti-TNF nor anti-p75 dAb were available at 
the time of our study, we used a monoclonal anti-TNF antibody for this, which may 
not be ideal, but was previously proved to eficiently reduce VILI-induced 
inflammation by our group [109]. Despite these limitations, our study provides novel, 
valuable insight to the role of TNF signaling in VILI pathophysiology with potentialy 
strong clinical significance.  
In conclusion, we have shown for the first time that specific inhibition of 
intraalveolar TNFRp55 signaling by a domain antibody can ameliorate pulmonary 
oedema and inflammation during VILI in mice. Targeting intraalveolar p55 receptor 
signaling by domain antibodies may open new therapeutic approaches for ventilated 
patients with ALI. 
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5. Selective targeting of p55 TNFR 
signaling during ventilator-induced 
lung injury by systemicaly delivered 
domain antibodies  
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Having demonstrated that selective inhibition of intraalveolar p55 TNFR signaling by 
domain antibodies directly delivered to the lungs can significantly atenuate VILI, we 
wanted to investigate if targeting the same receptors via an indirect route of delivery, 
namely systemic as opposed to topical, would be similarly efective. 
 To address this, we treated mice with a continuous intravenous infusion of 
dAb whilst being exposed to high-stretch mechanical ventilation, and assessed 
development of lung injury by monitoring changes in respiratory physiology and 
measuring levels of inflammatory chemokines/cytokines in the lungs and in the 
plasma.  
 We found that, although similar amounts of p55 dAb could be delivered to the 
alveolar space by intravenous infusion as with the intratracheal delivery in Chapter 4 
experiments, neither pulmonary oedema nor inflammation was atenuated. The 
reasons behind this lack of efect are not yet clear, and require further investigations 
before this route of delivery could be safely rejected. 
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5.1   Background 
Using TNFR knock-out mice, our group has previously demonstrated that the two 
receptors of TNF play a directly opposing role in the pathogenesis of VILI, i.e. mice 
lacking the p55 receptor were protected, whereas p75 knock-outs were more prone 
to develop pulmonary oedema. Interestingly, lack of total TNFR mediated signaling 
in TNFR double knock-out animals led to similar amount of injury to that in wild-type 
mice, which may explain why clinical trials with anti-TNF antibodies failed to improve 
the outcome in ALI.  These findings indicated that specific targeting of p55 receptor 
as opposed to total TNF blockade is potentialy necessary to atenuate VILI. 
However, it was not clear from this study where exactly in the lung p55 signaling 
should be targeted, on the pulmonary epithelial or endothelial cels or both. 
Therefore further studies in the lab were dedicated to investigate and characterise 
the role of individual TNFRs in the lungs. 
 As discussed in Chapter 3, we found that p55 is the dominant receptor on 
pulmonary endothelial cels and the major regulator of TNF-induced adhesion 
molecule expression, which could be a reflection of its relative expression level to 
that of p75. However, this role may subside during inflammatory conditions such as 
sepsis, when its expression is dramaticaly decreased compared to p75, which 
remains unafected. Similarly, using in vivo and ex vivo mouse models of VILI our 
group has previously demonstrated shedding of both TNFRs from the surface of 
pulmonary endothelial cels and lung marginated monocytes 2 hours after high-
stretch mechanical ventilation (A Dor – PhD thesis).  
On the contrary, situation seems to be the opposite in the alveolar 
compartment: the same author found surface expression of both TNFRs on 
pulmonary epithelial cels and alveolar macrophages with a dominance of p75 (only 
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subtle in the case of pulmonary epithelial cels). He also demonstrated that direct 
inflammatory insult to the lungs, i.e. i.t. LPS instilation did not alter the expression 
level of the two TNF receptors on pulmonary epithelial cels [819]. Intratracheal LPS 
stimulation also resulted to selective up-regulation of soluble p75 receptors in the 
lavage fluid, lending further indirect support that cel surface expression of p55 
receptor is wel maintained throughout the alveolar compartment. Al these findings 
let us to conclude that selectively targeting of p55 signaling in the alveolar space 
would be the most reasonable option to atenuate VILI pharmacologicaly. Indeed, 
when p55 receptor signaling was inhibited by intratrachealy instiled domain 
antibodies both pulmonary oedema and inflammation were atenuated in a mouse 
model of VILI, as demonstrated in the previous chapter. 
 Intrapulmonary delivery of drugs in the clinical practice, especialy in 
ventilated patients can be technicaly chalenging thus the intravenous route would 
be more appealing at least from a practical point of view. Although the biophysical 
properties of domain antibodies alow penetration through the alveolar-capilary 
membrane and consequent accumulation in the alveolar space, it is not clear 
whether giving the p55 targeting dAb systemicaly would have similar benefits in VILI 
compared to direct pulmonary delivery. On the other hand, data in Chapter 3 
demonstrated that p55 signaling may have an important role in pulmonary 
microvasculature activation, which is an important feature in the pathogenesis of 
VILI; therefore it is reasonable to think that giving the p55 dAb intravenously may 
even have additional benefits to the intratracheal route.  
215 
5.2   Aims 
In this chapter I investigated the efects of systemicaly delivered p55-specific 
domain antibody on the development of VILI using the in vivo mouse model 
established in chapter 4. There were 2 main aims: 
1. To identify an intravenous domain antibody dose that would ensure 
accumulation of substantial intraalveolar levels.  
2. To compare the efects of i.v. vs. i.t. delivered p55-specific domain antibody 
on pulmonary oedema and inflammation during VILI. 
 
5.3   Protocols 
Pharmacokinetic studies to identify the adequate intravenous dAb dose 
In this study I aimed to deliver the p55 receptor targeting domain antibody to the 
alveolar space indirectly by using the intravenous route. Because of its smal size 
and biochemical properties, domain antibodies can cross the alveolar-capilary 
membrane from each direction. However, the half-life of p55 dAb  in the plasma is 
extremely short (T1/2 ~ 20min, personal communication with GSK) due to rapid renal 
excretion; therefore, in order to achieve significant amount of dAb in the alveolar 
space, it has to be given in a continuous intravenous infusion. Domain antibodies 
can be modified structuraly, e.g. by PEGylation, to increase their plasma T1/2 without 
afecting their antigen specificity or neutralising activity, however this has an impact 
on their tissue penetration properties given the increased molecular size. As in this 
particular study the aim was to get the dAb across the alveolar-capilary membrane, 
such a modified molecule could not be used. 
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 In order to identify an intravenous dose that would ensure intraalveolar 
accumulation of the dAb in a comparable amount to that delivered in the i.t. dAb+VILI 
model, pharmacokinetic studies were caried out.  
 For this, mice were ventilated with high-stretch setings that would result in 
significant amount of injury within 240min, i.e. Pplateau=30cmH2O equating to 
VT=30.9±1.4ml/kg, PEEP=3cmH2O [858]. Immediately after seting high-stretch 
parameters, a continuous infusion of p55-specific dAb was started via the jugular 
vein at a rate of 50µg/h (2µg/g/h at an infusion pump rate of 0.2ml/h). After 30, 60 or 
120min experiments were terminated, mice euthanized by anaesthetic overdose and 
cardiac puncture and lung lavage performed. BALF and blood samples were 
centrifuged and the supernatant and plasma, respectively, stored at -80ºC until 
analysis for level of p55 dAb by ELISA (GSK, Stevenage, UK). 
 We found that p55 dAb given at this dose resulted in gradual accumulation of 
the antibody in the alveolar space reaching an average concentration of nearly 
15ng/ml (1nM) by 120min, approximately 20% of the circulating level (Figure 5.1). 
However, this was felt to be too low to suficiently inhibit p55 TNFR signaling, 
therefore, based on this pharmacokinetic study and calculations, a 5 times higher 
dose, i.e. 250µg/h was used in the subsequent experiments. Analysis of samples 
(performed by GSK) from these confirmed that a reasonable amount of alveolar p55 
dAb (~500ng/ml) was achieved by the end of the 240min protocol with this 
intravenous dose, but it is unclear how does this compare to the intraalveolar levels 
of p55 dAb in the intratracheal model (Chapter 4), as we did not measure it. 
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Figure 5.1 – Lavage fluid (BALF) and plasma levels of p55 dAb in mice with i.v. infusion of the 
antibody during high-stretch ventilation. Mice were ventilated with injurious setings 
(Pplateau=30cmH2O, VT~31ml/kg) whilst receiving a continuous infusion of p55 dAb (50µg/h) via the 
jugular vein, then kiled after 30, 60 or 120min, BALF and plasma samples obtained and analysed for 
p55 dAb levels by ELISA. Intravenous infusion of p55 dAb resulted in a gradual accumulation of the 
antibody in the alveolar space (BALF), reaching approximately 20% of the plasma level by 120min of 
infusion. Mean+SD, N=3/each time point. 
Ventilation protocol for i.v. dAb + VILI model 
To be able to compare the injury progression and respiratory physiology changes in 
this model with that in the intratracheal model as directly as possible, it was 
necessary in this set of experiments to administer an intratracheal bolus of dummy 
dAb the same way as described in Chapter 2 and 4 after seting high-stretch 
ventilation, whereas either dummy or p55 dAb was given intravenously in a 
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continuous infusion (250µg/h, 10µg/kg/h) via the jugular vein using an infusion pump 
(0.2ml/h). Other protocol parameters were the same as described in Chapter 4.  
In brief, folowing surgical preparation for the in vivo mouse mechanical 
ventilation system (during which animals were ventilated with 8-9 ml/kg) and 
baseline measurements, ventilation was then set to produce VILI standardized by 
inspiratory plateau pressure (Pplateau) of 14 cmH2O equating to VT of ~22 ml/kg, with 
3  cmH2O PEEP, 90/min respiratory rate, and oxygen+4% CO2 (to prevent 
hypocapnia). Immediately folowing this, mice received an intratracheal bolus of 
dummy dAb (25µg, 50µl) and at the same time continuous intravenous infusion of 
either dummy dAb or p55 dAb was started through the jugular vein (250µg/h, 
10µg/g/h, 0.2ml/h). To maintain the same fluid load as in the intratracheal model, 
saline infusion rate through the carotid line was set at 0.2ml/h. 
Ventilation using the same constant high VT was continued in al groups for 
240 minutes or until mean BP dropped below 45 mmHg [337]. Anaesthesia was 
maintained by bolus administrations of intraperitoneal ketamine:xylazine every 20-25 
minutes. Two animals displayed very rapid haemodynamic deterioration in the 
dummy group, whereas al p55 dAb treated mice completed the protocol.  These 
prematurely terminated experiments were excluded from analyses.  Pplateau, 
respiratory system elastance (Ers) and resistance (Rrs) were measured every 20 
minutes, folowed each time by sustained inflation (35cmH2O, 5 seconds) to avoid 
the  development  of  atelectasis.   ABG  were  assessed  at  predetermined  points 
throughout the protocol (Figure 5.2). 
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 Figure 5.2 - Scheme of ventilation protocol. Mice were anaesthetised, tracheostomised and 
ventilated with non-injurious ventilation for approximately 15-20min during instrumentation (doted 
line). Injurious ventilation parameters using high tidal volumes (VT) were then introduced, folowed 
immediately by instilation of i.t dummy dAb and continuous i.v. infusion of either dummy or p55 dAb 
via the jugular vein.  After instilation of i.t dummy dAb, 4 sustained inflations (35cmH2O, 5 seconds) 
were applied to help the fluid distribute within the lungs. Respiratory mechanics were assessed every 
20min, folowed each time  by  sustained inflation.  Arterial  blood  gases (ABG)  were  assessed  at 
predetermined time points (Start, 120min, End).  
Upon termination of experiments, mice were kiled by anaesthetic overdose 
and cardiac puncture and saline lavage performed, as described in chapter 2. 
Samples were centrifuged and BALF supernatants and plasma samples aliquoted 
and stored at -80°C. Thawed samples were quantified for total protein as a further 
indicator of pulmonary oedema/alveolar barier dysfunction, and for IL-6, KC, MIP-2 
and MCP-1 by colorimetric sandwich ELISA as indicator of intraalveolar and 
systemic inflammation. Samples from non-ventilated animals served as controls. 
5.4   Results 
Intravenous anti-p55 domain antibody does not atenuate high-stretch induced 
changes in respiratory physiology and pulmonary oedema 
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Al animals were ventilated with the same high stretch protocol (VT  22.1±1.7 ml/kg 
vs. 21.9±2.6 ml/kg for dummy dAb and p55-specific dAb treated mice respectively; 
n=6-7/group) for up to 240min.  High-stretch mechanical ventilation caused a 
substantial deterioration in lung function in dummy dAb treated animals (i.e. i.t.-
dummy + i.v.-dummy) consistent with pulmonary oedema formation. This was 
represented by an exponentialy increasing Pplateau, Ers and Rrs towards the end of 
the 4h ventilation protocol (Figure 5.3/A-C). The magnitude and nature of these 
ventilation-induced changes were very similar to that observed in the ‘intratracheal’ 
model (chapter 4).  In contrast to our findings using direct intratracheal blockade, 
inhibition of p55 signaling by i.v. p55-dAb did not atenuate the high-stretch induced 
changes seen in dummy dAb-treated animals. 
221 
 
Figure 5.3 - (A)  Plateau  pressure (Pplateau), (B) respiratory  system  elastance (Ers)  and (C) 
resistance (Rrs), (D)  mean  arterial pressure in mice treated with i.v. dummy or p55 dAb and 
ventilated with high-stretch setings. After completing surgical preparation ventilation setings were 
changed to produce high-stretch (Pplateau=14cmH2O, VT~22ml/kg, PEEP=3cmH2O) and mice received 
an intratracheal bolus of 25µg (50µl) dummy dAb and a continuous intravenous infusion of either 
dummy or p55 dAb (250µg/h) was started at the same time, and animals ventilated for up to 240min. 
Changes in Ers and Rrs are expressed as percentage increase in relation to ‘Start’ values. Treatment 
groups showed no significant diference in these parameters. N=6-7/group. 
Similarly, p55 dAb treatment had no beneficial efect on gas exchange (Figure 
5.4/A-C) or alveolar epithelial permeability as indicated by lavage fluid protein 
(Figure 5.4/D).  
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Figure 5.4 - (A) arterial PO2, (B) PCO2, (C) bicarbonate (HCO3-) and (D) lavage fluid protein  in 
mice treated with i.v. dummy or p55 dAb and exposed to high-stretch ventilation. VILI-induced 
changes were not atenuated by intravenous p55 dAb infusion, in fact decrease in arterial bicarbonate 
over time was significantly worse in the p55 dAb group (# P<0.05 for interaction between ‘treatment’ 
and ‘ventilation time’ by 2 way ANOVA). Doted line represents mean value in non-ventilated control 
animals. N=6-7/group. 
Continuous  i.v. infusion of p55-specific domain antibody does not atenuate 
levels of intraalveolar or systemic inflammatory cytokines/chemokines 
Having found that intravenous infusion of p55 targeting dAb had no efect on 
respiratory physiology, I wanted to see whether it had any positive efects on the 
inflammation aspect of VILI. Similarly to the ‘pure’ VILI model described in chapter 4, 
this VILI model did not result in substantial leukocyte infiltration to the lung based on 
BALF neutrophil counts in preliminary studies, therefore flow cytometry was not 
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performed on lung samples. Instead, levels of the same inflammatory 
cytokines/chemokines were analysed as in the LPS+VILI model in chapter 4, i.e. IL-
6, MCP-1, KC and MIP-2.  
High-stretch ventilation resulted in significant increase in IL-6, KC and MIP-2 
in the lavage fluid as compared to non-ventilated controls; however, there was no 
diference between treatment groups (Figure 5.5). Interestingly and unexpectedly, 
level of MCP-1 was lower in both treatment groups compared to non-ventilated 
control, however stil without diference between dummy and p55 dAb treated 
animals. 
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Figure 5.5 - Levels of lavage fluid (A) IL-6, (B) MCP-1, (C) KC and (D) MIP-2 after 240min high-
stretch ventilation in mice treated with intravenous dummy or p55 dAb.  No significant 
diferences were detected between treatment groups. Doted line represents mean value in non-
ventilated control animals (undetectable levels for IL-6). Mean+SD, N=6-7/group. 
Although i.v. p55 dAb infusion had no efect on the levels of inflammatory 
cytokines/chemokines in the alveolar space, it could have a positive impact on 
systemic inflammation. To address this, plasma levels of the same 
cytokines/chemokines were also measured. Levels of IL-6, MCP-1 and KC were 
significantly higher as compared to non-ventilated controls - which had undetectable 
levels - and IL-6 and KC were not diferent across the treatment groups (no MCP-1 
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data for p55 to compare) (Figure 5.6). Interestingly, MIP-2 levels were below the 
detection limit of the ELISA assay in both treatment groups (not shown).  
 
Figure 5.6 - Levels of plasma (A) IL-6, (B) MCP-1 and (C) KC at the end of 240min high-stretch 
ventilation in mice treated with intravenous dummy or p55 dAb. Note data is not available for 
plasma MCP-1 in p55 dAb treated group due to limited amount of sample (also used for p55 dAb 
detection). Treatment groups were not significantly diferent. Levels were undetectable in non-
ventilated control animals. Mean+SD, N=6-7/group. 
5.5   Discussion 
ARDS patients have elevated TNF in their BALF [200], and levels are also increased 
when patients are ventilated with higher VT as compared to those ventilated with 
226 
lung-protective, i.e. low VT setings [330, 331]. Similarly, high VT ventilation produces 
increases in BALF TNF levels in in vivo and ex vivo animal models of VILI [186, 322, 
334, 335, 351, 681]. Using a ‘pure’ VILI model where mice are exposed to high VT 
ventilation without any underlying lung injury, our group previously demonstrated that 
this up-regulation of biologicaly active intraalveolar TNF is transient and happens 
before lungs are flooded with oedema fluid [337]. Using geneticaly modified mice, 
the same authors later showed that the two receptors of TNF play directly opposing 
roles during injurious high-stretch mechanical ventilation, with p55 promoting but p75 
preventing pulmonary oedema [639]. These findings suggest that targeting p55 
receptor signaling specificaly rather than total TNF blockade, particularly in the 
alveolar space, could be beneficial in VILI. Data from Chapter 4 confirmed this 
hypothesis; however it remains unclear whether targeting p55 receptors systemicaly 
per se or in addition to intraalveolar p55 blockade could have further advantages. 
Therefore in this chapter we investigated the efects of systemicaly delivered 
p55 dAb on the progression of VILI with a primary focus on respiratory physiology. 
For the sake of comparability with the ‘intratracheal’ model (in terms of lung 
mechanics, tidal volumes, etc), it was necessary in this set of experiments to 
administer an intratracheal bolus of dummy dAb the same way as in the previous 
model, whereas either dummy or p55 dAb was given intravenously in a continuous 
infusion via the jugular vein using an infusion pump. The selected dose of 
intravenous dAb was based on preliminary pharmacokinetic studies and designed to 
achieve a reasonable concentration of p55 dAb (~500ng/ml) in the alveolar space. 
By this, at least theoreticaly, we could inhibit p55 signaling not only systemicaly 
(with a primary focus on pulmonary microvasculature) but also in the alveolar 
compartment. This is an important point as ventilator-induced lung injury is 
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considered to be a combined epithelial and endothelial injury at celular level [283]. 
Other protocol parameters were the same as in the previous ‘intratracheal’ model in 
Chapter 4. 
Efects of i.v. p55 dAb on respiratory physiology  
The magnitude and nature of the ventilation-induced changes (respiratory 
mechanics, gas exchange, BAL protein) in control animals (i.e. i.v.-dummy dAb 
treated) were very similar to that observed in the ‘intratracheal’ model, however, in 
contrast to our findings using direct intratracheal blockade, inhibition of p55 signaling 
by i.v. p55-dAb did not atenuate these. To see if systemic administration of p55 
blocking dAb had any efect on pulmonary and/or systemic inflammation, we 
assessed levels of IL-6, MCP-1, KC and MIP-2 in bronchoalveolar lavage fluid and 
plasma, but found no diferences between treatment groups.  
The apparently lacking benefits of intravenously given p55 dAb in VILI are not 
fuly understood. From the aspect of targeting intraalveolar p55 signaling, the dAb 
should be able to enter the alveolar compartment. Although preliminary 
pharmacokinetic studies did indeed indicate accumulating concentrations of p55 dAb 
in the alveolar space over time during high-stretch ventilation, TNF may have 
signaled through the p55 receptor already before efective concentrations of p55 
targeting dAb were achieved. Our group previously showed that TNF is produced 
early at the course of high-stretch ventilation before significant pulmonary oedema 
develops [337], indicating an intraalveolar source, but this study only looked at TNF 
levels 2 hours after the start of high VT ventilation and at later time points. Therefore 
it remains unclear how soon upon mechanical stretch TNF is produced, particularly 
in the model we used curently. 
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Using a mouse isolated perfused lung (IPL) model, von Bethmann and co-
workers showed that TNF is up-regulated almost 2-fold as early as 30 minutes after 
high-stretch mechanical ventilation at the transcription level, which then returns to 
control values by 150 minutes [336]. Although this study also examined changes in 
TNF protein in the perfusate, it lacked investigations of alveolar TNF levels. A later 
study by Tremblay et al. using a mouse isolated non-perfused system not only 
confirmed this transient up-regulation of TNF mRNA in the lungs, but also showed 
production of TNF protein in the alveolar space after 30 minutes of high-stretch 
ventilation with a gradual increase over time until the end of the 180 minutes 
ventilation protocol [682]. It is not clear why the protein expression did not folow the 
trend of mRNA, but it could be due to reduced removal of the cytokine by blood flow 
and lymphatic drainage [610]. More importantly from the perspective of our study, 
these findings by Tremblay and co-workers indicate that high-stretch ventilation can 
induce a very rapid release of TNF into the alveolar space. 
Although our preliminary pharmacokinetic studies demonstrated detectable 
concentration of p55 dAb in the alveolar compartment as soon as 30 minutes after 
starting the i.v. infusion (and high-stretch ventilation in fact), this was probably 
inadequate to suficiently inhibit p55 receptor signaling. There are two possible ways 
to overcome this issue. One is to increase the dose of i.v. p55 dAb and thus 
achieving higher and potentialy more suficient intraalveolar antibody 
concentrations. The second is to start the systemic administration of dAb some time 
before the start of high-stretch ventilation alowing the antibody to accumulate in the 
alveolar compartment before active TNF is produced. With VILI, this kind of 
prophylactic approach is possible even in the clinical seting. The most likely 
scenario is that both of these approaches are necessary to succeed. However, 
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further investigations wil first need to clarify the kinetics of alveolar TNF production 
in this model in order to adequately design an experimental protocol to suficiently 
inhibit alveolar p55 signaling by intravenously administered domain antibodies. 
Both the work by Dor (PhD thesis) and our characterisation study in Chapter 
3 clearly indicated that p55 receptor is shed from the surface of pulmonary 
endothelial cels early in the course of VILI and endotoxaemia, respectively; hence 
its blockade may not confer further benefits in ALI. However, in both of the above 
studies the receptor expression was assessed only 2 hours after the initiation of 
insult, and it is not clear how rapidly p55 was down-regulated on the cel surface. 
Therefore, it is stil possible that this receptor has a role in activating the pulmonary 
endothelium at a very early stage of VILI, thus contribute to injury progression.  
For this, however, TNF should be present in the circulation, either in a soluble 
or membrane bound form, almost at the start of high-stretch ventilation. Von 
Bethmann et al. showed in the study mentioned above that TNF is increased in the 
perfusate of the mouse IPL system as early as 30 minutes from the start of high-
stretch ventilation [336]. Although the source of TNF was not investigated in that 
study, as any increase in alveolo-capilary permeability is very unlikely at such early 
stage of VILI progression, an alveolar source is unlikely. Previous work from our 
group suggests that residing leukocytes in the pulmonary microvasculature, 
particularly monocytes could be the primary source (Wakabayashi – thesis). 
In our study, plasma content of TNF was only assessed at the end of the four 
hours ventilation protocol which showed undetectable levels, but this does not mean 
that TNF could not be present in the circulation at earlier stages of high-stretch 
ventilation. However, no mater how quickly TNF is produced systemicaly in VILI, in 
the curent study p55 blocking domain antibodies were present in the circulation in 
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high concentrations from the very beginning of high-stretch ventilation, and should 
be able to block p55 signaling on PECs at any stage of the injury development. 
Unfortunately, lung injury in this model was primarily assessed by development of 
pulmonary oedema (and consequent respiratory physiology changes), and although 
PECs have a very important role in maintaining alveolar-capilary integrity, this is but 
one of their many roles. For example, we did not investigate whether p55 dAb had 
any efect on activation of PECs specificaly, like up-regulation of adhesion 
molecules (Chapter 3) and subsequent leukocyte margination or release of cel-
specific activation markers such as von Wilebrand factor [864-869], the later of 
which has a predictive value for mortality and organ-failure in ARDS [63, 64, 869]. 
Overal, however, it seems that systemic TNF and thus p55 signaling has litle 
impact on the acute physiological changes in this and our previous VILI models, 
possibly because epithelial damage is the main pathogenesis.  
Efects of i.v. p55 dAb on respiratory physiology 
 We also measured the inflammatory cytokine IL-6 and inflammatory chemokines 
monocyte chemoatractant protein-1 (MCP-1), keratinocyte-derived chemokine (KC) 
and macrophage inflammatory protein-2 (MIP-2) (the murine counterparts of human 
IL-8) both in bronchoalveolar lavage fluid and plasma.  
These inflammatory mediators are increased in ARDS patients and their 
levels corelate with MOF and hence mortality [330, 333]. It was also demonstrated 
that high-stretch mechanical ventilation leads to increased pulmonary production of 
these substances, which then, along with other inflammatory  materials such as 
pathogens and endotoxin, translocate to the systemic circulation [331, 335, 351, 
356-358]. This is the fundamental element of the biotrauma hypothesis of VILI [291, 
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318]. Indeed, those patients who were ventilated with lung-protective strategy had 
lower levels of these cytokines/chemokines in their BALF and plasma and less likely 
developed organ-failure [330, 333]. Alveolar epithelial cels and macrophages are 
considered primary producers of these cytokines/chemokines [341, 342], 
nevertheless pulmonary endothelial cels also release them in response to stretch 
[343]. Their production is mediated at least in part by TNF signaling [660, 661, 663], 
and certainly their levels were reduced in the LPS+VILI model in mice given the p55 
blocking dAb (Chapter 4).  
In the curent model BALF levels of these mediators were not reduced by p55 
dAb treatment, suggesting that the antibody was not present in suficient amounts in 
the alveolar compartment when their production and/or release by alveolar epithelial 
cels and macrophages was triggered. Another potential explanation is that in the 
LPS+VILI model the inflammation was more pronounced so that TNF signaling may 
had a more significant role in mediating cytokine production thus p55 receptor 
blockade could be more efective.  
With regards to the plasma concentrations of these mediators, we found that 
they reflected the picture in BALF and p55 dAb was without efect. This suggests 
that PECs were either not major producers, or if were, then p55 blockade had no 
significant efect on their chemokine release. However, it is not clear why MIP-2 was 
not detectable in the systemic circulation. One possible explanation is that MIP-2, 
although produced in the alveolar compartment, did not cross the alveolar-capilary 
membrane. Quinton et al. demonstrated in i.t. LPS chalenged rats that both MIP-2 
and cytokine-induced neutrophil chemoatractant (CINC, rat homologue of KC) is 
produced and detectable in the alveolar compartment (BALF), but only CINC could 
be found in plasma [870]. They had the same findings when rats were instiled i.t. 
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with either recombinant or radiolabeled forms of these chemokines, and concluded 
that CINC is selectively transported from the lungs to the systemic circulation [870]. 
The same group later raised the possibility that MIP-2 may have entered the 
circulation but it was undetectable because it bound to celular receptors both on 
parenchymal and circulating cels [871]. For example, these chemokines are known 
to have high afinity to cel surface receptors such as CXCR2 on vascular endothelial 
cels [872] and leukocytes [873], and to Dufy antigen receptor for chemokines 
(DARC) on red blood cels [874, 875] and endothelial cels [876]. 
DARC is considered to be working as a sink for CXC chemokines and 
possibly plays a role in sequestering circulating chemokine concentrations to celular 
elements [874, 875]. Additionaly, DARC on venular endothelium has been proposed 
to mediate transcytosis of CXC chemokines from the abluminal to luminal surface 
[263]. To test this possibility, Zamjhan et al. treated rats with i.t. LPS and looked at 
plasma as wel as celular MIP-2 and CINC levels in isolated erythrocytes and 
leukocytes [871]. While they found CINC both in plasma and cels, MIP-2 was only 
detectable in the celular fraction of blood, indicating diferential celular binding and 
uptake dynamics between these chemokines. Indeed, it was demonstrated by 
Murakami et al. that CXCR2 receptors possess diferential afinities for each 
chemokine, with MIP-2 exhibiting 70-fold greater binding afinity over CINC [877]. 
Although it is most likely that our current findings with undetectable plasma 
MIP-2 can be explained by these mechanisms, an isolated perfused lung preparation 
would be a useful tool to confirm this, as any influence of these ‘sink receptors’ on 
circulating cels can be excluded. And truly, our group’s experience with a mouse IPL 
indicated that MIP-2 is detectable and increased in the perfusate in response to VILI 
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[878], suggesting that circulating cels are likely responsible for  the undetectable 
plasma MIP-2 levels in vivo. 
Due to the dilution efect of bronchoalveolar lavage and the ‘sink’ efect of red 
blood cels, it is not possible to tel from the whether the measured plasma 
cytokines/chemokines were originating, at least in part, from the alveolar 
compartment. However, while i.t. p55 dAb atenuated the level of these 
cytokines/chemokines, whereas i.v. p55 dAb did not, an alveolar source is likely.  
 In conclusion, although systemic targeting of p55 signaling by domain 
antibodies did not mitigate the curently investigated aspects of VILI, these data, in 
conjunction with findings of Chapter 4, support the hypothesis that specific inhibition 
of intraalveolar p55 signaling is essential to atenuate VILI. However, it is possible 
that targeting p55 receptor signaling systemicaly may have positive efects not clear 
from this study, and could ofer additional benefits to sole intraalveolar p55 blockade. 
Moreover, systemic administration as a route of delivering p55 dAbs to the alveolar 
space should not be condemned based on this study, as it stil may ofer 
practical/technical advantages over pulmonary delivery.  Further investigations are 
therefore a must to clarify the potential benefits of systemicaly delivered p55-
blocking dAb. 
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6. Selective targeting of intraalveolar p55 
TNFR signaling during acid-aspiration 
induced lung injury 
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Having successfuly demonstrated in Chapter 4 that selective targeting of p55 TNF 
receptor signaling by a domain antibody can ameliorate VILI, in this chapter we 
investigated if it would be similarly beneficial in ALI of other aetiology.  
A significant role of TNF signaling has been also implicated in the pathology 
of acid-induced ALI. Using TNF receptor knock-out mice our group has previously 
demonstrated that opposing TNF receptor signaling also occurs in acid-induced ALI 
in a similar manner as in VILI, where p55 signaling promoted, whereas p75 
signaling protected against pulmonary oedema. 
  To address the potential usefulness of the domain antibody, I developed an 
in vivo mouse model of acid-induced ALI in colaboration with Dr Brijesh Patel and Dr 
Kenji Wakabayashi where mice are treated with i.t. p55-specific domain antibody in a 
prophylactic manner prior to i.t. acid instilation.  
My model produced a substantial amount of pulmonary oedema, leukocyte 
infiltration and intraalveolar cytokines/chemokines 3h after i.t. acid instilation 
compared to saline control, which was significantly atenuated by pre-administration 
of i.t. p55-specific domain antibody. The findings suggest that targeting intraalveolar 
p55 TNFR signaling by domain antibodies may be a useful approach to prevent ALI 
of various aetiologies.  
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6.1   Background 
Acid aspiration induced lung injury or aspiration pneumonitis was first described by 
Mendelson in 1946 who reported 66 women who developed ARDS resulting from 
aspiration of gastric contents into the lungs during labour [879]. Since then this 
condition continues to be recognised as a potentialy lethal complication of the 
perioperative period. Its incidence was 1 in 2,131 patients receiving general 
anaesthesia according to a study in 1986 [880], which later reduced to approximately 
1 in 3,216 after the introduction of prophylactic measures such as the ‘nil by mouth’ 
order prior to anaesthesia [881]. However, the true incidence of clinical gastric 
aspiration is likely to be even higher as suggested by the findings of Warner et al. 
[881]. They have studied 67 patients who have aspirated while undergoing general 
anaesthesia. Sixty-three per cent (42 patients) of these cases had no symptoms at 
al despite arterial desaturation and the radiological evidence of aspiration. On the 
other hand, aspiration pneumonitis can be so severe that 10 to 30% of the witnessed 
aspiration cases progress to ALI and ARDS with a mortality rate of up to 30% [881, 
882]. Overal acid aspiration induced lung injury accounts for 11% of al ALI cases 
and up to 20% of al anaesthesia-related death [7, 881-883]. 
 Aspiration of gastric contents causes a chemical burn to the pulmonary 
parenchymal cels, leading to an intense inflammatory reaction. An experimental 
study by Kennedy et al. using rats showed that acid aspiration induced lung injury 
has a characteristic biphasic pathogenesis [884]. The first phase, which peaks 1 to 2 
hours after acid aspiration to the lungs, is a result of the direct, caustic efect of the 
low pH of the aspirate on the cels lining the alveolar–capilary interface leading to 
increased permeability and acute epithelial dyfunction [815]. The second phase, 
which peaks 4 to 6 hours post-aspiration, is characterised by neutrophil infiltration to 
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the lung parenchyma and alveoli, with a consequent destruction of alveolar-capilary 
wals, necrosis of parenchymal cels, fibrin deposition and haemorhage.  
The mechanisms of the lung injury after gastric aspiration involve a spectrum 
of inflammatory mediators including chemokines and cytokines, inflammatory cels, 
adhesion molecules, complement, cyclooxygenase and lipoxygenase products, 
destructive enzymes and reactive oxygen/nitrogen species released by inflammatory 
cels [80, 513, 685, 885-892]. Based on these experimental investigations numerous 
potential therapies were identified, such NOS inhibition [513], cytokine release 
inhibitor [890], P-selectin blockade [110] etc., however, to date no definite treatment 
exists, only supportive therapy. This and the fact that in many patients aspiration is, 
in theory, predictable (i.e. during or after anaesthesia) point to the potential 
application of a prophylactic approach, where the aspiration induced pathological 
process may be abrogated in a very early stage, thus preventing injury development. 
TNF seems to be a good candidate for such intervention, as it is one of the proximal, 
initiating pro-inflammatory cytokine in the pathogenesis of aspiration pneumonitis 
[685, 686, 893] and is likely to be involved in both phases.  
Our group has previously developed an in vivo mouse model of acid 
aspiration induced lung injury, in which anaesthetised, ventilated mice have 
hydrochloric acid (HCl) administered directly into the trachea [814].  Pulmonary 
oedema develops as a consequence (within 2-3 hours), which we have shown to be 
mediated by TNF signaling. Specificaly (and similarly to the situation with VILI), we 
demonstrated using TNF receptor knockout mice that blockade of p55 signaling 
protected from oedema formation, while blockade of p75 signaling may have 
exacerbated oedema. This suggests that pharmacological blockade of p55 TNFR 
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signaling might be beneficial in preventing and/or atenuating lung injury caused by 
acid aspiration. 
 As the pathogenesis of acid aspiration induced lung injury is (considered to 
be) primarily triggered by the initial pulmonary epithelial cel injury it is reasonable to 
target p55 TNFR signaling in the alveolar compartment of the lungs if one wants to 
prevent or ameliorate injury progression.  
 
6.2   Aims 
In this chapter we atempted to investigate the efects of blocking intraalveolar p55-
signaling by a domain antibody on pulmonary oedema and inflammation during ALI 
induced by acid-aspiration. There were two main aims: 
1. To develop a robust, reproducible in vivo mouse model of acid-induced ALI 
that is suitable for intratracheal administration of antibodies in a fluid phase. 
2. To investigate the efects of blocking intraalveolar p55 TNF receptor signaling 
by domain antibodies on pulmonary oedema and inflammation during acid-
induced ALI. 
 
6.3   Protocols 
Model development 
As dAb could be potentialy damaged when co-administered with HCl, we decided 
animals should receive dAb and HCl in separate boluses. However, intratracheal 
fluid instilation has certain impact on lung mechanics most likely secondary to 
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interference with the alveolar lining fluid, specificaly with surfactant proteins. 
Because of this, lungs are more prone to sufer injury from a further insult (the basic 
principle of VILI models with saline lavage folowed by mechanical ventilation). 
Therefore, to achieve similar kinetics of lung injury as in our previous knock-out 
model where only one intratracheal fluid instilation took place (i.e. HCl), in this model 
we had to titrate the dose of HCl given folowing the initial dAb instilation. 
 For this, after surgical preparation for the in vivo ventilation system (during 
which mice were ventilated with low-stretch setings, i.e. VT=8-9ml/kg, 
PEEP=3cmH2O, 100% O2) and baseline readings, mice received an i.t. bolus of 
25µg dummy dAb in a total volume of 50µl as described in chapter 2. Then low-
stretch ventilation continued for 60min after which mice received an i.t. bolus of HCl 
varying in concentration (0.05-0.1M) and volume (50-70µl) or normal saline (50µl) as 
control. Mice were then ventilated for further 180min or until BP dropped below 
45mmHg, whichever happened earlier. BP, airway pressure and gas flow was 
monitored throughout, and sustained inflations (35cmH2O, 5sec) were given every 
20min to prevent atelectasis. Development of lung injury was determined by changes 
in respiratory mechanics and deterioration in oxygenation. 
 Initial experiments with varying concentration of HCl (0.05-0.1M, or saline) but 
the same volume (50µl) suggested that the dose response is very tight as 0.05M and 
0.075M HCl caused almost negligible amounts of injury based on Pplateau increase 
and decrease in PO2, while administration of 0.1M acid led to substantial injury, and 
some animals did not even complete the 180min protocol (Figure 6.1/A-B). 
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Figure 6.1 – Plateau pressure and PO2 changes in mice treated with i.t. dummy dAb folowed 
by  50µl i.t.  hydrochloric  acid (HCl)  of  different  concentrations  or  normal  saline. After surgical 
preparation (i.e. VT=8-9ml/kg, PEEP=3cmH2O, 100% O2) and baseline readings, mice received an i.t. 
bolus of 25µg dummy dAb in a total volume of 50µl. Then low-stretch ventilation continued for 60min 
after which mice received an i.t. bolus of HCl varying in concentration (0.05-0.1M) or normal saline 
(50µl) as control. Mice were then ventilated for further 180min or until BP dropped below 45mmHg, 
whichever happened earlier. Mice treated with saline or HCl of 0.05 to 0.075 molar concentrations did 
not exhibit signs of lung injury as measured by (A) increase in plateau pressure and (B) decrease in 
PO2, while animals receiving 0.1M HCl showed such substantial injury that some of these did not 
even complete the 180min protocol. N=1-3/group. 
 
To reduce the harshness of the model, we therefore had to either use 0.1M 
acid but in a smaler volume or one of the lower concentrations in increased volume. 
We chose the later, as lowering the volume of the i.t. bolus may result in uneven 
distribution of acid in the lungs and thus inconsistent pulmonary injury and increased 
noise across experiments. In the folowing experiments therefore mice received 
0.075M HCl in volumes of 50 to 70µl the same way as described. We found that 
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administration of 65µl of 0.075M HCl resulted in substantial lung injury within 180min 
without afecting the lifespan of the model (Figure 6.2/A-B); therefore in further 
experiments this dose of acid was used. 
 
Figure 6.2 – Plateau pressure and PO2 changes in mice treated with i.t. dummy dAb folowed 
by 0.075M i.t. hydrochloric acid (HCl) of diferent volumes. Mice treated with 50 or 60µl of 0.075M 
HCl did not develop lung injury as measured by (A) increase in plateau pressure and (B) decrease in 
PO2. Animals receiving 65µl acid showed gradual but significant deterioration in these parameters, 
while those treated with 70µl of acid developed more severe injury with more rapid dynamics. N=1-
3/group. 
Finalised protocol for acid aspiration induced lung injury 
Folowing surgical preparation for the in vivo mouse mechanical ventilation system 
(during which animals were ventilated with VT=8-9ml/kg) and baseline 
measurements, mice received an intratracheal bolus of either dummy (non-targeting) 
dAb or p55-specific blocking dAb (25µg) in a total volume of 50µl as previously 
described, then ventilation continued with the same setings (i.e. VT=8-9ml/kg, 
PEEP=3cmH2O, 100% O2). 
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After 60min mice received a second i.t. bolus of 0.075M HCl in a total volume 
of 65µl, then ventilation continued for another 180 minutes or until mean BP dropped 
below 45 mmHg [337]. Anaesthesia was maintained by bolus administrations of 
intraperitoneal ketamine:xylazine every 20-25 minutes. One animal from the p55-
secific dAb group displayed very rapid haemodynamic deterioration. This 
prematurely terminated experiment was excluded from the analyses. Plateau 
pressure (Pplateau), respiratory system elastance (Ers) and resistance (Rrs) were 
measured every 20 minutes, folowed each time by sustained inflation (35cmH2O, 5 
seconds) to  avoid the  development  of  atelectasis.   ABG  were  assessed  at 
predetermined points throughout the protocol (Figure 6.3). 
 
  
Figure 6.3 - Scheme of ventilation protocol. Mice were anaesthetised, tracheostomised and 
instrumented for the ventilation system in approximately 15-20min (doted line). Then mice were 
instiled intratrachealy with either dummy or p55-specific dAb and ventilation continued for 60 minutes 
after which a bolus of hydrochloric acid or saline was instiled the same way.  After instilation of the 
reagents, 4 sustained inflations (35cmH2O, 5 seconds) were applied to help the fluid distribute within 
the lungs. Mice were ventilated with non-injurious setings throughout (VT=8-9ml/kg, PEEP=3cmH2O) 
and 100% oxygen. Respiratory mechanics were assessed every 20min, folowed each time by 
sustained inflation. Arterial blood gases (ABG) were assessed at predetermined time points (dAb 60’, 
Acid 60’, Acid 120’, End).  
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Upon termination of experiments, mice were kiled by anaesthetic overdose 
and cardiac puncture and saline lavage performed, as described in chapter 2. 
Samples were centrifuged and BALF supernatants aliquoted and stored at -80°C, 
whereas cel pelets were used for quantification of neutrophils by manual counting 
after diferential staining (chapter 2). Thawed samples were quantified for total 
protein as a further indicator of pulmonary oedema/alveolar barier dysfunction, and 
for IL-6, KC, MIP-2 and MCP-1 by colorimetric sandwich ELISA as indicator of 
intraalveolar inflammation. Lungs were excised and processed for flow cytometry to 
assess the degree of leukocyte infiltration.  
6.4   Results 
While saline instilation had no significant impact on respiratory mechanics, acid 
instilation caused a substantial deterioration in lung function in dummy dAb treated 
animals, consistent with pulmonary oedema formation.  This was represented by a 
rapidly increasing Pplateau and Ers that occured towards the end of the 3h ventilation 
protocol (Figure 6.4/A-B). In marked contrast, these parameters showed only a non-
significant tendency to increase in the p55 dAb group. Changes in Rrs and arterial 
pressure were not diferent across the treatment groups (Figure 6.4/C-D). 
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 Figure 6.4 - (A)  Plateau pressure (Pplateau), (B) respiratory  system  elastance (Ers)  and (C) 
resistance (Rrs), (D)  mean  arterial  pressure  were  determined in  ventilated  animals treated 
intratrachealy with either dummy or p55-specific domain antibody (dAb) folowed by HCl acid 
instilation or saline. Mice had i.t. dummy or p55-specific dAb and ventilation continued for 60 
minutes after which a bolus of hydrochloric acid or saline was instiled the same way.  Mice were 
ventilated with non-injurious setings throughout (VT=8-9ml/kg, PEEP=3cmH2O) and 100% oxygen. 
Changes in Ers and Rrs are expressed as percentage increase in relation to ‘Start’ (before instilation) 
values. Saline instilation had no deteriorating efect on lung mechanics, whereas intratracheal acid 
instilation resulted in significant increase in Pplateau and Ers in dummy dAb treated mice. Changes over 
time during ventilation were significantly diferent in p55 dAb treated group in these parameters (# 
P<0.05 for interaction between ‘treatment’ and ‘ventilation time’ by 2 way ANOVA). N=4-6/group. 
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Saline instilation did not afect gas exchange significantly throughout the 
ventilation protocol. Arterial PO2 and PCO2 levels were similar between the two acid 
treated groups at 60 minutes after the antibody and acid instilations, but the trends 
started to diverge 120 minutes after acid instilation and were overal significantly 
diferent (Figure 6.5/A-B).  By the end of the protocol, oxygenation deteriorated in 
dummy dAb treated animals (183±110mmHg), while PCO2 increased.  In contrast, 
PO2 was beter maintained in the p55 dAb group (304±124mmHg), and PCO2 was 
unchanged from the Acid 120’ level.  To assess alveolar epithelial permeability, we 
measured the protein content in lavage fluid. Acid instilation resulted in substantial 
protein levels in the dummy dAb group as compared to saline controls (4.53±2.27 vs 
0.33±0.10mg/ml), and this was tended to be lower in mice given the p55 dAb 
(2.51±1.38mg/ml) without statistical significance (Figure 6.5/D). 
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Figure 6.5  - (A)  Arterial  PO2, (B)  PCO2, (C)  bicarbonate (HCO3-)  and (D) lavage fluid  protein 
were determined in ventilated animals treated intratrachealy with either dummy or p55-
specific  domain  antibody (dAb). While oxygenation was wel maintained in mice instiled with i.t. 
saline, arterial PO2 significantly deteriorated after acid instilation in animals treated with the dummy 
dAb but not in mice given the p55-specific dAb, and changes over time were significantly diferent 
between these groups.  Similarly, PCO2 did not change significantly in saline controls, while acid-
induced changes over time were significantly diferent between dummy and p55 dAb treated animals 
(# P<0.05 for interaction by 2 way ANOVA). Changes in bicarbonate levels were similar across 
groups. Acid instilation led to a significant amount of lavage fluid protein in the dummy dAb group, 
which tended to be lowered by p55-specific dAb treatment.  Doted line represents mean value in 
saline control animals. N=4-6/group. 
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Anti-p55 domain antibody atenuates pulmonary inflammation in acid 
aspiration induced ALI 
Having demonstrated that p55-specific dAb can atenuate deterioration in respiratory 
physiology folowing acid aspiration, we went on to investigate whether it has 
beneficial efects on pulmonary inflammation. To address this, we assessed 
leukocyte margination to the lungs as wel as intraalveolar neutrophil influx along 
with lavage fluid levels of inflammatory chemokines and cytokines. 
 Leukocyte subsets in lung single cel suspension were identified based on 
characteristic antigen expression using flow cytometry (Chapter 2) and their number 
quantitatively assessed, whereas the number of lavage fluid neutrophils was 
manualy counted after diferential staining. Acid instilation increased the number of 
lung-recruited neutrophils as compared to saline control (2.19±0.78x106 vs 
1.03±0.42x106, respectively), which tended to be lowered by the p55-specific dAb 
(1.32±0.44x106) (Figure 6.6/A). A similar trend was found with margination of 
inflammatory  subset  Gr-1high monocytes, where an acid-induced increase in cel 
number (2.74±0.98x106 vs 1.77±0.65x106 for dummy dAb + acid and dummy dAb + 
saline, respectively) was significantly atenuated by p55 dAb (1.25±0.79x106, 
*p<0.05 vs dummy dAb + acid) (Figure 6.6/A). Transmigration of neutrophils to the 
alveolar space was also greatly increased by acid aspiration, and substantialy 
atenuated by p55 dAb treatment (Figure 6.6/B). 
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Figure 6.6 – Number of leukocyte subsets in the lungs and lavage fluid of dummy-dAb and 
p55-dAb treated mice folowing i.t. acid aspiration. Treatment with p55-specific dAb significantly 
atenuated the number of (A) lung-marginated  Gr-1high monocytes and (B) intraalveolar neutrophils. 
Doted line represents mean value in saline control animals. *P<0.05 by unpaired t-test. N=5/group. 
Finaly, acid aspiration substantialy increased the level of inflammatory 
cytokines/chemokines IL-6, MCP-1, KC and MIP-2 in the alveolar space, which were 
al significantly atenuated by pre-treatment with the p55 specific dAb (Figure 6.7/A-
D). 
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Figure 6.7 - Levels of lavage fluid (A) IL-6, (B) MCP-1, (C) KC and (D) MIP-2 in mice pre-treated 
intratrachealy with either dummy or p55 specific domain antibody folowed by intratracheal 
acid (HCl) instilation.  Doted line represents mean value in saline control animals. *P<0.05, 
***P<0.001 by unpaired t-test (B, C, D) or Mann-Whitney U-test (A). N=5/group. 
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6.5   Discussion 
TNF signaling in acid aspiration-induced lung injury 
Aspiration of gastric contents to the lung is a common complication of general 
anaesthesia, but other medical scenarios which are associated with a low conscious 
level, such as drug overdose, seizure or stroke generaly present a high risk [882, 
894]. The severity of the subsequent lung injury may vary from a mild, subclinical 
pneumonitis to the more severe picture of ALI/ARDS with associated high mortality 
[893]. 
 As with VILI, acid aspiration is another situation where the onset of ALI may, 
in theory, be predicted in some patients, and thus particularly amenable to 
prophylactic therapy. Tumour necrosis factor alpha seems to be an ideal therapeutic 
target, as it is expressed early at the course of acid aspiration [686], mediates, at 
least in part, the production of other cytokines/chemokines in the inflammatory 
cascade and expression of adhesion molecules on epithelial/endothelial cels and 
alveolar macrophages (see Chapter 3 and 4), regulates epithelial/endothelial cel 
death and remodeling [729, 776], and cytoskeleton re-arangement [776, 778] which 
is important in the early permeability changes during the first phase of acid aspiration 
pneumonitis [895].  
 Indeed, when blockade of TNF signaling by anti-TNF antisera was atempted 
systemicaly or intratrachealy in rat models of aspiration pneumonitis, it showed 
mitigation of lung injury by measures of lung oedema and neutrophil sequestration 
[685, 686]. However, these studies assessed lung injury 3 and 5 hours after acid 
aspiration, respectively, i.e. in the second phase of the pathogenesis, therefore it is 
dificult to tease out whether the protective efect of TNF blockade is solely 
251 
atributable to the reduction of neutrophil sequestration leading to an atenuation in 
permeability increase, or it also influenced oedema formation during the early phase 
in a more direct manner. 
In marked contrast to these studies, our group previously showed that genetic 
inhibition of total TNF receptor mediated signaling in TNF receptor double knockout 
mice did not atenuate acid aspiration induced pulmonary oedema [814]. In fact, in 
some respiratory physiology parameters that reflect oedema formation such as 
respiratory system elastance and peak-inspiratory pressure these animals did worse 
and diverged from their wild-type controls as soon as 30 minutes after aspiration and 
maintained this diference throughout the 3 hours protocol [814]. This diference 
between TNF receptor double knock-out and wild-type mice cannot be ascribed to 
diferential efect on neutrophil accumulation, because this could not happen as early 
as 30 minutes after acid aspiration, and overal this model did not cause a significant 
neutrophil sequestration to the alveoli (average total number of PMN <2000 in BALF 
in wild-types), and in fact it was even lower in DKOs at the end of protocol (average 
total number of PMN ~100). Therefore, it is possible that in a more prolonged model 
such as Davidson’s [686], where neutrophil accumulation in the alveolar 
compartment is more prominent, genetic knock-out of both TNF receptors would 
show similar results to the pharmacological blockade of total TNF signaling seen in 
their study. 
More interestingly, our previous study also found that mice lacking only the 
p55 TNF receptor were completely protected from acid induced pulmonary oedema 
and dysfunction, whereas p75 knockout mice behaved as the TNFR DKO mice, i.e. 
were more susceptible to oedema formation, and were either similar or, at least in 
some parameters, worse than wild-types. Again, it is worth to note that these 
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diferences could not be ascribed to diferential efect on neutrophil sequestration as 
the number of PMNs in lavage fluid was not diferent across the receptor knock-out 
animals, although the number of marginated leukocytes were not investigated. The 
findings of this study with TNFR knockouts indicated two important things. First, it 
confirmed that TNF signaling plays an important role in the early, leukocyte-
independent permeability changes upon acid aspiration, and second, that its two 
receptors have diferential role mediating this process, i.e. signaling through p55 
mediates oedema whereas p75 signaling opposes this, therefore specific targeting 
of p55 receptor signaling is potentialy more beneficial than total TNF signaling 
blockade.  
Efects of i.t. p55 dAb on respiratory physiology 
To test whether pharmacological inhibition of p55 receptor signaling is efective to 
mitigate acid aspiration pneumonitis, in the curent study we treated mice 
intratrachealy with p55-specific dAb in a prophylactic manner (i.e. 1 hour prior to 
acid instilation) and quantified acid aspiration-induced pulmonary responses. We 
found that inhibition of intraalveolar p55 TNF receptor signaling significantly 
atenuated pulmonary oedema (by means of elastance and plateau pressure 
changes) and respiratory dysfunction (by means of gas exchange).  
 Alveolar epithelial and pulmonary endothelial cels constituting the alveolar-
capilary membrane are the main regulators of alveolar fluid homeostasis. Under 
normal conditions, fluid transport across this barier is limited and wel controled by 
adherens and tight junctions between these cels [66]. Although some fluid filtration 
through the barier does occur, active celular transport and lymphatic drainage 
ensures that the alveoli are not flooded. This active celular transport is mediated by 
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ion-channels and is energy consuming for the cels[66]. Pulmonary oedema can 
develop if any element of this wel balanced active system fails, being either a 
damage/disruption to the cel-cel junctions or paralysis of the ion-channels caused 
by lack of energy, drugs or celular damage (or even cel death).  
 It is believed that acid aspiration induced permeability oedema is, at least in 
part, mediated by cytoskeleton re-arangement in epithelial/endothelial cels of the 
alveolar-capilary membrane. For example, in a study by Goldman et al. intratracheal 
administration of phaloidin, which facilitates assembly of cytoskeletal proteins [896, 
897], to rats 20 minutes after acid instilation atenuated pulmonary oedema [895]. 
The authors ascribed this to a direct efect on pulmonary endothelial cels, as the 
number of lung-marginated neutrophils was not atenuated by phaloidin treatment. 
Importantly, phaloidin treatment neither reduced inflammatory mediators such as 
leukotriene-B4 (LTB4) or thromboxane B2 (TxB2), which are known to mediate 
pulmonary oedema [886, 898, 899] through microfilament disassembly in endothelial 
cels [900, 901]. 
TNF is also known to cause cytoskeleton re-arangements in 
epithelial/endothelial cels via diferent mechanisms. For example, Ferero et al. 
showed in vitro that specific activation of the p55 but not the p75 TNF receptor 
results in cytoskeleton re-organisation in endothelial cels with associated increased 
permeability in a p38 MAPK dependent manner [813]. On the contrary, Hamm-
Alvarez et al. demonstrated that p75 receptor associated epithelial/endothelial 
tyrosine kinase (Etk) activation leads to an increase in transepithelial resistance 
(TER), a common measure of junctional tightness between epithelial cels, which 
was accompanied by changes in actin filaments organisation [778]. In another study 
Pan and co-workers showed that TNF activates the Etk/Bmx pathway in endothelial 
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cells specificaly via the p75 receptor, which then mediates tube formation and 
angiogenesis [776]. Together these findings suggest that p75 mediated TNF 
signaling can play an important role in maintaining the barier function of the 
alveolar-capilary membrane by strengthening the epithelial/endothelial cytoskeleton. 
However, it remains unclear whether these mechanisms are involved in the 
pathogenesis of acid aspiration-induced pulmonary oedema formation. 
Direct celular damage and apoptosis of the cels of the alveolar-capilary 
membrane may be an alternative mechanism as to how TNF may mediate 
pulmonary oedema formation in aspiration. A recent study by Maniatis et al.  
showed that acid aspiration in wild-type mice resulted in significant oedema 
formation associated with increased apoptotic activity in lung cels as measured by 
caspase-3 staining, and this response was completely abrogated in p55 receptor 
knockouts [902]. Importantly, genetic knockdown of TNF was without efect and 
resulted in similar injury as in wild-types. 
 The findings of these studies may help us to beter understand our previous 
knockout data and that of the curent study. For example, the potential importance of 
p75 signaling in barier function may explain why p75 knock-outs and mice lacking 
both of the receptors behaved very similarly upon acid chalenge. It also suggests 
that the positive efects of p55 signaling blockade, both geneticaly and 
pharmacologicaly, may be secondary to a combination of direct and indirect impact 
on barier function, i.e. 1) by prevention of TNF to elicit its deleterious efects through 
p55 receptor (direct), and 2) by directing proportionaly more TNF signaling through 
the p75 receptor, thus improving or helping the maintenance of barier function. 
Efects of i.t. p55 dAb on pulmonary inflammation in acid aspiration-induced 
lung injury 
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 As described by Kennedy et al., the second phase of lung injury propagation 
folowing acid aspiration is characterised by leukocyte infiltration to the lung 
parenchyma and alveolar space associated with additional increase in alveolar 
permeability which peaks 3-4 hours after the initial insult [884]. Inflammatory 
chemokines and cytokines seem to orchestrate this process, not only by traficking 
leukocytes to the pulmonary circulation, but also by retaining and activating them in 
situ via enhancement of cel to cel interactions with pulmonary endothelial and 
epithelial cels  in which expression of adhesion molecules and their counterpart 
molecules on leukocytes play a pivotal role [903, 904]. Upon activation, these 
leukocytes release their mediators such as thromboxane, oxygen radicals and 
proteases that eventualy cause a subsequent increase in vascular permeability and 
leads to pulmonary oedema and hypoxaemia [80, 888, 903]. 
 The inflammatory cytokine/chemokine TNF, IL-6, IL-8 or its murine homologs 
KC and MIP-2 seem to be key mediators in the pathogenesis of acid aspiration as 
pharmacological or genetic inhibition of these mediators atenuate neutrophil 
infiltration, thus the propagation of lung injury, and their level may predict the severity 
of pulmonary dysfunction [686, 885, 893, 905, 906]. In keeping with this, we 
observed here that atenuated lung injury in p55 dAb pre-treated mice was 
associated with a lower level of these mediators in lavage fluid, reduced number of 
inflammatory leukocytes in the lung tissue and of neutrophils in the alveolar space.  
The role of MCP-1 in acid aspiration is, however, a bit more controversial. 
Similarly to the mediators mentioned above its level is increased in BAL upon acid 
aspiration [893] and corelates with the degree of lung injury. However, when MCP-1 
was targeted with polyclonal antibodies in the same study, it failed to atenuate injury 
[893].  Moreover, chronic inhibition of MCP-1 in geneticaly modified mice results in 
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more profound lung injury by means of increase BAL protein, neutrophil numbers, 
histology changes and reduced survival [907]. One possible explanation for the 
neutral or even detrimental efect of MCP-1 inhibition is a compensatory change in 
other cytokines that produce similar end efects as postulated by Knight et al. [893]. 
Indeed, in the study by Raghavendran and co-workers acid aspiration resulted in 
significantly higher levels of BAL IL-6 and KC in  MCP- 1 knock-out mice compared 
to wild-type animals [908]. In the curent study, however, reduced MCP-1 levels were 
associated with improved lung function in p55 dAb treated mice, although the 
treatment also atenuated the levels of al the measured chemokines/cytokines, 
therefore the result may have been a combinatory and/or synergistic efect.  
 Neutrophils are clearly primary mediators of lung and multi-organ injury 
folowing acid aspiration as demonstrated by depletion studies [79, 80]; however the 
role of inflammatory monocytes, specificaly Gr-1high monocytes to my knowledge has 
not been investigated yet, although their pathognomic role in other forms of lung 
injury, such as sepsis and VILI has been wel established by our group [114-116]. 
Although the role of this inflammatory subset of monocytes was not investigated 
directly in the curent model, as acid aspiration led to their increased pulmonary 
margination and was atenuated by p55 dAb with associated mitigated injury, it is 
tempting to  speculate that  Gr-1high monocytes are also key players in the 
pathogenesis. It is also worth to note, that the substances used to deplete 
neutrophils in the previous studies by Knight et al. and Goldman and coleagues [79, 
80] (anti-CD18 and nitrogen mustard), are not neutrophil specific and may have also 
depleted monocytes, therefore their role may have been overlooked at the time. 
Depletion  studies targeting  Gr-1high monocytes wil help to dissect out the role of 
these cels in acid aspiration lung injury. 
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 It was interesting to find that while our previous acid model using TNFR 
knockout mice resulted in only a smal degree of alveolar neutrophil influx (<2000 
PMN in wild-type mice upon acid) [814], the curent model led to a more than 15-
times greater number of alveolar PMNs, despite the same length of post-acid 
incubation, i.e. injury time. One possible explanation for this discrepancy is the 
overal length of ventilation time, which was 60 minutes longer due to the pre-
incubation period with the dAb. This may have implicated additional inflammatory 
stimulus to the animals, which is wel supported by the fact that the saline control 
animals had 5-times higher number of alveolar neutrophils on average in the curent 
model (532 vs 100). Another possibility is that the curent model had a 2-hit nature, 
where the initial instilation of dAb primed the lungs for increased inflammatory 
response to the subsequent acid administration. However, our findings are overal in 
keeping with that of others showing intraalveolar neutrophil accumulation to manifest 
as soon as 2 hours post acid [886].  
 In summary, our results showed that selective targeting of intraalveolar p55 
TNF receptor signaling by domain antibodies significantly atenuates lung injury 
caused by acid aspiration, which may represent a novel preventative measure for 
patients at high risk of this condition. Further investigations are necessary to beter 
understand the mechanisms by which these positive efects were exerted, to rule out 
any potential downsides of this treatment, and to explore the possibility of using it as 
a therapeutic tool for patients in whom aspiration has already occured.  
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TNF signaling represents a complex system influenced by many factors, including 
distinct signaling pathways associated with each TNFR and modulation of signaling 
by the change in the relative expression of the receptor subtypes on cels. Increased 
levels of TNF in the systemic and alveolar compartments have been implicated in 
clinical and animal models of ALI/VILI. Diferential signaling of TNFRs has also been 
implicated in ALI of diferent aetiologies, including VILI and acid aspiration-induced 
lung injury. In this project we investigated expression profile and roles of TNFRs on 
pulmonary endothelial cels and the efect of specific receptor inhibition on the 
pathogenesis of VILI and acid-aspiration-induced lung injury. This discussion chapter 
wil summarise our major findings and discuss their implications and possible future 
directions. 
 
7.1   Background 
Despite an undisputable role of TNF in the pathogenesis of ALI/ARDS, clinical trials 
with anti-TNF therapy have been largely unsuccessful, which could be due in part to 
a rather complex TNF signaling. This is due to a number of factors, including the 
presence of cel-surface and soluble forms of TNF and its two receptors, p55 and 
p75, through which the majority of TNF-induced celular responses are mediated. 
Whether TNFRs signal co-operatively (via either ligand passing from p75 to 
p55 or by interactions between receptor-associated intracelular pathways) or in a 
directly opposing manner (via distinct pathways) could play an important role in 
directing TNF-mediated celular responses. TNFR p55 and p75 can act in opposition 
during VILI and acid aspiration-induced lung injury, wherein p55 promotes while p75 
protects from the development of pulmonary oedema [639, 814], by as yet unknown 
mechanisms.  
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Although these observations suggest that specific inhibition of p55 receptor 
signaling may confer more benefits than total TNF blockade in atenuating ALI/VILI, 
it remains unclear as to where these important diferential TNFR signaling 
mechanisms take place, be it intrapulmonary (alveolar) or extra-pulmonary 
(vasculature), thus where p55 signaling should be targeted.  
Also, in such diferential signaling the relative degree of TNFR p55 vs. p75 
signaling could be key to the overal biological efect of TNF. This could be largely 
influenced by cel-surface TNFR p55 and p75 expression, directed by the balance 
between rates of de novo celular receptor production and expression on the cel 
surface and receptor shedding, producing sTNFRs. However, the expression profile 
kinetics of cel-surface TNFRs in the lung and their relative roles in the pathogenesis 
of ALI/ARDS is yet unclear.  
Characterisation of TNFR subtype expression and signaling on the 
pulmonary endothelium and epithelium in vivo would help us to identify where 
TNFRs should be targeted to potentialy improve the outcome of ALI/ARDS. 
Previous work in our group showed expression of both receptors on pulmonary 
epithelial cels (Dor – PhD thesis) and that alveolar expression of the p55 receptor is 
wel during lung inflammation, whereas p75 is prone to shedding [819]. However, 
characterisation of TNFR expression and signaling on the endothelial side remains 
to be fuly elucidated as previous studies rely on semi-quantitative methods [735] or 
observations in prolonged in vitro cel cultures [53] which may not reflect the in vivo 
situation. 
This project therefore had two main aims: firstly, to quantitatively characterise 
the expression profile and roles of TNFRs on pulmonary endothelial cels using a 
combined in vivo and in vitro approach, and secondly, to investigate whether specific 
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targeting of p55 receptor signaling in the intraalveolar or intravascular space confers 
benefits in ALI of diferent aetiologies, namely VILI and acid aspiration-induced lung 
injury, using in vivo mouse models. 
 
7.2   Characterisation of TNFR subtype expression and signaling on PECs 
In the first aim of this project we investigated the expression profile of TNF receptor 
p55 and p75 on pulmonary microvascular endothelial cels (PECs) and their relative 
roles in cel activation using in vivo and in vitro approaches.  
This first required the development of a flow cytometry technique that alows 
reliable quantitative detection of TNFR expression in lung tissue. We found that 
TNFRs were extremely sensitive enzymatic digestion and heat during tissue 
processing therefore had to alter our previously established methodology. Therefore 
we used protease inhibitors and low working temperatures to preserve TNFR 
expression on the cels. Using this technique we found expression of both TNFRs on 
PECs, with dominance of p55. To validate our technique, we assessed receptor 
expression in TNFR knockout mice, and found no staining for p55 in TNFRp55 
knockout animal, whereas TNFRp75 knockout showed a very smal degree of non-
specific staining for p75. We also assessed TNFR expression on liver endothelial 
cels to rule out the possibility that the low level of p75 on PECs was not secondary 
to diferential susceptibility to shedding during tissue processing. Liver endothelial 
cels had higher p75 expression than that of p55, indicating that the relative 
expression of TNFRs on PECs is unlikely to be an artefact of tissue processing. It 
also points out the phenotypical heterogeneity of endothelial cels and the danger of 
extrapolating findings in one vascular bed to another. 
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We then assessed the role of individual TNFRs in mediating TNF-induced 
adhesion molecule expression on PECs, as a surogate marker of cel activation. 
The in vivo experiments using TNFR knockout mice indicated that p55 is the major 
regulator of TNF-induced expression of VCAM-1, ICAM-1 and E-selectin, whereas 
p75 played a similar role, although to a lesser extent, and did not seem to influence 
ICAM-1 expression. Complementary in vitro studies in primary mouse PEC culture 
utilising pharmacological inhibition of individual TNFRs confirmed the in vivo findings, 
indicating that they were specific to TNFR subtype signaling on PECs without the 
influence of TNFR signaling on other cels, such as circulating leukocytes. These 
findings indicating a minor role for p75 in TNF-mediated adhesion molecule 
expression may be consistent with ligand passing, or alternatively simply reflects the 
relative expression of the two receptors on PECs. 
We then investigated whether inflammation has an influence on TNFR 
expression on PECs. We found that during the early stages of endotoxaemia, 
expression of p55 dramaticaly decreased and did not recover completely within 24 
hours post-LPS, whereas p75 expression remained grossly unchanged, resulting in 
a significant change in p55:p75 ratio. The physiological significance of this is not 
clear from this study. It is possible that this rapid shedding of p55 from the cel 
surface has anti-inflammatory role, as it prevents further signaling through this 
receptor [850, 852]. With regard to adhesion molecule expression, the relative 
increase in p75 expression may not be significant as it played similar role to p55. 
However, may have a significant influence on other celular responses in which the 
two receptor play opposing role, for example in regulating cel death [853], which wil 
ultimately determine cel function. 
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In summary, we developed a new flow cytometry technique to quantitatively 
assess TNFR subtype expression profile on pulmonary endothelial cels in vivo for 
the first time, and demonstrated expression of both receptors with dominance of p55. 
The role of TNFRs in mediating TNF-induced adhesion molecule expression seemed 
to reflect their expression level on PECs, but their overal roles may vary at diferent 
stages of pulmonary microvascular inflammation folowing changes in their relative 
expression. Further investigations are indicated to elucidate this possibility. 
  
7.3   Selective targeting of intraalveolar p55 TNFR signaling during VILI 
As our previous work in TNFR knockout mice indicated a deleterious role for p55 and 
a protective role for p75 signaling in VILI [639] and acid aspiration-induced lung 
injury [814], the second aim of this project was to investigate whether 
pharmacological inhibition of p55 receptor specific signaling would atenuate the 
development of lung injury in these models. We initialy wanted to test this in a VILI 
model, but from the knockout data it was unclear whether p55 signaling should be 
targeted in the intraalveolar compartment or the intravascular space. 
Findings of Chapter 3 indicated that although p55 signaling is crucial in the 
activation of pulmonary endothelium, its expression dramaticaly decreased in 
inflammatory condition, and previous work from our group (Dor – PhD thesis) 
showed similar findings with high-stretch ventilation. On the contrary, it was also 
suggested that surface expression of p55 in the alveolar compartment is wel 
preserved during pulmonary inflammation [819]. Moreover, TNF is up-regulated in 
the alveolar space during high-stretch ventilation. Therefore, it seemed logical to first 
target p55 receptor signaling in the alveolar space. As monoclonal antibodies are 
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not optimal for this purpose mainly due to high risk of receptor cross-linking and 
activation as wel as poor biodistribution, we used a novel p55-specific domain 
antibody (dAb) that does not have such limitations.  
As high-stretch was standardised based on respiratory mechanics, and lung 
injury development was mainly monitored by these parameters, we first had to 
develop a VILI model that eliminates the impact of intratracheal fluid instilation, 
therefore alow to reveal an even a potentialy subtle efect of the p55 dAb. After 
investing a lot of time and efort, we finaly established a robust and reproducible VILI 
model with low variability in respiratory mechanics and using this model managed to 
produce some very exciting results. 
We showed that intratracheal administration of p55 targeting dAb at the 
beginning of high-stretch ventilation significantly atenuated pulmonary oedema 
formation, and reduced pulmonary inflammation in a clinicaly more relevant 
LPS+VILI model. Interestingly, we found that targeting total TNF-signaling by an 
intratrachealy delivered monoclonal anti-TNF antibody did not atenuate pulmonary 
oedema in the pure VILI model, despite the fact that the same antibody at the same 
dose and route of delivery successfuly atenuated high-stretch-induced alveolar 
neutrophil infiltration in one of our previous study [109]. Our findings therefore are in 
keeping with an opposing role for the two TNFRs during the pathogenesis of VILI. 
Future investigations comparing the efect of p55 dAb to anti-p75 and/or anti-TNF 
domain antibodies (once developed) could lend further support to this.  
The curent study did not investigate what mechanisms are involved in TNF-
mediated lung injury during high-stretch ventilation, and how p55 dAb influenced 
them, but we propose that diferential regulation of epithelial/endothelial integrity by 
the two receptors may be involved. For example, TNF has been implicated in 
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mediating increased endothelial cel permeability and pulmonary oedema formation 
[687, 689], which is associated with increases in actin stress fibres, formation of 
intercelular gaps and compromised vascular endothelial (VE)-cadherin-based cel-
cel junctions [690]. Ferero et al. showed that specific activation of the p55 but not 
the p75 TNF receptor results in cytoskeleton reorganisation with associated 
increased endothelial cel permeability in vitro [813].  In contrast, activation of the 
p75 receptor-associated endothelial/epithelial tyrosine kinase (Etk/Bmx) pathway 
[776] results in increased transepithelial resistance thus barier function in vitro [778]. 
The two receptors also have opposing roles in regulating endothelial/epithelial cel 
death, whereby p55 signaling is pro-apoptotic and p75 is anti-apoptotic [777], 
therefore could significantly influence cel function. In view of these studies, it is 
possible that the positive efects of p55 signaling blockade by dAb may be 
secondary to a combination of direct and indirect impact on barier function, i.e. 1) by 
prevention of TNF to elicit its deleterious efects through p55 receptor (direct), and 2) 
by directing proportionaly more TNF signaling through the p75 receptor, thus 
improving or helping the maintenance of barier function.  Future studies comparing 
the efects of p55 and p75 dAb could help us to explore these possible mechanisms. 
Atenuation of pulmonary inflammation by p55 dAb may also have additional 
benefits that are not clear from this study, because it is associated with atenuated 
organ injury and improved survival in clinical ARDS. Future studies therefore could 
be dedicated to investigate the efects of intrapulmonary delivered p55 dAb on high-
stretch related extra-pulmonary injury.  
Anti-TNF treatment in clinical studies is associated with increased 
susceptibility to infections and flare up of occult Mycobacterial infection. Therefore it 
is important to rule out  that such long-term complications also apply to p55 dAb 
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administration, as p55 signaling is involved in controling phagocytic function of 
leukocytes thus immune defence against air-borne pathogens [751, 752]. However, 
the pulmonary delivery of the dAb as opposed to systemic delivery of anti-TNF drugs, the 
rapid clearance from the lung and its selectivity to p55 signaling which may enhance anti-
inflammatory efects of TNF through p75, may reduce the chance of such complications. 
Future studies in more chronic lung injury models are required to elucidate this. 
In summary, specific targeting of intraalveolar p55 receptor signaling by domain 
antibodies atenuate pulmonary oedema and inflammation in VILI and thus may open a new 
therapeutic approach for ventilated patients with ALI/ARDS. 
 
7.4    Selective targeting of p55 TNFR signaling during VILI by systemicaly 
delivered dAb 
Having demonstrated that specific inhibition of intraalveolar p55 receptor signaling 
atenuates VILI, in Chapter 5 we investigated whether systemic delivery of the p55 
dAb would be similarly efective. This model was designed to target p55 receptor 
signaling both in the intravascular and the intraalveolar compartment, as p55 dAb 
can pass the alveolar-capilary membrane and showed increasing concentrations in 
the alveolar space during preliminary pharmacokinetic studies. By doing this, we 
were aiming to elucidate whether targeting p55 signaling in the pulmonary 
microvasculature would confer additional benefits to intraalveolar p55 receptor 
blockade. 
 We found that in contrast to the i.t. p55-dAb+VILI model, systemic 
administration of p55 dAb did not atenuate pulmonary oedema formation or the 
plasma and BALF levels of inflammatory cytokines/chemokines, despite evidence of 
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p55 dAb accumulation in the alveolar space measured at the end of the ventilation 
protocol.  
The exact reasons behind this lack of eficacy are not fuly understood, but are 
likely to be related to inadequate dosing and/or timing issues. For example, the 
concentration of p55 dAb in the BALF by the end of experiments was ~500ng/ml, but 
we do not know how this compares to the intratracheal VILI model, as antibody 
concentrations were not measured in that model, therefore could be insuficiently low 
in the curent model. Another possibility is that TNF already signaled through the 
p55 receptor before suficient concentration of intraalveolar p55 dAb was achieved. 
Further pharmacokinetic studies are therefore needed to solve these technical 
issues. 
The curent data also suggest that p55 signaling in the pulmonary 
microvasculature is unlikely to have a significant contribution to the development of 
high-stretch induced lung injury, despite a role in mediating endothelial permeability 
in vitro [813], and adhesion molecule expression in vivo (Chapter 3). This could be 
secondary to a rapid shedding of p55 receptor from PECs (Chapter 3 and Dor – 
PhD thesis), which may represent a protective mechanism against further p55-
mediated celular response, and suggests that receptor inhibition on these cels is 
unlikely to have further benefits in VILI.  
However, targeting p55 receptor signaling systemicaly may have benefits 
that are not clear from the curent study. For example, our group has previously 
demonstrated that high-stretch ventilation leads to margination of inflammatory 
leucocytes to the liver and kidney [363], where they can potentialy cause organ 
injury. This is important because patients with ALI or ARDS die from MOF rather 
than respiratory failure [324]. Margination of neutrophils to the liver, kidney and lung 
268 
in response to systemic TNF seems to be p55-mediated as p55 receptor knockout 
mice have an abrogated response [695].  
 TNF related systemic organ injury in response to high-stretch mechanical 
ventilation may not only be mediated by indirect mechanisms such as through 
upregulation of other circulating inflammatory cytokines/chemokines, endothelial 
adhesion molecules and consequent leucocyte infiltration to end-organs, but by more 
direct celular efects. For instance, Al-Lamki and co-workers showed in rejecting and 
ischaemic renal alografts, that injured tubular cels display down-regulation of 
TNFRp55 and activation of the pro-apoptotic apoptosis-signaling regulating kinase-1 
(ASK1) [777]. In the same study they also demonstrated in a kidney organ culture 
that activation of TNFR p55 with receptor-specific mutein results in activation of 
ASK1 and triggers apoptosis in tubular cels, whereas TNFRp75 mutein led to 
activation of epithelial/endothelial tyrosine kinase (Etk), tubular and endothelial cel 
proliferation and down-regulation of TNFRp55 on peritubular endothelial cels. 
Similarly to these findings the same group later showed that such diferential role of 
TNFRs also exists in the pathogenesis of cardiac alograft rejection [834], i.e. p55 
signaling  mediates  apoptosis  whereas  p75  signaling  triggers  cel  
survival/proliferation in cardiomyocytes. Al these findings suggest that targeting p55 
receptor signaling by domain antibodies systemicaly may prevent or atenuate VILI-
related end-organ injury and thus reduce mortality. Further investigations are 
required to explore these possible benefits. 
In summary, specific inhibition of p55 receptor signaling in the pulmonary 
microvasculature does not atenuate high-stretch induced lung injury, however 
systemic administration of p55 dAb may stil have benefits in atenuating end-organ 
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damage. Further investigations are needed to explore the potential of the systemic 
delivery route to target intraalveolar p55 signaling in VILI. 
 
7.5    Selective targeting of intraalveolar p55 TNFR signaling during acid 
aspiration-induced lung injury 
Having successfuly demonstrated the beneficial efects of targeting intraalveolar p55 
receptor signaling in VILI, we turned to investigate if this approach was similarly 
efective in acid aspiration-induced lung injury. 
 We showed that intratracheal administration of p55 targeting dAb one hour 
before acid instilation significantly atenuated pulmonary oedema formation, and 
reduced pulmonary inflammation. This timely separation of agent administration was 
necessary because the acid could potentialy damage the structure thus function of 
p55 dAb. From the curent data it is unclear whether giving the p55 dAb after the 
acid could be similarly efective. This would potentialy depend on the kinetics of TNF 
production in the alveolar space upon acid aspiration. Although we did not measure 
TNF kinetics in our model, previous literature suggests that TNF is produced within 1 
hour with a peak at 2 hours after acid aspiration [686], indicating that early 
intervention may be necessary to atenuate the deleterious efects of acid. Moreover, 
the respiratory mechanics in our study showed a trend for separation of p55 dAb 
group from dummy dAb treated mice by 2 hours post-acid, suggesting that TNF 
signaling via p55 receptor likely have occured before this time-point.  
This relatively early separation of the groups is unlikely to be secondary to an 
efect of p55 signaling inhibition on leukocyte infiltration, because this happens at 
later time-points [884]. It is more likely that pulmonary oedema formation in the early 
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stage of acid injury is secondary to TNF-induced alveolar epithelial cel apoptosis 
and dysfunction mediated via p55, as suggested by recent studies (since the 
completion of this PhD project) from our group and others [815, 902].  Our group 
showed that, acid aspiration up-regulated TUNEL positive cels and lung 
homogenate caspase-8 activity in wild-type mice, both of which were significantly 
atenuated in p55 knockout mice. Pharmacological caspase-8 inhibition in wild-type 
mice significantly improved pulmonary oxygenation and alveolar fluid clearance in 
this model, suggesting that epithelial cel apoptosis mediated by p55 signaling is the 
major determinant of lung injury.  
Acid-induced production of inflammatory cytokines/chemokines was also 
significantly reduced by intratracheal p55 dAb treatment, which may have 
contributed to atenuation of leukocyte margination to the lung. Alternatively, this 
reduction in the number of lung sequestered leukocytes may be due to atenuated 
adhesion molecule expression on alveolar epithelial and/or pulmonary endothelial 
cels (Chapter 3), but this remains just a speculation. It is also unclear from the 
curent model whether this reduced pulmonary inflammation leads to atenuated 
end-organ damage in this model. These aspects wil need to be further investigated. 
In summary, we have demonstrated that inhibition of intraalveolar p55 
receptor signaling by a domain antibody significantly atenuated pulmonary oedema 
and inflammation in acid-induced lung injury, and may ofer a prophylactic approach 
for patients who are at high risk of aspiration. Further investigations are needed to 
clarify the therapeutic potential of i.t. p55 dAb in situations where the treatment 
cannot be given in a prophylactic manner. 
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7.6   Future directions 
The findings of our characterisation study suggest that the two TNFRs may play 
diferent roles, particularly when their relative expression on cels changes, such as 
that observed during endotoxaemia. A two-hit model, whereby an i.v. LPS chalenge 
is folowed by i.v. TNF - 2 hours post-LPS, when the p55 expression was found to be 
lowest on PECs – could potentialy explore this possibility. In particular, the main 
interest of such model would be to assess wheher this results in an altered 
expression profile of adhesion molecules, and consequently in a diferential patern 
of leukocyte subset margination (measured by flow cytometry). This is important, 
because it is recognised that while ICAM-1 is important in neutrophil 
margination/sequestration, VCAM-1 preferentialy controls monocyte and lymphocyte 
margination in the microvasculature [909], which may have diferential impact on 
lung injury pathogenesis and recovery.  Should the in vivo studies prove to be 
dificult due to complexity, or the findings be inconclusive, an in vitro adhesion assay 
could be set up, where diferent leukocyte subsets are added to cultured PECs, and 
the percentage of adhered cels would be measured by flow cytometry.   
 Both of our VILI and acid model showed a beneficial efect of intratrachealy 
administered p55 targeting dAb on pulmonary oedema formation. While the 
mechanisms by which these positive efects were achieved were not investigated in 
this PhD project, more recent findings from our lab (since the completion of this PhD 
study) suggest that it might be related to prevention of alveolar epithelial cel 
apoptosis and consequently  atenuated  dysfunction (alveolar fluid clearance) [910]. 
Also, it is tempting to speculate that blockade of p55-mediated TNF signaling by dAb 
could potentialy result in proportionaly enhanced TNF signaling via the p75 
receptor, which may have beneficial efects on stabilising epithelial/endothelial 
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barier function by the activation of Etk/Bmx pathway [776, 778]. By measuring the 
level of phosphorylated Etk/Bmx in AECs and PECs in our VILI and acid models 
using flow cytometry, this potential mechanism could be further investigated. As p75 
antagonist dAb is now available, proof of concept studies could be also carried out, 
whereby blocking both of the receptors using dAbs we could model blockade of total 
TNF signaling. From these experiments we would expect less or no atenuation of 
lung injury, as seen in our previous knock-out model [639].     
 We also found in both the VILI and the acid model, that blockade of 
intraalveolar p55 signaling by dAb atenuated pulmonary inflammation and lung 
injury. According to the biotrauma hypothesis of VILI/ALI, this would result in 
atenuation of extrapulmonary organ dysfunction, which is the main cause of 
mortality in patients with ALI. Future experiments should be dedicated to investigate 
this potential benefit of p55 dAb, e.g. by measuring liver enzymes and creatinine in 
the serum at the end of experiments, and by assessing the number of marginated 
leukocytes to the liver and kidney using flow cytometry.     
 As p55 signaling is important in pathogen kiling and clearance, it is crucial to 
investigate any potential increase in susceptibility to infections. In order to test this, 
we wil use our recently developed mouse model of resolving acute lung injury [268]. 
In this model, spontaneously breathing mice are administered hydrochloric acid 
intratrachealy under anaesthesia and then supported by oxygen in a recovery 
chamber. Acute lung injury develops by day 1, which then peaks by day 2 and 3 but 
almost completely resolves by day 10, athough with evidence of lung fibrosis. 
Animals could be intratrachealy instiled with p55 dAb prior to acid insult, and then 
be intranasaly inoculated with live bacteria or LPS/LTA during the recovery period to 
see if they are more prone to infection/inflammation compared to those animals not 
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receiving p55 dAb. Using this model of resolving lung injury it could be also tested 
whether the p55 dAb has any positive efects on the resolution period, such as lung 
fibrosis. 
 
7.7  Concluding remarks 
This project has addressed a wide aray of aspects of TNFR biology in ALI of 
diferent aetiologies. Firstly, we have developed a new flow cytometry technique and 
quantitatively characterised the expression profile and roles of TNFRs on pulmonary 
endothelial cels in vivo for the first time. We showed that TNFR p55 is the 
dominantly expressed receptor on PECs and demonstrated a crucial in vivo role of 
p55 and an auxiliary role of p75 in TNF-mediated adhesion molecule expression. We 
also demonstrated that the relative expression of the receptors change during 
inflammatory conditions, which may influence their overal role in TNF-mediated 
responses, but further investigations are needed to explore this possibility. Our data 
also highlight the importance of endothelial cel heterogeneity and thus the danger of 
extrapolating findings in one vascular bed to another. 
Secondly, we have investigated the efect of inhibiting intraalveolar TNFR p55 
signaling with a domain antibody in a mouse model of VILI. For this, we have first 
developed a robust model that eliminated the influence of intratracheal fluid 
instilation on respiratory mechanics and thus standardisation of high-stretch. Using 
this model we found that selective targeting of intraalveolar p55 signaling 
significantly reduced pulmonary oedema and inflammation during VILI, and this 
efect did not seem to require significant pre-incubation with the antibody. 
Importantly, anti-TNF treatment with a monoclonal antibody did not atenuate 
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pulmonary oedema. The data suggest that selective targeting of intraalveolar p55 
signaling with domain antibodies may be beneficial for ventilated patients with ALI. 
Thirdly, we assessed if systemicaly delivered p55 domain antibody would be 
similarly efective in atenuating VILI. We found no atenuation of lung injury 
(measured by pulmonary oedema and inflammatory cytokines/chemokine levels) 
with this delivery method despite evidence of antibody accumulation in the alveolar 
space. This lack of benefit may be related to inadequate antibody dosing or timing 
issues, as intraalveolar delivery of p55 dAb atenuated lung injury in the previous 
model. This issue wil need to be investigated further, before this route of delivery is 
completely rejected. Our findings, also suggest that targeting p55 in the intravascular 
space has no obvious benefits in atenuating high stretch-induced lung injury. 
However, whether it has benefits in VILI-induced extra-pulmonary organ injury is 
unclear and warants further investigations. 
Fourthly, we showed that selective inhibition of intraalveolar p55 signaling 
also atenuates ALI of a diferent aetiology, namely acid aspiration-induced lung 
injury. Intratrachealy delivered p55 specific dAb significantly atenuated pulmonary 
oedema and pulmonary inflammation. In this set of experiments the p55 dAb was 
administered one hour prior the acid chalenge, therefore from the curent data it is 
unclear whether it would have been similarly efective had been given after the initial 
insult. Although further investigations are required to elucidate this, intrapulmonary 
delivered p55 dAb may be stil beneficial after acid aspiration by atenuating VILI in 
the already injured and ventilated lung. 
This project adds a large quantity of interesting data to our knowledge in the 
fields of ALI and TNFR signaling. In particular, the data from p55 receptor targeting 
studies using domain antibodies are potentialy very clinicaly applicable, and 
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requires further investigation. We have also developed a novel methodology that 
enables quantitative investigation of pulmonary TNFR expression in vivo. Moreover, 
our model development of intrapulmonary dAb delivery in high-stretch ventilation 
could be very useful for future research investigating the roles of other intraalveolar 
molecules in the pathogenesis of VILI. 
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Bertok S, Wilson MR, Dorr AD, Dokpesi JO, O’Dea KP,
Marczin N, Takata M. Characterization of TNF receptor subtype
expression and signaling on pulmonary endothelial cels in mice.Am
J Physiol Lung Cel Mol Physiol300: L781–L789, 2011. First pub-
lished March 4, 2011; doi:10.1152/ajplung.00326.2010.—TNF plays
a crucial role in the pathogenesis of acute lung injury. However, the
expression proﬁle of its two receptors, p55 and p75, on pulmonary
endothelium and their inﬂuence on TNF signaling during lung micro-
vascular inﬂammation remain uncertain. Using ﬂow cytometry, we
characterized the expression proﬁle of TNF receptors on the surface of
freshly harvested pulmonary endothelial cels (PECs) from mice and
found expression of both receptors with dominance of p55. To
investigate the impact of stimulating individual TNF receptors, we
treated wild-type and TNF receptor knockout mice with intravenous
TNF and determined surface expression of adhesion molecules (E-
selectin, VCAM-1, ICAM-1) on PECs by ﬂow cytometry. TNF-
induced upregulation of al adhesion molecules was substantialy
atenuated by absence of p55, whereas lack of p75 had a similar but
smaler efect that varied between adhesion molecules. Selective
blockade of individual TNF receptors by speciﬁc antibodies in wild-
type primary PEC culture conﬁrmed that the in vivo ﬁndings were due
to direct efects of TNF receptor inhibition on endothelium and not
other cels (e.g., circulating leukocytes). Finaly, we found that PEC
surface expression of p55 dramaticaly decreased in the early stages of
endotoxemia folowing intravenous LPS, while no change in p75
expression was detected. These data demonstrate a crucial in vivo role
of p55 and an auxiliary role of p75 in TNF-mediated adhesion
molecule upregulation on PECs. It is possible that the importance of
the individual receptors varies at diferent stages of pulmonary mi-
crovascular inﬂammation folowing changes in their relative expres-
sion.
cytokine; adhesion molecule; inﬂammation; ﬂow cytometry; lipopoly-
saccharide
PULMONARY MICROVASCULAR INFLAMMATIONis one of the ﬁrst
manifestations during the pathogenesis of acute lung injury
(ALI), involving production of cytokines and upregulation of
adhesion molecules on endothelial cels. Together these or-
chestrate the margination of inﬂammatory leukocytes within
the microvasculature and their subsequent migration into lung
parenchyma (42). The proinﬂammatory cytokine TNF has been
implicated as a key player in regulating this process (12, 42,
50, 63).
Celular efects of TNF are mediated via two cel surface
receptors, p55 and p75 (also known as receptor type I and I,
CD120a and CD120b, or TNF receptor superfamily 1a and 1b,
respectively) (62). Historicaly, p55 has been considered as the
major efector of TNF-mediated responses, with p75 proposed
merely to enhance p55 signaling via “ligand-passing.” This
dogma may need reevaluation, as it is becoming clear that p75
can mediate celular responses partly or completely indepen-
dently from p55 (6, 31, 36, 62). Moreover, it has been reported
that the two receptors can even play directly opposing roles in
some acute inﬂammatory conditions, including sepsis, retinal
ischemia, and lung injury induced by high-stretch mechanical
ventilation (17, 18, 22, 64). Thus tissue-speciﬁc expression of
each individual TNF receptor would play a major role in
determining the inﬂammatory response of an organ to TNF
stimulation. Indeed, cel-speciﬁc diferential expression of
TNF receptors has been proposed as being important in deter-
mining the outcome of heart transplant rejection (5).
The majority of previous studies on the roles of each TNF
receptor in endothelial cels have indicated that p55 receptor
almost exclusively regulates TNF-induced inﬂammatory gene
activation, such as adhesion molecule expression (35, 37, 47,
59, 67), although such studies primarily utilized human um-
bilical vein endothelial cels (HUVEC) cultured in vitro. In
direct contrast, Chandrasekharan et al. (10) observed an essen-
tial role for p75 in regulating TNF-induced expression of
adhesion molecules in aortic endothelial cels. Such inconsis-
tencies reﬂect the crucial importance of endothelial cel heter-
ogeneity across the diferent vascular beds (4), highlighting the
danger of extrapolating ﬁndings obtained in HUVECs to en-
dothelial cels in other tissues. The lung microvasculature, in
particular, is known to be functionaly and phenotypicaly
distinct from most other vascular beds, in terms of the site and
adhesion molecule requirements of leukocyte extravasation,
for example (14). While a smal number of studies have
atempted to investigate the speciﬁc role of pulmonary endo-
thelial TNF receptors, they may be considered somewhat
limited in terms of using either semiquantitative methodologies
(20, 44) or cultured lung cels (26). Cel culture often results in
changes in the phenotype of primary cels, and, therefore,
reconciliation of in vitro results with in vivo ﬁndings is
essential to deﬁne the role of each TNF receptor during the
activation of pulmonary endothelium. Thus the relative expres-
sion of each TNF receptor within the pulmonary circulation
and their precise roles in pulmonary microvascular inﬂamma-
tion in vivo stil remain unclear.
In this study, we established a ﬂow cytometry-based tech-
nique to quantitatively evaluate for the ﬁrst time in situ ex-
pression of TNF receptors and cel adhesion molecules on
pulmonary endothelial cels (PECs), in lung single-cel suspen-
sions freshly harvested from in vivo treated mice. These data
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show that p55 is dominant over p75 in terms of both expression
and inﬂuence on TNF-induced adhesion molecule upregulation
on PECs. However, the importance of individual receptors may
vary during diferent stages of pulmonary microvascular in-
ﬂammation folowing changes in their relative expression.
MATERIALS AND METHODS
Animals.Al experimental protocols involving animals were ap-
proved by the Ethical Review Board of Imperial Colege London and
caried out under the authority of the UK Home Ofﬁce, in accordance
with the Animals (Scientiﬁc Procedures) Act 1986. Experiments were
performed using male wild-type C57/Bl6 mice, aged 9 –12 wk, or age-
and sex-matched mice lacking p55 [p55 knockout (p55KO)], p75
(p75KO), or both [double knockout (DKO)] TNF receptors (generous
gifts from Amgen, Thousand Oaks, CA) (50).
Adhesion molecule expression on PECs in response to TNF in vivo.
Wild-type or TNF receptor knockout mice were injected with 500 ng
recombinant mouse TNF (R&D Systems Europe, Abingdon, UK) via
tail vein. Two or four hours later, animals were kiled by isoﬂurane
overdose and exsanguinated by cardiac puncture, the lungs were
excised, and a single-cel suspension was prepared for ﬂow cytometric
analysis of adhesion molecules. Untreated animals served as controls.
TNF receptor expression on PECs in vivo.Wild-type mice were
kiled, and 1 ml of ice-cold inhibitor cocktail was instiled through
tracheostomy into the lungs to minimize TNF receptors shedding
during lung tissue processing. The cocktail consists of serine/cysteine
protease inhibitor (1 mM PMSF, Sigma-Aldrich, Poole, UK) and
metaloprotease inhibitor (10 M BB94, British Biotech, Abingdon,
UK) in PBS with 2% FCS, 1% sodium azide, and 5 mM EDTA. Lungs
were then excised to prepare a single-cel suspension, and TNF
receptor expression on PECs was assessed by ﬂow cytometry. In a
separate series of experiments, mice were injected with 20 g LPS
(Ultra-pure LPS fromE. coli O111:B4, Source BioScience UK,
Notingham, UK) via the tail vein. After 2, 4, 8, or 24 h, animals were
kiled, and the lungs processed as described.
Preparation of lung single-cel suspensions.Lung single-cel sus-
pensions were prepared slightly diferently, depending on whether
adhesion molecule or TNF receptor expression was to be studied. For
adhesion molecule expression, mechanical disruption and enzymatic
digestion of excised lungs was caried out using an established
technique, described and validated by our laboratory previously (46).
Brieﬂy, after harvest, the lung was rinsed in saline and ﬁnely minced
in a petri dish by manual chopping using a surgical blade. The tissue
was resuspended in saline and incubated in 0.5 mg/ml colagenase
(type IV, Sigma) at 37°C for 30 min. The resultant digest was then
pushed through a 40- m nylon mesh sieve (BD Falcon, Oxford, UK)
with a syringe plunger and ﬂushed through using FACS wash bufer
(2% FCS, 1% sodium azide, and 5 mM EDTA), to produce the
single-cel suspension.
The tissue processing method was adapted slightly for assessment
of TNF receptors. These molecules are highly sensitive to protease-
induced shedding (much more so than adhesion molecules), and pilot
experiments indicated that even a very short enzymatic digestion step
had a major adverse efect on surface expression of the receptors.
Therefore, to maximize cel yield while maintaining receptor expres-
sion, lungs were chopped (without colagenase, in the inhibitor cock-
tail described above) using a gentleMACS tissue dissociator (Miltenyi
Biotec, Bisley, UK), after which they were also ﬁltered and ﬂushed
through a sieve.
The lung single-cel suspension was ﬁnaly centrifuged at 1,300
rpm for 7 min, the supernatant discarded, and the pelet resuspended.
The samples were kept on ice throughout the procedure (except the
short colagenase incubation period where utilized) until analyzed by
ﬂow cytometry.
Isolation and culture of primary PECs.Wild-type mice were kiled,
and 1 ml of 1 mg/ml dispase (Gibco, Invitrogen, Paisley, UK) was
instiled through tracheostomy into the lungs and left for 5 min, after
which lungs were excised and washed in HBSS (Sigma-Aldrich)
containing 0.5% FCS. Samples were ﬁnely minced, digested in 1
mg/ml dispase at 37°C for 45 min, and then mechanicaly dissociated
by triturating and ﬁltered through a 40- m nylon mesh to form a
single-cel suspension. PECs were isolated from the suspension by a
magnetic labeling method, using the midiMACS separation unit
(Miltenyi), according to the manufacturer’s instructions. In brief,
depletion of CD45 (pan-leukocyte marker) cels was folowed by
two repeated steps of enrichment of CD31(PECAM-1, endothelial
cel marker) cels. By this method, we could obtain 6 milion PECs on
average per mouse [determined by ﬂow cytometry using microsphere
counting beads (Caltag Medsystems, Towcester, UK)]. Cels were
then cultured at 37°C in 5% CO2in DMEM supplemented with 1%
nonessential amino acids (Sigma), 1% sodium pyruvate (Sigma), 12
U/ml heparin (Leo Laboratories, Princes Risborough, UK), 25 mM
HEPES (VWR, Luterworth, UK), 10% heat-inactivated FCS, 2 mM
glutamine, 100 g/ml streptomycin, 100 U/ml penicilin (al from
Gibco), and 50 g/ml endothelial cel growth supplement (Sigma) in
ﬂasks coated with 1% type B gelatin (Sigma). After overnight culture,
cels were washed to remove nonadherent cels, and fresh medium
was added. Once the cels reached conﬂuence, they were replated
using trypsin-EDTA (Sigma) and used for experiments between
passages 3and8.
Adhesion molecule expression on PECs in response to TNF in
vitro.Cultured PECs were seeded at a density of 105cels/wel in a
24-wel plate coated with 1% type B gelatin. After overnight culture,
the medium was replaced with RPMI containing 10% FCS, and
triplicate wels were alocated into one of four groups: no treatment
(control); 10 ng/ml recombinant mouse TNF for 4 h; and preincuba-
tion with anti-p55 (90 g/ml; 55R-170, BD Biosciences) or anti-p75
(20 g/ml; TR75-32, BD Biosciences) neutralizing antibody for 1 h
before TNF treatment. The anti-TNF receptor antibodies are validated
by the manufacturer as having no cross-reactivity between receptor
subtypes. Cels were recovered/detached with 1% trypsin-EDTA at
37°C for 1 min and processed for ﬂow cytometry.
Flow cytometry.In both the in vivo and in vitro studies, experi-
ments were ﬁrst caried out to characterize phenotype of PECs. Cel
samples were stained in the dark on ice for 30 min with ﬂuorophore-
conjugated anti-mouse antibodies for general endothelial cel markers
PECAM-1 (CD31, clone MEC13.3), Endoglin (CD105, MJ7/18),
VE-cadherin (CD144, BV13), and ICAM-2 (CD102, 3C4), capilary/
microvascular markers Mucosialin (CD34, RAM34) and Grifonia
simplicifolialectin, and their appropriate controls (i.e., isotype or
unstained). Antibodies were al from BD Biosciences, apart from
Grifonia simplicifolialectin (Sigma). For TNF receptor expression,
samples were stained for PECAM-1 and for TNF receptor p55
(55R-286), p75 (TR75-89), and their isotype controls (AbD Serotec,
Kidlington, UK). For adhesion molecule expression, samples were
stained for PECAM-1 and for VCAM-1 (CD106, 429), ICAM-1
(CD54, 3E2), and E-selectin (CD62E, 10E9.6) and their isotype
controls (antibodies al from BD Biosciences). Samples were analyzed
using a FACSCalibur ﬂow cytometer (BD) and FlowJo software (Tree
Star, Ashland, OR). Expression levels of TNF receptors and adhesion
molecules were assessed on PECs (deﬁned as the high PECAM
cels, at least 2,000 gated events in each analysis), expressed as mean
ﬂuorescence intensity after subtraction of isotype control values.
Statistical analysis.Data are expressed as means SD. Statistical
comparisons were made by ANOVA with Bonferoni tests or by
t-tests. A value ofP 0.05 was considered as signiﬁcant.
RESULTS
Basal expression of p55 and p75 receptors on PECs.To
clarify the expression of individual TNF receptors on PECs in
vivo, we developed a quantitative ﬂow cytometry technique to
assess the expression of the two receptor subtypes in single-cel
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suspensions freshly prepared from the excised lungs of mice.
Endothelial cels were identiﬁed as PECAM-1 high events on
the dot plot, which consistentlydisplayed positive expression
of endoglin (CD105), VE-cadherin (CD144), and ICAM-2
(CD102), conﬁrming the endothelial origin of these cels
(Fig. 1A). Additionaly, cels were stained for mucosialin
(CD34) and the lectinGrifonia simplicifolia. Positive staining
for both of these markers suggests that the vast majority of
endothelial cels analyzed were microvascular in origin (32, 43,
56), although some contamination by macrovascular cels can-
not be entirely excluded.
Under resting conditions, both the p55 and p75 receptors
were expressed on PECs, with signiﬁcantly greater expression
for p55 compared with p75 (Fig. 1B). To conﬁrm that the
relative level of expression of the individual receptors was not
due to diferential susceptibility to shedding during cel harvest
and processing, we determined TNF receptor levels on endo-
thelial cels harvested from the liver using the same tissue
processing methodologies. On these cels, we found that p55
expression was similar to that found on pulmonary endothelia,
but p75 expression was much greater, indicating that tissue
processing artifacts did not explain the relative expression
levels (Fig. 1C). As a ﬁnal validation of the ﬂow cytometry
technique, TNF receptor expression was also assessed on PECs
from geneticaly modiﬁed animals lacking TNF receptors (Fig.
1D). The p55 signal was completely absent in the p55KO mice,
while the p75 signal was efectively nil in the p75KO animals
with a very smal degree of nonspeciﬁc staining with this
antibody, demonstrating that low-level p75 expression on wild-
type PECs was indeed an authentic signal. The histograms of
p55 or p75 staining in wild-type animals are consistent with the
patern of normal distribution, suggesting that al PECs are
expressing a moderate (p55) or low (p75) level of receptors,
with no evidence of subpopulations of positive and negative
cels.
p55 and p75 TNF receptors both inﬂuence upregulation of
adhesion molecules on PECs in vivo.Having identiﬁed both
p55 and p75 receptors on the surface of PECs, we then
atempted to dissect the speciﬁc roles of the receptors in
pulmonary endothelial activation. Wild-type and TNF receptor
knockout mice were treated with intravenous (iv) TNF, and the
surface expression of leukocyte adhesion molecules VCAM-1,
E-selectin, and ICAM-1 was quantitatively assessed on PECs
by ﬂow cytometry. Although these cels were harvested using
a slightly modiﬁed technique compared with the TNF receptor
expression studies (i.e., inclusion of a short colagenase diges-
tion step), we conﬁrmed that they had the same phenotypic
characteristics, i.e., positive expression of ICAM-2, VE-cad-
herin, and endoglin (not shown). Although it is possible that
such a short warming period during the cel isolation procedure
(i.e., colagenase digestion) could induce nonspeciﬁc efects on
PECs, pilot studies indicated that these were negligible, at least
with regards to adhesion molecule expression (not shown). In
preliminary time course experiments using wild-type mice,
E-selectin showed peak expression on PECs at 2 h after TNF
treatment, while VCAM-1 and ICAM-1 expression was greater
Fig. 1. Flow cytometric analysis of TNF receptor (TNFR) expression on
pulmonary endothelial cels (PECs).A: in characterization studies, PECs were
identiﬁed as PECAM-1 events (R1), and their endothelial phenotype was
conﬁrmed by positive staining for endothelial cel markers, i.e., endoglin
(CD105), VE-cadherin (CD144), ICAM-2 (CD102), mucosialin (CD34), and
Grifonia simplicifolialectin. Staining with the respective antibody (solid line)
and isotype control (unstained in the case of lectin; shaded ﬁl) is shown on
histograms.B: in control condition, PECs showed greater expression of p55
(open bar) than p75 (solid bar). Values are means SD;N 4. ***P 0.001
by pairedt-test.C: liver endothelial cels expressed similar amount of the p55
(open bar) and p75 (solid bar) receptors. Values are means SD;N 3.
D: validation of ﬂow cytometry technique using wild-type (WT) and p55 and
p75 knockout animals (TNFRp55KO and TNFRp75KO, respectively) indi-
cated smal nonspeciﬁc binding of the p75 antibody. Staining with the
respective antibody (solid line) and isotype control (shaded ﬁl) is shown on
histograms. MFI, mean ﬂuorescence intensity; SSC, side scater.
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at 4 h (data not shown). Subsequent experiments compared
E-selectin expression between strains at 2 h, and VCAM-1 and
ICAM-1 expression at 4 h.
VCAM-1 had a moderate basal expression on PECs from al
mouse strains, which was somewhat variable, although no strain
was signiﬁcantly diferent compared with wild types (Fig. 2A).
Surfaceexpression was substantialy upregulated upon TNF
treatment in wild-type mice. Expression of VCAM-1 folowing
stimulation was reduced in p75KO animals compared with
wild-type mice and decreased to an even greater extent in
p55KO and DKO mice. Unlike VCAM-1, E-selectin was not
expressed under resting conditions (Fig. 2B), but it was in-
duced in wild-type mice upon iv TNF treatment. E-selectin
expression tended to be reduced (although not signiﬁcantly) in
p75KO animals compared with wild types, whereas both
strains of mice lacking the p55 receptor (i.e., p55KO and
DKO) showed efectively zero expression. In contrast to
VCAM-1 and E-selectin, ICAM-1 is expressed on PECs at a
relatively high basal level in al strains (Fig. 2C) and was
upregulated further after TNF treatment in wild-type mice.
While absence of the p75 receptor caused some tendency to
decreased ICAM-1 expression, this was not signiﬁcant. In
contrast, mice lacking the p55 receptor (p55KO and DKO
animals) expressed signiﬁcantly less ICAM-1 after TNF stim-
ulation compared with wild types.
Diferences in adhesion molecule expression are due to TNF
receptor signaling speciﬁcaly on PECs.The in vivo data
demonstrated that lack of p55 receptor signaling inﬂuenced
TNF-induced adhesion molecule upregulation on PECs to a
much greater extent than that of p75. To clarify that our in vivo
ﬁndings reﬂect the importance of TNF receptors on “endothe-
lial cels” per se, rather than an indirect consequence of TNF
receptors signaling on other cels [e.g., leukocytes, which are
known to activate PECs in a TNF-dependent manner (46)], we
took an in vitro approach utilizing acute receptor blockade. For
this purpose, PECs were isolated from wild-type mice and
cultured and then treated with TNF in the presence or absence
of a vast excess of neutralizing antibody for p55 or p75
receptors, and surface expression of adhesion molecules was
quantiﬁed by ﬂow cytometry as in vivo. Isolation of PECs by this
method resulted in 95% purity of PECAM-1 cels (Fig. 3A).
Before each set of experiments, cels were stained for various
endothelial cel markers, to conﬁrm both that they stil retained
their phenotype across passages, and that measurement of
adhesion molecule expression did not include the presence of
any contaminating nonendothelial cels (Fig. 3B).
Consistent with the in vivo ﬁndings, p75 blockade resulted
in signiﬁcant reduction of TNF-induced VCAM-1 and E-
selectin expression by 28 and 23%, respectively (P 0.05),
but had no signiﬁcant efect on ICAM-1 (Fig. 4A). On the other
hand, as with in vivo experiments, p55 blockade signiﬁcantly
decreased the expression of al adhesion molecules (P 0.01)
(Fig. 4B).
p55 Receptor expression decreases, while p75 remains sta-
ble, during acute endotoxemia.Finaly, we determined the
inﬂuence of acute inﬂammation on the relative levels of TNF
receptor expression. Historicaly, it is reported that p75 is more
readily upregulated than p55 on stimulation (20, 26, 27), while
both receptors also show a propensity to be shed on celular
activation (15, 54, 61). However, such data almost exclusively
relate to primary leukocytes or leukocytic cel lines. Folowing
iv LPS administration, we found that p75 expression on PECs
did not change substantialy over the folowing 24 h. In marked
contrast, there was a substantial decrease of p55 expression at
2 h after LPS, which started to recover by 4 h and reached
80% of baseline levels by 24 h (Fig. 5).
Fig. 2. Efects of chronic absence of TNFR subtype signaling on TNF-induced
expression of adhesion molecules on PECs in vivo. Surface expression of
VCAM-1 (A), E-selectin (B), and ICAM-1 (C) was assessed by ﬂow cytometry
on PECs in diferent mousestrains either 2 (E-selectin) or 4 h (VCAM-1,
ICAM-1) after intravenous (iv) TNF injection (500 ng). p75KO, TNFRp75
knockout; p55KO, TNFRp55 knockout; DKO, TNFRp55/p75 double
knockout. Values are means SD of MFI;N 3– 6/group. **P 0.01,
***P 0.001 vs. TNF-treated WT by one-way ANOVA with Bonferroni
postests.
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DISCUSSION
In this study we investigated for the ﬁrst time the quantita-
tive expression proﬁle of TNF receptors on the surface of
freshly harvested mouse PECs using ﬂow cytometry and elu-
cidated their roles in mediating TNF-induced expression of
adhesion molecules as surogate markers of endothelial acti-
vation. We found that, under resting conditions, both receptors
are expressed on PECs, with p55 expressed at substantialy
higher levels than p75. Both receptors played some role in
mediating TNF-induced expression of adhesion molecules,
although the p55 receptor had a much greater impact than the
p75 receptor in vivo. Finaly, we demonstrated that acute
endotoxemia induced a rapid downregulation of p55 expres-
sion on PECs, but no change in p75, which may have important
consequences for TNF signaling during pulmonary microvas-
cular inﬂammation.
Although TNF plays an indisputable role in sepsis/ALI (9,
25, 40, 41, 48), blockade of total TNF signaling using anti-TNF
antibodies is clinicaly not efective (1–3, 11, 21), suggesting
more complex mechanisms in TNF-mediated responses during
sepsis/ALI than originaly considered. Our laboratory previ-
ously demonstrated a novel role for diferential TNF receptor
signaling in ALI induced by mechanical stretch (64) and acid
aspiration (49). Using TNF receptor knockout mice, we found
that signaling through p55 receptor promoted the development
of pulmonary edema and respiratory failure, whereas signaling
through TNF receptor p75 opposed this. Such diferential
signaling through the two TNF receptors has been observed in
other acute inﬂammatory conditions (17, 18, 22, 29), indicating
that the relative expression of the two receptor subtypes within
the lung is criticaly important in determining the consequences
of TNF signaling during the course of ALI.
Most of our curent understanding of TNF receptor expres-
sion on endothelial cels comes from HUVEC data, where TNF
binding studies suggest that p55 is marginaly the dominantly
expressed receptor (47, 53, 60), while ﬂow cytometric analysis
showed similar or slightly higher expression of p75 (37, 59).
The expression on endothelial cels in the pulmonary micro-
vasculature is not clear. Previous studies suggested relatively
similar expression of p55 compared with p75 on PECs of rats
Fig. 4. Efects of acute TNFR inhibition on TNF-induced expression of
adhesion molecules in primary PEC culture. Fold changes (compared with
untreated cels in the same experiment) are shown of adhesion molecule
expressions on WT primary mouse lung endothelial cels folowing 4-h TNF
treatment (10 ng/ml) in the presence or absence of p75 (20 g/ml;A)orp55
(90 g/ml;B) receptor neutralizing monoclonal antibody (MAb). p55 and p75
blockade experiments were conducted separately. Values are means SD;
N 3– 4. *P 0.05, **P 0.01, ***P 0.001 vs. TNF by pairedt-test.
Fig. 3. Analysis of puriﬁcation and characterization of mouse primary PECs by
ﬂow cytometry.A: primary PECs were isolated from WT mice by enzymatic
digestion and mechanical dissociation, folowed by depletion of CD45 cels
and enrichment of PECAM-1 cels by a magnetic labeling method, using the
midiMACS separation unit. This provided a 95% purity of PECs for culture.
Dot plots represent composition of cel suspension before and after CD45 cel
depletion and after PECAM-1 cel enrichment.B: before experiments (as
wel as at time of puriﬁcation), PECAM-1 cels were characterized by
staining for endoglin, VE-cadherin, and ICAM-2 to ensure their endothelial
phenotype was maintained from passage to passage. Staining with the respec-
tive antibody (solid line) and isotype control (shaded ﬁl) is shown on
histograms inpassage 6cels. FSC, forward scater.
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and humans, although these ﬁndings rely on data from pro-
longed in vitro cultures (26) and semiquantitative methods,
such as immunohistochemistry (20). Therefore, quantitative in
vivo analysis of TNF receptors on PECs has been lacking.
To address this, we established a ﬂow cytometry method that
enabled us to quantitatively evaluate the receptor expression on
PECs in a single-cel suspension. Positive cel staining for a
panel of endothelial cel markers, including mucosialin and
Grifonia simplicifolialectin, suggest that the PECs analyzed
were primarily microvascular in origin. This distinction is
potentialy important, as phenotypic and functional heteroge-
neity has been described among PECs of microvascular and
macrovascular origin (24, 32, 65). Using a mixture of protease
inhibitors and keeping the working temperature close to 4°C,
we atempted to minimize loss/shedding of the receptors during
the lung processing and analysis procedures. In untreated mice,
we found that both TNF receptors were expressed on PECs,
with p55 expression substantialy higher than that of p75. By
the use of knockout mice, we were able to demonstrate that the
antibody binding was indeed speciﬁc to each receptor, with
only a smal nonspeciﬁc signal for p75. We also measured the
relative expression of TNF receptors on endothelial cels har-
vested from the liver using the same techniques and found that,
while p55 expression was similar to that found in PECs, p75
expression was greater, exceeding the levels of p55. These data
strongly support that the low signal of p75 on PECs is not due
to processing artifacts and, more importantly, highlight the
potential risks of extrapolating between endothelial cels from
diferent sources.
A previous in vivo study by Neumann et al. (44) using
knockout mice suggested a crucial role of p55 in TNF-induced
expression of E-selectin and VCAM-1 (measured by immuno-
histochemistry) and recruitment of leukocytes within the lung,
although this study lacked investigation into any involvement
of p75. To clearly dissect out the roles of the receptor subtypes,
we injected TNF iv to wild-type mice or mice lacking one or
both of the TNF receptors and quantitatively evaluated E-
selectin, VCAM-1, and ICAM-1 expression on PECs using
ﬂow cytometry. We found that p55 receptor signaling was
necessary for each adhesion molecule upregulation (in agree-
ment with the study by Neumann et al.), while p75 signaling
contributed to VCAM-1 upregulation, but any efects on E-
selectin and ICAM-1 expression were less clear. To further
clarify our observations from geneticaly modiﬁed mice, we
used in vitro receptor blockade experiments. We found that the
consequences of individual TNF receptor signaling observed in
vivo were very likely due to direct efects on PECs and
conﬁrmed that p75 signaling inﬂuenced VCAM-1 and E-
selectin expression. The inﬂuence of p75 signaling on ICAM-1
was less clear, which may indicate some diferential efect of
p75 on the diferent adhesion molecules, or reﬂect a relative
lack of sensitivity as a result of the much higher basal expres-
sion of ICAM-1.
Our ﬁndings indicating a minor role for p75 in TNF-
mediated adhesion molecule expression may be consistent with
the ligand-passing theory of TNF signaling on PECs, whereby
p75 functions primarily to modulate signaling through p55.
Alternatively, it could be a reﬂection of the relative level of
receptor expression (i.e., p55 p75) on PECs, and p75 may be
more important in other organ beds (e.g., liver) or conditions,
where the relative expression of the receptors are changed. For
example, our ﬁnding that the p75 receptor does not contribute
much to ICAM-1 upregulation contrasts with a previous report
by Chandrasekharan et al. (10). Using aortic endothelial cels
from TNF receptor knockout animals, they reported that p75
receptor signaling was greatly responsible for ICAM-1 expres-
sion, although they did not assess the relative levels of TNF
receptor expression on their cels. This suggests that the role of
p75 in signaling varies between vascular beds, which would
tend to argue against a generalized ligand-passing concept for
this receptor.
Expression of the TNF receptors is regulated by protein
synthesis, both at the transcriptional/translational level, by the
action of sheddases, such as TNF- converting enzyme (33,
57, 62) and by internalization mechanisms (28). Both p55 and
p75 may be shed or internalized from the surface of cels, and
under certain circumstances both can be upregulated, p75 more
dynamicaly than p55 (13, 15, 16, 28, 30, 61). However, the
vast bulk of this knowledge comes from hematopoietic cels
and cancer cel lines, which may not be applicable to endothe-
lial cels. To assess the changes in TNF receptor expression on
PECs folowing an inﬂammatory stimulus, we treated mice
with LPS and determined the expression of the two receptors
over 24 h. For the ﬁrst time in freshly harvested PECs, we
showed that surface p75 expression was efectively unchanged,
while expression of the p55 receptor decreased greatly folow-
ing LPS. Such a loss of surface p55 is likely to represent a
regulatory mechanism to limit ongoing stimulation of the
receptors folowing the initial ligand-receptor interaction. In-
deed, TNF-induced TNF receptor shedding leading to deacti-
vation of cels has been observed and investigated extensively
in leukocytes (15, 55, 58), and impaired shedding of p55 leads
to an exaggerated inﬂammatory state in humans and mice (39,
66). Although mice lacking the p55 receptor show atenuation
in pulmonary neutrophil accumulation folowing systemic LPS
chalenge (8), suggesting that TNF likely signals through the
p55 receptor before shedding occurs, the subsequent down-
regulation of p55 receptors on endothelial cels may have
signiﬁcant long-term consequences (e.g., endothelial hypore-
Fig. 5. Changes in TNFR expression on PECs during endotoxemia in vivo.
Mice were injected with iv LPS (20 g), and after 2, 4, 8, and 24 h, the lungs
were processed for ﬂow cytometric analysis. Untreated animals served as
controls. Surface expression of TNFR p55 and p75 was quantiﬁed on
PECAM-1 events, as described before. Values are means SD of MFI;N
4 –5/each time point. ***P 0.001 vs. control for p55 expression by one-way
ANOVA with Bonferoni postests.
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sponsiveness to further TNF stimuli) beyond the efect on
adhesion molecules that we observed here.
Our ﬁndings regarding the changes in TNF receptor expres-
sion during inﬂammation are apparently inconsistent with
those reported by Grau et al. (26) investigating the functional
characteristics of PECs isolated from lungs of patients who
died with acute respiratory distress syndrome. They demon-
strated greater p75 expression on PECs from the patients than
controls, which appeared to positively corelate with the dura-
tion of the disease, while no diference in p55 was observed.
However, their study investigated TNF receptor expression on
PECs in vitro after 2- to 3-wk culture, which may not reﬂect
the phenotype at the time of isolation. Both our study and that
by Grau et al. do, however, indicate a change in the ratio of p55
to p75 receptors on PECs during ALI/inﬂammation. The down-
stream consequences of such changes in the p55-to-p75 ex-
pression ratio remain unclear. As the present data indicate that
p75 plays a similar role to p55 signaling in regards to adhesion
molecule upregulation (albeit of lesser magnitude), it may be
concluded that a relative shift in the contribution of signaling
through p75 vs. p55 would have litle impact.However, adhe-
sion molecule upregulation is but one consequence of TNF re-
ceptor activation, and it is now clear that the two TNF receptors
are able to signal independently. For example, TNF has been
shown in neurons to mediate proapoptotic signaling through p55,
but antiapoptotic signaling through p75 (38). Changes in the
relative levels of TNF receptor expression may, therefore, have
substantial consequences not apparent from the present observa-
tions.
In more complicated models than used curently, our labo-
ratory previously found that p75 signaling opposed, rather than
complemented, that of p55 during the development of high
stretch-induced pulmonary edema (64). We consider that any
apparent discrepancy between the present study and our labo-
ratory’s previous ﬁndings is likely to be a reﬂection of the
relative complexity of the models and the parameters being
investigated. The present study evaluated a single TNF-medi-
ated response in a speciﬁc cel type (i.e., pulmonary endothelial
adhesion molecule expression in response to iv TNF). In
contrast, the previous study represented a much more complex
efect of TNF receptor signaling on various pathophysiological
processes during ful-blown ALI models, involving endotheli-
al/epithelial cel permeability (34, 45, 51, 52) and ﬂuid reab-
sorption (7, 19, 23). One possible interpretation is that the
“protective” role of p75 signaling observed in our laboratory’s
previous study is not related to endothelial cel adhesion
molecule upregulation (as we found p75 signaling plays a
similar “injurious” role to that of p55, albeit less potent),
although it is not certain that various ALI models cause injury
in similar ways.
In summary, the present study provides invaluable new data
of individual TNF receptor expression and signaling on pul-
monary endothelium in vivo, by quantitative assessment of
TNF receptors and TNF-induced expression of adhesion mol-
ecules on freshly harvested PECs using ﬂow cytometry. The
results highlight the potential risks in extrapolating data ob-
tained in cel lines/endothelial cels from other vascular beds or
using semiquantitative methods. Our ﬁndings add crucial
pieces of information to our knowledge base of endothelial cel
biology within the lung, which would lead to novel insights
into TNF-mediated pathophysiology within the pulmonary
microvasculature. Further work needs to be caried out to
elucidate the functional consequences of individual TNF re-
ceptor signaling during pulmonary inﬂammation.
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ORIGINAL ARTICLE
Selective inhibition of intra-alveolar p55 TNF receptor
atenuates ventilator-induced lung injury
Szabolcs Bertok,1Michael R Wilson,1Peter J Morley,2Ruud de Wildt,2
Andrew Baylife,2Masao Takata1
ABSTRACT
BackgroundTumour necrosis factor (TNF) is upregulated
in the alveolar space early in the course of ventilator-
induced lung injury (VILI). Studies in geneticaly modiﬁed
mice indicate that the two TNF receptors play opposing
roles during injurious high-stretch mechanical ventilation,
with p55 promoting but p75 preventing pulmonary
oedema.
AimTo investigate the efects of selective inhibition of
intra-alveolar p55 TNF receptor on pulmonary oedema
and inﬂammation during ventilator-induced lung injury
using a newly developed domain antibody.
Methods Anaesthetised mice were ventilated with high
tidal volume and given an intratracheal bolus of p55-
speciﬁc domain antibody or anti-TNF monoclonal
antibody (‘pure’ VILI model). As a model of enhanced
inﬂammation, a subclinical dose of lipopolysaccharide
(LPS) was included in the intratracheal antibody bolus
(LPS+VILI model). Development of lung injury was
assessed by respiratory mechanics and blood gases and
protein levels in lavage ﬂuid. Flow cytometry was used to
determine leucocyte recruitment and alveolar
macrophage activation, while lavage ﬂuid cytokines were
assessed by ELISA.
ResultsThe ventilation protocol produced deteriorations
in respiratory mechanics and gas exchange with
increased lavage ﬂuid protein levels in the two models.
The p55-speciﬁc domain antibody substantialy
atenuated al of these changes in the ‘pure‘ VILI model,
while anti-TNF antibody was inefective. In the LPS+VILI
model, p55 blockade prevented deteriorations in
respiratory mechanics and oxygenation and signiﬁcantly
decreased neutrophil recruitment, expression of
intercelular adhesion molecule 1 on alveolar
macrophages, and interleukin 6 and monocyte
chemotactic protein 1 levels in lavage ﬂuid.
ConclusionsSelective inhibition of intra-alveolar p55
TNF receptor signaling by domain antibodies may open
new therapeutic approaches for ventilated patients with
acute lung injury.
INTRODUCTION
Mechanical ventilation is essential for the treat-
ment of patients with acute lung injury/acute
respiratory  distress  syndrome  (ALI/ARDS),
although this frequently results in the development
of ventilator-induced lung injury (VILI).1While the
initiating trigger is unique, theﬁnal pathophysi-
ology of VILI is indistinguishable from that of ALI
of other aetiologiesdthat is, characterised by
pulmonary oedema and inﬂammation.23VILI may
be particularly amenable to early pharmacological
intervention as its iatrogenic nature means that
onset occurs in a predictable manner and within
the hospital setting.
The proinﬂammatory cytokinetumournecrosis
factor (TNF) has been consistently implicated in
the pathogenesis of ALI/VILI, both clinicaly and
in experimental models.3e6Clinical trials of anti-
TNF therapy in patients with sepsis/ALI7e10have
unfortunately shown little or no beneﬁts, and in
some cases may have led to increased morbidity.
The reasons behind such a lack of beneﬁt are
unclear, but are likely to include issues relating to
the design of the agents used and also to the
complicated biology of TNF signaling. TNF signals
through two cel surface receptors, p55 and p75,
and recent evidence suggests that signaling
through these individual receptors  may have
differentialdeven opposingdroles in a number of
pathological conditions.11e13We previously found
that biologicaly active TNF is upregulated within
the alveolar space early during the development of
VILI.14Moreover, using TNF receptor knock-out
mice, we found that the two receptors of TNF play
opposing roles during VILI: p55 receptor knock-out
mice were protected while p75 receptor knock-out
animals  were  more susceptible to pulmonary
oedema.15In light of these data, we propose that
‘selective’ inhibition  of ‘p55  TNF receptor’
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signaling, speciﬁcaly within the alveolar space, would be clin-
icaly much more effective than total TNF inhibition to
ameliorate the deleterious effects of mechanical ventilation.
Conventional antibody technologies are not optimal for this
purposefor a variety of reasons, perhaps the most important of
which being that monoclonal antibodies to this and, in general,
other cel surface receptors have a tendency to induce receptor
cross-linking, thereby activating rather than inhibiting signal-
ling.1617To investigate the possibility of pharmacological inhi-
bition of p55 signaling, we therefore used a novel IgG fragment
known as a domain antibody (GlaxoSmithKline, Stevenage, UK)
that was selected to speciﬁcaly bind and inhibit mouse p55
TNF receptor. Domain antibodies (dAbs) comprise the variable
domains of either the heavy or light chain, and are thus
the smalest functional antigen-binding portions of the IgG
molecule.18 19Domain antibodies ofer multiple advantages over
conventional antibody technology: they bind monovalently to
their targets, avoiding the potential for receptor cross-linking;
they lack the Fc portions and do not induce Fc effector responses
such as complement-dependent cytotoxicity or antibody-depen-
dent cytotoxicity; their smal size (w12 kD) enables better tissue
penetration, delivery at much higher concentrations per unit mass
and potentialy fewer long-term adverse efects (eg, immuno-
suppression) due to more rapid excretion; and they can be
manufactured to be suitable for local delivery such as inhalation.
In this study we investigated the effects of an intratrachealy
delivered p55 TNFreceptor-targeting dAb in in vivo mouse
models of VILI. We found that selective blockade of intra-alve-
olar p55 signaling reduced alveolar-epithelial barrier perme-
ability and pulmonary inﬂammation, which suggests potential
for new treatments of VILI and ALI.
METHODS
Ventilation protocol
Male  C57BL6  mice (Charles  River,  Margate,  UK)  aged
8e12 weeks were anaesthetised (intraperitoneal ketamine 80 mg/
kg and xylazine 8 mg/kg), tracheostomised and ventilated using
a custom-made jet ventilator.1420 21Airwayﬂow was monitored
by a miniature pneumotach in the ventilator system and tidal
volume (VT) was calculated by integratingﬂow during inspira-
tion. The left carotid artery was cannulated for blood pressure
(BP) and arterial blood gas (ABG) measurements. Ventilation was
then set to produce VILI (‘pure’VILI model), standardised by
inspiratory plateau pressure (Pplateau)of14cm H2Oequatingto
VTofw22 ml/kg with positive end-expiratory pressure 3 cm
H2O, respiratory rate 90/min and oxygen+4% carbon dioxide (to
prevent hypocapnia). Immediately afterwards, mice received an
intratracheal bolus of either dummy (non-targeting) dAb or p55-
speciﬁc blocking dAb (25mg), or either mouse anti-TNF mono-
clonal antibody (50mg; TN3-19.12; BD Pharmingen, Oxford, UK)
or its isotype control (hamster IgG, BD Pharmingen) in a total
volume of 50ml. We previously demonstrated the efﬁcacy of the
monoclonal anti-TNF used (with the same route and dose) to
reduce alveolar neutrophil inﬁltration associated with VILI.22In
a separate series of experiments, a subclinical dose of lipopoly-
saccharide (LPS, 20 ng;Escherichia coliO111:B4, Source Bioscience,
Nottingham, UK) was co-administered intratrachealy with the
dAb bolus to enhance the inﬂammatory component of the model.
In this LPS+VILI model, slightly lower Pplateau(13 cm H2O) and
VT(w20 ml/kg) were used as described previously21because LPS
was expected to enhance the degree of VILI.
Ventilation using the same constant high VTwas continued in
al groups for 240 min or until the mean BP dropped below 45 mm
Hg.14Anaesthesia was maintained by bolus administrations of
intraperitoneal ketamine:xylazine every 20e25 min. A smal
number of animals showed very rapid haemodynamic deteriora-
tion: in the‘pure VILI’model, three mice treated with dummy
dAb, one treated with p55-speciﬁc dAb, one treated with isotype
control and two mice treated with anti-TNF; in the LPS +VILI
model, one mouse treated with dummy dAb. These prematurely
terminated experiments were excluded from the analyses. Pplateau,
respiratory system elastance (Ers) and resistance (Rrs) were deter-
mined by the end-inﬂation occlusion technique20every 20 min,
folowed each time by sustained inﬂation (35 cm H2O, 5 s) to
avoid the development of atelectasis. ABG were assessed at
predetermined points throughout the protocol (ﬁgure 1).
Lung lavage
Folowing termination, lung lavage was performed14and lavage
ﬂuid was analysed for protein concentration (Bio-Rad Labora-
tories, Hemel Hempstead, UK) and, in some cases, for TNF
levels by ELISA (R&D Systems, Abingdon, UK). In the LPS
+VILI model, levels of interleukin 6 (IL-6), monocyte chemo-
tactic protein 1 (MCP-1), keratinocyte chemoattractant (KC)
and macrophage inﬂammatory protein 2 (MIP-2) in the lavage
ﬂuid were evaluated by ELISA (R&D) and cel pelets were used
forﬂow cytometry. Cytokine levels are expressed as total
amount (pg) recovered by lavage.
Lung histology
In some experiments, lungs were removed and instiled with 1%
low  melting point agarose in 4% paraformaldehyde and
processed for histological evaluation by H&E staining.
Flow cytometry
In the LPS+VILI model, lung single cel suspensions were
prepared from excised lungs by mechanical disruption forﬂow
cytometry analysis, as described previously.23e25Lung and lavage
cels were stained withﬂuorophore-conjugated anti-mouse anti-
bodies for CD11b, CD11c, Gr-1 (Ly6C/G), F4/80 and intercelular
adhesion molecule 1 (ICAM-1) or appropriate isotype-matched
controls, and analysed using a FACSCaliburﬂow cytometer with
CelQuest (Becton Dickinson, Oxford, UK) and Flowjo (Tree Star,
Ashland, OR, USA) software. Cels were quantiﬁed using
microsphere counting beads (Caltag Medsystems, Towcester,
UK) added to the samples. Activation state of alveolar macro-
phages was evaluated based on surface ICAM-1 expression.
VT 8 ml/kg 15-20 min 
VT 20-22 ml/kg up to 240 min 
Anaesthesia, 
tracheostomy 
Baseline 
readings 
Instilation of 
antibody ± LPS 
bolus 
Instrumentation 
Start of 
injurious 
ventilation 
(ABG) 
120 min 
(ABG) 
End 
(ABG) 
Figure 1 Scheme of ventilation protocol. Mice were anaesthetised,
tracheostomised and ventilated with non-injurious ventilation for
approximately 15e20 min during instrumentation (doted line). Injurious
ventilation parameters using high tidal volumes (VT) were then introduced,folowed immediately by instilation of the antibody of interest. As a model
of ventilation-induced lung injury with enhanced inﬂammation, a subclin-
ical dose of lipopolysaccharide (LPS, 20 ng) was co-administered with the
domain antibody bolus. After instilation of the reagents, four sustained
inﬂations (35 cm H2O, 5 s) were applied to help the ﬂuid distribute withinthe lungs. Respiratory mechanics were assessed every 20 min, folowed
each time by sustained inﬂation. Arterial blood gases (ABG) were
assessed at predetermined time points (start, 120 min, end).
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Statistical analysis
Data are expressed as mean6SD. Statistical comparisons were
made by two-way repeated measures ANOVA for time course
data or unpaired t tests for end point data using Prism software
Version 5.0. A value of p<0.05 was considered signiﬁcant. For
some end point analyses, data were compared with those of
non-ventilated mice for qualitative purposes.
RESULTS
Efects of anti-p55 domain antibody on respiratory physiology in
the ‘pure’ VILImodel
Mechanical ventilation with the high stretch protocol caused
a substantial deterioration in lung function in dummy dAb-
treated animals, consistent with pulmonary oedema formation.
This was represented by a rapidly increasing Pplateau,Ersand Rrs
that occurred towards the end of the 4 h ventilation protocol
(ﬁgure 2AeC). In marked contrast, no deteriorations were seen
in respiratory mechanics in the p55 dAb group.
Arterial oxygen and carbon dioxide tensions (PO2and PCO2)
were similar between the two groups at the start and 120 min
after drug instilation (ﬁgure 2E,F). By the end of the protocol,
oxygenation tended to deteriorate in dummy dAb-treated
animals (3656146 mm Hg) while PCO2increased. In contrast,
PO2was better maintained in the p55 dAb group (440641 mm
Hg) and PCO2was unchanged from the 120 min level. To assess
alveolar epithelial permeability we measured the protein content
in lavageﬂuid. VILI resulted in substantial protein levels in the
dummy dAb group compared with non-ventilated controls
(2.8261.73 vs 0.2160.03 mg/ml), and this was signiﬁcantly
attenuated in  mice given the p55 dAb (1.3460.4 mg/ml,
ﬁgure 2H). TNF levels in bronchoalveolar lavageﬂuid evaluated
at the end of the ventilation protocol in the dummy dAb group
were found to be upregulated (1476144 pg, n¼11) compared
with untreated mice (less than the assay detection limit of
15 pg/ml).
Lung histology indicated a moderate degree of injury after
VILI with dummy dAb treatment, characterised by neutrophil
inﬁltration and proteinaceous material in the alveolar space
(ﬁgure 3A,B) that was substantialy reduced folowing p55 dAb
(ﬁgure 3C,D).
Efects of anti-TNF monoclonal antibody on respiratory
physiology during VILI
Having found that blockade of p55 TNF receptor signaling
attenuated VILI, we investigated whether total TNF blockade
would be similarly efﬁcacious. To address this, we treated mice
with anti-TNF monoclonal antibody (or isotype control) using
the same instilation strategy and ventilation protocol as for the
dAb experiments.
We found that changes in respiratory mechanics in the isotype
control-treated group folowed a very similar pattern as was
observed for the dummy dAb group (ﬁgure 4AeC). In marked
contrast to the beneﬁcial effect of the p55-speciﬁc dAb, however,
the anti-TNF monoclonal antibody did not attenuate the
changes seen in isotype-treated animals. Similarly, anti-TNF
treatment had no beneﬁcial effect on blood gases (ﬁgure 4EeG)
or alveolar epithelial permeability (ﬁgure 4H).
Efects of anti-p55 domain antibody on inﬂammation folowing
LPS+VILI
Finaly, we evaluated whether the p55-speciﬁc dAb would also
have a beneﬁcial effect on pulmonary inﬂammation during VILI.
Our group and others26have shown that pure mechanical
Figure 2 (A) Plateau pressure (Pplateau), (B) respiratory systemelastance (Ers), (C) respiratory system resistance (Rrs), (D) mean arterialpressure, (E) arterial oxygen tension (PO2), (F) arterial carbon dioxidetension (PCO2), (G) bicarbonate (HCO3) and (H) lavage ﬂuid proteinwere determined in ventilated animals treated intratrachealy with either
dummy or p55-speciﬁc domain antibody (dAb). Changes in Ersand Rrsare expressed as percentage increase in relation to Start (before
instilation) values. Pplateau,Ersand Rrschanges over time duringventilation were signiﬁcantly diferent between treatment groups
(#p<0.05 for interaction between treatment and ventilation time by
two-way ANOVA). Arterial PO2showed a tendency to deteriorate inanimals treated with the dummy dAb but not in mice given the p55-
speciﬁc dAb. Changes in PCO2over time were signiﬁcantly diferentbetween treatment groups (#p<0.05 for interaction by two-way
ANOVA), while changes in bicarbonate levels were similar across
groups. Lavage ﬂuid protein was signiﬁcantly atenuated in the p55-
speciﬁc dAb group (*p<0.05 by unpaired t tests). The doted line
represents the mean value in non-ventilated control animals (N¼8e11
per group).
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ventilation induces a relatively limited degree of alveolar
neutrophil inﬁltration (within the time frame of ventilation
used currently), one of the halmarks of clinical ALI. We there-
fore included a‘subclinical’dose of LPS (20 ng) mixed with the
dummy or p55-speciﬁc dAbs at the start of mechanical venti-
lation to enhance the degree of inﬂammation within the model.
Preliminary studies demonstrated that this dose of LPS did not
induce changes in respiratory mechanics with low tidal volume
ventilation.
As with the‘pure’VILI model, LPS+VILIinducedsubstantial
changes in respiratory mechanics which were signiﬁcantly
attenuated by treatment with p55-speciﬁc dAb (ﬁgure 5AeC).
Similarly, administration of the p55 dAb prevented the deterio-
ration of oxygenation (ﬁgure 5E) and tended to attenuate the
rise in PCO2(ﬁgure 5F). p55 dAb also tended to decrease protein
levels in lavageﬂuid (2.9461.62 vs 2.0661.45 mg/ml for dummy
and p55 dAb, respectively), although this did not reach statis-
tical signiﬁcance (ﬁgure 5H).
Leucocyte subsets in lung single cel suspension and lavage
ﬂuid were identiﬁed based on characteristic antigen expression
usingﬂow cytometry (ﬁgure 6AeC) and their number or acti-
vation state was quantitatively assessed. LPS+VILI increased
the number of lung-recruited neutrophils compared with non-
ventilated controls (2.3260.573106vs 0.1360.053106), which
was  signiﬁcantly  attenuated  by  the  p55-speciﬁc  dAb
(1.2560.313106,p<0.01 vs dummy;ﬁgure 6A). A similar trend
was found with margination of inﬂammatory subset Gr-1high
monocytes, although this was not signiﬁcant (ﬁgure 6A).
Transmigration of neutrophils to the alveolar space was also
greatly increased by LPS+VILI and substantialy attenuated by
p55 dAb treatment (ﬁgure 6B). Alveolar macrophages in lavage
ﬂuid of dummy dAb-treated mice showed increased expression
of ICAM-1 compared with non-ventilated controls, indicative of
activation,27which was also reduced in the p55 dAb group
(ﬁgure 6C). Finaly, treatment with p55 dAb signiﬁcantly
decreased IL-6 and MCP-1 in lavageﬂuid, with similar trends for
KC and MIP-2 (ﬁgure 7).
DISCUSSION
ALI and ARDS are characterised by pulmonary oedema, hypo-
xaemia and inﬂammation. While mechanical ventilation is an
essential aspect of treatment, this can exacerbate underlying
lung injury and cause VILI. It has been suggested that this can
progress to systemic inﬂammation and multiple system organ
failure, which is a major cause of death among patients with
ARDS.2829Although mortality is improved by the use of low
tidal volume ventilation in conjunction with other interven-
tions, it is not possible to eliminate completely the consequences
of VILI in this manner. An ideal therapeutic agent would
therefore attenuate both the respiratory dysfunction which
drives the requirement for ventilation and the inﬂammatory
response which may ultimately lead to death. In this study we
investigated the use of a novel therapeutic technologyddomain
antibodiesdfor theﬁrst time in the area of ALI, and showed
that intratracheal administration of dAb targeting the p55 TNF
receptor attenuated the development of VILI.
Using a mouse model of ‘pure’VILI wefoundthatdeterio-
rations in respiratory function and alveolar-epithelial barrier
permeability were substantialy improved when p55-speciﬁc
blocking dAb was given intratrachealy at the start of the
ventilation  protocol. In  complete  contrast, intratracheal
administration of a monoclonal anti-TNF antibody did not
attenuate stretch-induced respiratory dysfunction. In addition,
in an LPS+VILI model incorporating a greater degree of
pulmonary inﬂammation, administration of the p55-speciﬁc
dAb led to decreased levels of the proinﬂammatory cytokine IL-6
and the monocyte/neutrophil chemoattractant MCP-1 in lavage
ﬂuid, and showed strong trends towards decreases in the
Figure 3 Photomicrographs oflung
tissue. Samplefrom dummy domain
antibody (dAb)-treated mouse (A, B)
showed marked celularity, alveolar wal
thickening (arow), hyaline membrane
formation and intra-alveolar debris
(arowhead) whereas minimal changes
were seen in p55 dAb-treated mouse
(C, D). H&E stain. Magniﬁcation3100
(A and C),3400 (B and D).
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chemokines MIP-2 and KC. While the precise sources of these
inﬂammatory mediators in VILI remain uncertain, alveolar
macrophages are likely contributors and, indeed, we observed
that alveolar macrophage activation (surface ICAM-1 expres-
sion27)  was signiﬁcantly attenuated  by  dAb treatment.
Presumably as a consequence of this reduced intra-alveolar
inﬂammation,  margination and  migration of  neutrophils
within the lung was also attenuated. These data demonstrate
clearly that speciﬁc blockade of p55 TNF-receptor signaling
within the alveolar space attenuates multiple markers of VILI
development.
Figure 4 (A) Plateau pressure (Pplateau), (B) respiratory systemelastance (Ers), (C) respiratory system resistance (Rrs), (D) mean arterialpressure, (E) arterial oxygen tension (PO2), (F) arterial carbon dioxidetension (PCO2), (G) bicarbonate (HCO3) and (H) lavage ﬂuid proteinwere not signiﬁcantly diferent between animals treated intratrachealy
with either isotype or mouse anti-tumour necrosis factor (TNF)
monoclonal antibody (mAb). Doted line represents mean value in non-
ventilated control animals (N¼6 per group).
Figure 5 (A) Plateau pressure (Pplateau), (B) respiratory systemelastance (Ers) and (C) resistance (Rrs), (D) mean arterial pressure, (E)arterial oxygen tension (PO2), (F) arterial carbon dioxide tension (PCO2),(G) bicarbonate (HCO3) and (H) lavage ﬂuid protein of dummy domainantibody (dAb)-treated and p55 dAb-treated mice in the lipopolysaccha-
ride + ventilation-induced lung injury (LPS+VILI) model. Changes in Ersand Rrsare expressed as percentage increase in relation to Start values.Changes in Pplateau,Ers,Rrs, arterial PO2and bicarbonate over time weresigniﬁcantly diferent between treatment groups (#p<0.05 for interaction
between treatment and ventilation time by two-way ANOVA). The p55-
speciﬁc dAb tended to atenuate the rise in PCO2, but this did not reachstatistical signiﬁcance (p¼0.055 for interaction by two-way ANOVA).
Lavage ﬂuid protein levels tended to be reduced in p55-speciﬁc dAb-
treated animals, but not signiﬁcantly. The doted line represents the mean
value in non-ventilated controls (N¼8e11 per group).
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The ventilation parameters used within this study (VT
20e22 ml/kg), although higher than used clinicaly in humans,
would have induced only a moderately high degree of lung
stretch in untreated healthy mice as mouse lungs are much more
compliant than those of humans.30However, due to the impact
of the intratrachealﬂuid instilation, such settings were sufﬁ-
cient to induce injury within 4 h of ventilation. While the
timeframe of the current experiment is much shorter than
patients with ALI would be ventilated, it is comparable with the
majority of published rodent studies of VILI and ALI. Sustained
inﬂations  and  post  end-expiratory  pressure  were  used
throughout the ventilation protocols as mouse lungs have a very
high tendency for atelectasis even at such VT, which could have
substantial confounding effects. Since atelectasis was minimised
by these recruitment measures, the major component of the
observed physiological changes can be ascribed to the develop-
ment of stretch-induced pulmonary oedema. The dAb was given
immediately after setting ventilation parameters in order to
alow robust standardisation of the VILI protocol, avoiding
the unpredictable inﬂuence of instilation on respiratory
mechanics (upon which the degree of VILI was standardised).
Theﬁnding that pulmonary oedema and inﬂammation during
VILI were attenuated under these conditions would indicate
that a substantial prophylactic period was unnecessary for dAb
efﬁcacy.
From the current data it is not possible to determine precisely
why thep55-speciﬁcdAbwas clearly more effective in attenu-
ating VILI than the anti-TNF monoclonal antibody. One possi-
bility is that greater efﬁcacy of the dAb was related to its
biophysical propertiesdits smal size (w12 kDa compared to
w150 kDa for IgG) and monovalent target antigen binding
alows more potency per unit mass, greater tissue penetration
and better biodistribution, and reduced risk of receptor cross-
linking and activation compared with conventional antibody
technology. Thus, despite the fact that we used a 23 larger
amount (in terms of weight) of the monoclonal antibody, the
dAb could be delivered at an approximately 63greater dose than
the monoclonal antibody which may simply induce more
effective inhibition of TNF receptor binding. This lack of efﬁcacy
of anti-TNF treatment to attenuate the physiological manifes-
tations of VILI are somewhat at odds with a previous study
showing a positive effect of anti-TNF in a rabbit model of saline
Figure 6 Flow cytometricanalysisof
leucocytesubsets in the lungs and
lavage ﬂuid of dummy domain antibody
(dAb)-treated and p55 dAb-treated
mice in the lipopolysaccharide +
ventilation-induced lung injury (LPS
+VILI) model. (A) In lung single-cel
suspensions, monocytes were
identiﬁed as CD11b+, F4/80+events,
and their subsets were deﬁned as either
Gr-1low(R1) or Gr-1high(R2),
diferentiated from CD11b+, F4/80,
Gr-1very highneutrophils (R3). (B)
Neutrophils in lavage ﬂuid were
similarly identiﬁed as CD11b+, F4/80,
Gr-1very highevents (R4), whereas
monocytes were not present. (C)
Alveolar macrophages in lavage ﬂuid
were recognised as forward/side
scaterhigh, F4/80+, CD11c+events
(R5) and their intercelular adhesion
molecule (ICAM-1) expression was
quantitatively assessed (mean
ﬂuorescence intensity (MFI) after
isotype subtraction). The doted line
represents the mean value in non-
ventilated control animals. *p<0.05,
**p<0.01 by unpaired t test (N¼8e11
per group).
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lavage folowed by injurious ventilation,4but do reﬂect the
disappointing results from clinical trials in patients with
sepsis/ARDS.7e10 31
In addition to the biophysical properties of the respective
antibodies, we believe target antigen speciﬁcity is vitaly
important. Despite the large number of studies investigating
TNF as a potential therapeutic agent, the complexity of TNF
biology remains rather poorly appreciated. It has been assumed
that the majority of TNF signaling occurs through the p55
receptor, with p75 playing only an auxiliary role, but it is
becoming clearer that the two receptors can signal indepen-
dently and, in some cases, may exert directly opposite effects to
each other.1115For example, we previously showed using knock-
out mice that signaling through p55 promoted the development
of high stretch-induced pulmonary oedema, while signaling
through p75 protected against oedema formation during VILI,
and that these opposing effects seemed to be independent of
TNF-mediated leucocyte recruitment.15Such was the nature of
this opposing signaling that mice devoid of al TNF receptors
showed no protection from oedema (aﬁnding consistent with
others32). These data from geneticaly modiﬁed animals suggest
that non-selective anti-TNF treatment would not be effective
however high a dose of antibody we may be able to deliver.
Interestingly, in an earlier study we showed that the monoclonal
anti-TNF antibody used currently attenuated neutrophilic
alveolitis in VILI.22Similarly, Wolthuiset alfound that total
blockade of TNF signaling by etanercept, a p75 receptor-Fc
fusion protein, failed to attenuate high stretch-induced pulmo-
nary oedema but had some positive effects on inﬂammation.33
Taken together, these data suggest that, while treatment
designed to block TNF per se may be effective in reducing
pulmonary inﬂammation associated with VILI, it has little
impact on pulmonary oedema, presumably as any beneﬁcial
effects of signaling through the p75 receptor on pulmonaryﬂuid
balance are inhibited. The nature of these beneﬁcial effects of
p75 signaling remains unclear, but we speculate that it may
involve actin cytoskeleton rearrangements34 35or prevention of
epithelial/endothelial apoptosis.12
In conclusion, we have shown for theﬁrst time that speciﬁc
and selective pharmacological inhibition of intra-alveolar TNF
receptor p55 signaling by a dAb can ameliorate pulmonary
oedema and inﬂammation during VILI in mice. Targeting intra-
alveolar TNF receptor p55 signaling may open new therapeutic
approaches for ventilated patients with ALI.
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